

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Resmetirom (Rezdiffra®)

Madrigal Pharmaceuticals EU Limited

Modul 4 A – Anhang 4-H

Resmetirom ist indiziert in Kombination mit Ernährung und Bewegung zur Behandlung von Erwachsenen mit nicht zirrhotischer, nicht alkoholischer Steatohepatitis (MASH), bei denen eine mäßige bis fortgeschrittene Leberfibrose (Fibrostadien F2 bis F3) besteht.

Weitere Analysen zu den in Abschnitt 4.3.1.3
gezeigten Ergebnissen

Stand: 15.09.2025

Table Of Contents

[AMNOG Table MORB12.2 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Gender \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->19](#)

[AMNOG Table MORB12.3 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Ethnicity \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->21](#)

[AMNOG Table MORB12.4 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Fibrosis Stage at Baseline \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->23](#)

[AMNOG Table MORB12.5 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Baseline MRI-PDFF \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->25](#)

[AMNOG Table MORB12.6 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Stage of NASH \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->27](#)

[AMNOG Table MORB12.7 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Type 2 Diabetes \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->29](#)

[AMNOG Table MORB12.8 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Baseline ALT by Gender \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->31](#)

[AMNOG Table MORB12.9 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by LDL at Baseline \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->33](#)

[AMNOG Table MORB12.10 Proportion of Patients Achieving \$\geq 1\$ Stage Reduction in Fibrosis at Week 36 by Triglycerides at Baseline \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->35](#)

Table Of Contents

AMNOG Table MORB12.11 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36 by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->37

AMNOG Table MORB12.12 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36 by Baseline HA (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->39

AMNOG Table MORB12.13 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36 by Baseline PRO-C3 (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->41

AMNOG Table MORB13.2 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Gender (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->43

AMNOG Table MORB13.3 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Ethnicity (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->45

AMNOG Table MORB13.4 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Fibrosis Stage at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->47

AMNOG Table MORB13.5 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Baseline MRI-PDF F (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->49

AMNOG Table MORB13.6 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Stage of NASH (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->51

AMNOG Table MORB13.7 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Type 2 Diabetes (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->53

Table Of Contents

AMNOG Table MORB13.8 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Baseline ALT by Gender (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->55

AMNOG Table MORB13.9 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by LDL at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->57

AMNOG Table MORB13.10 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Triglycerides at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->59

AMNOG Table MORB13.11 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->61

AMNOG Table MORB13.12 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Baseline HA (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->63

AMNOG Table MORB13.13 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36 by Baseline PRO-C3 (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->65

AMNOG Table MORB15.2 Proportion of NASH Resolution Responders at Week 36 by Gender (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->67

AMNOG Table MORB15.3 Proportion of NASH Resolution Responders at Week 36 by Ethnicity (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->69

AMNOG Table MORB15.4 Proportion of NASH Resolution Responders at Week 36 by Fibrosis Stage at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->71

Table Of Contents

[AMNOG Table MORB15.5 Proportion of NASH Resolution Responders at Week 36 by Baseline MRI-PDFF \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->73](#)

[AMNOG Table MORB15.6 Proportion of NASH Resolution Responders at Week 36 by Stage of NASH \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->75](#)

[AMNOG Table MORB15.7 Proportion of NASH Resolution Responders at Week 36 by Type 2 Diabetes \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->77](#)

[AMNOG Table MORB15.8 Proportion of NASH Resolution Responders at Week 36 by Baseline ALT by Gender \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->79](#)

[AMNOG Table MORB15.9 Proportion of NASH Resolution Responders at Week 36 by LDL at Baseline \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->81](#)

[AMNOG Table MORB15.10 Proportion of NASH Resolution Responders at Week 36 by Triglycerides at Baseline \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->83](#)

[AMNOG Table MORB15.11 Proportion of NASH Resolution Responders at Week 36 by Baseline TIMP \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->85](#)

[AMNOG Table MORB15.12 Proportion of NASH Resolution Responders at Week 36 by Baseline HA \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->87](#)

[AMNOG Table MORB15.13 Proportion of NASH Resolution Responders at Week 36 by Baseline PRO-C3 \(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy\) --->89](#)

Table Of Contents

AMNOG Table MORB18.2 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Gender (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->91

AMNOG Table MORB18.3 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Ethnicity (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->93

AMNOG Table MORB18.4 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Fibrosis Stage at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->95

AMNOG Table MORB18.5 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Baseline MRI-PDFF (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->97

AMNOG Table MORB18.6 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Stage of NASH (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->99

AMNOG Table MORB18.7 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Type 2 Diabetes (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->101

AMNOG Table MORB18.8 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Baseline ALT by Gender (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) -->103

AMNOG Table MORB18.9 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by LDL at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->105

Table Of Contents

AMNOG Table MORB18.10 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Triglycerides at Baseline (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->107

AMNOG Table MORB18.11 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->109

AMNOG Table MORB18.12 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Baseline HA (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->111

AMNOG Table MORB18.13 Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36 by Baseline PRO-C3 (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy) --->113

AMNOG Table PRO2.2 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Gender (Label Population based on Modified Intent-to-Treat Population) --->115

AMNOG Table PRO2.3 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->135

AMNOG Table PRO2.4 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Fibrosis Stage at Baseline (Label Population based on Modified Intent-to-Treat Population) --->155

AMNOG Table PRO2.5 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Baseline MRI-PDFF (Label Population based on Modified Intent-to-Treat Population) --->175

Table Of Contents

AMNOG Table PRO2.6 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Stage of NASH (Label Population based on Modified Intent-to-Treat Population) --->195

AMNOG Table PRO2.7 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Type 2 Diabetes (Label Population based on Modified Intent-to-Treat Population) --->215

AMNOG Table PRO2.8 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Baseline ALT by Gender (Label Population based on Modified Intent-to-Treat Population) --->235

AMNOG Table PRO2.9 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by LDL at Baseline (Label Population based on Modified Intent-to-Treat Population) --->255

AMNOG Table PRO2.10 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Triglycerides at Baseline (Label Population based on Modified Intent-to-Treat Population) --->275

AMNOG Table PRO2.11 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population) --->295

AMNOG Table PRO2.12 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Baseline HA (Label Population based on Modified Intent-to-Treat Population) --->315

AMNOG Table PRO2.13 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component by Baseline PRO-C3 (Label Population based on Modified Intent-to-Treat Population) --->335

AMNOG Table PRO4.2 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Gender (Label Population based on Modified Intent-to-Treat Population) --->355

Table Of Contents

AMNOG Table PRO4.3 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Ethnicity (Label Population based on Modified Intent-to-Treat Population) --->	376
AMNOG Table PRO4.4 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Fibrosis Stage at Baseline (Label Population based on Modified Intent-to-Treat Population) --->	397
AMNOG Table PRO4.5 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Baseline MRI-PDFF (Label Population based on Modified Intent-to-Treat Population) --->	418
AMNOG Table PRO4.6 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Stage of NASH (Label Population based on Modified Intent-to-Treat Population) --->	439
AMNOG Table PRO4.7 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Type 2 Diabetes (Label Population based on Modified Intent-to-Treat Population) --->	460
AMNOG Table PRO4.8 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Baseline ALT by Gender (Label Population based on Modified Intent-to-Treat Population) --->	481
AMNOG Table PRO4.9 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by LDL at Baseline (Label Population based on Modified Intent-to-Treat Population) --->	502
AMNOG Table PRO4.10 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Triglycerides at Baseline (Label Population based on Modified Intent-to-Treat Population) --->	523
AMNOG Table PRO4.11 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population) --->	544

Table Of Contents

[AMNOG Table PRO4.12 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Baseline HA \(Label Population based on Modified Intent-to-Treat Population\) --->565](#)

[AMNOG Table PRO4.13 Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model by Baseline PRO-C3 \(Label Population based on Modified Intent-to-Treat Population\) --->586](#)

[AMNOG Table PRO5.2 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Gender \(Label Population based on Modified Intent-to-Treat Population\) --->607](#)

[AMNOG Table PRO5.3 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Ethnicity \(Label Population based on Modified Intent-to-Treat Population\) --->628](#)

[AMNOG Table PRO5.4 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Fibrosis Stage at Baseline \(Label Population based on Modified Intent-to-Treat Population\) --->649](#)

[AMNOG Table PRO5.5 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Baseline MRI-PDFF \(Label Population based on Modified Intent-to-Treat Population\) --->670](#)

[AMNOG Table PRO5.6 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Stage of NASH \(Label Population based on Modified Intent-to-Treat Population\) --->691](#)

[AMNOG Table PRO5.7 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Type 2 Diabetes \(Label Population based on Modified Intent-to-Treat Population\) --->712](#)

[AMNOG Table PRO5.8 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Baseline ALT by Gender \(Label Population based on Modified Intent-to-Treat Population\) --->733](#)

Table Of Contents

AMNOG Table PRO5.9 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by LDL at Baseline (Label Population based on Modified Intent-to-Treat Population) --->754

AMNOG Table PRO5.10 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Triglycerides at Baseline (Label Population based on Modified Intent-to-Treat Population) --->775

AMNOG Table PRO5.11 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Baseline TIMP (Label Population based on Modified Intent-to-Treat Population) --->796

AMNOG Table PRO5.12 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Baseline HA (Label Population based on Modified Intent-to-Treat Population) --->817

AMNOG Table PRO5.13 Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component by Baseline PRO-C3 (Label Population based on Modified Intent-to-Treat Population) --->838

AMNOG Table S1.2 Treatment-Emergent Adverse Events - Overall Summary by Gender (Label Population based on Safety Population) --->859

AMNOG Table S1.3 Treatment-Emergent Adverse Events - Overall Summary by Ethnicity (Label Population based on Safety Population) --->870

AMNOG Table S1.4 Treatment-Emergent Adverse Events - Overall Summary by Fibrosis Stage at Baseline (Label Population based on Safety Population) --->881

AMNOG Table S1.5 Treatment-Emergent Adverse Events - Overall Summary by Baseline MRI-PDFF (Label Population based on Safety Population) --->892

AMNOG Table S1.6 Treatment-Emergent Adverse Events - Overall Summary by Stage of NASH (Label Population based on Safety Population) --->903

Table Of Contents

AMNOG Table S1.7 Treatment-Emergent Adverse Events - Overall Summary by Type 2 Diabetes (Label Population based on Safety Population) --->	914
AMNOG Table S1.8 Treatment-Emergent Adverse Events - Overall Summary by Baseline ALT by Gender (Label Population based on Safety Population) --->	925
AMNOG Table S1.9 Treatment-Emergent Adverse Events - Overall Summary by LDL at Baseline (Label Population based on Safety Population) --->	936
AMNOG Table S1.10 Treatment-Emergent Adverse Events - Overall Summary by Triglycerides at Baseline (Label Population based on Safety Population) --->	947
AMNOG Table S1.11 Treatment-Emergent Adverse Events - Overall Summary by Baseline TIMP (Label Population based on Safety Population) --->	958
AMNOG Table S1.12 Treatment-Emergent Adverse Events - Overall Summary by Baseline HA (Label Population based on Safety Population) --->	969
AMNOG Table S1.13 Treatment-Emergent Adverse Events - Overall Summary by Baseline PRO-C3 (Label Population based on Safety Population) --->	980
AMNOG Table S2.2 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Gender (Label Population based on Safety Population) --->	991
AMNOG Table S2.3 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Ethnicity (Label Population based on Safety Population) --->	994

Table Of Contents

[AMNOG Table S2.4 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Fibrosis Stage at Baseline \(Label Population based on Safety Population\) --->996](#)

[AMNOG Table S2.5 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline MRI-PDFF \(Label Population based on Safety Population\) --->998](#)

[AMNOG Table S2.6 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Stage of NASH \(Label Population based on Safety Population\) --->1000](#)

[AMNOG Table S2.7 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Type 2 Diabetes \(Label Population based on Safety Population\) --->1003](#)

[AMNOG Table S2.8 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline ALT by Gender \(Label Population based on Safety Population\) --->1005](#)

[AMNOG Table S2.9 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by LDL at Baseline \(Label Population based on Safety Population\) --->1008](#)

[AMNOG Table S2.10 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Triglycerides at Baseline \(Label Population based on Safety Population\) --->1010](#)

[AMNOG Table S2.11 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline TIMP \(Label Population based on Safety Population\) --->1013](#)

[AMNOG Table S2.12 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline HA \(Label Population based on Safety Population\) --->1016](#)

Table Of Contents

[AMNOG Table S2.13 Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline PRO-C3 \(Label Population based on Safety Population\) --->1019](#)

[AMNOG Table S3.2 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Gender \(Label Population based on Safety Population\) --->1021](#)

[AMNOG Table S3.3 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Ethnicity \(Label Population based on Safety Population\) --->1023](#)

[AMNOG Table S3.4 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Fibrosis Stage at Baseline \(Label Population based on Safety Population\) --->1025](#)

[AMNOG Table S3.5 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline MRI-PDFF \(Label Population based on Safety Population\) --->1027](#)

[AMNOG Table S3.6 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Stage of NASH \(Label Population based on Safety Population\) --->1029](#)

[AMNOG Table S3.7 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Type 2 Diabetes \(Label Population based on Safety Population\) --->1031](#)

[AMNOG Table S3.8 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline ALT by Gender \(Label Population based on Safety Population\) --->1033](#)

[AMNOG Table S3.9 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by LDL at Baseline \(Label Population based on Safety Population\) --->1035](#)

Table Of Contents

[AMNOG Table S3.10 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Triglycerides at Baseline \(Label Population based on Safety Population\) --->1037](#)

[AMNOG Table S3.11 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline TIMP \(Label Population based on Safety Population\) --->1039](#)

[AMNOG Table S3.12 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline HA \(Label Population based on Safety Population\) --->1041](#)

[AMNOG Table S3.13 Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline PRO-C3 \(Label Population based on Safety Population\) --->1043](#)

[AMNOG Table S4.2 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Gender \(Label Population based on Safety Population\) --->1045](#)

[AMNOG Table S4.3 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Ethnicity \(Label Population based on Safety Population\) --->1047](#)

[AMNOG Table S4.4 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Fibrosis Stage at Baseline \(Label Population based on Safety Population\) --->1049](#)

[AMNOG Table S4.5 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline MRI-PDFF \(Label Population based on Safety Population\) --->1051](#)

[AMNOG Table S4.6 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Stage of NASH \(Label Population based on Safety Population\) --->1053](#)

Table Of Contents

AMNOG Table S4.7 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Type 2 Diabetes (Label Population based on Safety Population) --->1055

AMNOG Table S4.8 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline ALT by Gender (Label Population based on Safety Population) --->1057

AMNOG Table S4.9 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by LDL at Baseline (Label Population based on Safety Population) --->1059

AMNOG Table S4.10 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Triglycerides at Baseline (Label Population based on Safety Population) --->1061

AMNOG Table S4.11 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline TIMP (Label Population based on Safety Population) --->1063

AMNOG Table S4.12 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline HA (Label Population based on Safety Population) --->1065

AMNOG Table S4.13 Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term by Baseline PRO-C3 (Label Population based on Safety Population) --->1067

AMNOG Table S6.2 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Gender (Label Population based on Safety Population) --->1069

AMNOG Table S6.3 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Ethnicity (Label Population based on Safety Population) --->1071

Table Of Contents

[AMNOG Table S6.4 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Fibrosis Stage at Baseline \(Label Population based on Safety Population\) --->1073](#)

[AMNOG Table S6.5 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Baseline MRI-PDFF \(Label Population based on Safety Population\) --->1075](#)

[AMNOG Table S6.6 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Stage of NASH \(Label Population based on Safety Population\) --->1077](#)

[AMNOG Table S6.7 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Type 2 Diabetes \(Label Population based on Safety Population\) --->1079](#)

[AMNOG Table S6.8 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Baseline ALT by Gender \(Label Population based on Safety Population\) --->1081](#)

[AMNOG Table S6.9 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by LDL at Baseline \(Label Population based on Safety Population\) --->1083](#)

[AMNOG Table S6.10 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Triglycerides at Baseline \(Label Population based on Safety Population\) --->1085](#)

[AMNOG Table S6.11 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Baseline TIMP \(Label Population based on Safety Population\) --->1087](#)

[AMNOG Table S6.12 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Baseline HA \(Label Population based on Safety Population\) --->1089](#)

Table Of Contents

[AMNOG Table S6.13 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term by Base line PRO-C3 \(Label Population based on Safety Population\) --->1091](#)

[AMNOG Table S7.2 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Gender \(Label Population based on Safety Population\) --->1093](#)

[AMNOG Table S7.3 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Ethnicity \(Label Population based on Safety Population\) --->1104](#)

[AMNOG Table S7.4 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Fibrosis Stage at Baseline \(Label Population based on Safety Population\) --->1115](#)

[AMNOG Table S7.5 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Baseline MRI-PDFF \(Label Population based on Safety Population\) --->1126](#)

[AMNOG Table S7.6 Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary by Stage of NASH \(Label Population based on Safety Population\) --->1137](#)

[AMNOG Table S7.7 Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary by Type 2 Diabetes \(Label Population based on Safety Population\) --->1148](#)

[AMNOG Table S7.8 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Baseline ALT by Gender \(Label Population based on Safety Population\) --->1159](#)

[AMNOG Table S7.9 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by LDL at Baseline \(Label Population based on Safety Population\) --->1170](#)

Table Of Contents

[AMNOG Table S7.10 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Triglycerides at Baseline \(Label Population based on Safety Population\) --->1181](#)

[AMNOG Table S7.11 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Baseline TIMP \(Label Population based on Safety Population\) --->1192](#)

[AMNOG Table S7.12 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Baseline HA \(Label Population based on Safety Population\) --->1203](#)

[AMNOG Table S7.13 Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary by Baseline PRO-C3 \(Label Population based on Safety Population\) --->1214](#)

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.2
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Gender: Male

Statistic/Category	MGL-3196 (N=5)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (20.0)	4 (40.0)
No	4 (80.0)	6 (60.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-20.00	
95% CI of the difference	(-66.38, 26.38)	
p-value	0.6004	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.67	
95% CI of the inverse odds ratio	(0.15, 163.64)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.30, 13.51)	
p-value	0.6004	
p-value of Breslow-Day Test for Homogeneity [2]	0.9500	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.2
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Gender: Female

Statistic/Category	MGL-3196 (N=10)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (20.0)	3 (37.5)
No	8 (80.0)	5 (62.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-17.50	
95% CI of the difference	(-59.21, 24.21)	
p-value	0.6078	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.40	
95% CI of the inverse odds ratio	(0.19, 36.86)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.88	
95% CI of the inverse risk ratio	(0.41, 8.65)	
p-value	0.6078	
p-value of Breslow-Day Test for Homogeneity [2]	0.9500	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.3
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Hispanic or Latino

Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	4 (36.4)
No	7 (87.5)	7 (63.6)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-23.86	
95% CI of the difference	(-60.38, 12.65)	
p-value	0.3378	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	4.00	
95% CI of the inverse odds ratio	(0.27, 224.60)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.91	
95% CI of the inverse risk ratio	(0.40, 21.35)	
p-value	0.3378	
p-value of Breslow-Day Test for Homogeneity [2]	0.6503	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.3
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Not Hispanic or Latino

Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (28.6)	3 (42.9)
No	5 (71.4)	4 (57.1)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-14.29	
95% CI of the difference	(-63.92, 35.35)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.88	
95% CI of the inverse odds ratio	(0.13, 32.14)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.50	
95% CI of the inverse risk ratio	(0.35, 6.40)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.6503	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 1 of 2
 Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.4
 Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
 by Fibrosis Stage at Baseline
 (Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
 Fibrosis Stage at Baseline: 2

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (25.0)	6 (50.0)
No	6 (75.0)	6 (50.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-25.00	
95% CI of the difference	(-66.24, 16.24)	
p-value	0.3729	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	3.00	
95% CI of the inverse odds ratio	(0.32, 40.16)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.53, 7.54)	
p-value	0.3729	
p-value of Breslow-Day Test for Homogeneity [2]	0.6146	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.4
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 3

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	1 (16.7)
No	6 (85.7)	5 (83.3)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-2.38	
95% CI of the difference	(-41.89, 37.13)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.20	
95% CI of the inverse odds ratio	(0.01, 109.70)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.17	
95% CI of the inverse risk ratio	(0.09, 14.92)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.6146	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.5
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: $< 20\%$

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (25.0)	4 (50.0)
No	6 (75.0)	4 (50.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-25.00	
95% CI of the difference	(-70.83, 20.83)	
p-value	0.6084	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	3.00	
95% CI of the inverse odds ratio	(0.25, 45.77)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.50, 8.00)	
p-value	0.6084	
p-value of Breslow-Day Test for Homogeneity [2]	0.9267	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.5
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: $\geq 20\%$

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	3 (30.0)
No	6 (85.7)	7 (70.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-15.71	
95% CI of the difference	(-54.17, 22.74)	
p-value	0.6029	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.57	
95% CI of the inverse odds ratio	(0.15, 157.12)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.10	
95% CI of the inverse risk ratio	(0.27, 16.26)	
p-value	0.6029	
p-value of Breslow-Day Test for Homogeneity [2]	0.9267	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.6
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: <5

Statistic/Category	MGL-3196 (N=4)	Placebo (N=5)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = Non-alcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.6
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: ≥ 5

Statistic/Category	MGL-3196 (N=11)	Placebo (N=13)

Not enough data to perform this subgroup analysis.

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = Non-alcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.7
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Type 2 Diabetes: Yes

Statistic/Category	MGL-3196 (N=9)	Placebo (N=7)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (11.1)	4 (57.1)
No	8 (88.9)	3 (42.9)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-46.03	
95% CI of the difference	(-88.05, -4.01)	
p-value	0.1058	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	10.67	
95% CI of the inverse odds ratio	(0.59, 588.98)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	5.14	
95% CI of the inverse risk ratio	(0.73, 36.37)	
p-value	0.1058	
p-value of Breslow-Day Test for Homogeneity [2]	0.1082	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.7
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Type 2 Diabetes: No

Statistic/Category	MGL-3196 (N=6)	Placebo (N=11)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (33.3)	3 (27.3)
No	4 (66.7)	8 (72.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	6.06	
95% CI of the difference	(-39.93, 52.05)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	0.75	
95% CI of the inverse odds ratio	(0.06, 12.72)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.82	
95% CI of the inverse risk ratio	(0.18, 3.62)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.1082	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.8
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Statistic/Category	MGL-3196 (N=11)	Placebo (N=14)

Not enough data to perform this subgroup analysis.

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.8
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT < 30 U/L and males with baseline ALT < 45 U/L

Statistic/Category	MGL-3196 (N=4)	Placebo (N=4)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.9
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: <100 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (28.6)	3 (50.0)
No	5 (71.4)	3 (50.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-21.43	
95% CI of the difference	(-73.59, 30.73)	
p-value	0.5921	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.50	
95% CI of the inverse odds ratio	(0.16, 44.95)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.75	
95% CI of the inverse risk ratio	(0.42, 7.23)	
p-value	0.5921	
p-value of Breslow-Day Test for Homogeneity [2]	0.8425	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.9
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: ≥ 100 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	4 (33.3)
No	7 (87.5)	8 (66.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-20.83	
95% CI of the difference	(-56.00, 14.33)	
p-value	0.6027	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	3.50	
95% CI of the inverse odds ratio	(0.24, 196.55)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.67	
95% CI of the inverse risk ratio	(0.36, 19.71)	
p-value	0.6027	
p-value of Breslow-Day Test for Homogeneity [2]	0.8425	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.10
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Triglycerides at Baseline: ≤ 150 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	3 (37.5)	5 (38.5)
No	5 (62.5)	8 (61.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-0.96	
95% CI of the difference	(-43.68, 41.76)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.04	
95% CI of the inverse odds ratio	(0.12, 9.82)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.03	
95% CI of the inverse risk ratio	(0.33, 3.17)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.1999	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.10
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Triglycerides at Baseline: >150 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=5)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	0	2 (40.0)
No	7 (100)	3 (60.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-35.42	
95% CI of the difference	(-78.28, 7.45)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	10.71	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	6.67	
95% CI of the inverse risk ratio	(0.39, 114.78)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1999	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.11
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: <229 ug/L

Statistic/Category	MGL-3196 (N=2)	Placebo (N=6)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.11
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: ≥ 229 ug/L

Statistic/Category	MGL-3196 (N=13)	Placebo (N=12)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.12
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: <50 ug/L

Statistic/Category	MGL-3196 (N=7)	Placebo (N=9)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	3 (33.3)
No	6 (85.7)	6 (66.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-19.05	
95% CI of the difference	(-59.30, 21.21)	
p-value	0.5846	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	3.00	
95% CI of the inverse odds ratio	(0.17, 183.28)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.33	
95% CI of the inverse risk ratio	(0.30, 17.88)	
p-value	0.5846	
p-value of Breslow-Day Test for Homogeneity [2]	0.8935	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.12
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline HA

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: ≥ 50 ug/L

Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (25.0)	4 (44.4)
No	6 (75.0)	5 (55.6)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-19.44	
95% CI of the difference	(-63.65, 24.76)	
p-value	0.6199	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.40	
95% CI of the inverse odds ratio	(0.21, 35.67)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.78	
95% CI of the inverse risk ratio	(0.44, 7.25)	
p-value	0.6199	
p-value of Breslow-Day Test for Homogeneity [2]	0.8935	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.13
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: <17.5 ng/mL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	5 (50.0)
No	6 (85.7)	5 (50.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-35.71	
95% CI of the difference	(-76.12, 4.69)	
p-value	0.3043	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	6.00	
95% CI of the inverse odds ratio	(0.40, 330.09)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.50	
95% CI of the inverse risk ratio	(0.51, 23.81)	
p-value	0.3043	
p-value of Breslow-Day Test for Homogeneity [2]	0.2841	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB12.13
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: ≥ 17.5 ng/mL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis at Week 36, n (%)		
Yes	2 (25.0)	2 (25.0)
No	6 (75.0)	6 (75.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	0.00	
95% CI of the difference	(-42.43, 42.43)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse odds ratio	(0.05, 18.27)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse risk ratio	(0.18, 5.46)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.2841	

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.2

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36

by Gender

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Gender: Male

Statistic/Category	MGL-3196 (N=5)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	1 (20.0)	3 (30.0)
No	4 (80.0)	7 (70.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-10.00	
95% CI of the difference	(-55.12, 35.12)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.71	
95% CI of the inverse odds ratio	(0.09, 112.18)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.50	
95% CI of the inverse risk ratio	(0.20, 11.00)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.7645	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.2
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Gender: Female

Statistic/Category	MGL-3196 (N=10)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	1 (10.0)	2 (25.0)
No	9 (90.0)	6 (75.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-15.00	
95% CI of the difference	(-50.30, 20.30)	
p-value	0.5588	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	3.00	
95% CI of the inverse odds ratio	(0.12, 196.28)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.50	
95% CI of the inverse risk ratio	(0.27, 22.86)	
p-value	0.5588	
p-value of Breslow-Day Test for Homogeneity [2]	0.7645	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.3
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Hispanic or Latino

Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	1 (12.5)	3 (27.3)
No	7 (87.5)	8 (72.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-14.77	
95% CI of the difference	(-49.67, 20.13)	
p-value	0.6027	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.63	
95% CI of the inverse odds ratio	(0.16, 157.16)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.18	
95% CI of the inverse risk ratio	(0.27, 17.32)	
p-value	0.6027	
p-value of Breslow-Day Test for Homogeneity [2]	0.9616	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.3

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36

by Ethnicity

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Ethnicity: Not Hispanic or Latino

Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	1 (14.3)	2 (28.6)
No	6 (85.7)	5 (71.4)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-14.29	
95% CI of the difference	(-56.62, 28.05)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.40	
95% CI of the inverse odds ratio	(0.09, 164.80)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.23, 17.34)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.9616	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.4
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 2

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (25.0)	5 (41.7)
No	6 (75.0)	7 (58.3)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-16.67	
95% CI of the difference	(-57.64, 24.30)	
p-value	0.6424	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.14	
95% CI of the inverse odds ratio	(0.22, 29.41)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.67	
95% CI of the inverse risk ratio	(0.42, 6.59)	
p-value	0.6424	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.4
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 3

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	0
No	7 (100)	6 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.5

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Baseline MRI-PDFF: $<20\%$

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (25.0)	3 (37.5)
No	6 (75.0)	5 (62.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-12.50	
95% CI of the difference	(-57.51, 32.51)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.80	
95% CI of the inverse odds ratio	(0.14, 28.99)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.50	
95% CI of the inverse risk ratio	(0.34, 6.70)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.6436	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.5
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: $\geq 20\%$

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	2 (20.0)
No	7 (100)	8 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-16.48	
95% CI of the difference	(-46.39, 13.43)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	4.41	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.64	
95% CI of the inverse risk ratio	(0.20, 65.86)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.6436	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.6
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: < 5

Statistic/Category	MGL-3196 (N=4)	Placebo (N=5)
Not enough data to perform this subgroup analysis.		

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = Non-alcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.6
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: ≥ 5

Statistic/Category	MGL-3196 (N=11)	Placebo (N=13)

Not enough data to perform this subgroup analysis.

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = Non-alcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.7
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Type 2 Diabetes: Yes

Statistic/Category	MGL-3196 (N=9)	Placebo (N=7)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	2 (28.6)
No	9 (100)	5 (71.4)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-26.25	
95% CI of the difference	(-61.09, 8.59)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	8.64	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	6.25	
95% CI of the inverse risk ratio	(0.35, 112.52)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1918	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.7
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Type 2 Diabetes: No

Statistic/Category	MGL-3196 (N=6)	Placebo (N=11)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (33.3)	3 (27.3)
No	4 (66.7)	8 (72.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	6.06	
95% CI of the difference	(-39.93, 52.05)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	0.75	
95% CI of the inverse odds ratio	(0.06, 12.72)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.82	
95% CI of the inverse risk ratio	(0.18, 3.62)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.1918	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.8
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Statistic/Category	MGL-3196 (N=11)	Placebo (N=14)

Not enough data to perform this subgroup analysis.

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.8		
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36		
by Baseline ALT by Gender		
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)		
Baseline ALT by Gender: Females with baseline ALT < 30 U/L and males with baseline ALT < 45 U/L		
Statistic/Category	MGL-3196 (N=4)	Placebo (N=4)

Not enough data to perform this subgroup analysis.

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.9

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

LDL at Baseline: <100 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (28.6)	2 (33.3)
No	5 (71.4)	4 (66.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-4.76	
95% CI of the difference	(-55.19, 45.66)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.25	
95% CI of the inverse odds ratio	(0.06, 24.71)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.17	
95% CI of the inverse risk ratio	(0.23, 5.95)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.4043	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.9

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

LDL at Baseline: ≥ 100 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	3 (25.0)
No	8 (100)	9 (75.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-21.37	
95% CI of the difference	(-49.75, 7.01)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	6.26	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	4.85	
95% CI of the inverse risk ratio	(0.28, 82.84)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.4043	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.10

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Triglycerides at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Triglycerides at Baseline: ≤ 150 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (25.0)	4 (30.8)
No	6 (75.0)	9 (69.2)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-5.77	
95% CI of the difference	(-44.88, 33.34)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.33	
95% CI of the inverse odds ratio	(0.13, 18.99)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.23	
95% CI of the inverse risk ratio	(0.29, 5.25)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.5028	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.10

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Triglycerides at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Triglycerides at Baseline: >150 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=5)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	1 (20.0)
No	7 (100)	4 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-18.75	
95% CI of the difference	(-57.24, 19.74)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	5.00	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	4.00	
95% CI of the inverse risk ratio	(0.20, 82.01)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.5028	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.11
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: <229 ug/L

Statistic/Category	MGL-3196 (N=2)	Placebo (N=6)
Not enough data to perform this subgroup analysis.		

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.11
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: ≥ 229 ug/L

Statistic/Category	MGL-3196 (N=13)	Placebo (N=12)
Not enough data to perform this subgroup analysis.		

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.12
Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: < 50 ug/L

Statistic/Category	MGL-3196 (N=7)	Placebo (N=9)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	3 (33.3)
No	7 (100)	6 (66.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-28.75	
95% CI of the difference	(-62.74, 5.24)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	8.08	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	5.60	
95% CI of the inverse risk ratio	(0.34, 93.35)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.2330	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.12

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline HA

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Baseline HA: ≥ 50 ug/L

Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (25.0)	2 (22.2)
No	6 (75.0)	7 (77.8)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	2.78	
95% CI of the difference	(-37.70, 43.25)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	0.86	
95% CI of the inverse odds ratio	(0.05, 15.48)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.89	
95% CI of the inverse risk ratio	(0.16, 4.93)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.2330	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.13

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Baseline PRO-C3: <17.5 ng/mL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	0	4 (40.0)
No	7 (100)	6 (60.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-34.66	
95% CI of the difference	(-68.21, -1.11)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	10.38	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	6.55	
95% CI of the inverse risk ratio	(0.41, 105.10)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.0984	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB13.13

Proportion of Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Baseline PRO-C3: ≥ 17.5 ng/mL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
Patients Achieving ≥ 1 Stage Reduction in Fibrosis and No Worsening of NAS at Week 36, n (%)		
Yes	2 (25.0)	1 (12.5)
No	6 (75.0)	7 (87.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	12.50	
95% CI of the difference	(-25.26, 50.26)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	0.43	
95% CI of the inverse odds ratio	(0.01, 10.79)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.50	
95% CI of the inverse risk ratio	(0.06, 4.47)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.0984	

Abbreviations: NAS = non-alcoholic fatty liver disease activity score; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.2
Proportion of NASH Resolution Responders at Week 36
by Gender

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Gender: Male

Statistic/Category	MGL-3196 (N=5)	Placebo (N=10)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (20.0)	2 (20.0)
No	4 (80.0)	8 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	0.00	
95% CI of the difference	(-42.94, 42.94)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse odds ratio	(0.04, 73.57)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse risk ratio	(0.12, 8.56)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.5034	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 2 of 2
 Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.2
 Proportion of NASH Resolution Responders at Week 36
 by Gender

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Gender: Female

Statistic/Category	MGL-3196 (N=10)	Placebo (N=8)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	1 (12.5)
No	10 (100)	7 (87.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-12.12	
95% CI of the difference	(-39.40, 15.16)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	4.20	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.67	
95% CI of the inverse risk ratio	(0.17, 79.54)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.5034	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.3
Proportion of NASH Resolution Responders at Week 36
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Hispanic or Latino

Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	1 (9.1)
No	8 (100)	10 (90.9)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-6.94	
95% CI of the difference	(-30.90, 17.02)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.43	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.25	
95% CI of the inverse risk ratio	(0.10, 49.04)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.9957	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 2 of 2
 Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.3
 Proportion of NASH Resolution Responders at Week 36
 by Ethnicity

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
 Ethnicity: Not Hispanic or Latino

Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (14.3)	2 (28.6)
No	6 (85.7)	5 (71.4)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-14.29	
95% CI of the difference	(-56.62, 28.05)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.40	
95% CI of the inverse odds ratio	(0.09, 164.80)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.23, 17.34)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.9957	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 1 of 2
 Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.4
 Proportion of NASH Resolution Responders at Week 36
 by Fibrosis Stage at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
 Fibrosis Stage at Baseline: 2

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (12.5)	3 (25.0)
No	7 (87.5)	9 (75.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-12.50	
95% CI of the difference	(-46.05, 21.05)	
p-value	0.6186	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.33	
95% CI of the inverse odds ratio	(0.14, 139.71)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.00	
95% CI of the inverse risk ratio	(0.25, 15.99)	
p-value	0.6186	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.4
Proportion of NASH Resolution Responders at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 3

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	0
No	7 (100)	6 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 1 of 2
 Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.5
 Proportion of NASH Resolution Responders at Week 36
 by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Baseline MRI-PDFF: <20%

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (12.5)	1 (12.5)
No	7 (87.5)	7 (87.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	0.00	
95% CI of the difference	(-32.41, 32.41)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse odds ratio	(0.01, 89.58)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse risk ratio	(0.07, 13.37)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.4944	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.5
Proportion of NASH Resolution Responders at Week 36
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: >=20%

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	2 (20.0)
No	7 (100)	8 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-16.48	
95% CI of the difference	(-46.39, 13.43)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	4.41	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.64	
95% CI of the inverse risk ratio	(0.20, 65.86)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.4944	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.6
Proportion of NASH Resolution Responders at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: <5

Statistic/Category	MGL-3196 (N=4)	Placebo (N=5)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = nonalcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.6
Proportion of NASH Resolution Responders at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: >=5

Statistic/Category	MGL-3196 (N=11)	Placebo (N=13)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = nonalcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.7
Proportion of NASH Resolution Responders at Week 36
by Type 2 Diabetes

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Type 2 Diabetes: Yes

Statistic/Category	MGL-3196 (N=9)	Placebo (N=7)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	0
No	9 (100)	7 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.7
Proportion of NASH Resolution Responders at Week 36
by Type 2 Diabetes

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Type 2 Diabetes: No

Statistic/Category	MGL-3196 (N=6)	Placebo (N=11)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (16.7)	3 (27.3)
No	5 (83.3)	8 (72.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-10.61	
95% CI of the difference	(-50.38, 29.17)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.88	
95% CI of the inverse odds ratio	(0.11, 117.83)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.64	
95% CI of the inverse risk ratio	(0.21, 12.49)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.8
Proportion of NASH Resolution Responders at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Statistic/Category	MGL-3196 (N=11)	Placebo (N=14)

Not enough data to perform this subgroup analysis.

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.8
Proportion of NASH Resolution Responders at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Statistic/Category	MGL-3196 (N=4)	Placebo (N=4)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.9
Proportion of NASH Resolution Responders at Week 36
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: <100 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (14.3)	0
No	6 (85.7)	6 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.61	
95% CI of the difference	(-21.49, 44.71)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.38	
95% CI of the inverse risk ratio	(0.02, 7.93)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1789	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.9
Proportion of NASH Resolution Responders at Week 36
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: ≥ 100 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	3 (25.0)
No	8 (100)	9 (75.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-21.37	
95% CI of the difference	(-49.75, 7.01)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	4.85	
95% CI of the inverse risk ratio	(0.28, 82.84)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1789	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.10
Proportion of NASH Resolution Responders at Week 36
by Triglycerides at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Triglycerides at Baseline: ≤150 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (12.5)	2 (15.4)
No	7 (87.5)	11 (84.6)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-2.88	
95% CI of the difference	(-33.05, 27.28)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.27	
95% CI of the inverse odds ratio	(0.06, 85.67)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.23	
95% CI of the inverse risk ratio	(0.13, 11.48)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.5237	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.10
Proportion of NASH Resolution Responders at Week 36
by Triglycerides at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Triglycerides at Baseline: >150 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=5)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	1 (20.0)
No	7 (100)	4 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-18.75	
95% CI of the difference	(-57.24, 19.74)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	5.00	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	4.00	
95% CI of the inverse risk ratio	(0.20, 82.01)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.5237	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.11
Proportion of NASH Resolution Responders at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: <229 ug/L

Statistic/Category	MGL-3196 (N=2)	Placebo (N=6)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.11
Proportion of NASH Resolution Responders at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: >=229 ug/L

Statistic/Category	MGL-3196 (N=13)	Placebo (N=12)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.12
Proportion of NASH Resolution Responders at Week 36
by Baseline HA

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: <50 ug/L

Statistic/Category	MGL-3196 (N=7)	Placebo (N=9)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	3 (33.3)
No	7 (100)	6 (66.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-28.75	
95% CI of the difference	(-62.74, 5.24)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	5.60	
95% CI of the inverse risk ratio	(0.34, 93.35)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1084	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.12
Proportion of NASH Resolution Responders at Week 36
by Baseline HA

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: >=50 ug/L

Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (12.5)	0
No	7 (87.5)	9 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.67	
95% CI of the difference	(-16.18, 39.51)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.30	
95% CI of the inverse risk ratio	(0.01, 6.47)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1084	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.13
Proportion of NASH Resolution Responders at Week 36
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: <17.5 ng/mL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
NASH Resolution Responders at Week 36, n (%)		
Yes	0	3 (30.0)
No	7 (100)	7 (70.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-25.57	
95% CI of the difference	(-57.80, 6.66)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	5.09	
95% CI of the inverse risk ratio	(0.30, 85.39)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1415	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB15.13
Proportion of NASH Resolution Responders at Week 36
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: ≥ 17.5 ng/mL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
NASH Resolution Responders at Week 36, n (%)		
Yes	1 (12.5)	0
No	7 (87.5)	8 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.11	
95% CI of the difference	(-17.47, 39.69)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.33	
95% CI of the inverse risk ratio	(0.02, 7.14)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1415	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.2
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Gender: Male

Statistic/Category	MGL-3196 (N=5)	Placebo (N=10)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (20.0)	1 (10.0)
No	4 (80.0)	9 (90.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	10.00	
95% CI of the difference	(-29.69, 49.69)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	0.44	
95% CI of the inverse odds ratio	(0.01, 43.53)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.50	
95% CI of the inverse risk ratio	(0.04, 6.44)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.3077	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.2
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Gender: Female

Statistic/Category	MGL-3196 (N=10)	Placebo (N=8)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	1 (12.5)
No	10 (100)	7 (87.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-12.12	
95% CI of the difference	(-39.40, 15.16)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	4.20	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.67	
95% CI of the inverse risk ratio	(0.17, 79.54)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.3077	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.3
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Hispanic or Latino

Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	1 (9.1)
No	8 (100)	10 (90.9)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-6.94	
95% CI of the difference	(-30.90, 17.02)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.43	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.25	
95% CI of the inverse risk ratio	(0.10, 49.04)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.6953	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.3
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Ethnicity: Not Hispanic or Latino

Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	1 (14.3)
No	6 (85.7)	6 (85.7)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	0.00	
95% CI of the difference	(-36.66, 36.66)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse odds ratio	(0.01, 91.43)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse risk ratio	(0.08, 13.02)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.6953	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.4
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 2

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	2 (16.7)
No	7 (87.5)	10 (83.3)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-4.17	
95% CI of the difference	(-35.31, 26.98)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.40	
95% CI of the inverse odds ratio	(0.06, 94.23)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.33	
95% CI of the inverse risk ratio	(0.14, 12.37)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.4
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Fibrosis Stage at Baseline: 3

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	0
No	7 (100)	6 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.5
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: <20%

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	1 (12.5)
No	7 (87.5)	7 (87.5)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	0.00	
95% CI of the difference	(-32.41, 32.41)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse odds ratio	(0.01, 89.58)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.00	
95% CI of the inverse risk ratio	(0.07, 13.37)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	0.7030	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.5
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline MRI-PDFF: >=20%

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	1 (10.0)
No	7 (100)	9 (90.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-7.39	
95% CI of the difference	(-33.70, 18.93)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	2.37	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	2.18	
95% CI of the inverse risk ratio	(0.10, 46.92)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.7030	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.6
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: <5

Statistic/Category	MGL-3196 (N=4)	Placebo (N=5)
Not enough data to perform this subgroup analysis.		

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = nonalcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.6
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Stage of NASH: >=5

Statistic/Category	MGL-3196 (N=11)	Placebo (N=13)

Not enough data to perform this subgroup analysis.

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = nonalcoholic steatohepatitis.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.7
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Type 2 Diabetes: Yes

Statistic/Category	MGL-3196 (N=9)	Placebo (N=7)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	0
No	9 (100)	7 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.7
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Type 2 Diabetes: No

Statistic/Category	MGL-3196 (N=6)	Placebo (N=11)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (16.7)	2 (18.2)
No	5 (83.3)	9 (81.8)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-1.52	
95% CI of the difference	(-39.05, 36.02)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.11	
95% CI of the inverse odds ratio	(0.05, 78.50)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.09	
95% CI of the inverse risk ratio	(0.12, 9.70)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.8
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Statistic/Category	MGL-3196 (N=11)	Placebo (N=14)

Not enough data to perform this subgroup analysis.

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.8
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Statistic/Category	MGL-3196 (N=4)	Placebo (N=4)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.9
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: <100 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=6)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (14.3)	0
No	6 (85.7)	6 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.61	
95% CI of the difference	(-21.49, 44.71)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.38	
95% CI of the inverse risk ratio	(0.02, 7.93)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.2672	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.9
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
LDL at Baseline: >=100 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=12)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	2 (16.7)
No	8 (100)	10 (83.3)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-13.68	
95% CI of the difference	(-39.81, 12.46)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.46	
95% CI of the inverse risk ratio	(0.19, 63.86)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.2672	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.10

Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36

by Triglycerides at Baseline

(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)

Triglycerides at Baseline: <=150 mg/dL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	2 (15.4)
No	7 (87.5)	11 (84.6)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-2.88	
95% CI of the difference	(-33.05, 27.28)	
p-value	>0.9999	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	1.27	
95% CI of the inverse odds ratio	(0.06, 85.67)	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	1.23	
95% CI of the inverse risk ratio	(0.13, 11.48)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.

[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.10
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Triglycerides at Baseline: >150 mg/dL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=5)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	0
No	7 (100)	5 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	NE	
95% CI of the difference	NE	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse risk ratio	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	NE	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.11
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: <229 ug/L

Statistic/Category	MGL-3196 (N=2)	Placebo (N=6)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 05SEP2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.11
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline TIMP: >=229 ug/L

Statistic/Category	MGL-3196 (N=13)	Placebo (N=12)
Not enough data to perform this subgroup analysis.		

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Date of creation: 05SEP2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.12
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: <50 ug/L

Statistic/Category	MGL-3196 (N=7)	Placebo (N=9)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	2 (22.2)
No	7 (100)	7 (77.8)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-18.75	
95% CI of the difference	(-50.40, 12.90)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	4.00	
95% CI of the inverse risk ratio	(0.22, 72.01)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1820	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.12
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline HA: >=50 ug/L

Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	0
No	7 (87.5)	9 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.67	
95% CI of the difference	(-16.18, 39.51)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.30	
95% CI of the inverse risk ratio	(0.01, 6.47)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.1820	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.13
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: <17.5 ng/mL

Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	0	2 (20.0)
No	7 (100)	8 (80.0)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	-16.48	
95% CI of the difference	(-46.39, 13.43)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	3.64	
95% CI of the inverse risk ratio	(0.20, 65.86)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.2240	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table MORB18.13
Proportion of NASH Resolution Responders with At Least a 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population - Subjects with Post-Baseline Liver Biopsy)
Baseline PRO-C3: >=17.5 ng/mL

Statistic/Category	MGL-3196 (N=8)	Placebo (N=8)
NASH Resolution Responders with At Least A 2-point Reduction in NAS and No Worsening of Fibrosis at Week 36, n (%)		
Yes	1 (12.5)	0
No	7 (87.5)	8 (100)
Difference in percentage of responders, MGL-3196 treatment group - Placebo [1]	11.11	
95% CI of the difference	(-17.47, 39.69)	
p-value	NE	
Inverse odds ratio, MGL-3196 treatment group / Placebo [1]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, MGL-3196 treatment group / Placebo [1]	0.33	
95% CI of the inverse risk ratio	(0.02, 7.14)	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [2]	0.2240	

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.
[1] The difference in percentage of responders between MGL-3196 versus placebo, inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained from Fisher's exact test. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.
Program: t-morb12-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Physical Functioning				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	91.0 (12.4)	66.8 (34.6)		
Median	100.0	85.0		
IQR: Q1, Q3	80.0, 100.0	30.0, 95.0		
Min, Max	75, 100	10, 100		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	84.0 (23.3)	73.2 (30.7)	-7.0 (5.8)	6.4 (10.2)
Median	95.0	85.0	0	5.0
IQR: Q1, Q3	80.0, 100.0	50.0, 95.0	-5.0, 0.0	-10.0, 30.0
Min, Max	45, 100	5, 100	-30, 0	-50, 70
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	88.0 (19.6)	79.0 (31.4)	-3.0 (4.4)	8.5 (7.3)
Median	100.0	95.0	0	0
IQR: Q1, Q3	85.0, 100.0	60.0, 100.0	0.0, 0.0	0.0, 5.0
Min, Max	55, 100	5, 100	-20, 5	-10, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Role Physical				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	77.52 (43.45)	67.62 (41.34)		
Median	93.80	87.50		
IQR: Q1, Q3	93.80, 100.00	12.50, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	81.26 (38.53)	71.61 (33.11)	3.74 (2.50)	3.99 (6.38)
Median	100.00	87.50	0	0
IQR: Q1, Q3	93.80, 100.00	43.80, 100.00	0.00, 6.20	-12.50, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 12.5	-31.2, 37.5
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	86.26 (20.92)	81.88 (33.13)	8.74 (10.39)	8.75 (6.40)
Median	93.80	100.00	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-6.3, 50.0	-25.0, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Bodily Pain				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	63.8 (31.1)	68.4 (31.5)		
Median	72.0	74.0		
IQR: Q1, Q3	32.0, 84.0	41.0, 100.0		
Min, Max	31, 100	0, 100		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	71.0 (32.3)	62.0 (35.5)	7.2 (6.8)	-6.4 (6.7)
Median	72.0	72.0	0	0
IQR: Q1, Q3	61.0, 100.0	51.0, 100.0	0.0, 16.0	-28.0, 8.0
Min, Max	22, 100	0, 100	-9, 29	-41, 31
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	70.8 (27.7)	72.7 (30.5)	7.0 (5.3)	2.9 (7.5)
Median	62.0	79.0	10.0	0
IQR: Q1, Q3	51.0, 100.0	62.0, 100.0	0.0, 16.0	-2.0, 16.0
Min, Max	41, 100	0, 100	-10, 19	-49, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
General Health				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	70.6 (11.7)	65.8 (18.6)		
Median	75.0	72.0		
IQR: Q1, Q3	67.0, 77.0	47.0, 82.0		
Min, Max	52, 82	35, 92		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	70.6 (10.4)	63.4 (20.8)	0.0 (4.3)	-2.5 (4.1)
Median	72.0	72.0	0	-5.0
IQR: Q1, Q3	67.0, 77.0	45.0, 80.0	-3.0, 0.0	-10.0, 0.0
Min, Max	55, 82	30, 97	-12, 15	-23, 30
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	72.6 (7.0)	75.4 (23.1)	2.0 (5.1)	7.5 (4.3)
Median	72.0	77.0	0	5.0
IQR: Q1, Q3	67.0, 77.0	72.0, 92.0	-5.0, 5.0	0.0, 20.0
Min, Max	65, 82	25, 100	-10, 20	-10, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Vitality				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	65.04 (21.46)	56.28 (20.16)		
Median	75.00	50.00		
IQR: Q1, Q3	56.30, 81.30	43.80, 81.30		
Min, Max	31.3, 81.3	25.0, 81.3		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	61.26 (17.91)	53.43 (25.06)	-3.78 (7.02)	-2.85 (4.72)
Median	62.50	56.30	0	0
IQR: Q1, Q3	50.00, 75.00	50.00, 68.80	0.00, 6.20	-12.50, 6.20
Min, Max	37.5, 81.3	0.0, 87.5	-31.3, 6.2	-31.3, 25.0
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	70.04 (11.19)	67.52 (28.69)	5.00 (6.06)	8.11 (6.98)
Median	68.80	71.90	6.20	18.70
IQR: Q1, Q3	62.50, 81.30	56.30, 81.30	0.00, 6.30	0.00, 25.00
Min, Max	56.3, 81.3	0.0, 100.0	-12.5, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Social Functioning				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	87.50 (21.65)	82.95 (24.54)		
Median	100.00	100.00		
IQR: Q1, Q3	87.50, 100.00	62.50, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	85.00 (33.54)	75.00 (34.91)	-2.50 (6.12)	-7.95 (6.37)
Median	100.00	100.00	0	0
IQR: Q1, Q3	100.00, 100.00	50.00, 100.00	0.00, 0.00	-25.00, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 12.5	-50.0, 25.0
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	90.00 (13.69)	86.25 (31.43)	2.50 (8.29)	1.25 (5.42)
Median	100.00	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	0.00, 12.50	0.00, 0.00
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Role Emotional				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	88.34 (21.73)	71.22 (37.52)		
Median	100.00	91.70		
IQR: Q1, Q3	91.70, 100.00	33.30, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	80.00 (44.72)	77.27 (32.93)	-8.34 (10.54)	6.05 (4.65)
Median	100.00	91.70	0	0
IQR: Q1, Q3	100.00, 100.00	50.00, 100.00	0.00, 0.00	0.00, 25.00
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 8.3	-16.7, 33.3
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	90.00 (10.87)	77.50 (36.23)	1.66 (6.13)	0.83 (4.01)
Median	91.70	100.00	0	0
IQR: Q1, Q3	83.30, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30
Min, Max	75.0, 100.0	0.0, 100.0	-8.4, 25.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Mental Health				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	83.00 (13.04)	66.36 (23.88)		
Median	80.00	80.00		
IQR: Q1, Q3	80.00, 90.00	45.00, 90.00		
Min, Max	65.0, 100.0	30.0, 90.0		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	80.00 (16.96)	63.18 (30.60)	-3.00 (5.15)	-3.18 (6.62)
Median	85.00	70.00	0	0
IQR: Q1, Q3	85.00, 90.00	35.00, 95.00	-15.00, 5.00	-15.00, 15.00
Min, Max	50.0, 90.0	15.0, 100.0	-15.0, 10.0	-50.0, 25.0
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	88.00 (7.58)	75.50 (31.75)	5.00 (2.74)	5.50 (7.24)
Median	85.00	90.00	5.00	10.00
IQR: Q1, Q3	85.00, 90.00	60.00, 100.00	0.00, 5.00	5.00, 15.00
Min, Max	80.0, 100.0	0.0, 100.0	0.0, 15.0	-45.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Mental Component Score				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	53.92 (7.89)	47.54 (12.16)		
Median	57.30	53.80		
IQR: Q1, Q3	53.10, 57.60	34.20, 57.40		
Min, Max	40.7, 60.9	29.1, 61.2		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	51.12 (12.93)	46.20 (14.91)	-2.80 (3.00)	-1.34 (2.77)
Median	55.70	51.10	1.20	-0.30
IQR: Q1, Q3	53.40, 58.80	36.20, 59.20	-7.50, 2.00	-4.60, 4.50
Min, Max	28.4, 59.3	12.9, 61.3	-12.3, 2.6	-19.5, 11.3
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	55.92 (2.16)	50.67 (14.86)	2.00 (2.97)	1.29 (2.88)
Median	56.40	56.65	-1.20	3.15
IQR: Q1, Q3	54.00, 56.50	45.50, 60.50	-1.90, 3.40	-0.50, 5.10
Min, Max	53.7, 59.0	13.9, 62.3	-3.3, 13.0	-18.5, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=11)	MGL-3196 (N=5)	Placebo (N=11)
Physical Component Score				
Baseline				
m	5	11		
n	5	11		
Mean (SD)	49.94 (9.14)	47.97 (10.67)		
Median	54.40	50.70		
IQR: Q1, Q3	43.20, 54.60	38.90, 55.60		
Min, Max	37.7, 59.8	25.8, 59.2		
Week 12				
m	5	11		
n	5	11	5	11
Mean (SD/SE)	51.18 (8.64)	48.27 (9.20)	1.24 (0.92)	0.30 (1.85)
Median	54.50	49.90	0.10	1.10
IQR: Q1, Q3	47.60, 56.80	36.50, 57.90	0.10, 2.20	-5.10, 3.30
Min, Max	37.8, 59.2	34.5, 58.6	-0.6, 4.4	-8.0, 10.7
Week 36				
m	5	11		
n	5	10	5	10
Mean (SD/SE)	51.06 (7.91)	52.03 (9.67)	1.12 (1.05)	3.15 (2.12)
Median	54.40	53.60	0.70	2.95
IQR: Q1, Q3	48.30, 55.30	50.90, 58.10	0.00, 0.90	-2.30, 7.40
Min, Max	38.6, 58.7	28.7, 64.5	-1.1, 5.1	-5.7, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Physical Functioning				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	65.4 (26.2)	71.9 (19.6)		
Median	75.0	72.5		
IQR: Q1, Q3	47.5, 82.5	60.0, 85.0		
Min, Max	5, 90	40, 100		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	67.1 (29.1)	77.5 (16.3)	1.7 (3.3)	5.6 (4.6)
Median	77.5	77.5	2.5	5.0
IQR: Q1, Q3	50.0, 87.5	65.0, 90.0	-2.5, 7.5	-5.0, 12.5
Min, Max	5, 95	55, 100	-20, 20	-10, 30
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	72.0 (22.6)	76.9 (17.9)	7.0 (5.0)	5.0 (4.5)
Median	80.0	77.5	5.0	5.0
IQR: Q1, Q3	65.0, 85.0	67.5, 90.0	0.0, 10.0	0.0, 15.0
Min, Max	30, 95	45, 100	-15, 40	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Role Physical				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	73.98 (30.70)	57.83 (31.12)		
Median	81.30	56.25		
IQR: Q1, Q3	56.25, 100.00	34.40, 87.50		
Min, Max	6.3, 100.0	12.5, 93.8		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	76.59 (24.88)	61.73 (19.03)	2.61 (5.19)	3.90 (7.74)
Median	90.65	50.00	6.25	0
IQR: Q1, Q3	59.40, 93.80	50.00, 71.90	-9.35, 15.60	-12.50, 21.85
Min, Max	18.8, 100.0	50.0, 100.0	-25.0, 31.3	-25.0, 37.5
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	76.27 (19.94)	57.83 (19.12)	1.87 (9.82)	0.00 (9.37)
Median	75.00	50.00	6.25	-3.10
IQR: Q1, Q3	56.30, 93.80	50.00, 62.55	-25.00, 18.70	-18.75, 21.85
Min, Max	50.0, 100.0	37.5, 100.0	-50.0, 50.0	-37.5, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Bodily Pain				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	53.8 (28.2)	67.0 (29.1)		
Median	62.0	74.0		
IQR: Q1, Q3	36.5, 74.0	41.0, 92.0		
Min, Max	0, 84	22, 100		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	66.1 (24.7)	70.1 (27.7)	12.3 (10.1)	3.1 (7.4)
Median	67.0	68.0	11.0	0
IQR: Q1, Q3	51.0, 84.0	46.5, 100.0	-5.0, 24.5	-15.5, 22.5
Min, Max	22, 100	32, 100	-43, 100	-22, 33
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	62.7 (25.3)	60.4 (30.7)	13.9 (10.8)	-6.6 (9.1)
Median	62.0	57.5	13.0	0
IQR: Q1, Q3	42.0, 74.0	36.0, 87.0	-10.0, 40.0	-16.5, 0.0
Min, Max	22, 100	22, 100	-40, 64	-53, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
General Health				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	55.8 (17.4)	61.1 (17.5)		
Median	54.5	64.5		
IQR: Q1, Q3	43.5, 66.0	49.5, 77.0		
Min, Max	30, 92	30, 77		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	54.9 (15.3)	62.4 (20.0)	-0.8 (4.3)	1.3 (3.1)
Median	57.0	69.5	-2.5	-2.5
IQR: Q1, Q3	46.0, 64.5	44.5, 79.5	-7.5, 2.5	-5.0, 5.0
Min, Max	25, 82	30, 82	-25, 35	-5, 20
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	60.5 (22.2)	52.5 (14.8)	9.0 (6.9)	-8.6 (3.5)
Median	57.0	53.5	2.5	-5.0
IQR: Q1, Q3	45.0, 77.0	46.0, 62.0	-5.0, 27.0	-18.5, -2.5
Min, Max	35, 100	25, 72	-25, 48	-22, 5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Vitality				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	60.45 (18.33)	50.80 (23.49)		
Median	59.40	53.15		
IQR: Q1, Q3	50.05, 68.80	34.40, 65.65		
Min, Max	31.3, 100.0	12.5, 87.5		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	60.96 (21.66)	54.73 (15.21)	0.51 (6.41)	3.93 (5.78)
Median	59.40	46.90	3.15	6.25
IQR: Q1, Q3	43.80, 78.15	43.80, 65.65	-15.65, 18.70	-9.35, 12.50
Min, Max	31.3, 100.0	43.8, 81.3	-37.5, 31.2	-18.7, 31.3
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	60.02 (23.79)	46.90 (14.56)	0.61 (6.42)	-3.90 (6.57)
Median	65.65	46.90	6.25	-3.10
IQR: Q1, Q3	43.80, 75.00	37.55, 56.25	0.00, 18.70	-18.75, 12.50
Min, Max	12.5, 100.0	25.0, 68.8	-43.8, 18.7	-31.3, 18.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Social Functioning				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	83.33 (22.19)	68.75 (25.88)		
Median	93.75	68.75		
IQR: Q1, Q3	68.75, 100.00	43.75, 93.75		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	81.25 (18.84)	68.75 (25.88)	-2.08 (4.82)	0.00 (4.72)
Median	87.50	50.00	0	0
IQR: Q1, Q3	68.75, 100.00	50.00, 100.00	-12.50, 6.25	-6.25, 12.50
Min, Max	50.0, 100.0	50.0, 100.0	-25.0, 25.0	-25.0, 12.5
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	75.00 (24.30)	65.63 (17.36)	-10.00 (11.30)	-3.13 (8.10)
Median	75.00	62.50	-6.25	6.25
IQR: Q1, Q3	62.50, 100.00	50.00, 75.00	-37.50, 12.50	-25.00, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Role Emotional				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	77.78 (31.04)	66.66 (30.54)		
Median	91.65	66.65		
IQR: Q1, Q3	62.50, 100.00	41.65, 95.85		
Min, Max	0.0, 100.0	25.0, 100.0		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	84.04 (26.45)	70.84 (21.36)	6.27 (3.26)	4.18 (5.90)
Median	95.85	66.70	0	0
IQR: Q1, Q3	79.20, 100.00	50.00, 91.65	0.00, 16.70	-4.20, 12.50
Min, Max	16.7, 100.0	50.0, 100.0	-8.3, 25.0	-16.6, 33.4
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	80.00 (19.72)	68.75 (21.25)	1.67 (8.77)	2.09 (8.59)
Median	75.00	62.50	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 87.50	-8.30, 25.00	-12.50, 16.65
Min, Max	50.0, 100.0	50.0, 100.0	-50.0, 50.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Mental Health				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	78.54 (16.67)	60.63 (22.43)		
Median	82.50	55.00		
IQR: Q1, Q3	70.00, 88.75	47.50, 75.00		
Min, Max	45.0, 100.0	30.0, 100.0		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	78.33 (13.20)	66.88 (19.81)	-0.21 (2.99)	6.25 (3.37)
Median	80.00	60.00	0	7.50
IQR: Q1, Q3	70.00, 85.00	52.50, 82.50	-5.00, 2.50	0.00, 12.50
Min, Max	55.0, 100.0	45.0, 100.0	-20.0, 20.0	-10.0, 20.0
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	74.50 (20.74)	61.88 (19.81)	-4.75 (5.75)	1.25 (4.09)
Median	77.50	52.50	-8.75	0
IQR: Q1, Q3	65.00, 90.00	50.00, 72.50	-20.00, 10.00	-2.50, 7.50
Min, Max	35.0, 100.0	45.0, 100.0	-30.0, 25.0	-20.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Visit				
Statistic				
Mental Component Score				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	52.82 (9.48)	43.19 (12.43)		
Median	56.80	40.75		
IQR: Q1, Q3	46.70, 59.75	34.90, 51.00		
Min, Max	32.2, 62.3	26.9, 65.3		
Week 12				
m	12	8		
n	12	8		
Mean (SD/SE)	53.00 (7.48)	45.16 (11.31)	0.18 (1.39)	1.98 (1.76)
Median	52.85	41.40	0.40	1.55
IQR: Q1, Q3	48.25, 60.90	36.90, 52.45	-4.30, 3.80	-1.50, 5.35
Min, Max	41.1, 63.1	33.7, 66.1	-6.5, 9.9	-4.8, 9.8
Week 36				
m	10	8		
n	10	8		
Mean (SD/SE)	50.18 (7.45)	43.01 (11.05)	-3.23 (2.64)	-0.18 (2.91)
Median	51.80	38.85	-5.80	-0.20
IQR: Q1, Q3	44.40, 56.50	35.85, 49.00	-8.10, 7.00	-4.60, 6.15
Min, Max	37.5, 59.6	32.7, 64.0	-18.2, 7.4	-14.6, 10.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=8)	MGL-3196 (N=12)	Placebo (N=8)
Physical Component Score				
Baseline				
m	12	8		
n	12	8		
Mean (SD)	43.62 (8.35)	47.83 (8.87)		
Median	44.90	48.40		
IQR: Q1, Q3	38.65, 50.00	39.90, 55.00		
Min, Max	27.0, 54.5	35.5, 60.5		
Week 12				
m	12	8		
n	12	8	12	8
Mean (SD/SE)	45.23 (9.37)	48.78 (8.08)	1.61 (1.27)	0.95 (1.99)
Median	49.35	47.05	3.25	1.15
IQR: Q1, Q3	39.85, 51.55	42.30, 57.20	-1.55, 4.75	-4.15, 5.15
Min, Max	27.2, 54.8	38.5, 58.6	-6.4, 7.0	-5.8, 9.1
Week 36				
m	10	8		
n	10	8	10	8
Mean (SD/SE)	46.99 (7.94)	46.40 (9.72)	4.68 (2.54)	-1.43 (2.43)
Median	47.10	48.40	5.15	-0.30
IQR: Q1, Q3	42.90, 53.20	38.55, 52.55	0.10, 10.80	-3.35, 1.45
Min, Max	30.7, 56.5	31.5, 60.7	-9.6, 15.9	-15.6, 8.6

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Physical Functioning				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	66.1 (30.6)	63.8 (26.9)		
Median	75.0	67.5		
IQR: Q1, Q3	50.0, 90.0	35.0, 85.0		
Min, Max	5, 100	30, 100		
Week 12				
m	9	12		
n	9	12	9	12
Mean (SD/SE)	64.4 (31.9)	70.0 (28.4)	-1.7 (5.2)	6.3 (8.7)
Median	70.0	77.5	0	7.5
IQR: Q1, Q3	45.0, 90.0	52.5, 90.0	-5.0, 5.0	-7.5, 22.5
Min, Max	5, 100	5, 100	-30, 20	-50, 70
Week 36				
m	8	12		
n	8	11	8	11
Mean (SD/SE)	76.9 (23.7)	77.3 (20.8)	8.8 (6.3)	10.5 (7.1)
Median	82.5	80.0	5.0	5.0
IQR: Q1, Q3	65.0, 95.0	60.0, 100.0	2.5, 17.5	0.0, 20.0
Min, Max	30, 100	45, 100	-20, 40	-20, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Role Physical				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	60.44 (39.77)	60.95 (38.90)		
Median	81.30	75.00		
IQR: Q1, Q3	31.30, 93.80	15.65, 96.90		
Min, Max	0.0, 100.0	6.3, 100.0		
Week 12				
m	9	12		
n	9	12	9	12
Mean (SD/SE)	67.38 (34.06)	64.60 (22.82)	6.93 (4.70)	3.65 (6.86)
Median	75.00	56.25	12.50	0
IQR: Q1, Q3	50.00, 93.80	50.00, 84.40	6.20, 12.50	-12.50, 25.00
Min, Max	12.5, 100.0	31.3, 100.0	-25.0, 18.7	-31.2, 37.5
Week 36				
m	8	12		
n	8	11	8	11
Mean (SD/SE)	82.06 (20.44)	68.19 (22.09)	20.31 (8.07)	2.84 (8.10)
Median	93.80	56.30	15.60	0
IQR: Q1, Q3	62.55, 96.90	50.00, 100.00	0.00, 43.75	-25.00, 31.20
Min, Max	50.0, 100.0	50.0, 100.0	-6.2, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Bodily Pain				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	46.2 (30.8)	67.9 (27.2)		
Median	61.0	74.0		
IQR: Q1, Q3	22.0, 72.0	41.0, 92.0		
Min, Max	0, 84	22, 100		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	60.0 (29.4)	65.5 (28.7)	13.8 (13.1)	-2.4 (7.6)
Median	72.0	67.0	12.0	0
IQR: Q1, Q3	31.0, 84.0	51.5, 87.0	-9.0, 23.0	-25.0, 22.5
Min, Max	22, 100	0, 100	-43, 100	-41, 33
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	63.1 (19.7)	69.3 (27.7)	20.4 (11.2)	0.1 (8.2)
Median	62.0	74.0	24.0	0
IQR: Q1, Q3	46.0, 74.0	41.0, 100.0	-10.0, 45.0	-10.0, 21.0
Min, Max	41, 100	22, 100	-19, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
General Health				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	55.8 (14.5)	66.9 (15.9)		
Median	52.0	72.0		
IQR: Q1, Q3	47.0, 67.0	51.0, 78.5		
Min, Max	35, 77	45, 92		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	57.8 (15.2)	62.3 (16.4)	2.0 (5.1)	-4.6 (3.0)
Median	55.0	69.5	0	-5.0
IQR: Q1, Q3	47.0, 67.0	46.0, 74.5	-5.0, 5.0	-10.0, -2.5
Min, Max	35, 82	35, 82	-15, 35	-23, 20
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	68.1 (20.5)	68.5 (20.9)	13.1 (6.8)	-0.4 (4.2)
Median	69.5	67.0	2.5	0
IQR: Q1, Q3	56.0, 79.5	52.0, 92.0	0.0, 28.5	-10.0, 8.0
Min, Max	35, 100	40, 100	-5, 48	-22, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Vitality				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	59.77 (22.76)	54.19 (23.59)		
Median	56.30	53.15		
IQR: Q1, Q3	43.80, 68.80	37.55, 75.05		
Min, Max	31.3, 100.0	12.5, 87.5		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	67.38 (22.26)	53.68 (16.74)	7.61 (4.63)	-0.52 (4.58)
Median	62.50	50.00	6.20	0
IQR: Q1, Q3	50.00, 87.50	43.80, 56.30	0.00, 18.70	-12.50, 6.25
Min, Max	37.5, 100.0	25.0, 87.5	-12.5, 31.2	-25.0, 31.3
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	71.11 (15.64)	55.70 (20.81)	10.91 (3.68)	-1.15 (6.47)
Median	71.90	50.00	12.45	0
IQR: Q1, Q3	59.40, 78.15	43.80, 68.80	0.00, 18.70	-25.00, 18.70
Min, Max	50.0, 100.0	25.0, 100.0	0.0, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Social Functioning				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	75.00 (25.77)	77.08 (26.02)		
Median	75.00	87.50		
IQR: Q1, Q3	50.00, 100.00	56.25, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	75.00 (28.64)	69.79 (26.89)	0.00 (5.51)	-7.29 (5.21)
Median	87.50	50.00	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-12.50, 0.00	-18.75, 0.00
Min, Max	25.0, 100.0	37.5, 100.0	-25.0, 25.0	-50.0, 12.5
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	79.69 (24.94)	77.27 (20.01)	1.56 (13.45)	-1.14 (6.18)
Median	81.25	75.00	6.25	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	-12.50, 25.00	-25.00, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Role Emotional				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	66.67 (32.54)	63.89 (32.44)		
Median	75.00	62.50		
IQR: Q1, Q3	50.00, 91.70	33.30, 95.85		
Min, Max	0.0, 100.0	16.7, 100.0		
Week 12				
m	9	12		
n	9	12	9	12
Mean (SD/SE)	70.38 (39.77)	71.53 (22.59)	3.71 (7.37)	7.63 (4.97)
Median	100.00	75.00	8.30	0
IQR: Q1, Q3	50.00, 100.00	50.00, 91.65	0.00, 16.70	-4.20, 25.00
Min, Max	0.0, 100.0	41.7, 100.0	-50.0, 25.0	-16.7, 33.4
Week 36				
m	8	12		
n	8	11	8	11
Mean (SD/SE)	82.29 (17.50)	72.73 (25.58)	13.54 (7.38)	4.55 (6.19)
Median	79.15	75.00	12.50	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-4.15, 25.00	-8.30, 25.00
Min, Max	50.0, 100.0	25.0, 100.0	-8.4, 50.0	-25.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Mental Health				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	74.44 (19.11)	60.00 (23.65)		
Median	80.00	52.50		
IQR: Q1, Q3	60.00, 90.00	45.00, 82.50		
Min, Max	45.0, 100.0	30.0, 100.0		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	76.11 (17.81)	61.67 (22.70)	1.67 (3.54)	1.67 (5.82)
Median	80.00	60.00	0	5.00
IQR: Q1, Q3	60.00, 90.00	42.50, 75.00	-5.00, 5.00	-5.00, 15.00
Min, Max	50.0, 100.0	30.0, 100.0	-15.0, 20.0	-50.0, 25.0
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	81.25 (20.83)	69.09 (21.43)	5.00 (5.43)	6.36 (5.14)
Median	85.00	60.00	5.00	10.00
IQR: Q1, Q3	77.50, 95.00	50.00, 95.00	-5.00, 17.50	0.00, 15.00
Min, Max	35.0, 100.0	45.0, 100.0	-20.0, 25.0	-20.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Mental Component Score				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	49.62 (10.83)	44.30 (12.82)		
Median	49.80	41.70		
IQR: Q1, Q3	40.70, 59.20	34.65, 55.60		
Min, Max	32.2, 62.3	26.9, 65.3		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	50.86 (11.89)	44.68 (10.83)	1.23 (1.99)	0.38 (1.99)
Median	53.50	41.40	1.20	0.70
IQR: Q1, Q3	42.10, 61.20	35.30, 51.95	0.50, 3.90	-3.05, 5.35
Min, Max	28.4, 63.1	33.6, 66.1	-12.3, 9.9	-15.9, 9.8
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	53.30 (6.25)	46.85 (10.99)	2.55 (2.48)	1.16 (2.46)
Median	55.05	42.40	3.00	1.90
IQR: Q1, Q3	52.05, 56.65	36.60, 56.90	-3.50, 7.25	-2.80, 9.70
Min, Max	39.3, 59.6	32.7, 64.0	-6.1, 13.0	-14.6, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=12)	MGL-3196 (N=9)	Placebo (N=12)
Physical Component Score				
Baseline				
m	9	12		
n	9	12		
Mean (SD)	42.42 (8.91)	48.02 (8.85)		
Median	43.50	49.70		
IQR: Q1, Q3	37.70, 47.50	40.00, 54.75		
Min, Max	27.0, 54.4	34.3, 60.5		
Week 12				
m	9	12		
n	9	12		
Mean (SD/SE)	44.66 (9.28)	47.85 (9.25)	2.23 (1.06)	-0.17 (1.74)
Median	46.90	48.90	3.10	-0.80
IQR: Q1, Q3	37.80, 51.90	42.30, 55.25	0.10, 4.40	-5.45, 5.15
Min, Max	27.2, 54.8	34.5, 58.0	-3.3, 7.0	-8.0, 9.1
Week 36				
m	8	12		
n	8	11		
Mean (SD/SE)	48.64 (6.50)	49.75 (9.82)	6.64 (2.30)	0.90 (2.66)
Median	49.95	49.80	5.25	0.20
IQR: Q1, Q3	43.25, 53.80	45.00, 58.10	0.50, 12.85	-4.70, 8.60
Min, Max	38.6, 56.5	31.5, 64.5	0.0, 15.9	-15.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Physical Functioning				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	80.6 (17.2)	77.9 (31.5)		
Median	80.0	90.0		
IQR: Q1, Q3	77.5, 92.5	70.0, 95.0		
Min, Max	45, 100	10, 100		
Week 12				
m	8	7		
n	8	7	8	7
Mean (SD/SE)	80.6 (21.6)	83.6 (16.8)	0.0 (2.7)	5.7 (7.8)
Median	85.0	90.0	0	5.0
IQR: Q1, Q3	80.0, 92.5	60.0, 95.0	-2.5, 5.0	-10.0, 5.0
Min, Max	30, 100	60, 100	-15, 10	-10, 50
Week 36				
m	7	7		
n	7	7	7	7
Mean (SD/SE)	77.9 (22.5)	79.3 (33.7)	-2.1 (2.9)	1.4 (1.4)
Median	80.0	95.0	0	0
IQR: Q1, Q3	65.0, 100.0	75.0, 95.0	-10.0, 5.0	0.0, 5.0
Min, Max	35, 100	5, 100	-15, 5	-5, 5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Role Physical				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	91.43 (13.33)	67.86 (35.25)		
Median	96.90	75.00		
IQR: Q1, Q3	87.55, 100.00	50.00, 100.00		
Min, Max	62.5, 100.0	0.0, 100.0		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	89.88 (14.14)	72.33 (36.42)	-1.55 (5.64)	4.47 (6.21)
Median	93.80	87.50	0	0
IQR: Q1, Q3	90.65, 96.90	50.00, 100.00	-9.35, 0.00	0.00, 18.80
Min, Max	56.3, 100.0	0.0, 100.0	-25.0, 31.3	-25.0, 25.0
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	76.79 (20.95)	75.90 (40.58)	-14.30 (8.27)	8.04 (6.21)
Median	75.00	100.00	-6.30	0
IQR: Q1, Q3	50.00, 100.00	37.50, 100.00	-31.30, 0.00	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 12.5	-12.5, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Bodily Pain				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	68.6 (21.5)	67.6 (35.9)		
Median	68.0	74.0		
IQR: Q1, Q3	56.5, 84.0	41.0, 100.0		
Min, Max	32, 100	0, 100		
Week 12				
m	8	7		
n	8	7	8	7
Mean (SD/SE)	76.0 (20.7)	65.3 (39.3)	7.4 (5.9)	-2.3 (4.4)
Median	67.0	74.0	5.0	0
IQR: Q1, Q3	61.5, 100.0	32.0, 100.0	0.0, 21.0	-9.0, 0.0
Min, Max	51, 100	0, 100	-22, 29	-23, 16
Week 36				
m	7	7		
n	7	7	7	7
Mean (SD/SE)	68.0 (32.3)	64.0 (36.2)	1.6 (8.4)	-3.6 (8.0)
Median	62.0	72.0	0	0
IQR: Q1, Q3	41.0, 100.0	41.0, 100.0	-10.0, 19.0	-2.0, 10.0
Min, Max	22, 100	0, 100	-40, 26	-49, 16

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
General Health				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	65.0 (19.3)	58.6 (21.0)		
Median	66.0	67.0		
IQR: Q1, Q3	54.5, 78.5	35.0, 77.0		
Min, Max	30, 92	30, 82		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	61.5 (16.7)	64.0 (26.4)	-3.5 (4.0)	5.4 (4.4)
Median	64.5	72.0	-1.5	0
IQR: Q1, Q3	58.5, 69.5	30.0, 82.0	-7.5, 0.0	0.0, 8.0
Min, Max	25, 82	30, 97	-25, 15	-5, 30
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	60.4 (18.1)	60.0 (25.7)	-0.7 (6.3)	1.4 (6.0)
Median	65.0	72.0	-5.0	0
IQR: Q1, Q3	45.0, 77.0	25.0, 82.0	-10.0, 20.0	-10.0, 20.0
Min, Max	35, 82	25, 87	-25, 20	-20, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Vitality				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	64.09 (14.08)	53.60 (18.00)		
Median	65.65	50.00		
IQR: Q1, Q3	56.30, 75.00	37.50, 68.80		
Min, Max	37.5, 81.3	31.3, 81.3		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	53.93 (15.64)	54.49 (28.35)	-10.16 (8.01)	0.89 (6.46)
Median	56.25	56.30	-9.40	6.20
IQR: Q1, Q3	40.65, 65.65	43.80, 75.00	-31.25, 6.25	-6.20, 6.30
Min, Max	31.3, 75.0	0.0, 87.5	-37.5, 25.0	-31.3, 25.0
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	54.50 (23.04)	62.53 (32.28)	-8.03 (7.57)	8.93 (7.58)
Median	62.50	68.80	6.20	18.70
IQR: Q1, Q3	43.80, 68.80	43.80, 81.30	-25.00, 6.30	0.00, 25.00
Min, Max	12.5, 81.3	0.0, 100.0	-43.8, 6.3	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Social Functioning				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	95.31 (6.47)	76.79 (26.45)		
Median	100.00	87.50		
IQR: Q1, Q3	87.50, 100.00	50.00, 100.00		
Min, Max	87.5, 100.0	37.5, 100.0		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	90.63 (11.08)	76.79 (38.48)	-4.69 (5.25)	0.00 (7.22)
Median	93.75	100.00	0	0
IQR: Q1, Q3	81.25, 100.00	50.00, 100.00	-18.75, 6.25	0.00, 12.50
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 12.5	-37.5, 25.0
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	80.36 (20.23)	76.79 (38.48)	-14.29 (7.43)	0.00 (7.22)
Median	75.00	100.00	-12.50	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-37.50, 0.00	0.00, 12.50
Min, Max	50.0, 100.0	0.0, 100.0	-37.5, 12.5	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Role Emotional				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	96.88 (8.84)	78.57 (36.91)		
Median	100.00	100.00		
IQR: Q1, Q3	100.00, 100.00	66.70, 100.00		
Min, Max	75.0, 100.0	0.0, 100.0		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	96.89 (4.30)	79.77 (37.22)	0.01 (2.73)	1.20 (4.60)
Median	100.00	100.00	0	0
IQR: Q1, Q3	91.70, 100.00	66.70, 100.00	-4.15, 0.00	0.00, 0.00
Min, Max	91.7, 100.0	0.0, 100.0	-8.3, 16.7	-16.6, 25.0
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	84.53 (18.90)	75.00 (38.19)	-11.90 (7.24)	-3.57 (5.09)
Median	91.70	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-25.00, 0.00	0.00, 0.00
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 0.0	-33.3, 8.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Mental Health				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	85.94 (6.81)	70.71 (21.30)		
Median	85.00	85.00		
IQR: Q1, Q3	80.00, 88.75	45.00, 90.00		
Min, Max	80.0, 100.0	45.0, 90.0		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	81.88 (7.53)	70.00 (32.15)	-4.06 (3.53)	-0.71 (5.71)
Median	85.00	90.00	-2.50	5.00
IQR: Q1, Q3	80.00, 85.00	45.00, 95.00	-11.25, 2.50	-10.00, 10.00
Min, Max	65.0, 90.0	15.0, 100.0	-20.0, 10.0	-30.0, 15.0
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	76.43 (16.26)	70.00 (36.63)	-8.93 (5.05)	-0.71 (7.90)
Median	80.00	85.00	-7.50	5.00
IQR: Q1, Q3	65.00, 85.00	50.00, 100.00	-20.00, 5.00	-5.00, 15.00
Min, Max	50.0, 100.0	0.0, 100.0	-30.0, 5.0	-45.0, 15.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Mental Component Score				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	57.10 (3.13)	48.11 (11.37)		
Median	57.60	54.70		
IQR: Q1, Q3	54.40, 59.70	34.20, 57.20		
Min, Max	52.5, 60.9	32.4, 58.3		
Week 12				
m	8	7		
n	8	7		
Mean (SD/SE)	54.24 (4.10)	47.61 (17.29)	-2.86 (1.39)	-0.50 (3.61)
Median	53.25	57.00	-4.30	2.20
IQR: Q1, Q3	51.55, 57.50	39.40, 59.20	-5.85, 1.15	-3.60, 4.10
Min, Max	48.7, 60.6	12.9, 61.3	-7.5, 2.6	-19.5, 11.3
Week 36				
m	7	7		
n	7	7		
Mean (SD/SE)	50.71 (7.42)	47.93 (17.74)	-6.10 (2.55)	-0.19 (3.64)
Median	52.10	55.60	-5.80	2.80
IQR: Q1, Q3	44.40, 56.50	36.60, 61.10	-8.80, -1.90	-6.40, 5.10
Min, Max	37.5, 59.0	13.9, 62.3	-18.2, 3.4	-18.5, 11.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=7)	MGL-3196 (N=8)	Placebo (N=7)
Physical Component Score				
Baseline				
m	8	7		
n	8	7		
Mean (SD)	48.91 (7.83)	47.73 (11.73)		
Median	50.00	54.30		
IQR: Q1, Q3	43.60, 54.55	38.70, 56.10		
Min, Max	35.2, 59.8	25.8, 57.2		
Week 12				
m	8	7		
n	8	7	8	7
Mean (SD/SE)	49.59 (9.24)	49.57 (9.52)	0.68 (1.57)	1.84 (2.07)
Median	50.70	49.90	1.60	2.50
IQR: Q1, Q3	48.60, 55.05	38.50, 58.60	-2.75, 3.95	-0.20, 3.30
Min, Max	28.8, 59.2	36.5, 58.6	-6.4, 6.2	-7.8, 10.7
Week 36				
m	7	7		
n	7	7	7	7
Mean (SD/SE)	48.01 (9.80)	49.19 (10.64)	-0.10 (2.07)	1.46 (1.08)
Median	48.30	53.70	0.70	2.00
IQR: Q1, Q3	40.60, 55.30	40.70, 55.30	-4.50, 5.10	-0.80, 3.00
Min, Max	30.7, 58.7	28.7, 58.4	-9.6, 5.5	-2.3, 6.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Physical Functioning				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	73.1 (23.1)	66.2 (30.2)		
Median	75.0	75.0		
IQR: Q1, Q3	60.0, 90.0	40.0, 95.0		
Min, Max	35, 100	10, 100		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	68.1 (28.9)	78.5 (26.6)	-5.0 (4.6)	12.3 (7.4)
Median	77.5	85.0	-2.5	5.0
IQR: Q1, Q3	37.5, 92.5	70.0, 95.0	-10.0, 0.0	-5.0, 30.0
Min, Max	30, 100	5, 100	-30, 15	-25, 70
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	76.9 (22.2)	78.8 (27.2)	3.8 (6.2)	9.6 (6.1)
Median	82.5	90.0	2.5	2.5
IQR: Q1, Q3	65.0, 92.5	67.5, 95.0	-5.0, 7.5	0.0, 15.0
Min, Max	35, 100	5, 100	-20, 40	-10, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Role Physical				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	73.46 (37.46)	61.55 (38.26)		
Median	87.55	75.00		
IQR: Q1, Q3	56.30, 100.00	18.80, 93.80		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	75.03 (32.05)	65.40 (30.47)	1.56 (4.83)	3.85 (5.73)
Median	93.80	68.80	0	0
IQR: Q1, Q3	53.15, 96.90	50.00, 93.80	-3.10, 12.50	-12.50, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-25.0, 18.7	-31.2, 37.5
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	80.49 (21.25)	70.33 (30.87)	7.03 (9.19)	4.69 (5.66)
Median	90.65	71.90	0	3.15
IQR: Q1, Q3	59.40, 96.90	50.00, 100.00	-6.25, 25.00	-6.25, 15.65
Min, Max	50.0, 100.0	0.0, 100.0	-31.3, 50.0	-25.0, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Bodily Pain				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	58.1 (29.0)	71.0 (33.0)		
Median	56.0	74.0		
IQR: Q1, Q3	31.5, 84.0	54.0, 100.0		
Min, Max	22, 100	0, 100		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	67.9 (26.9)	69.5 (30.8)	9.8 (5.8)	-1.5 (5.7)
Median	67.5	72.0	8.0	0
IQR: Q1, Q3	51.0, 92.0	51.0, 100.0	-4.5, 26.0	-22.0, 8.0
Min, Max	22, 100	0, 100	-10, 29	-33, 33
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	63.9 (25.1)	67.3 (33.0)	5.8 (6.8)	-5.1 (5.8)
Median	56.5	74.0	5.0	0
IQR: Q1, Q3	41.5, 87.0	46.0, 100.0	-10.0, 17.5	-6.0, 0.0
Min, Max	41, 100	0, 100	-19, 40	-49, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
General Health				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	55.4 (17.8)	65.4 (18.6)		
Median	51.0	77.0		
IQR: Q1, Q3	43.5, 71.0	47.0, 80.0		
Min, Max	30, 82	35, 92		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	60.4 (19.5)	62.5 (19.1)	5.0 (5.5)	-2.8 (3.0)
Median	61.0	72.0	-1.5	-5.0
IQR: Q1, Q3	50.0, 77.0	47.0, 80.0	-5.0, 15.0	-10.0, 5.0
Min, Max	25, 82	30, 82	-12, 35	-23, 20
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	63.1 (15.2)	64.3 (21.6)	7.8 (5.5)	-2.8 (4.0)
Median	67.0	64.5	2.5	-2.5
IQR: Q1, Q3	55.0, 74.5	52.0, 77.0	-5.0, 23.5	-13.5, 6.5
Min, Max	35, 77	25, 100	-10, 30	-22, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Vitality				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	58.64 (16.34)	51.95 (21.87)		
Median	56.30	56.30		
IQR: Q1, Q3	50.05, 71.90	31.30, 68.80		
Min, Max	31.3, 81.3	12.5, 81.3		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	62.50 (20.04)	50.99 (21.93)	3.86 (7.27)	-0.96 (5.29)
Median	62.50	56.30	6.20	0
IQR: Q1, Q3	43.75, 81.25	43.80, 56.30	-9.40, 18.70	-12.50, 6.30
Min, Max	37.5, 87.5	0.0, 87.5	-31.3, 31.2	-31.3, 31.3
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	61.74 (21.51)	53.15 (26.86)	3.10 (7.84)	-1.05 (6.25)
Median	65.65	50.00	6.25	0
IQR: Q1, Q3	59.40, 75.00	37.55, 68.80	-3.15, 18.70	-21.90, 18.75
Min, Max	12.5, 81.3	0.0, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Social Functioning				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	85.94 (19.41)	74.04 (25.75)		
Median	93.75	75.00		
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	81.25 (28.35)	71.15 (33.22)	-4.69 (4.05)	-2.88 (4.93)
Median	93.75	87.50	0	0
IQR: Q1, Q3	68.75, 100.00	50.00, 100.00	-12.50, 0.00	-12.50, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 12.5	-37.5, 25.0
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	84.38 (12.94)	75.00 (30.62)	-1.56 (6.44)	0.00 (5.76)
Median	75.00	81.25	0	0
IQR: Q1, Q3	75.00, 100.00	56.25, 100.00	-18.75, 12.50	-12.50, 12.50
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Role Emotional				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	85.41 (22.60)	62.18 (35.62)		
Median	100.00	66.70		
IQR: Q1, Q3	66.65, 100.00	33.30, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	81.25 (37.20)	71.15 (30.16)	-4.16 (6.87)	8.97 (4.67)
Median	100.00	83.30	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	0.00, 0.00	0.00, 25.00
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 16.7	-16.7, 33.4
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	89.59 (12.40)	70.83 (29.41)	4.18 (4.72)	4.86 (5.57)
Median	95.85	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	54.15, 100.00	-4.15, 12.50	0.00, 16.65
Min, Max	75.0, 100.0	0.0, 100.0	-8.3, 25.0	-25.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Mental Health				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	82.50 (16.26)	58.08 (21.65)		
Median	82.50	50.00		
IQR: Q1, Q3	72.50, 97.50	45.00, 80.00		
Min, Max	55.0, 100.0	30.0, 90.0		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	83.13 (15.34)	63.08 (23.41)	0.63 (4.27)	5.00 (4.08)
Median	85.00	65.00	2.50	10.00
IQR: Q1, Q3	80.00, 92.50	55.00, 75.00	-10.00, 7.50	0.00, 15.00
Min, Max	50.0, 100.0	15.0, 95.0	-15.0, 20.0	-30.0, 25.0
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	83.75 (11.88)	62.08 (27.09)	1.25 (5.49)	1.67 (6.32)
Median	82.50	60.00	2.50	5.00
IQR: Q1, Q3	77.50, 92.50	50.00, 85.00	-10.00, 10.00	-10.00, 12.50
Min, Max	65.0, 100.0	0.0, 100.0	-20.0, 25.0	-45.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Mental Component Score				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	54.46 (8.04)	42.57 (11.91)		
Median	58.25	38.50		
IQR: Q1, Q3	48.35, 60.45	32.40, 54.70		
Min, Max	40.7, 60.9	26.9, 61.2		
Week 12				
m	8	13		
n	8	13		
Mean (SD/SE)	53.75 (11.40)	43.89 (13.16)	-0.71 (2.11)	1.32 (2.21)
Median	57.50	45.50	1.55	2.30
IQR: Q1, Q3	50.60, 61.15	34.40, 52.80	-3.60, 3.25	-1.50, 6.20
Min, Max	28.4, 63.1	12.9, 59.7	-12.3, 4.2	-19.5, 11.3
Week 36				
m	8	13		
n	8	12		
Mean (SD/SE)	54.80 (3.24)	44.06 (13.39)	0.34 (2.55)	0.37 (2.93)
Median	53.85	43.95	-1.45	1.75
IQR: Q1, Q3	52.30, 57.75	35.85, 56.00	-4.70, 5.40	-6.00, 10.10
Min, Max	51.0, 59.6	13.9, 60.5	-8.8, 13.0	-18.5, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=13)	MGL-3196 (N=8)	Placebo (N=13)
Physical Component Score				
Baseline				
m	8	13		
n	8	13		
Mean (SD)	44.20 (9.51)	49.04 (10.55)		
Median	43.35	53.90		
IQR: Q1, Q3	36.45, 51.05	41.10, 56.10		
Min, Max	32.1, 59.8	25.8, 60.5		
Week 12				
m	8	13		
n	8	13	8	13
Mean (SD/SE)	45.78 (10.48)	49.68 (8.42)	1.58 (1.35)	0.65 (1.87)
Median	47.25	50.20	2.80	1.20
IQR: Q1, Q3	37.50, 54.35	43.90, 57.90	-0.25, 4.40	-5.10, 7.80
Min, Max	28.8, 59.2	34.5, 58.6	-6.4, 5.1	-8.0, 10.7
Week 36				
m	8	13		
n	8	12	8	12
Mean (SD/SE)	46.93 (9.21)	50.43 (9.76)	2.73 (2.09)	0.55 (1.70)
Median	47.65	52.20	0.80	-0.70
IQR: Q1, Q3	41.10, 54.25	48.40, 55.10	-0.50, 5.40	-3.35, 1.90
Min, Max	30.7, 58.7	28.7, 64.5	-4.5, 14.9	-5.7, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Physical Functioning				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	72.8 (29.0)	75.0 (26.5)		
Median	80.0	77.5		
IQR: Q1, Q3	75.0, 90.0	65.0, 100.0		
Min, Max	5, 100	30, 100		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	75.6 (28.3)	67.5 (21.9)	2.8 (3.5)	-7.5 (9.0)
Median	85.0	65.0	5.0	0
IQR: Q1, Q3	70.0, 90.0	50.0, 90.0	0.0, 5.0	-10.0, 5.0
Min, Max	5, 100	40, 95	-20, 20	-50, 10
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	77.9 (24.3)	76.7 (24.4)	3.6 (4.5)	1.7 (5.3)
Median	80.0	82.5	5.0	2.5
IQR: Q1, Q3	65.0, 95.0	50.0, 100.0	0.0, 5.0	0.0, 5.0
Min, Max	30, 100	45, 100	-15, 25	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Role Physical				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	76.41 (31.83)	67.72 (36.30)		
Median	93.80	75.00		
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00		
Min, Max	6.3, 100.0	6.3, 100.0		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	80.58 (26.22)	71.88 (22.95)	4.17 (5.71)	4.17 (9.50)
Median	93.80	75.00	6.20	0
IQR: Q1, Q3	75.00, 93.80	50.00, 87.50	-6.20, 12.50	-12.50, 25.00
Min, Max	18.8, 100.0	43.8, 100.0	-25.0, 31.3	-25.0, 37.5
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	78.59 (20.36)	72.92 (30.02)	0.89 (12.08)	5.20 (12.54)
Median	75.00	75.00	0	0
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	-25.00, 18.70	-12.50, 37.50
Min, Max	50.0, 100.0	37.5, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Bodily Pain				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	55.6 (29.7)	60.8 (22.0)		
Median	62.0	57.5		
IQR: Q1, Q3	62.0, 74.0	41.0, 84.0		
Min, Max	0, 84	41, 84		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	67.2 (27.1)	56.7 (35.4)	11.7 (13.2)	-4.2 (10.6)
Median	72.0	67.0	10.0	-4.5
IQR: Q1, Q3	62.0, 84.0	32.0, 74.0	0.0, 22.0	-22.0, 16.0
Min, Max	22, 100	0, 100	-43, 100	-41, 31
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	67.1 (27.7)	67.0 (27.1)	18.3 (13.9)	6.2 (13.2)
Median	62.0	73.0	26.0	13.0
IQR: Q1, Q3	50.0, 100.0	41.0, 84.0	-10.0, 50.0	0.0, 21.0
Min, Max	22, 100	31, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
General Health				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	64.3 (16.2)	60.5 (17.2)		
Median	62.0	69.5		
IQR: Q1, Q3	57.0, 72.0	50.0, 72.0		
Min, Max	35, 92	30, 72		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	58.8 (12.2)	63.8 (23.4)	-5.6 (3.2)	3.3 (5.4)
Median	60.0	69.5	0	0
IQR: Q1, Q3	57.0, 67.0	45.0, 72.0	-10.0, 0.0	-5.0, 0.0
Min, Max	35, 77	30, 97	-25, 5	-5, 30
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	66.1 (24.0)	67.2 (26.5)	5.4 (8.8)	6.7 (5.7)
Median	72.0	69.5	0	1.0
IQR: Q1, Q3	45.0, 82.0	52.0, 87.0	-10.0, 20.0	-5.0, 20.0
Min, Max	35, 100	25, 100	-25, 48	-5, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Vitality				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	64.61 (21.19)	58.35 (20.80)		
Median	68.80	50.00		
IQR: Q1, Q3	56.30, 75.00	43.80, 81.30		
Min, Max	31.3, 100.0	37.5, 87.5		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	59.76 (21.21)	60.43 (18.82)	-4.86 (6.65)	2.08 (2.07)
Median	56.30	50.00	0	3.10
IQR: Q1, Q3	43.80, 68.80	50.00, 81.30	-12.50, 6.30	0.00, 6.20
Min, Max	31.3, 100.0	43.8, 87.5	-37.5, 25.0	-6.2, 6.3
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	65.21 (20.99)	68.77 (19.35)	0.90 (5.00)	10.42 (7.68)
Median	68.80	68.75	0	15.60
IQR: Q1, Q3	43.80, 81.30	56.30, 75.00	0.00, 6.30	6.30, 25.00
Min, Max	43.8, 100.0	43.8, 100.0	-25.0, 18.7	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Social Functioning				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	83.33 (24.21)	83.33 (25.82)		
Median	100.00	100.00		
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00		
Min, Max	37.5, 100.0	50.0, 100.0		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	83.33 (18.75)	75.00 (27.39)	0.00 (6.25)	-8.33 (8.33)
Median	87.50	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 12.50	0.00, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	-25.0, 25.0	-50.0, 0.0
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	75.00 (29.76)	81.25 (22.01)	-10.71 (16.01)	-2.08 (8.18)
Median	87.50	87.50	0	0
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	-37.50, 25.00	0.00, 0.00
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Role Emotional				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	76.86 (33.54)	84.72 (26.06)		
Median	91.70	95.85		
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00		
Min, Max	0.0, 100.0	33.3, 100.0		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	84.28 (27.45)	81.95 (23.80)	7.42 (4.04)	-2.77 (3.52)
Median	91.70	91.65	8.30	0
IQR: Q1, Q3	91.70, 100.00	66.70, 100.00	0.00, 16.70	-8.40, 0.00
Min, Max	16.7, 100.0	41.7, 100.0	-8.3, 25.0	-16.6, 8.4
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	76.19 (20.65)	79.17 (33.23)	-1.20 (12.26)	-5.55 (5.95)
Median	75.00	100.00	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-25.00, 25.00	-8.30, 0.00
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 50.0	-33.3, 8.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Mental Health				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	77.50 (15.21)	76.67 (21.60)		
Median	80.00	85.00		
IQR: Q1, Q3	80.00, 87.50	55.00, 90.00		
Min, Max	45.0, 90.0	45.0, 100.0		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	75.00 (11.99)	68.33 (33.12)	-2.50 (3.06)	-8.33 (9.19)
Median	80.00	70.00	0	-5.00
IQR: Q1, Q3	65.00, 80.00	35.00, 100.00	-5.00, 0.00	-10.00, 5.00
Min, Max	55.0, 90.0	35.0, 100.0	-20.0, 15.0	-50.0, 15.0
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	73.57 (23.58)	84.17 (22.89)	-4.64 (6.23)	7.50 (3.35)
Median	80.00	97.50	-7.50	10.00
IQR: Q1, Q3	50.00, 90.00	60.00, 100.00	-15.00, 10.00	0.00, 15.00
Min, Max	35.0, 100.0	50.0, 100.0	-30.0, 20.0	-5.0, 15.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Mental Component Score				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	51.97 (9.77)	52.50 (10.39)		
Median	55.70	55.50		
IQR: Q1, Q3	49.80, 57.90	43.00, 58.30		
Min, Max	32.2, 62.3	37.4, 65.3		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	51.29 (6.71)	49.82 (13.42)	-0.68 (1.74)	-2.68 (2.84)
Median	52.60	48.70	-1.10	-0.75
IQR: Q1, Q3	48.70, 53.50	37.90, 61.30	-4.80, 1.20	-3.60, 0.80
Min, Max	41.1, 61.2	36.2, 66.1	-6.5, 9.9	-15.9, 4.1
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	49.00 (8.46)	53.68 (12.33)	-3.57 (3.37)	1.18 (1.80)
Median	52.10	59.95	-5.80	2.35
IQR: Q1, Q3	39.30, 56.50	39.30, 62.30	-8.10, 7.00	-1.30, 5.00
Min, Max	37.5, 56.8	36.6, 64.0	-18.2, 7.1	-6.4, 5.1

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=6)	MGL-3196 (N=9)	Placebo (N=6)
Physical Component Score				
Baseline				
m	9	6		
n	9	6		
Mean (SD)	46.61 (8.55)	45.47 (7.75)		
Median	49.80	46.85		
IQR: Q1, Q3	44.00, 51.70	38.70, 50.70		
Min, Max	27.0, 54.5	34.3, 55.4		
Week 12				
m	9	6		
n	9	6		
Mean (SD/SE)	48.04 (8.65)	45.88 (8.90)	1.43 (1.33)	0.42 (1.36)
Median	50.20	45.60	1.00	1.00
IQR: Q1, Q3	49.10, 53.30	38.50, 51.60	0.10, 3.50	-0.20, 3.20
Min, Max	27.2, 54.8	35.4, 58.6	-4.9, 7.0	-5.8, 3.3
Week 36				
m	7	6		
n	7	6		
Mean (SD/SE)	49.97 (6.39)	47.72 (10.63)	4.37 (3.05)	2.25 (3.79)
Median	52.90	48.80	4.80	4.50
IQR: Q1, Q3	42.90, 55.30	40.70, 58.10	0.00, 10.80	2.00, 7.40
Min, Max	40.6, 56.5	31.5, 58.4	-9.6, 15.9	-15.6, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Physical Functioning				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	71.5 (26.7)	67.8 (25.8)		
Median	77.5	70.0		
IQR: Q1, Q3	75.0, 85.0	55.0, 95.0		
Min, Max	5, 100	30, 95		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	76.5 (26.5)	72.8 (31.1)	5.0 (2.5)	5.0 (6.1)
Median	82.5	85.0	2.5	5.0
IQR: Q1, Q3	75.0, 90.0	70.0, 85.0	0.0, 10.0	-10.0, 10.0
Min, Max	5, 95	5, 100	-5, 20	-25, 30
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	77.5 (21.9)	75.0 (20.9)	5.0 (3.9)	2.5 (4.9)
Median	82.5	80.0	5.0	0
IQR: Q1, Q3	72.5, 90.0	55.0, 95.0	2.5, 7.5	-5.0, 15.0
Min, Max	30, 100	45, 95	-15, 25	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Role Physical				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	76.90 (30.05)	61.81 (40.07)		
Median	87.55	87.50		
IQR: Q1, Q3	62.50, 100.00	12.50, 87.50		
Min, Max	6.3, 100.0	6.3, 100.0		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	84.41 (23.39)	64.60 (23.99)	7.51 (3.82)	2.79 (8.97)
Median	93.80	62.50	6.25	12.50
IQR: Q1, Q3	93.80, 93.80	50.00, 75.00	0.00, 12.50	-25.00, 18.80
Min, Max	18.8, 100.0	31.3, 100.0	-6.2, 31.3	-31.2, 37.5
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	82.05 (19.60)	71.88 (24.78)	3.90 (10.02)	3.90 (10.08)
Median	90.65	62.50	6.25	6.25
IQR: Q1, Q3	65.65, 96.90	50.00, 100.00	-6.25, 15.60	-18.75, 25.00
Min, Max	50.0, 100.0	50.0, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Bodily Pain				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	61.5 (24.0)	72.4 (22.7)		
Median	62.0	74.0		
IQR: Q1, Q3	61.0, 84.0	54.0, 84.0		
Min, Max	10, 84	41, 100		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	65.2 (23.8)	63.6 (30.0)	3.7 (7.2)	-8.9 (8.9)
Median	67.0	62.0	11.0	-22.0
IQR: Q1, Q3	61.0, 84.0	51.0, 74.0	-10.0, 22.0	-28.0, 8.0
Min, Max	22, 100	0, 100	-43, 29	-41, 33
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	65.6 (27.2)	73.4 (21.9)	8.5 (11.7)	-1.4 (8.9)
Median	68.0	74.0	8.0	0
IQR: Q1, Q3	46.5, 87.0	67.0, 87.0	-14.5, 28.5	-6.0, 10.5
Min, Max	22, 100	31, 100	-40, 64	-53, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
General Health				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	61.2 (16.5)	68.0 (15.8)		
Median	59.5	77.0		
IQR: Q1, Q3	50.0, 72.0	50.0, 80.0		
Min, Max	35, 92	45, 82		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	59.9 (14.2)	61.6 (17.6)	-1.3 (5.2)	-6.4 (2.6)
Median	63.5	67.0	-4.0	-5.0
IQR: Q1, Q3	47.0, 67.0	45.0, 72.0	-10.0, 0.0	-10.0, -5.0
Min, Max	35, 82	35, 82	-25, 35	-23, 5
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	57.3 (16.0)	66.1 (14.9)	0.0 (6.2)	-4.8 (4.2)
Median	56.0	62.0	-2.5	-2.5
IQR: Q1, Q3	45.0, 72.0	53.5, 77.0	-10.0, 10.0	-15.0, 3.5
Min, Max	35, 77	52, 92	-25, 30	-22, 12

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Vitality				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	60.04 (15.92)	59.06 (21.45)		
Median	62.55	62.50		
IQR: Q1, Q3	56.30, 68.80	43.80, 68.80		
Min, Max	31.3, 81.3	25.0, 87.5		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	57.52 (18.34)	54.89 (16.48)	-2.52 (7.91)	-4.17 (4.53)
Median	53.15	56.30	-0.05	-6.20
IQR: Q1, Q3	43.80, 62.50	50.00, 56.30	-31.20, 18.70	-12.50, 6.20
Min, Max	31.3, 87.5	25.0, 81.3	-37.5, 31.2	-25.0, 18.7
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	60.96 (13.25)	60.96 (11.47)	2.33 (5.27)	-2.35 (6.78)
Median	65.65	59.40	6.20	0
IQR: Q1, Q3	46.90, 71.90	50.00, 68.80	-6.25, 12.50	-18.75, 15.60
Min, Max	43.8, 75.0	50.0, 81.3	-25.0, 18.7	-31.3, 18.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Social Functioning				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	85.00 (23.42)	77.78 (24.83)		
Median	100.00	87.50		
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	86.25 (18.11)	76.39 (28.26)	1.25 (5.09)	-1.39 (3.87)
Median	93.75	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 12.50	0.00, 0.00
Min, Max	50.0, 100.0	37.5, 100.0	-25.0, 25.0	-25.0, 12.5
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	81.25 (18.90)	84.38 (17.36)	-6.25 (11.08)	4.69 (7.06)
Median	81.25	87.50	-12.50	6.25
IQR: Q1, Q3	68.75, 100.00	68.75, 100.00	-31.25, 12.50	0.00, 18.75
Min, Max	50.0, 100.0	62.5, 100.0	-37.5, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Role Emotional				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	78.33 (32.20)	66.67 (35.60)		
Median	91.65	75.00		
IQR: Q1, Q3	75.00, 100.00	33.30, 100.00		
Min, Max	0.0, 100.0	16.7, 100.0		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	85.85 (26.36)	75.00 (26.35)	7.52 (3.82)	8.33 (5.38)
Median	95.85	83.30	8.35	0
IQR: Q1, Q3	91.70, 100.00	50.00, 100.00	0.00, 16.70	0.00, 25.00
Min, Max	16.7, 100.0	41.7, 100.0	-8.3, 25.0	-16.7, 33.3
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	80.21 (21.34)	76.04 (29.02)	1.05 (10.14)	3.13 (5.88)
Median	83.35	87.50	0	0
IQR: Q1, Q3	62.50, 100.00	54.15, 100.00	-8.30, 12.50	-4.15, 16.65
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 50.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Mental Health				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	81.50 (17.49)	63.33 (27.84)		
Median	82.50	55.00		
IQR: Q1, Q3	80.00, 95.00	45.00, 90.00		
Min, Max	45.0, 100.0	30.0, 100.0		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	79.50 (14.99)	66.11 (25.10)	-2.00 (3.35)	2.78 (4.26)
Median	82.50	70.00	-2.50	0
IQR: Q1, Q3	65.00, 90.00	50.00, 90.00	-5.00, 5.00	0.00, 5.00
Min, Max	55.0, 100.0	30.0, 100.0	-20.0, 15.0	-15.0, 25.0
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	75.63 (23.37)	79.38 (19.90)	-7.50 (4.82)	11.88 (4.72)
Median	80.00	85.00	-5.00	7.50
IQR: Q1, Q3	60.00, 95.00	60.00, 97.50	-17.50, 2.50	2.50, 17.50
Min, Max	35.0, 100.0	50.0, 100.0	-30.0, 10.0	0.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Mental Component Score				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	52.79 (9.53)	45.69 (13.60)		
Median	56.50	44.90		
IQR: Q1, Q3	49.80, 59.20	37.40, 57.00		
Min, Max	32.2, 60.9	26.9, 65.3		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	52.60 (7.46)	47.12 (12.73)	-0.19 (1.74)	1.43 (1.46)
Median	53.00	51.10	0.80	2.20
IQR: Q1, Q3	48.70, 59.30	34.40, 57.00	-5.20, 3.70	-1.20, 4.50
Min, Max	41.1, 63.1	33.6, 66.1	-7.5, 9.9	-4.8, 7.5
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	50.46 (8.83)	51.30 (10.60)	-3.06 (2.91)	3.54 (1.65)
Median	53.55	56.00	-2.60	2.25
IQR: Q1, Q3	41.85, 57.90	40.20, 58.70	-7.10, 3.00	0.20, 6.60
Min, Max	37.5, 59.6	36.6, 64.0	-18.2, 7.1	-1.3, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=9)	MGL-3196 (N=10)	Placebo (N=9)
Physical Component Score				
Baseline				
m	10	9		
n	10	9		
Mean (SD)	46.20 (8.01)	48.94 (8.90)		
Median	46.65	53.90		
IQR: Q1, Q3	43.50, 51.70	41.10, 55.60		
Min, Max	27.0, 54.6	34.3, 59.2		
Week 12				
m	10	9		
n	10	9	10	9
Mean (SD/SE)	47.87 (8.30)	47.18 (8.71)	1.67 (1.11)	-1.77 (1.94)
Median	49.90	47.60	2.65	-4.40
IQR: Q1, Q3	46.90, 51.90	41.30, 54.10	0.20, 4.40	-5.80, 2.50
Min, Max	27.2, 56.8	34.5, 58.6	-4.9, 6.2	-8.0, 9.1
Week 36				
m	8	9		
n	8	8	8	8
Mean (SD/SE)	48.45 (6.00)	48.68 (7.64)	3.24 (2.51)	-1.53 (2.94)
Median	47.75	50.35	4.00	-2.45
IQR: Q1, Q3	43.25, 54.25	47.35, 53.60	0.40, 5.40	-5.20, 4.00
Min, Max	40.6, 56.5	31.5, 55.3	-9.6, 15.9	-15.6, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Physical Functioning				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	75.0 (25.8)	70.0 (32.4)		
Median	80.0	80.0		
IQR: Q1, Q3	45.0, 100.0	40.0, 100.0		
Min, Max	35, 100	10, 100		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	65.7 (30.9)	77.0 (19.7)	-9.3 (4.8)	7.0 (10.5)
Median	70.0	80.0	-5.0	0
IQR: Q1, Q3	30.0, 100.0	60.0, 95.0	-20.0, 0.0	-5.0, 15.0
Min, Max	30, 100	50, 100	-30, 5	-50, 70
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	77.1 (24.6)	80.5 (29.8)	2.1 (7.1)	10.5 (6.9)
Median	80.0	92.5	0	5.0
IQR: Q1, Q3	55.0, 100.0	75.0, 100.0	-10.0, 5.0	0.0, 5.0
Min, Max	35, 100	5, 100	-20, 40	-5, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Role Physical				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	72.34 (40.32)	65.01 (35.62)		
Median	93.80	68.75		
IQR: Q1, Q3	31.30, 100.00	50.00, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	68.76 (31.66)	70.01 (31.98)	-3.59 (6.66)	5.00 (4.73)
Median	75.00	84.40	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	-25.00, 12.50	0.00, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-25.0, 18.7	-12.5, 31.2
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	76.80 (21.87)	70.64 (34.49)	4.46 (11.31)	5.63 (6.00)
Median	75.00	81.30	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-25.00, 37.50	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-31.3, 50.0	-25.0, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Bodily Pain				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	50.0 (34.7)	63.6 (35.6)		
Median	51.0	74.0		
IQR: Q1, Q3	22.0, 74.0	41.0, 100.0		
Min, Max	0, 100	0, 100		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	70.9 (30.9)	67.1 (35.0)	20.9 (14.3)	3.5 (4.7)
Median	72.0	73.0	0	0
IQR: Q1, Q3	51.0, 100.0	41.0, 100.0	0.0, 29.0	0.0, 16.0
Min, Max	22, 100	0, 100	-9, 100	-22, 31
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	65.1 (25.3)	62.3 (36.1)	15.1 (9.1)	-1.3 (7.9)
Median	62.0	67.5	10.0	0
IQR: Q1, Q3	41.0, 100.0	41.0, 100.0	-10.0, 40.0	0.0, 10.0
Min, Max	41, 100	0, 100	-10, 50	-49, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
General Health				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	58.6 (19.0)	60.1 (19.5)		
Median	62.0	62.0		
IQR: Q1, Q3	40.0, 77.0	47.0, 72.0		
Min, Max	30, 82	30, 92		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	59.0 (18.5)	64.2 (22.7)	0.4 (3.2)	4.1 (4.0)
Median	57.0	72.0	0	0
IQR: Q1, Q3	55.0, 77.0	47.0, 80.0	-5.0, 5.0	-5.0, 8.0
Min, Max	25, 82	30, 97	-12, 15	-12, 30
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	72.9 (20.1)	64.5 (28.0)	14.3 (7.0)	4.4 (4.9)
Median	77.0	72.0	5.0	0
IQR: Q1, Q3	67.0, 82.0	40.0, 87.0	0.0, 27.0	-5.0, 20.0
Min, Max	35, 100	25, 100	-5, 48	-17, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Vitality				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	64.31 (23.29)	49.40 (20.94)		
Median	62.50	50.00		
IQR: Q1, Q3	43.80, 81.30	37.50, 56.30		
Min, Max	31.3, 100.0	12.5, 81.3		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	66.09 (22.79)	53.15 (25.21)	1.77 (4.25)	3.75 (5.53)
Median	68.80	50.00	0	6.20
IQR: Q1, Q3	37.50, 81.30	43.80, 68.80	0.00, 6.30	0.00, 6.30
Min, Max	37.5, 100.0	0.0, 87.5	-18.8, 18.7	-31.3, 31.3
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	66.10 (27.69)	56.27 (32.93)	1.79 (8.38)	6.87 (7.07)
Median	68.80	56.30	6.30	18.70
IQR: Q1, Q3	56.30, 81.30	31.30, 75.00	0.00, 18.70	-6.20, 25.00
Min, Max	12.5, 100.0	0.0, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Social Functioning				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	83.93 (20.04)	76.25 (27.29)		
Median	87.50	87.50		
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	76.79 (29.25)	68.75 (33.98)	-7.14 (5.36)	-7.50 (7.26)
Median	87.50	68.75	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-25.00, 0.00	-25.00, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 12.5	-50.0, 25.0
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	78.57 (26.73)	71.25 (33.36)	-5.36 (12.46)	-5.00 (5.95)
Median	75.00	81.25	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 12.50	-25.00, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Role Emotional				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	84.53 (23.78)	71.67 (34.07)		
Median	100.00	87.50		
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	78.57 (39.34)	74.17 (31.04)	-5.96 (7.43)	2.50 (4.82)
Median	100.00	83.30	0	0
IQR: Q1, Q3	50.00, 100.00	66.70, 100.00	0.00, 0.00	-8.40, 0.00
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 8.3	-16.6, 33.4
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	86.90 (12.60)	71.67 (32.20)	2.37 (6.74)	0.00 (6.33)
Median	83.30	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-8.40, 25.00	0.00, 8.30
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 25.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Mental Health				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	77.50 (12.83)	64.50 (18.77)		
Median	80.00	60.00		
IQR: Q1, Q3	65.00, 87.50	45.00, 85.00		
Min, Max	55.0, 90.0	45.0, 90.0		
Week 12				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	77.86 (13.18)	63.50 (28.09)	0.36 (4.10)	-1.00 (7.06)
Median	80.00	60.00	0	10.00
IQR: Q1, Q3	75.00, 85.00	45.00, 95.00	-7.50, 5.00	-10.00, 15.00
Min, Max	50.0, 90.0	15.0, 100.0	-15.0, 20.0	-50.0, 15.0
Week 36				
m	7	10		
n	7	10	7	10
Mean (SD/SE)	82.86 (10.75)	61.50 (30.65)	5.36 (6.04)	-3.00 (6.24)
Median	80.00	57.50	5.00	5.00
IQR: Q1, Q3	80.00, 90.00	50.00, 95.00	-7.50, 20.00	-20.00, 10.00
Min, Max	65.0, 100.0	0.0, 100.0	-20.0, 25.0	-45.0, 15.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Mental Component Score				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	53.64 (8.38)	45.72 (11.39)		
Median	57.60	45.15		
IQR: Q1, Q3	43.60, 60.30	34.20, 57.20		
Min, Max	40.7, 62.3	31.9, 61.2		
Week 12				
m	7	10		
n	7	10		
Mean (SD/SE)	52.23 (11.50)	44.54 (14.12)	-1.41 (2.11)	-1.18 (3.14)
Median	55.70	43.60	0.30	0.15
IQR: Q1, Q3	47.80, 60.60	39.40, 58.00	-4.80, 2.60	-3.60, 4.10
Min, Max	28.4, 61.2	12.9, 61.3	-12.3, 4.2	-19.5, 11.3
Week 36				
m	7	10		
n	7	10		
Mean (SD/SE)	53.96 (2.49)	44.04 (15.21)	0.31 (3.01)	-1.68 (3.26)
Median	53.70	43.95	-1.20	0
IQR: Q1, Q3	51.50, 56.50	35.10, 58.80	-5.80, 7.40	-9.20, 5.10
Min, Max	51.0, 56.5	13.9, 62.3	-8.8, 13.0	-18.5, 11.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=10)	MGL-3196 (N=7)	Placebo (N=10)
Physical Component Score				
Baseline				
m	7	10		
n	7	10		
Mean (SD)	44.44 (10.43)	46.98 (10.73)		
Median	42.10	49.70		
IQR: Q1, Q3	35.20, 54.40	38.70, 55.40		
Min, Max	32.1, 59.8	25.8, 60.5		
Week 12				
m	7	10		
n	7	10		
Mean (SD/SE)	45.70 (11.17)	49.66 (8.62)	1.26 (1.67)	2.68 (1.61)
Median	49.10	50.75	0.10	2.20
IQR: Q1, Q3	37.20, 54.50	43.30, 58.00	-0.60, 5.10	-0.20, 7.80
Min, Max	28.8, 59.2	36.5, 58.6	-6.4, 7.0	-5.8, 10.7
Week 36				
m	7	10		
n	7	10		
Mean (SD/SE)	48.23 (10.17)	50.21 (11.67)	3.79 (2.63)	3.23 (1.63)
Median	52.90	53.75	0.90	2.45
IQR: Q1, Q3	38.60, 55.30	40.70, 58.40	-1.10, 10.80	0.20, 6.00
Min, Max	30.7, 58.7	28.7, 64.5	-4.5, 14.9	-2.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Physical Functioning				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	83.8 (11.1)	72.5 (30.5)		
Median	80.0	85.0		
IQR: Q1, Q3	77.5, 90.0	40.0, 95.0		
Min, Max	75, 100	30, 100		
Week 12				
m	4	6		
n	4	6	4	6
Mean (SD/SE)	83.8 (8.5)	68.3 (33.9)	0.0 (2.0)	-4.2 (6.0)
Median	82.5	85.0	0	-7.5
IQR: Q1, Q3	77.5, 90.0	55.0, 85.0	-2.5, 2.5	-10.0, 10.0
Min, Max	75, 95	5, 95	-5, 5	-25, 15
Week 36				
m	4	6		
n	4	5	4	5
Mean (SD/SE)	86.3 (9.5)	87.0 (16.0)	2.5 (1.4)	6.0 (4.0)
Median	82.5	95.0	2.5	0
IQR: Q1, Q3	80.0, 92.5	85.0, 95.0	0.0, 5.0	0.0, 10.0
Min, Max	80, 100	60, 100	0, 5	0, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Role Physical				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	93.78 (8.82)	64.60 (40.44)		
Median	96.90	78.15		
IQR: Q1, Q3	87.55, 100.00	18.80, 100.00		
Min, Max	81.3, 100.0	12.5, 100.0		
Week 12				
m	4	6		
n	4	6	4	6
Mean (SD/SE)	93.78 (5.10)	59.40 (18.86)	0.00 (5.10)	-5.20 (10.13)
Median	93.80	59.40	0	-12.50
IQR: Q1, Q3	90.65, 96.90	50.00, 75.00	-6.25, 6.25	-25.00, 18.80
Min, Max	87.5, 100.0	31.3, 81.3	-12.5, 12.5	-31.2, 31.2
Week 36				
m	4	6		
n	4	5	4	5
Mean (SD/SE)	89.08 (10.68)	68.76 (20.73)	-4.70 (7.81)	-6.26 (10.45)
Median	90.65	68.80	-3.15	-12.50
IQR: Q1, Q3	81.25, 96.90	50.00, 75.00	-15.65, 6.25	-25.00, 0.00
Min, Max	75.0, 100.0	50.0, 100.0	-25.0, 12.5	-25.0, 31.2

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Bodily Pain				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	62.8 (22.6)	68.0 (27.1)		
Median	67.5	74.0		
IQR: Q1, Q3	46.5, 79.0	54.0, 84.0		
Min, Max	32, 84	22, 100		
Week 12				
m	4	6		
n	4	6	4	6
Mean (SD/SE)	86.3 (18.4)	67.5 (26.0)	23.5 (2.8)	-0.5 (9.5)
Median	92.0	56.5	24.5	4.0
IQR: Q1, Q3	72.5, 100.0	51.0, 100.0	19.5, 27.5	-23.0, 19.0
Min, Max	61, 100	41, 100	16, 29	-33, 26
Week 36				
m	4	6		
n	4	5	4	5
Mean (SD/SE)	73.3 (31.1)	68.4 (28.4)	10.5 (10.1)	-2.4 (1.9)
Median	75.5	74.0	17.5	0
IQR: Q1, Q3	46.5, 100.0	72.0, 74.0	-1.5, 22.5	-2.0, 0.0
Min, Max	42, 100	22, 100	-19, 26	-10, 0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
General Health				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	59.8 (11.4)	70.0 (15.4)		
Median	57.0	77.0		
IQR: Q1, Q3	51.0, 68.5	57.0, 82.0		
Min, Max	50, 75	45, 82		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	61.5 (11.7)	70.0 (17.7)	1.8 (4.5)	0.0 (4.7)
Median	64.5	74.5	-1.5	-2.5
IQR: Q1, Q3	53.5, 69.5	72.0, 82.0	-4.0, 7.5	-10.0, 5.0
Min, Max	45, 72	35, 82	-5, 15	-10, 20
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	66.0 (15.6)	64.2 (16.6)	6.3 (8.0)	-10.8 (4.0)
Median	68.5	72.0	7.5	-10.0
IQR: Q1, Q3	55.0, 77.0	55.0, 72.0	-7.5, 20.0	-17.0, -5.0
Min, Max	45, 82	40, 82	-10, 20	-22, 0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Vitality				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	67.23 (10.68)	47.93 (23.29)		
Median	65.65	59.40		
IQR: Q1, Q3	59.40, 75.05	25.00, 62.50		
Min, Max	56.3, 81.3	12.5, 68.8		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	67.20 (15.63)	44.83 (11.49)	-0.03 (10.83)	-3.10 (7.35)
Median	65.65	43.80	6.25	-9.35
IQR: Q1, Q3	56.25, 78.15	43.80, 56.30	-12.55, 12.50	-12.50, 0.00
Min, Max	50.0, 87.5	25.0, 56.3	-31.3, 18.7	-18.7, 31.3
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	68.78 (5.10)	51.28 (23.98)	1.55 (4.68)	-1.24 (9.58)
Median	68.80	50.00	6.20	0
IQR: Q1, Q3	65.65, 71.90	31.30, 68.80	-3.15, 6.25	-12.50, 18.80
Min, Max	62.5, 75.0	25.0, 81.3	-12.5, 6.3	-31.3, 18.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Social Functioning				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	100.00 (0.00)	77.08 (26.71)		
Median	100.00	81.25		
IQR: Q1, Q3	100.00, 100.00	62.50, 100.00		
Min, Max	100.0, 100.0	37.5, 100.0		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	90.63 (11.97)	72.92 (30.02)	-9.38 (5.98)	-4.17 (5.27)
Median	93.75	75.00	-6.25	0
IQR: Q1, Q3	81.25, 100.00	50.00, 100.00	-18.75, 0.00	-12.50, 0.00
Min, Max	75.0, 100.0	37.5, 100.0	-25.0, 0.0	-25.0, 12.5
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	93.75 (12.50)	80.00 (20.92)	-6.25 (6.25)	0.00 (6.85)
Median	100.00	75.00	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 12.50
Min, Max	75.0, 100.0	50.0, 100.0	-25.0, 0.0	-25.0, 12.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Role Emotional				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	95.83 (8.35)	65.28 (36.67)		
Median	100.00	70.85		
IQR: Q1, Q3	91.65, 100.00	33.30, 100.00		
Min, Max	83.3, 100.0	16.7, 100.0		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	100.00 (0.00)	72.22 (20.18)	4.18 (4.18)	6.93 (8.73)
Median	100.00	75.00	0	0
IQR: Q1, Q3	100.00, 100.00	50.00, 83.30	0.00, 8.35	-8.40, 33.30
Min, Max	100.0, 100.0	50.0, 100.0	0.0, 16.7	-16.7, 33.4
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	85.43 (12.51)	75.00 (15.59)	-10.40 (5.25)	0.00 (12.36)
Median	83.35	75.00	-8.30	0
IQR: Q1, Q3	75.00, 95.85	66.70, 75.00	-16.65, -4.15	-25.00, 8.30
Min, Max	75.0, 100.0	58.3, 100.0	-25.0, 0.0	-25.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Mental Health				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	91.88 (9.87)	62.50 (24.24)		
Median	93.75	60.00		
IQR: Q1, Q3	83.75, 100.00	45.00, 90.00		
Min, Max	80.0, 100.0	30.0, 90.0		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	87.50 (6.45)	63.33 (21.13)	-4.38 (5.24)	0.83 (3.75)
Median	87.50	65.00	-6.25	0
IQR: Q1, Q3	82.50, 92.50	55.00, 75.00	-11.25, 2.50	0.00, 10.00
Min, Max	80.0, 95.0	30.0, 90.0	-15.0, 10.0	-15.0, 10.0
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	91.25 (10.31)	71.00 (24.85)	-0.63 (2.58)	2.00 (5.61)
Median	92.50	60.00	0	5.00
IQR: Q1, Q3	82.50, 100.00	55.00, 95.00	-3.75, 2.50	5.00, 10.00
Min, Max	80.0, 100.0	45.0, 100.0	-7.5, 5.0	-20.0, 10.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Mental Component Score				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	59.18 (1.84)	43.53 (12.30)		
Median	59.25	42.90		
IQR: Q1, Q3	57.60, 60.75	31.90, 57.00		
Min, Max	57.3, 60.9	29.1, 57.4		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	56.88 (4.30)	44.82 (10.38)	-2.30 (2.30)	1.28 (2.28)
Median	56.35	44.80	-1.85	1.40
IQR: Q1, Q3	53.25, 60.50	33.70, 52.80	-6.15, 1.55	-4.60, 4.50
Min, Max	53.1, 61.7	33.6, 59.2	-7.5, 2.0	-4.8, 9.8
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	56.18 (3.70)	46.72 (11.62)	-3.00 (1.05)	0.30 (4.14)
Median	56.50	42.40	-2.60	2.60
IQR: Q1, Q3	53.05, 59.30	41.10, 56.90	-4.55, -1.45	-0.50, 3.50
Min, Max	52.1, 59.6	32.7, 60.5	-5.8, -1.0	-14.6, 10.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=4)	Placebo (N=6)	MGL-3196 (N=4)	Placebo (N=6)
Physical Component Score				
Baseline				
m	4	6		
n	4	6		
Mean (SD)	47.78 (5.47)	49.78 (10.08)		
Median	46.65	54.10		
IQR: Q1, Q3	43.35, 52.20	38.90, 55.60		
Min, Max	43.2, 54.6	35.5, 60.5		
Week 12				
m	4	6		
n	4	6		
Mean (SD/SE)	51.15 (4.73)	47.72 (8.68)	3.38 (0.45)	-2.07 (2.53)
Median	50.45	47.05	3.45	-3.45
IQR: Q1, Q3	47.25, 55.05	43.30, 56.40	2.80, 3.95	-7.80, 2.50
Min, Max	46.9, 56.8	34.5, 58.0	2.2, 4.4	-8.0, 7.8
Week 36				
m	4	6		
n	4	5		
Mean (SD/SE)	50.63 (5.73)	50.30 (8.85)	2.85 (1.42)	-1.66 (1.15)
Median	51.80	50.90	2.90	-0.60
IQR: Q1, Q3	45.95, 55.30	49.80, 53.70	0.40, 5.30	-4.10, 0.20
Min, Max	43.6, 55.3	36.4, 60.7	0.1, 5.5	-4.7, 0.9

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Physical Functioning				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	69.6 (28.1)	67.3 (28.9)		
Median	75.0	70.0		
IQR: Q1, Q3	50.0, 90.0	55.0, 90.0		
Min, Max	5, 100	10, 100		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	68.5 (31.1)	78.1 (20.9)	-1.2 (3.8)	10.8 (8.2)
Median	80.0	85.0	0	5.0
IQR: Q1, Q3	45.0, 90.0	60.0, 95.0	-5.0, 5.0	-5.0, 30.0
Min, Max	5, 100	40, 100	-30, 20	-50, 70
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	74.1 (25.1)	74.6 (28.2)	4.1 (5.2)	7.3 (6.0)
Median	80.0	80.0	5.0	5.0
IQR: Q1, Q3	55.0, 95.0	60.0, 95.0	-10.0, 10.0	0.0, 5.0
Min, Max	30, 100	5, 100	-20, 40	-20, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Role Physical				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	69.25 (36.39)	62.98 (36.66)		
Median	81.30	75.00		
IQR: Q1, Q3	50.00, 100.00	50.00, 87.50		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	73.10 (30.87)	71.16 (31.10)	3.85 (4.61)	8.18 (5.07)
Median	93.80	87.50	6.20	0
IQR: Q1, Q3	56.30, 93.80	50.00, 100.00	-6.20, 12.50	0.00, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-25.0, 31.3	-25.0, 37.5
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	76.15 (21.98)	72.12 (33.23)	7.38 (9.45)	9.14 (6.15)
Median	75.00	93.80	0	6.30
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-6.20, 37.50	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Bodily Pain				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	54.9 (30.6)	67.7 (31.9)		
Median	62.0	74.0		
IQR: Q1, Q3	31.0, 74.0	41.0, 100.0		
Min, Max	0, 100	0, 100		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	61.8 (26.0)	64.5 (35.2)	6.8 (9.3)	-3.2 (6.0)
Median	62.0	72.0	0	0
IQR: Q1, Q3	51.0, 74.0	52.0, 100.0	-9.0, 12.0	-22.0, 0.0
Min, Max	22, 100	0, 100	-43, 100	-41, 33
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	62.5 (24.1)	66.8 (32.1)	12.0 (9.6)	-0.9 (8.0)
Median	62.0	74.0	0	0
IQR: Q1, Q3	41.0, 74.0	41.0, 100.0	-10.0, 40.0	0.0, 16.0
Min, Max	22, 100	0, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
General Health				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	60.2 (18.8)	61.0 (18.7)		
Median	62.0	67.0		
IQR: Q1, Q3	47.0, 72.0	47.0, 72.0		
Min, Max	30, 92	30, 92		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	58.9 (16.9)	59.7 (20.7)	-1.3 (4.1)	-1.3 (3.4)
Median	57.0	57.0	0	-5.0
IQR: Q1, Q3	55.0, 67.0	45.0, 72.0	-10.0, 0.0	-5.0, 0.0
Min, Max	25, 82	30, 97	-25, 35	-23, 30
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	64.0 (20.9)	65.6 (25.1)	6.8 (6.2)	4.6 (3.9)
Median	67.0	67.0	0	2.0
IQR: Q1, Q3	45.0, 77.0	52.0, 87.0	-5.0, 27.0	-5.0, 12.0
Min, Max	35, 100	25, 100	-25, 48	-20, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Vitality				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	60.13 (20.65)	56.76 (20.49)		
Median	56.30	50.00		
IQR: Q1, Q3	43.80, 75.00	43.80, 81.30		
Min, Max	31.3, 100.0	31.3, 87.5		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	59.15 (21.43)	58.19 (23.30)	-0.98 (5.69)	1.43 (4.25)
Median	56.30	56.30	0	6.20
IQR: Q1, Q3	43.80, 75.00	50.00, 75.00	-12.50, 12.50	0.00, 6.30
Min, Max	31.3, 100.0	0.0, 87.5	-37.5, 31.2	-31.3, 25.0
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	61.39 (23.85)	61.08 (26.04)	2.26 (6.21)	4.32 (5.94)
Median	62.50	62.50	6.30	12.50
IQR: Q1, Q3	43.80, 81.30	50.00, 75.00	0.00, 18.70	-6.20, 18.70
Min, Max	12.5, 100.0	0.0, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Social Functioning				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	79.81 (22.56)	76.92 (25.94)		
Median	87.50	87.50		
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	79.81 (25.28)	72.12 (32.34)	0.00 (4.48)	-4.81 (5.76)
Median	87.50	87.50	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-12.50, 12.50	0.00, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 25.0	-50.0, 25.0
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	75.00 (23.05)	75.96 (30.39)	-5.68 (10.84)	-0.96 (5.91)
Median	75.00	87.50	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	-37.50, 25.00	0.00, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Role Emotional				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	76.28 (30.97)	71.15 (33.96)		
Median	91.70	83.30		
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	77.58 (34.42)	75.65 (31.81)	1.29 (5.16)	4.49 (3.61)
Median	91.70	91.70	0	0
IQR: Q1, Q3	66.70, 100.00	50.00, 100.00	0.00, 16.70	0.00, 8.40
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 25.0	-16.6, 25.0
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	82.57 (19.53)	73.08 (34.55)	6.05 (7.71)	1.92 (4.02)
Median	83.30	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	0.00, 25.00	0.00, 8.30
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 50.0	-33.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Mental Health				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	76.15 (15.16)	64.62 (23.14)		
Median	80.00	55.00		
IQR: Q1, Q3	65.00, 85.00	45.00, 85.00		
Min, Max	45.0, 95.0	30.0, 100.0		
Week 12				
m	13	13		
n	13	13		
Mean (SD/SE)	76.15 (14.60)	65.38 (28.76)	0.00 (2.94)	0.77 (5.91)
Median	80.00	65.00	0	5.00
IQR: Q1, Q3	65.00, 85.00	45.00, 95.00	-5.00, 5.00	-10.00, 15.00
Min, Max	50.0, 100.0	15.0, 100.0	-20.0, 20.0	-50.0, 25.0
Week 36				
m	11	13		
n	11	13		
Mean (SD/SE)	74.55 (18.90)	68.85 (29.09)	-1.82 (5.53)	4.23 (5.71)
Median	80.00	60.00	0	10.00
IQR: Q1, Q3	65.00, 90.00	50.00, 95.00	-20.00, 15.00	0.00, 15.00
Min, Max	35.0, 100.0	0.0, 100.0	-30.0, 25.0	-45.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Mental Component Score				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	51.28 (9.32)	46.71 (12.41)		
Median	53.10	44.90		
IQR: Q1, Q3	43.60, 59.10	37.40, 57.20		
Min, Max	32.2, 62.3	26.9, 65.3		
Week 12				
m	13	13		
n	13	13		
Mean (SD/SE)	51.08 (9.74)	46.20 (14.65)	-0.20 (1.58)	-0.51 (2.40)
Median	52.60	45.50	0.50	0.80
IQR: Q1, Q3	47.80, 58.80	37.90, 58.00	-3.80, 3.70	-1.50, 4.10
Min, Max	28.4, 63.1	12.9, 66.1	-12.3, 9.9	-19.5, 11.3
Week 36				
m	11	13		
n	11	13		
Mean (SD/SE)	50.61 (7.04)	47.48 (14.61)	-0.94 (2.82)	0.77 (2.38)
Median	53.10	52.00	-1.20	1.90
IQR: Q1, Q3	44.40, 56.50	36.60, 58.80	-8.10, 7.10	-2.80, 5.10
Min, Max	37.5, 56.8	13.9, 64.0	-18.2, 13.0	-18.5, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=13)	Placebo (N=13)	MGL-3196 (N=13)	Placebo (N=13)
Physical Component Score				
Baseline				
m	13	13		
n	13	13		
Mean (SD)	44.77 (9.68)	47.05 (9.79)		
Median	45.80	49.70		
IQR: Q1, Q3	37.70, 51.70	41.10, 55.40		
Min, Max	27.0, 59.8	25.8, 59.2		
Week 12				
m	13	13		
n	13	13	13	13
Mean (SD/SE)	45.69 (10.13)	48.84 (8.77)	0.92 (1.16)	1.79 (1.49)
Median	49.60	50.20	0.20	1.20
IQR: Q1, Q3	37.80, 51.90	41.30, 57.90	-0.60, 4.40	-0.20, 3.30
Min, Max	27.2, 59.2	35.4, 58.6	-6.4, 7.0	-5.8, 10.7
Week 36				
m	11	13		
n	11	13	11	13
Mean (SD/SE)	47.52 (8.64)	49.23 (10.51)	3.73 (2.37)	2.18 (2.19)
Median	47.20	52.60	3.20	2.90
IQR: Q1, Q3	40.60, 54.40	45.00, 55.30	-1.10, 10.80	-2.30, 7.40
Min, Max	30.7, 58.7	28.7, 64.5	-9.6, 15.9	-15.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; NASH = Non-alcoholic steatohepatitis.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Physical Functioning				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	73.2 (20.8)	72.9 (23.4)		
Median	80.0	75.0		
IQR: Q1, Q3	50.0, 90.0	55.0, 95.0		
Min, Max	35, 100	30, 95		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	73.6 (23.6)	79.3 (19.5)	0.5 (3.3)	6.4 (4.8)
Median	80.0	85.0	0	5.0
IQR: Q1, Q3	70.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 10.0
Min, Max	30, 100	40, 100	-20, 20	-10, 30
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	78.3 (19.7)	81.4 (15.7)	3.9 (5.1)	8.6 (3.2)
Median	80.0	85.0	5.0	5.0
IQR: Q1, Q3	75.0, 95.0	75.0, 95.0	0.0, 5.0	0.0, 20.0
Min, Max	35, 100	50, 95	-15, 40	0, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Role Physical				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	79.57 (22.72)	54.47 (35.11)		
Median	81.30	62.50		
IQR: Q1, Q3	62.50, 100.00	12.50, 87.50		
Min, Max	31.3, 100.0	6.3, 100.0		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	82.41 (18.30)	64.30 (21.86)	2.84 (5.55)	9.83 (9.82)
Median	93.80	50.00	6.20	12.50
IQR: Q1, Q3	62.50, 93.80	50.00, 87.50	-12.50, 18.70	-12.50, 37.50
Min, Max	50.0, 100.0	43.8, 100.0	-25.0, 31.3	-31.2, 37.5
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	78.49 (19.80)	68.76 (23.10)	-2.79 (9.21)	14.29 (10.08)
Median	75.00	56.30	0	12.50
IQR: Q1, Q3	68.80, 93.80	50.00, 100.00	-25.00, 12.50	-12.50, 37.50
Min, Max	50.0, 100.0	50.0, 100.0	-50.0, 37.5	-25.0, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Bodily Pain				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	56.7 (24.8)	69.7 (21.7)		
Median	62.0	74.0		
IQR: Q1, Q3	51.0, 74.0	41.0, 84.0		
Min, Max	0, 84	41, 100		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	69.9 (21.4)	64.4 (34.6)	13.2 (10.9)	-5.3 (10.7)
Median	72.0	74.0	10.0	0
IQR: Q1, Q3	51.0, 84.0	51.0, 100.0	0.0, 26.0	-33.0, 26.0
Min, Max	31, 100	0, 100	-43, 100	-41, 33
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	60.1 (26.1)	72.7 (18.2)	8.3 (10.4)	3.0 (8.1)
Median	62.0	74.0	0	0
IQR: Q1, Q3	42.0, 62.0	62.0, 84.0	-10.0, 38.0	-10.0, 21.0
Min, Max	22, 100	41, 100	-40, 50	-33, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
General Health				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	60.4 (17.4)	65.3 (15.0)		
Median	62.0	72.0		
IQR: Q1, Q3	50.0, 72.0	50.0, 77.0		
Min, Max	30, 92	47, 82		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	56.3 (13.8)	61.7 (16.4)	-4.1 (3.1)	-3.6 (1.8)
Median	57.0	72.0	-5.0	-5.0
IQR: Q1, Q3	47.0, 67.0	45.0, 72.0	-10.0, 0.0	-5.0, 0.0
Min, Max	25, 77	42, 82	-25, 15	-10, 5
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	63.9 (22.0)	58.9 (9.2)	7.2 (7.2)	-6.4 (4.2)
Median	67.0	55.0	5.0	0
IQR: Q1, Q3	45.0, 82.0	52.0, 72.0	-5.0, 20.0	-20.0, 2.0
Min, Max	35, 100	52, 72	-25, 48	-22, 5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Vitality				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	65.37 (17.31)	53.60 (13.91)		
Median	68.80	50.00		
IQR: Q1, Q3	56.30, 75.00	43.80, 68.80		
Min, Max	37.5, 100.0	31.3, 68.8		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	61.95 (21.36)	54.49 (10.02)	-3.42 (6.15)	0.89 (4.80)
Median	62.50	50.00	0	6.20
IQR: Q1, Q3	43.80, 81.30	50.00, 56.30	-18.80, 18.70	-12.50, 6.30
Min, Max	31.3, 100.0	43.8, 75.0	-37.5, 25.0	-18.7, 18.7
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	61.83 (25.47)	58.96 (11.89)	-3.48 (6.35)	5.36 (5.17)
Median	68.80	56.30	0	0
IQR: Q1, Q3	43.80, 75.00	50.00, 68.80	0.00, 6.30	-6.20, 18.70
Min, Max	12.5, 100.0	43.8, 75.0	-43.8, 18.7	-12.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
 Protocol: MGL-3196-05

Page 6 of 20
 Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
 Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
 by Type 2 Diabetes
 (Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Social Functioning				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	87.50 (17.68)	73.21 (24.40)		
Median	100.00	75.00		
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	82.95 (18.77)	71.43 (26.73)	-4.55 (4.55)	-1.79 (5.05)
Median	87.50	50.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 0.00	-12.50, 12.50
Min, Max	50.0, 100.0	50.0, 100.0	-25.0, 25.0	-25.0, 12.5
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	76.39 (26.84)	80.36 (20.23)	-13.89 (10.30)	7.14 (6.60)
Median	75.00	75.00	0	12.50
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	-37.50, 0.00	0.00, 25.00
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 25.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Role Emotional				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	84.09 (19.53)	65.47 (33.49)		
Median	91.70	50.00		
IQR: Q1, Q3	75.00, 100.00	33.30, 100.00		
Min, Max	50.0, 100.0	25.0, 100.0		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	90.16 (16.59)	67.86 (25.64)	6.07 (3.39)	2.39 (4.72)
Median	100.00	50.00	0	0
IQR: Q1, Q3	91.70, 100.00	50.00, 100.00	0.00, 16.70	0.00, 8.40
Min, Max	50.0, 100.0	41.7, 100.0	-8.3, 25.0	-16.7, 25.0
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	81.48 (16.55)	65.47 (27.82)	-4.63 (7.75)	0.00 (5.75)
Median	75.00	58.30	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-8.40, 0.00	-8.30, 8.30
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 25.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Mental Health				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	81.14 (13.10)	63.57 (24.45)		
Median	85.00	55.00		
IQR: Q1, Q3	80.00, 90.00	45.00, 90.00		
Min, Max	55.0, 100.0	30.0, 90.0		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	79.09 (11.14)	66.43 (21.74)	-2.05 (2.84)	2.86 (4.74)
Median	80.00	65.00	0	5.00
IQR: Q1, Q3	75.00, 85.00	50.00, 90.00	-5.00, 0.00	-10.00, 15.00
Min, Max	55.0, 95.0	35.0, 95.0	-20.0, 20.0	-15.0, 20.0
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	80.56 (16.67)	72.14 (22.33)	-1.94 (6.09)	8.57 (2.83)
Median	80.00	60.00	0	10.00
IQR: Q1, Q3	70.00, 90.00	50.00, 100.00	-15.00, 10.00	0.00, 15.00
Min, Max	50.0, 100.0	50.0, 100.0	-30.0, 25.0	0.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Visit				
Statistic				
Mental Component Score				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	54.55 (7.17)	44.44 (12.25)		
Median	57.60	38.50		
IQR: Q1, Q3	49.80, 60.30	37.40, 57.40		
Min, Max	40.6, 62.3	26.9, 58.3		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	53.60 (6.51)	44.74 (10.85)	-0.95 (1.10)	0.30 (1.67)
Median	53.10	41.10	0.30	-0.30
IQR: Q1, Q3	48.70, 60.60	34.40, 57.00	-4.80, 1.20	-4.60, 3.20
Min, Max	41.1, 61.7	33.7, 58.0	-6.5, 4.2	-4.8, 7.5
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	51.76 (6.97)	46.53 (10.90)	-3.83 (2.68)	2.09 (1.47)
Median	52.10	41.10	-5.80	1.90
IQR: Q1, Q3	51.00, 56.50	36.60, 56.90	-8.10, -1.00	-0.50, 2.80
Min, Max	37.5, 59.6	35.1, 61.1	-18.2, 7.4	-2.8, 9.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=11)	Placebo (N=7)	MGL-3196 (N=11)	Placebo (N=7)
Physical Component Score				
Baseline				
m	11	7		
n	11	7		
Mean (SD)	45.75 (7.36)	48.19 (8.15)		
Median	45.80	49.70		
IQR: Q1, Q3	42.10, 51.70	41.10, 55.60		
Min, Max	32.1, 54.5	34.3, 56.1		
Week 12				
m	11	7		
n	11	7	11	7
Mean (SD/SE)	47.10 (8.02)	48.86 (7.77)	1.35 (1.36)	0.67 (2.19)
Median	49.60	49.90	3.10	2.50
IQR: Q1, Q3	42.50, 53.30	43.90, 56.40	-3.30, 5.10	-5.80, 3.30
Min, Max	28.8, 54.8	35.4, 58.6	-6.4, 7.0	-8.0, 9.1
Week 36				
m	9	7		
n	9	7	9	7
Mean (SD/SE)	47.58 (8.40)	50.06 (3.40)	2.80 (2.48)	1.87 (2.42)
Median	47.20	49.80	3.20	-0.80
IQR: Q1, Q3	43.60, 54.40	47.10, 52.60	0.00, 5.50	-4.10, 8.60
Min, Max	30.7, 56.5	45.0, 55.3	-9.6, 14.9	-4.7, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Physical Functioning				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	72.5 (35.0)	66.7 (32.1)		
Median	77.5	70.0		
IQR: Q1, Q3	75.0, 100.0	35.0, 97.5		
Min, Max	5, 100	10, 100		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	69.2 (37.1)	72.5 (28.4)	-3.3 (6.0)	5.8 (9.4)
Median	85.0	77.5	0	0
IQR: Q1, Q3	45.0, 95.0	57.5, 95.0	-5.0, 0.0	-10.0, 22.5
Min, Max	5, 100	5, 100	-30, 15	-50, 70
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	75.8 (27.8)	75.9 (30.9)	3.3 (6.0)	5.9 (7.1)
Median	85.0	95.0	2.5	0
IQR: Q1, Q3	55.0, 100.0	60.0, 100.0	0.0, 10.0	-5.0, 5.0
Min, Max	30, 100	5, 100	-20, 25	-20, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Role Physical				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	66.68 (49.31)	68.76 (38.15)		
Median	96.90	87.50		
IQR: Q1, Q3	6.30, 100.00	34.40, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	69.82 (22.10)	69.28 (31.58)	3.13 (3.12)	0.53 (5.07)
Median	93.80	78.15	0	0
IQR: Q1, Q3	18.80, 100.00	50.00, 96.90	0.00, 12.50	-12.50, 15.65
Min, Max	12.5, 100.0	0.0, 100.0	-6.2, 12.5	-25.0, 31.2
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	81.27 (22.36)	72.74 (34.27)	14.58 (11.26)	-1.14 (5.77)
Median	90.65	93.80	0	0
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	-6.20, 50.00	-12.50, 12.50
Min, Max	50.0, 100.0	0.0, 100.0	-6.3, 50.0	-37.5, 31.2

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Bodily Pain				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	56.8 (36.9)	66.7 (34.4)		
Median	58.0	79.0		
IQR: Q1, Q3	31.0, 84.0	41.0, 100.0		
Min, Max	10, 100	0, 100		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	63.2 (35.3)	66.0 (31.8)	6.3 (6.3)	-0.7 (5.2)
Median	67.5	67.0	6.0	0
IQR: Q1, Q3	22.0, 100.0	46.0, 100.0	-9.0, 16.0	-15.5, 12.0
Min, Max	22, 100	0, 100	-10, 29	-28, 31
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	73.3 (24.4)	63.7 (36.5)	16.5 (10.5)	-4.1 (8.1)
Median	74.0	72.0	13.0	0
IQR: Q1, Q3	51.0, 100.0	31.0, 100.0	0.0, 19.0	-2.0, 0.0
Min, Max	41, 100	0, 100	-10, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
General Health				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	59.7 (18.0)	63.0 (19.9)		
Median	59.5	69.5		
IQR: Q1, Q3	47.0, 75.0	46.0, 78.5		
Min, Max	35, 82	30, 92		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	65.5 (18.1)	63.7 (22.4)	5.8 (6.8)	0.7 (4.1)
Median	69.5	69.5	0	0
IQR: Q1, Q3	55.0, 82.0	45.0, 81.0	-3.0, 15.0	-7.5, 6.5
Min, Max	35, 82	30, 97	-12, 35	-23, 30
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	65.5 (15.7)	69.3 (27.7)	5.8 (6.4)	4.6 (4.5)
Median	69.5	72.0	0	0
IQR: Q1, Q3	65.0, 77.0	40.0, 92.0	-5.0, 20.0	-5.0, 20.0
Min, Max	35, 77	25, 100	-10, 30	-17, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Vitality				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	55.25 (21.06)	54.19 (25.06)		
Median	56.30	53.15		
IQR: Q1, Q3	31.30, 75.00	34.40, 81.30		
Min, Max	31.3, 81.3	12.5, 87.5		
Week 12				
m	6	12		
n	6	12		
Mean (SD/SE)	59.38 (25.26)	53.68 (25.77)	4.13 (8.33)	-0.52 (5.19)
Median	56.25	53.15	6.20	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.05	0.00, 12.50	-9.35, 6.25
Min, Max	37.5, 87.5	0.0, 87.5	-31.3, 31.2	-31.3, 31.3
Week 36				
m	6	12		
n	6	11		
Mean (SD/SE)	65.65 (11.70)	57.97 (31.51)	10.40 (5.51)	1.13 (7.54)
Median	65.65	62.50	12.50	18.70
IQR: Q1, Q3	56.30, 75.00	31.30, 81.30	6.20, 18.70	-31.30, 18.80
Min, Max	50.0, 81.3	0.0, 100.0	-12.5, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Social Functioning				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	79.17 (28.14)	79.17 (26.83)		
Median	93.75	100.00		
IQR: Q1, Q3	50.00, 100.00	56.25, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	81.25 (31.37)	72.92 (34.06)	2.08 (6.78)	-6.25 (6.06)
Median	100.00	93.75	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	0.00, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 25.0	-50.0, 25.0
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	85.42 (12.29)	75.00 (32.11)	6.25 (11.97)	-5.68 (5.93)
Median	81.25	87.50	6.25	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-25.00, 25.00	-25.00, 0.00
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Role Emotional				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	75.00 (41.83)	71.53 (35.44)		
Median	100.00	87.50		
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	69.45 (47.62)	78.48 (29.82)	-5.55 (9.30)	6.94 (5.01)
Median	100.00	87.50	0	0
IQR: Q1, Q3	16.70, 100.00	66.70, 100.00	0.00, 0.00	-4.20, 25.00
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 16.7	-16.6, 33.4
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	86.12 (20.19)	78.79 (31.48)	11.12 (9.04)	2.27 (6.16)
Median	95.85	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	0.00, 25.00	0.00, 8.30
Min, Max	50.0, 100.0	0.0, 100.0	-8.3, 50.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Mental Health				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	77.50 (20.19)	64.17 (22.95)		
Median	80.00	60.00		
IQR: Q1, Q3	65.00, 95.00	45.00, 85.00		
Min, Max	45.0, 100.0	30.0, 100.0		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	78.33 (19.15)	63.75 (29.09)	0.83 (5.23)	-0.42 (6.08)
Median	85.00	62.50	5.00	5.00
IQR: Q1, Q3	60.00, 90.00	40.00, 92.50	-15.00, 10.00	-5.00, 12.50
Min, Max	50.0, 100.0	15.0, 100.0	-15.0, 15.0	-50.0, 25.0
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	76.67 (22.06)	67.73 (30.93)	-0.83 (5.07)	0.45 (6.82)
Median	82.50	60.00	2.50	5.00
IQR: Q1, Q3	75.00, 85.00	50.00, 95.00	-10.00, 5.00	-20.00, 15.00
Min, Max	35.0, 100.0	0.0, 100.0	-20.0, 15.0	-45.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Mental Component Score				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	50.57 (11.56)	46.44 (12.54)		
Median	55.20	46.10		
IQR: Q1, Q3	40.70, 59.20	33.30, 57.10		
Min, Max	32.2, 60.9	29.1, 65.3		
Week 12				
m	6	12		
n	6	12		
Mean (SD/SE)	50.33 (12.89)	46.36 (14.79)	-0.23 (3.32)	-0.08 (2.69)
Median	54.55	46.70	2.30	1.50
IQR: Q1, Q3	42.10, 59.30	38.65, 59.45	-7.50, 3.90	-2.55, 5.35
Min, Max	28.4, 63.1	12.9, 66.1	-12.3, 9.9	-19.5, 11.3
Week 36				
m	6	12		
n	6	11		
Mean (SD/SE)	52.60 (6.88)	47.74 (15.44)	2.03 (2.93)	-0.28 (3.18)
Median	53.85	52.00	0.75	3.50
IQR: Q1, Q3	53.10, 56.50	36.60, 60.50	-3.30, 7.10	-9.20, 10.50
Min, Max	39.3, 59.0	13.9, 64.0	-6.1, 13.0	-18.5, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=6)	Placebo (N=12)	MGL-3196 (N=6)	Placebo (N=12)
Physical Component Score				
Baseline				
m	6	12		
n	6	12		
Mean (SD)	44.97 (11.82)	47.75 (10.83)		
Median	45.35	50.20		
IQR: Q1, Q3	37.70, 54.60	38.80, 56.30		
Min, Max	27.0, 59.8	25.8, 60.5		
Week 12				
m	6	12		
n	6	12	6	12
Mean (SD/SE)	46.75 (12.21)	48.27 (9.25)	1.78 (0.91)	0.52 (1.74)
Median	49.75	49.05	1.20	0.35
IQR: Q1, Q3	37.80, 56.80	39.90, 57.95	0.10, 4.40	-4.75, 5.50
Min, Max	27.2, 59.2	34.5, 58.6	-0.6, 4.4	-7.8, 10.7
Week 36				
m	6	12		
n	6	11	6	11
Mean (SD/SE)	49.50 (7.69)	49.19 (12.53)	4.53 (2.52)	0.64 (2.28)
Median	50.75	53.70	3.00	0.90
IQR: Q1, Q3	42.90, 55.30	36.40, 58.40	0.70, 5.70	-2.30, 3.00
Min, Max	38.6, 58.7	28.7, 64.5	-1.1, 15.9	-15.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Physical Functioning				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	77.5 (19.7)	70.0 (23.9)		
Median	80.0	72.5		
IQR: Q1, Q3	75.0, 90.0	55.0, 90.0		
Min, Max	35, 100	30, 100		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	75.0 (25.8)	78.2 (20.5)	-2.5 (3.8)	8.2 (7.0)
Median	85.0	85.0	0	5.0
IQR: Q1, Q3	57.5, 92.5	60.0, 95.0	-10.0, 5.0	-5.0, 15.0
Min, Max	30, 100	40, 100	-30, 15	-50, 70
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	78.6 (20.4)	79.3 (19.1)	1.8 (4.7)	9.3 (5.5)
Median	80.0	82.5	0	5.0
IQR: Q1, Q3	65.0, 95.0	60.0, 95.0	-10.0, 5.0	0.0, 20.0
Min, Max	35, 100	45, 100	-20, 40	-20, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Role Physical				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	78.67 (32.25)	64.29 (32.92)		
Median	93.80	68.75		
IQR: Q1, Q3	71.90, 100.00	50.00, 87.50		
Min, Max	0.0, 100.0	6.3, 100.0		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	79.71 (27.07)	73.22 (23.82)	1.04 (5.03)	8.93 (5.19)
Median	93.80	75.00	0	6.25
IQR: Q1, Q3	65.65, 96.90	50.00, 100.00	-9.35, 15.60	0.00, 25.00
Min, Max	12.5, 100.0	43.8, 100.0	-25.0, 31.3	-25.0, 37.5
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	77.85 (20.99)	74.11 (26.27)	0.56 (8.82)	9.82 (6.10)
Median	75.00	75.05	0	9.40
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-25.00, 18.70	0.00, 31.20
Min, Max	50.0, 100.0	37.5, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Bodily Pain				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	58.7 (28.7)	69.7 (27.3)		
Median	62.0	74.0		
IQR: Q1, Q3	41.0, 79.0	41.0, 100.0		
Min, Max	0, 100	22, 100		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	70.8 (30.5)	69.9 (30.5)	12.2 (9.1)	0.2 (6.1)
Median	72.0	73.0	0	0
IQR: Q1, Q3	56.5, 92.0	52.0, 100.0	-4.5, 24.0	-22.0, 19.0
Min, Max	22, 100	0, 100	-22, 100	-41, 33
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	64.9 (26.5)	68.9 (27.6)	8.5 (8.2)	-0.9 (7.4)
Median	62.0	74.0	0	0
IQR: Q1, Q3	41.0, 100.0	41.0, 100.0	-10.0, 38.0	0.0, 16.0
Min, Max	22, 100	22, 100	-40, 50	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
General Health				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	62.3 (18.0)	63.7 (16.9)		
Median	64.5	69.5		
IQR: Q1, Q3	49.5, 74.5	50.0, 77.0		
Min, Max	30, 92	30, 92		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	62.2 (15.4)	63.9 (18.5)	-0.2 (4.3)	0.2 (3.5)
Median	61.0	69.5	0	-2.5
IQR: Q1, Q3	56.0, 72.0	47.0, 77.0	-7.5, 2.5	-5.0, 5.0
Min, Max	25, 82	30, 97	-25, 35	-23, 30
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	68.3 (19.1)	65.9 (22.6)	8.6 (6.3)	2.2 (4.2)
Median	72.0	62.0	5.0	1.0
IQR: Q1, Q3	47.0, 82.0	52.0, 87.0	-5.0, 27.0	-5.0, 12.0
Min, Max	35, 100	25, 100	-25, 48	-22, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Vitality				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	63.05 (19.48)	55.83 (22.13)		
Median	65.65	50.00		
IQR: Q1, Q3	50.05, 75.00	43.80, 81.30		
Min, Max	31.3, 100.0	12.5, 87.5		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	62.00 (21.72)	60.29 (16.37)	-1.05 (6.09)	4.46 (4.01)
Median	62.50	53.15	0	6.20
IQR: Q1, Q3	40.65, 78.15	50.00, 75.00	-15.65, 12.50	0.00, 6.30
Min, Max	31.3, 100.0	43.8, 87.5	-37.5, 31.2	-25.0, 31.3
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	63.10 (23.63)	62.52 (20.35)	1.14 (6.01)	6.69 (5.05)
Median	68.80	59.40	6.30	15.60
IQR: Q1, Q3	43.80, 81.30	50.00, 75.00	0.00, 18.70	-6.20, 18.80
Min, Max	12.5, 100.0	31.3, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Social Functioning				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	87.50 (16.85)	75.89 (25.22)		
Median	93.75	81.25		
IQR: Q1, Q3	81.25, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	83.33 (24.03)	74.11 (25.22)	-4.17 (4.70)	-1.79 (4.88)
Median	93.75	68.75	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-18.75, 6.25	0.00, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	-25.0, 25.0	-50.0, 25.0
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	76.14 (24.01)	79.46 (21.15)	-10.23 (9.36)	3.57 (4.80)
Median	75.00	81.25	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	-37.50, 12.50	0.00, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Role Emotional				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	86.81 (19.61)	72.02 (28.62)		
Median	100.00	79.15		
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	25.0, 100.0		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	85.43 (30.39)	78.58 (23.27)	-1.38 (5.21)	6.56 (3.93)
Median	100.00	87.50	0	0
IQR: Q1, Q3	91.70, 100.00	50.00, 100.00	-4.15, 4.15	0.00, 25.00
Min, Max	0.0, 100.0	41.7, 100.0	-50.0, 25.0	-16.6, 33.4
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	84.85 (16.59)	77.38 (26.24)	-0.76 (6.79)	5.36 (4.67)
Median	83.30	87.50	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-8.40, 25.00	0.00, 8.30
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 25.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Mental Health				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	81.04 (11.15)	63.93 (22.38)		
Median	82.50	55.00		
IQR: Q1, Q3	80.00, 88.75	45.00, 85.00		
Min, Max	55.0, 95.0	30.0, 100.0		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	79.58 (12.52)	67.50 (24.08)	-1.46 (2.93)	3.57 (4.96)
Median	80.00	60.00	0	7.50
IQR: Q1, Q3	77.50, 85.00	50.00, 95.00	-6.25, 2.50	0.00, 15.00
Min, Max	50.0, 100.0	35.0, 100.0	-20.0, 20.0	-50.0, 25.0
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	78.64 (13.62)	72.14 (20.64)	-1.59 (5.50)	8.21 (3.69)
Median	80.00	60.00	0	10.00
IQR: Q1, Q3	70.00, 90.00	55.00, 95.00	-20.00, 15.00	0.00, 15.00
Min, Max	50.0, 100.0	50.0, 100.0	-30.0, 25.0	-20.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Mental Component Score				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	54.32 (6.72)	46.09 (12.17)		
Median	56.65	43.95		
IQR: Q1, Q3	51.15, 59.15	37.40, 57.20		
Min, Max	40.7, 62.3	26.9, 65.3		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	52.83 (9.17)	47.36 (11.18)	-1.48 (1.48)	1.28 (1.85)
Median	53.30	43.60	-0.40	1.55
IQR: Q1, Q3	49.60, 59.70	37.90, 58.00	-5.00, 3.15	-1.50, 6.20
Min, Max	28.4, 63.1	33.7, 66.1	-12.3, 4.2	-15.9, 11.3
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	51.77 (5.96)	49.06 (10.61)	-2.11 (2.72)	2.97 (1.73)
Median	53.10	48.75	-5.80	2.70
IQR: Q1, Q3	51.00, 56.50	39.30, 58.80	-8.10, 7.00	-1.30, 9.70
Min, Max	37.5, 56.8	35.1, 64.0	-18.2, 13.0	-9.2, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=12)	Placebo (N=14)	MGL-3196 (N=12)	Placebo (N=14)
Physical Component Score				
Baseline				
m	12	14		
n	12	14		
Mean (SD)	46.58 (8.50)	48.23 (8.13)		
Median	48.65	49.70		
IQR: Q1, Q3	39.90, 53.05	41.10, 55.40		
Min, Max	32.1, 59.8	34.3, 59.2		
Week 12				
m	12	14		
n	12	14	12	14
Mean (SD/SE)	48.13 (8.87)	49.86 (8.06)	1.55 (1.21)	1.64 (1.29)
Median	50.70	50.90	2.05	1.85
IQR: Q1, Q3	43.45, 53.90	43.30, 57.90	-0.25, 4.75	-0.20, 3.30
Min, Max	28.8, 59.2	35.4, 58.6	-6.4, 7.0	-5.8, 9.1
Week 36				
m	11	14		
n	11	14	11	14
Mean (SD/SE)	48.65 (8.78)	49.82 (9.05)	2.78 (2.05)	1.59 (2.07)
Median	52.90	51.20	3.20	1.45
IQR: Q1, Q3	40.60, 55.30	45.00, 55.30	-1.10, 5.70	-2.60, 7.40
Min, Max	30.7, 58.7	31.5, 64.5	-9.6, 14.9	-15.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Physical Functioning				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	62.0 (36.5)	66.0 (42.6)		
Median	75.0	95.0		
IQR: Q1, Q3	50.0, 80.0	30.0, 95.0		
Min, Max	5, 100	10, 100		
Week 12				
m	5	5		
n	5	5	5	5
Mean (SD/SE)	65.0 (34.8)	66.0 (36.5)	3.0 (4.4)	0.0 (12.9)
Median	75.0	85.0	0	-10.0
IQR: Q1, Q3	70.0, 80.0	60.0, 85.0	0.0, 0.0	-10.0, -5.0
Min, Max	5, 95	5, 95	-5, 20	-25, 50
Week 36				
m	4	5		
n	4	4	4	4
Mean (SD/SE)	73.8 (30.4)	73.8 (45.9)	8.8 (5.5)	-1.3 (1.3)
Median	82.5	95.0	5.0	0
IQR: Q1, Q3	55.0, 92.5	50.0, 97.5	2.5, 15.0	-2.5, 0.0
Min, Max	30, 100	5, 100	0, 25	-5, 0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Role Physical				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	66.28 (38.67)	61.26 (50.47)		
Median	81.30	93.80		
IQR: Q1, Q3	50.00, 93.80	12.50, 100.00		
Min, Max	6.3, 100.0	0.0, 100.0		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	73.78 (34.06)	51.28 (34.64)	7.50 (3.06)	-9.98 (8.97)
Median	93.80	68.80	12.50	-12.50
IQR: Q1, Q3	62.50, 93.80	31.30, 75.00	0.00, 12.50	-25.00, 0.00
Min, Max	18.8, 100.0	0.0, 81.3	0.0, 12.5	-31.2, 18.8
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	84.40 (19.42)	60.95 (42.81)	14.05 (12.60)	-12.50 (7.22)
Median	90.65	71.90	6.25	-12.50
IQR: Q1, Q3	71.90, 96.90	34.40, 87.50	-3.15, 31.25	-25.00, 0.00
Min, Max	56.3, 100.0	0.0, 100.0	-6.3, 50.0	-25.0, 0.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Bodily Pain				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	52.2 (30.6)	62.4 (38.7)		
Median	61.0	74.0		
IQR: Q1, Q3	32.0, 74.0	54.0, 84.0		
Min, Max	10, 84	0, 100		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	59.6 (33.4)	52.8 (35.7)	7.4 (12.9)	-9.6 (7.8)
Median	61.0	51.0	16.0	0
IQR: Q1, Q3	31.0, 84.0	51.0, 62.0	12.0, 23.0	-23.0, 0.0
Min, Max	22, 100	0, 100	-43, 29	-33, 8
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	66.8 (25.9)	61.5 (42.9)	20.0 (17.0)	-3.0 (2.4)
Median	62.5	73.0	17.5	-1.0
IQR: Q1, Q3	46.5, 87.0	36.0, 87.0	-1.5, 41.5	-6.0, 0.0
Min, Max	42, 100	0, 100	-19, 64	-10, 0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
General Health				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	54.8 (14.9)	64.2 (22.5)		
Median	52.0	77.0		
IQR: Q1, Q3	50.0, 62.0	45.0, 82.0		
Min, Max	35, 75	35, 82		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	53.2 (15.7)	60.2 (25.7)	-1.6 (4.9)	-4.0 (2.9)
Median	47.0	72.0	-3.0	-5.0
IQR: Q1, Q3	45.0, 67.0	35.0, 82.0	-5.0, 0.0	-10.0, 0.0
Min, Max	35, 72	30, 82	-15, 15	-10, 5
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	54.3 (17.2)	62.8 (25.6)	1.3 (6.6)	-6.3 (2.4)
Median	55.0	72.0	-2.5	-7.5
IQR: Q1, Q3	40.0, 68.5	48.5, 77.0	-7.5, 10.0	-10.0, -2.5
Min, Max	35, 72	25, 82	-10, 20	-10, 0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Vitality				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	58.80 (18.54)	48.78 (19.47)		
Median	56.30	56.30		
IQR: Q1, Q3	56.30, 68.80	31.30, 62.50		
Min, Max	31.3, 81.3	25.0, 68.8		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	58.76 (17.44)	36.28 (23.99)	-0.04 (8.84)	-12.50 (5.24)
Median	50.00	43.80	6.20	-12.50
IQR: Q1, Q3	50.00, 62.50	25.00, 56.30	-6.30, 12.50	-12.50, -6.20
Min, Max	43.8, 87.5	0.0, 56.3	-31.3, 18.7	-31.3, 0.0
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	64.08 (10.68)	43.78 (37.87)	4.65 (6.43)	-10.95 (12.36)
Median	65.65	46.90	6.20	-15.65
IQR: Q1, Q3	56.25, 71.90	12.50, 75.05	-3.15, 12.45	-31.30, 9.40
Min, Max	50.0, 75.0	0.0, 81.3	-12.5, 18.7	-31.3, 18.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Social Functioning				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	77.50 (31.12)	80.00 (28.78)		
Median	100.00	100.00		
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	80.00 (22.71)	67.50 (46.44)	2.50 (6.12)	-12.50 (7.91)
Median	87.50	100.00	0	0
IQR: Q1, Q3	62.50, 100.00	37.50, 100.00	0.00, 0.00	-25.00, 0.00
Min, Max	50.0, 100.0	0.0, 100.0	-12.5, 25.0	-37.5, 0.0
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	90.63 (11.97)	68.75 (47.32)	6.25 (15.73)	-15.63 (9.38)
Median	93.75	87.50	0	-12.50
IQR: Q1, Q3	81.25, 100.00	37.50, 100.00	-12.50, 25.00	-31.25, 0.00
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 50.0	-37.5, 0.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Role Emotional				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	66.66 (42.49)	61.68 (49.16)		
Median	83.30	91.70		
IQR: Q1, Q3	50.00, 100.00	16.70, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	76.68 (36.50)	63.32 (39.78)	10.02 (4.09)	1.64 (8.50)
Median	100.00	83.30	16.70	0
IQR: Q1, Q3	66.70, 100.00	50.00, 83.30	0.00, 16.70	-8.40, 0.00
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 16.7	-16.7, 33.3
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	79.18 (22.05)	60.43 (42.70)	8.35 (14.02)	-12.50 (7.22)
Median	83.35	70.85	-4.15	-12.50
IQR: Q1, Q3	62.50, 95.85	33.35, 87.50	-8.30, 25.00	-25.00, 0.00
Min, Max	50.0, 100.0	0.0, 100.0	-8.3, 50.0	-25.0, 0.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Mental Health				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	77.00 (24.39)	64.00 (26.79)		
Median	80.00	65.00		
IQR: Q1, Q3	60.00, 100.00	45.00, 90.00		
Min, Max	45.0, 100.0	30.0, 90.0		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	77.00 (18.23)	57.00 (32.52)	0.00 (5.48)	-7.00 (7.00)
Median	85.00	75.00	-5.00	0
IQR: Q1, Q3	60.00, 90.00	30.00, 75.00	-5.00, 10.00	-15.00, 0.00
Min, Max	55.0, 95.0	15.0, 90.0	-15.0, 15.0	-30.0, 10.0
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	80.00 (30.82)	60.00 (47.08)	-1.25 (3.15)	-12.50 (12.67)
Median	92.50	70.00	0	-7.50
IQR: Q1, Q3	60.00, 100.00	22.50, 97.50	-5.00, 2.50	-32.50, 7.50
Min, Max	35.0, 100.0	0.0, 100.0	-10.0, 5.0	-45.0, 10.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Mental Component Score				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	50.32 (13.13)	44.64 (13.36)		
Median	57.30	47.30		
IQR: Q1, Q3	40.60, 60.60	32.40, 57.00		
Min, Max	32.2, 60.9	29.1, 57.4		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	51.52 (9.55)	41.28 (18.45)	1.20 (2.76)	-3.36 (4.30)
Median	53.40	47.90	1.10	0.60
IQR: Q1, Q3	42.10, 59.30	33.60, 52.80	0.50, 2.00	-4.60, 2.20
Min, Max	41.1, 61.7	12.9, 59.2	-7.5, 9.9	-19.5, 4.5
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	52.98 (9.46)	41.00 (21.88)	0.23 (2.34)	-7.53 (5.33)
Median	56.50	44.80	-1.45	-7.55
IQR: Q1, Q3	46.65, 59.30	23.30, 58.70	-2.60, 3.05	-16.55, 1.50
Min, Max	39.3, 59.6	13.9, 60.5	-3.3, 7.1	-18.5, 3.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=5)	Placebo (N=5)	MGL-3196 (N=5)	Placebo (N=5)
Physical Component Score				
Baseline				
m	5	5		
n	5	5		
Mean (SD)	42.82 (9.98)	47.02 (14.36)		
Median	43.50	54.30		
IQR: Q1, Q3	43.20, 45.80	38.90, 55.60		
Min, Max	27.0, 54.6	25.8, 60.5		
Week 12				
m	5	5		
n	5	5		
Mean (SD/SE)	44.20 (10.83)	44.62 (9.48)	1.38 (1.36)	-2.40 (3.44)
Median	46.90	46.50	2.20	-4.40
IQR: Q1, Q3	42.50, 47.60	36.50, 47.60	0.20, 3.40	-7.80, -2.50
Min, Max	27.2, 56.8	34.5, 58.0	-3.3, 4.4	-8.0, 10.7
Week 36				
m	4	5		
n	4	4		
Mean (SD/SE)	47.53 (5.71)	48.50 (13.83)	5.45 (3.66)	-0.55 (1.57)
Median	45.95	52.30	2.90	-0.20
IQR: Q1, Q3	43.25, 51.80	39.80, 57.20	0.40, 10.50	-2.65, 1.55
Min, Max	42.9, 55.3	28.7, 60.7	0.1, 15.9	-4.7, 2.9

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; ALT = Alanine aminotransferase.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Physical Functioning				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	65.7 (33.6)	68.6 (30.5)		
Median	75.0	75.0		
IQR: Q1, Q3	35.0, 90.0	30.0, 95.0		
Min, Max	5, 100	30, 100		
Week 12				
m	7	7		
n	7	7	7	7
Mean (SD/SE)	67.9 (36.2)	72.9 (34.3)	2.1 (2.4)	4.3 (14.7)
Median	80.0	85.0	0	5.0
IQR: Q1, Q3	30.0, 95.0	50.0, 100.0	0.0, 5.0	-25.0, 30.0
Min, Max	5, 100	5, 100	-5, 15	-50, 70
Week 36				
m	7	7		
n	7	6	7	6
Mean (SD/SE)	78.6 (23.0)	91.7 (9.8)	12.9 (5.4)	16.7 (11.2)
Median	85.0	95.0	5.0	5.0
IQR: Q1, Q3	75.0, 95.0	85.0, 100.0	5.0, 25.0	0.0, 20.0
Min, Max	30, 100	75, 100	0, 40	0, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Role Physical				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	69.69 (36.15)	67.86 (40.09)		
Median	81.30	87.50		
IQR: Q1, Q3	31.30, 93.80	12.50, 100.00		
Min, Max	6.3, 100.0	12.5, 100.0		
Week 12				
m	7	7		
n	7	7	7	7
Mean (SD/SE)	78.60 (31.63)	69.66 (27.09)	8.91 (3.56)	1.80 (8.70)
Median	93.80	68.80	12.50	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	0.00, 18.70	-12.50, 18.80
Min, Max	18.8, 100.0	31.3, 100.0	-6.2, 18.7	-31.2, 37.5
Week 36				
m	7	7		
n	7	6	7	6
Mean (SD/SE)	84.86 (16.07)	79.17 (24.58)	15.17 (8.28)	2.08 (8.79)
Median	93.80	87.50	12.50	0
IQR: Q1, Q3	68.80, 93.80	50.00, 100.00	-6.20, 37.50	-12.50, 12.50
Min, Max	56.3, 100.0	50.0, 100.0	-6.3, 50.0	-25.0, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Bodily Pain				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	49.0 (27.7)	70.6 (25.7)		
Median	61.0	74.0		
IQR: Q1, Q3	22.0, 72.0	41.0, 100.0		
Min, Max	10, 84	41, 100		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	64.0 (22.0)	79.9 (20.3)	15.0 (5.7)	9.3 (8.8)
Median	72.0	74.0	22.0	8.0
IQR: Q1, Q3	51.0, 84.0	62.0, 100.0	0.0, 29.0	0.0, 31.0
Min, Max	22, 84	51, 100	-10, 29	-33, 33
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	66.4 (18.8)	84.3 (12.7)	17.4 (11.9)	11.0 (8.8)
Median	62.0	79.0	19.0	0
IQR: Q1, Q3	51.0, 74.0	74.0, 100.0	-10.0, 40.0	0.0, 33.0
Min, Max	42, 100	74, 100	-19, 64	-10, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
General Health				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	53.3 (15.7)	70.3 (17.7)		
Median	50.0	77.0		
IQR: Q1, Q3	40.0, 72.0	47.0, 82.0		
Min, Max	35, 77	45, 92		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	61.1 (17.0)	65.0 (18.7)	7.9 (5.5)	-5.3 (2.3)
Median	67.0	72.0	0	-5.0
IQR: Q1, Q3	45.0, 77.0	42.0, 80.0	-5.0, 15.0	-10.0, 0.0
Min, Max	35, 82	35, 82	-5, 35	-12, 5
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	64.3 (17.5)	72.7 (22.3)	11.0 (5.4)	-1.8 (7.8)
Median	72.0	64.5	5.0	-2.5
IQR: Q1, Q3	45.0, 77.0	55.0, 100.0	0.0, 27.0	-20.0, 8.0
Min, Max	35, 82	52, 100	-5, 30	-22, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Vitality				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	58.09 (16.81)	55.39 (20.87)		
Median	56.30	62.50		
IQR: Q1, Q3	43.80, 68.80	31.30, 68.80		
Min, Max	31.3, 81.3	25.0, 81.3		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	68.77 (16.91)	55.37 (20.54)	10.69 (5.40)	-0.01 (4.71)
Median	62.50	50.00	12.50	0
IQR: Q1, Q3	56.30, 87.50	43.80, 75.00	0.00, 18.70	-12.50, 6.20
Min, Max	43.8, 87.5	25.0, 87.5	-12.5, 31.2	-18.7, 18.7
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	67.87 (10.49)	68.77 (18.54)	9.79 (3.29)	8.32 (5.96)
Median	68.80	68.80	6.20	9.35
IQR: Q1, Q3	62.50, 75.00	50.00, 75.00	0.00, 18.70	0.00, 18.70
Min, Max	50.0, 81.3	50.0, 100.0	0.0, 18.7	-12.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Social Functioning				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	82.14 (24.85)	78.57 (24.70)		
Median	100.00	87.50		
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	85.71 (20.95)	69.64 (28.74)	3.57 (5.92)	-8.93 (8.50)
Median	100.00	50.00	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-12.50, 25.00	-25.00, 12.50
Min, Max	50.0, 100.0	37.5, 100.0	-12.5, 25.0	-50.0, 12.5
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	87.50 (12.50)	89.58 (16.61)	5.36 (10.15)	8.33 (4.17)
Median	87.50	100.00	0	6.25
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	-25.00, 25.00	0.00, 12.50
Min, Max	75.0, 100.0	62.5, 100.0	-25.0, 50.0	0.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Role Emotional				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	71.43 (35.96)	69.06 (37.48)		
Median	83.30	91.70		
IQR: Q1, Q3	50.00, 100.00	25.00, 100.00		
Min, Max	0.0, 100.0	16.7, 100.0		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	80.96 (33.91)	73.80 (23.28)	9.53 (3.83)	4.74 (6.77)
Median	100.00	83.30	8.30	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	0.00, 16.70	-8.40, 25.00
Min, Max	16.7, 100.0	50.0, 100.0	0.0, 25.0	-16.7, 33.3
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	82.14 (17.63)	80.55 (22.78)	10.71 (8.67)	2.77 (6.69)
Median	83.30	87.50	0	4.15
IQR: Q1, Q3	75.00, 100.00	58.30, 100.00	-8.30, 25.00	0.00, 8.30
Min, Max	50.0, 100.0	50.0, 100.0	-8.4, 50.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Mental Health				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	77.86 (20.59)	65.00 (26.46)		
Median	80.00	80.00		
IQR: Q1, Q3	55.00, 95.00	30.00, 85.00		
Min, Max	45.0, 100.0	30.0, 90.0		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	84.29 (13.67)	61.43 (25.77)	6.43 (3.40)	-3.57 (8.84)
Median	90.00	55.00	5.00	0
IQR: Q1, Q3	75.00, 95.00	35.00, 90.00	0.00, 15.00	-15.00, 15.00
Min, Max	60.0, 100.0	30.0, 95.0	-5.0, 20.0	-50.0, 20.0
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	79.29 (21.10)	75.00 (20.98)	1.43 (5.42)	4.17 (5.54)
Median	85.00	72.50	0	7.50
IQR: Q1, Q3	75.00, 90.00	60.00, 95.00	-10.00, 10.00	0.00, 10.00
Min, Max	35.0, 100.0	50.0, 100.0	-20.0, 25.0	-20.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Mental Component Score				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	51.47 (10.41)	45.94 (14.17)		
Median	57.30	53.80		
IQR: Q1, Q3	43.60, 59.20	29.10, 57.40		
Min, Max	32.2, 60.6	26.9, 61.2		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	55.19 (7.79)	44.16 (11.81)	3.71 (1.14)	-1.79 (2.92)
Median	58.80	37.90	3.70	-1.50
IQR: Q1, Q3	47.80, 61.70	33.70, 57.00	1.20, 4.20	-4.80, 4.50
Min, Max	42.1, 63.1	33.6, 59.7	1.1, 9.9	-15.9, 7.5
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	52.89 (6.61)	50.17 (9.15)	1.41 (2.13)	1.42 (2.58)
Median	54.00	53.80	-1.00	1.75
IQR: Q1, Q3	51.00, 56.80	41.10, 56.90	-3.30, 7.10	-0.50, 5.00
Min, Max	39.3, 59.6	36.6, 58.8	-6.1, 7.4	-9.2, 9.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=7)	Placebo (N=7)	MGL-3196 (N=7)	Placebo (N=7)
Physical Component Score				
Baseline				
m	7	7		
n	7	7		
Mean (SD)	42.77 (10.01)	49.43 (6.89)		
Median	43.50	50.70		
IQR: Q1, Q3	32.10, 51.70	41.10, 55.60		
Min, Max	27.0, 54.4	38.9, 56.1		
Week 12				
m	7	7		
n	7	7		
Mean (SD/SE)	45.73 (10.15)	50.97 (8.36)	2.96 (0.77)	1.54 (2.34)
Median	47.60	51.60	3.40	2.50
IQR: Q1, Q3	37.20, 54.50	47.60, 57.90	0.20, 4.40	-4.40, 8.20
Min, Max	27.2, 54.8	34.5, 58.6	0.1, 5.1	-8.0, 9.1
Week 36				
m	7	7		
n	7	6		
Mean (SD/SE)	49.41 (5.37)	54.72 (5.86)	6.64 (2.43)	3.53 (3.23)
Median	48.30	53.10	5.10	3.30
IQR: Q1, Q3	43.60, 54.40	49.80, 58.10	0.10, 14.90	-4.10, 8.60
Min, Max	42.9, 56.5	49.7, 64.5	0.0, 15.9	-4.7, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Physical Functioning				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	78.0 (18.4)	69.2 (28.9)		
Median	80.0	72.5		
IQR: Q1, Q3	75.0, 90.0	52.5, 92.5		
Min, Max	45, 100	10, 100		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	75.0 (22.2)	76.3 (19.7)	-3.0 (4.7)	7.1 (5.1)
Median	82.5	77.5	0	5.0
IQR: Q1, Q3	70.0, 90.0	60.0, 95.0	-15.0, 5.0	-5.0, 12.5
Min, Max	30, 100	40, 100	-30, 20	-10, 50
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	76.3 (23.3)	71.3 (28.6)	-4.4 (3.3)	2.1 (3.2)
Median	80.0	77.5	0	2.5
IQR: Q1, Q3	60.0, 97.5	55.0, 95.0	-12.5, 2.5	-2.5, 5.0
Min, Max	35, 100	5, 100	-20, 5	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Role Physical				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	78.76 (32.97)	60.95 (36.25)		
Median	96.90	68.75		
IQR: Q1, Q3	62.50, 100.00	34.40, 90.65		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	77.52 (27.52)	66.16 (29.37)	-1.24 (5.50)	5.21 (5.90)
Median	90.65	68.75	0	0
IQR: Q1, Q3	62.50, 93.80	50.00, 90.65	-12.50, 12.50	-6.25, 21.90
Min, Max	12.5, 100.0	0.0, 100.0	-25.0, 31.3	-25.0, 37.5
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	75.00 (23.15)	67.20 (32.22)	-5.48 (10.79)	6.25 (7.05)
Median	75.00	62.55	0	3.15
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-28.15, 6.25	-6.25, 25.00
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Bodily Pain				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	62.2 (29.1)	66.2 (32.8)		
Median	68.0	74.0		
IQR: Q1, Q3	51.0, 84.0	41.0, 92.0		
Min, Max	0, 100	0, 100		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	70.0 (29.7)	57.0 (35.1)	7.8 (11.9)	-9.2 (5.3)
Median	67.0	57.0	0	-4.5
IQR: Q1, Q3	51.0, 100.0	36.5, 87.0	-9.0, 16.0	-22.5, 0.0
Min, Max	22, 100	0, 100	-43, 100	-41, 19
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	64.5 (31.4)	58.7 (33.3)	6.5 (9.3)	-7.5 (7.0)
Median	56.0	56.5	5.0	0
IQR: Q1, Q3	41.0, 100.0	36.0, 92.0	-5.0, 21.0	-17.5, 5.0
Min, Max	22, 100	0, 100	-40, 50	-53, 21

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
General Health				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	64.9 (17.1)	60.1 (17.5)		
Median	64.5	62.0		
IQR: Q1, Q3	57.0, 75.0	48.5, 74.5		
Min, Max	30, 92	30, 82		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	58.4 (15.2)	61.8 (21.3)	-6.5 (2.8)	1.7 (3.9)
Median	58.5	62.0	-4.0	0
IQR: Q1, Q3	55.0, 67.0	46.0, 79.5	-12.0, 0.0	-5.0, 6.5
Min, Max	25, 82	30, 97	-25, 5	-23, 30
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	64.8 (21.7)	61.5 (22.7)	2.9 (7.9)	1.4 (3.5)
Median	66.0	69.5	-2.5	0
IQR: Q1, Q3	46.0, 79.5	46.0, 77.0	-10.0, 12.5	-5.0, 7.0
Min, Max	35, 100	25, 92	-25, 48	-17, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Vitality				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	64.40 (20.42)	53.15 (22.22)		
Median	65.65	50.00		
IQR: Q1, Q3	56.30, 75.00	40.65, 71.90		
Min, Max	31.3, 100.0	12.5, 87.5		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	55.64 (21.13)	53.16 (22.06)	-8.76 (6.40)	0.01 (5.22)
Median	50.00	53.15	-3.15	3.10
IQR: Q1, Q3	37.50, 68.80	43.80, 62.55	-31.20, 6.20	-9.35, 6.30
Min, Max	31.3, 100.0	0.0, 87.5	-37.5, 25.0	-31.3, 31.3
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	59.41 (26.73)	53.15 (27.11)	-4.68 (7.64)	0.00 (6.80)
Median	62.55	53.15	3.15	9.40
IQR: Q1, Q3	43.80, 75.05	37.55, 71.90	-18.75, 6.30	-28.15, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Social Functioning				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	86.25 (19.94)	76.04 (26.89)		
Median	93.75	87.50		
IQR: Q1, Q3	87.50, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	80.00 (25.14)	73.96 (33.05)	-6.25 (4.66)	-2.08 (4.57)
Median	87.50	93.75	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-25.00, 0.00	0.00, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 12.5	-37.5, 25.0
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	73.44 (27.09)	70.83 (30.31)	-15.63 (11.51)	-5.21 (6.24)
Median	75.00	75.00	-6.25	0
IQR: Q1, Q3	56.25, 100.00	50.00, 100.00	-37.50, 6.25	-25.00, 6.25
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Role Emotional				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	87.50 (21.25)	69.44 (33.40)		
Median	100.00	79.15		
IQR: Q1, Q3	75.00, 100.00	41.65, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	84.18 (31.29)	75.01 (31.58)	-3.32 (5.86)	5.57 (4.27)
Median	95.85	87.50	0	0
IQR: Q1, Q3	91.70, 100.00	58.35, 100.00	-8.30, 0.00	0.00, 16.70
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 16.7	-16.6, 33.4
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	84.38 (18.60)	70.14 (33.42)	-6.25 (7.83)	0.70 (5.66)
Median	87.50	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 0.00	-4.15, 4.15
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 25.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Mental Health				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	81.25 (11.62)	63.33 (21.67)		
Median	82.50	52.50		
IQR: Q1, Q3	80.00, 87.50	45.00, 87.50		
Min, Max	60.0, 100.0	45.0, 100.0		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	75.00 (13.33)	66.67 (27.08)	-6.25 (2.56)	3.33 (4.23)
Median	80.00	67.50	-5.00	7.50
IQR: Q1, Q3	65.00, 85.00	50.00, 92.50	-15.00, 0.00	-5.00, 12.50
Min, Max	50.0, 85.0	15.0, 100.0	-20.0, 5.0	-30.0, 25.0
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	78.75 (17.06)	66.67 (30.40)	-4.06 (6.12)	3.33 (6.04)
Median	80.00	60.00	-3.75	7.50
IQR: Q1, Q3	67.50, 92.50	50.00, 97.50	-17.50, 10.00	-2.50, 15.00
Min, Max	50.0, 100.0	0.0, 100.0	-30.0, 20.0	-45.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Mental Component Score				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	54.31 (7.88)	45.57 (11.45)		
Median	56.80	43.95		
IQR: Q1, Q3	52.50, 60.30	35.80, 57.10		
Min, Max	40.6, 62.3	31.9, 65.3		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	50.53 (9.68)	46.70 (14.33)	-3.78 (1.41)	1.13 (2.26)
Median	52.85	46.70	-4.30	1.50
IQR: Q1, Q3	48.70, 55.70	40.25, 58.60	-6.50, 0.30	-0.75, 5.15
Min, Max	28.4, 61.2	12.9, 66.1	-12.3, 2.6	-19.5, 11.3
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	51.40 (7.15)	45.82 (15.40)	-4.03 (3.26)	0.25 (2.79)
Median	52.90	43.95	-5.80	2.35
IQR: Q1, Q3	47.95, 56.50	35.85, 60.80	-8.45, 0.75	-4.60, 7.80
Min, Max	37.5, 59.0	13.9, 64.0	-18.2, 13.0	-18.5, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=10)	Placebo (N=12)	MGL-3196 (N=10)	Placebo (N=12)
Physical Component Score				
Baseline				
m	10	12		
n	10	12		
Mean (SD)	47.37 (7.85)	47.03 (11.19)		
Median	47.80	48.40		
IQR: Q1, Q3	42.10, 54.50	37.10, 56.30		
Min, Max	35.2, 59.8	25.8, 60.5		
Week 12				
m	10	12		
n	10	12	10	12
Mean (SD/SE)	47.85 (9.14)	47.03 (8.62)	0.48 (1.41)	0.01 (1.65)
Median	49.90	45.20	0.55	0.45
IQR: Q1, Q3	42.50, 53.30	39.90, 56.05	-3.30, 3.50	-5.45, 3.25
Min, Max	28.8, 59.2	35.4, 58.6	-6.4, 7.0	-7.8, 10.7
Week 36				
m	8	12		
n	8	12	8	12
Mean (SD/SE)	47.41 (9.89)	46.93 (10.57)	0.74 (2.19)	-0.09 (1.87)
Median	50.05	49.85	0.80	0.55
IQR: Q1, Q3	39.60, 55.30	38.55, 54.30	-2.80, 4.35	-2.45, 2.95
Min, Max	30.7, 58.7	28.7, 60.7	-9.6, 10.8	-15.6, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; LDL = low density lipoprotein.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Physical Functioning				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	70.0 (30.2)	71.5 (30.2)		
Median	80.0	75.0		
IQR: Q1, Q3	75.0, 85.0	55.0, 95.0		
Min, Max	5, 100	10, 100		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	70.6 (31.8)	74.2 (19.5)	0.6 (3.3)	2.7 (6.5)
Median	85.0	85.0	0	5.0
IQR: Q1, Q3	70.0, 90.0	60.0, 85.0	0.0, 5.0	-10.0, 10.0
Min, Max	5, 100	40, 100	-20, 15	-50, 50
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	76.9 (21.9)	75.4 (28.6)	8.8 (6.0)	3.8 (3.2)
Median	82.5	85.0	5.0	0
IQR: Q1, Q3	70.0, 90.0	60.0, 95.0	0.0, 17.5	0.0, 10.0
Min, Max	30, 100	5, 100	-15, 40	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: <=150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Role Physical				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	79.89 (35.31)	62.99 (40.29)		
Median	93.80	87.50		
IQR: Q1, Q3	93.80, 100.00	18.80, 100.00		
Min, Max	6.3, 100.0	0.0, 100.0		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	78.50 (27.08)	62.99 (27.18)	-1.39 (4.39)	0.00 (6.52)
Median	93.80	62.50	0	0
IQR: Q1, Q3	75.00, 93.80	50.00, 81.30	-6.20, 6.20	-12.50, 12.50
Min, Max	18.8, 100.0	0.0, 100.0	-25.0, 18.7	-31.2, 37.5
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	78.15 (18.60)	63.95 (30.42)	0.00 (11.27)	0.95 (6.89)
Median	81.25	50.00	-3.10	0
IQR: Q1, Q3	62.55, 93.80	50.00, 100.00	-15.65, 18.75	-12.50, 12.50
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Bodily Pain				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	48.9 (33.0)	60.5 (31.4)		
Median	62.0	74.0		
IQR: Q1, Q3	22.0, 74.0	41.0, 84.0		
Min, Max	0, 84	0, 100		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	68.2 (24.0)	60.2 (35.6)	19.3 (11.7)	-0.2 (6.8)
Median	72.0	62.0	12.0	0
IQR: Q1, Q3	61.0, 74.0	41.0, 100.0	0.0, 29.0	-22.0, 19.0
Min, Max	22, 100	0, 100	-22, 100	-41, 33
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	61.9 (22.7)	64.2 (31.8)	17.4 (12.4)	3.7 (6.4)
Median	62.0	74.0	22.5	0
IQR: Q1, Q3	50.5, 74.0	41.0, 84.0	-10.0, 45.0	0.0, 16.0
Min, Max	22, 100	0, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
General Health				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	58.6 (18.4)	63.5 (17.8)		
Median	52.0	72.0		
IQR: Q1, Q3	47.0, 70.0	50.0, 77.0		
Min, Max	35, 92	30, 82		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	62.4 (13.6)	65.4 (21.5)	3.9 (5.6)	1.9 (3.1)
Median	62.0	72.0	0	0
IQR: Q1, Q3	57.0, 67.0	45.0, 82.0	0.0, 15.0	-5.0, 5.0
Min, Max	35, 82	30, 97	-25, 35	-10, 30
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	70.0 (21.0)	60.5 (22.7)	15.6 (7.8)	-3.0 (4.0)
Median	74.5	57.0	20.0	-5.0
IQR: Q1, Q3	56.0, 82.0	52.0, 72.0	2.5, 28.5	-10.0, 2.0
Min, Max	35, 100	25, 100	-25, 48	-22, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Vitality				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	63.92 (20.42)	53.39 (21.59)		
Median	62.50	56.30		
IQR: Q1, Q3	56.30, 75.00	37.50, 68.80		
Min, Max	31.3, 100.0	12.5, 87.5		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	64.61 (22.52)	52.43 (21.73)	0.69 (7.39)	-0.96 (4.52)
Median	62.50	50.00	6.20	0
IQR: Q1, Q3	43.80, 81.30	43.80, 56.30	0.00, 12.50	-12.50, 6.20
Min, Max	31.3, 100.0	0.0, 87.5	-37.5, 31.2	-31.3, 31.3
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	67.99 (17.81)	54.83 (26.17)	5.45 (5.20)	1.44 (5.63)
Median	65.65	56.30	6.25	6.30
IQR: Q1, Q3	56.25, 78.15	43.80, 68.80	0.00, 18.70	-12.50, 18.70
Min, Max	43.8, 100.0	0.0, 100.0	-25.0, 18.7	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Social Functioning				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	87.50 (22.53)	74.04 (28.17)		
Median	100.00	87.50		
IQR: Q1, Q3	87.50, 100.00	50.00, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	86.11 (19.21)	69.23 (32.52)	-1.39 (4.86)	-4.81 (5.21)
Median	100.00	50.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 0.00	0.00, 0.00
Min, Max	50.0, 100.0	0.0, 100.0	-25.0, 25.0	-50.0, 12.5
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	73.44 (25.39)	73.08 (29.25)	-12.50 (13.15)	-0.96 (5.74)
Median	75.00	75.00	-12.50	0
IQR: Q1, Q3	62.50, 93.75	62.50, 100.00	-31.25, 6.25	0.00, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Role Emotional				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	82.41 (34.97)	69.87 (36.10)		
Median	100.00	91.70		
IQR: Q1, Q3	91.70, 100.00	33.30, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	83.34 (29.75)	71.15 (29.77)	0.93 (2.58)	1.28 (3.99)
Median	100.00	83.30	0	0
IQR: Q1, Q3	91.70, 100.00	50.00, 100.00	0.00, 0.00	-8.40, 0.00
Min, Max	16.7, 100.0	0.0, 100.0	-8.3, 16.7	-16.7, 33.4
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	78.13 (19.89)	69.23 (32.17)	-2.09 (10.65)	-0.64 (5.62)
Median	79.15	75.00	-4.15	0
IQR: Q1, Q3	62.50, 95.85	50.00, 100.00	-16.70, 12.50	-8.30, 8.30
Min, Max	50.0, 100.0	0.0, 100.0	-50.0, 50.0	-33.3, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Mental Health				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	78.06 (16.95)	67.31 (22.79)		
Median	80.00	65.00		
IQR: Q1, Q3	80.00, 90.00	45.00, 85.00		
Min, Max	45.0, 95.0	30.0, 100.0		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	82.22 (11.21)	63.08 (27.35)	4.17 (3.06)	-4.23 (5.34)
Median	80.00	55.00	0	0
IQR: Q1, Q3	80.00, 90.00	45.00, 90.00	0.00, 10.00	-10.00, 10.00
Min, Max	60.0, 100.0	15.0, 100.0	-7.5, 20.0	-50.0, 20.0
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	74.38 (21.45)	68.85 (30.15)	-2.19 (6.64)	1.54 (4.82)
Median	80.00	60.00	-3.75	5.00
IQR: Q1, Q3	62.50, 87.50	50.00, 95.00	-15.00, 12.50	0.00, 10.00
Min, Max	35.0, 100.0	0.0, 100.0	-30.0, 25.0	-45.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Mental Component Score				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	53.88 (9.66)	46.37 (12.16)		
Median	57.60	47.30		
IQR: Q1, Q3	55.70, 59.10	37.40, 57.00		
Min, Max	32.2, 62.3	26.9, 65.3		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	54.28 (6.89)	44.65 (14.62)	0.40 (1.78)	-1.72 (2.31)
Median	53.10	41.70	1.20	0.60
IQR: Q1, Q3	50.50, 59.30	36.20, 57.00	-4.80, 3.90	-4.60, 2.30
Min, Max	42.1, 63.1	12.9, 66.1	-6.5, 9.9	-19.5, 9.8
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	49.99 (7.42)	46.21 (14.83)	-3.24 (2.90)	-0.16 (2.37)
Median	52.60	42.40	-4.55	1.90
IQR: Q1, Q3	45.15, 55.20	36.60, 58.80	-5.95, 2.95	-1.30, 5.00
Min, Max	37.5, 56.5	13.9, 64.0	-18.2, 7.4	-18.5, 10.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=13)	MGL-3196 (N=9)	Placebo (N=13)
Physical Component Score				
Baseline				
m	9	13		
n	9	13		
Mean (SD)	44.53 (9.59)	46.85 (10.69)		
Median	47.50	50.70		
IQR: Q1, Q3	42.10, 50.20	38.70, 55.40		
Min, Max	27.0, 54.5	25.8, 60.5		
Week 12				
m	9	13		
n	9	13		
Mean (SD/SE)	46.84 (8.92)	47.88 (8.48)	2.31 (1.20)	1.04 (1.67)
Median	49.60	47.60	3.50	1.10
IQR: Q1, Q3	47.60, 51.90	41.30, 56.40	0.20, 4.40	-2.50, 3.20
Min, Max	27.2, 54.5	35.4, 58.6	-4.9, 7.0	-8.0, 10.7
Week 36				
m	8	13		
n	8	13		
Mean (SD/SE)	49.33 (5.52)	47.61 (10.45)	6.04 (2.93)	0.76 (1.86)
Median	50.60	49.80	5.60	0.90
IQR: Q1, Q3	44.95, 53.80	40.70, 55.30	2.55, 12.85	-0.80, 3.00
Min, Max	40.6, 55.3	28.7, 60.7	-9.6, 15.9	-15.6, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Physical Functioning				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	76.3 (20.7)	63.3 (26.8)		
Median	75.0	72.5		
IQR: Q1, Q3	62.5, 95.0	30.0, 85.0		
Min, Max	45, 100	30, 90		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	73.8 (25.0)	76.7 (36.8)	-2.5 (5.3)	13.3 (13.5)
Median	77.5	92.5	0	5.0
IQR: Q1, Q3	57.5, 95.0	70.0, 100.0	-10.0, 5.0	-5.0, 30.0
Min, Max	30, 100	5, 100	-30, 20	-25, 70
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	77.9 (24.6)	85.0 (15.8)	-2.1 (3.6)	15.0 (14.1)
Median	80.0	90.0	0	5.0
IQR: Q1, Q3	55.0, 100.0	80.0, 95.0	-10.0, 5.0	5.0, 5.0
Min, Max	35, 100	60, 100	-20, 5	-10, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Role Physical				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	69.55 (32.81)	64.58 (31.04)		
Median	81.30	68.75		
IQR: Q1, Q3	56.25, 90.65	50.00, 87.50		
Min, Max	0.0, 100.0	12.5, 100.0		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	77.36 (31.51)	77.10 (29.22)	7.81 (5.88)	12.52 (4.27)
Median	93.80	90.65	12.50	15.65
IQR: Q1, Q3	59.40, 100.00	50.00, 100.00	0.00, 15.60	0.00, 18.80
Min, Max	12.5, 100.0	31.3, 100.0	-25.0, 31.3	0.0, 25.0
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	81.26 (23.11)	90.02 (19.04)	8.91 (9.24)	15.02 (6.43)
Median	93.80	100.00	12.50	12.50
IQR: Q1, Q3	50.00, 100.00	93.80, 100.00	0.00, 18.70	6.30, 18.80
Min, Max	50.0, 100.0	56.3, 100.0	-31.3, 50.0	0.0, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Bodily Pain				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	65.6 (20.9)	83.7 (19.3)		
Median	62.0	87.0		
IQR: Q1, Q3	56.0, 79.0	74.0, 100.0		
Min, Max	31, 100	54, 100		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	66.8 (30.1)	76.7 (19.7)	1.1 (7.5)	-7.0 (5.9)
Median	73.0	73.0	0	0
IQR: Q1, Q3	41.0, 92.0	62.0, 100.0	-4.5, 19.0	-22.0, 0.0
Min, Max	22, 100	52, 100	-43, 23	-28, 8
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	69.4 (29.5)	75.2 (27.7)	5.0 (7.0)	-14.4 (11.3)
Median	62.0	84.0	0	0
IQR: Q1, Q3	41.0, 100.0	51.0, 100.0	-10.0, 16.0	-33.0, 0.0
Min, Max	41, 100	41, 100	-19, 38	-49, 10

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
General Health				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	61.9 (16.4)	64.7 (19.5)		
Median	64.5	62.0		
IQR: Q1, Q3	53.5, 73.5	47.0, 80.0		
Min, Max	30, 82	45, 92		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	56.3 (17.8)	57.7 (16.4)	-5.6 (1.9)	-7.0 (4.4)
Median	56.0	56.0	-5.0	-7.5
IQR: Q1, Q3	46.0, 69.5	47.0, 72.0	-8.5, -1.5	-12.0, 0.0
Min, Max	25, 82	35, 80	-15, 0	-23, 8
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	58.3 (15.8)	77.6 (18.9)	-3.6 (2.1)	9.0 (4.6)
Median	65.0	72.0	-5.0	8.0
IQR: Q1, Q3	45.0, 72.0	72.0, 92.0	-10.0, 0.0	0.0, 12.0
Min, Max	35, 77	52, 100	-10, 5	0, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Vitality				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	59.41 (17.68)	55.23 (22.17)		
Median	62.55	50.00		
IQR: Q1, Q3	46.90, 71.90	43.80, 81.30		
Min, Max	31.3, 81.3	25.0, 81.3		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	57.04 (17.50)	57.32 (20.70)	-2.38 (6.68)	2.08 (6.59)
Median	53.15	56.30	-3.15	3.10
IQR: Q1, Q3	43.75, 68.75	50.00, 68.80	-15.65, 12.45	0.00, 6.30
Min, Max	37.5, 87.5	25.0, 87.5	-31.3, 25.0	-25.0, 25.0
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	58.07 (23.59)	67.52 (22.26)	-1.79 (8.16)	6.24 (11.01)
Median	68.80	68.80	6.20	18.70
IQR: Q1, Q3	43.80, 75.00	50.00, 75.00	-12.50, 6.30	-6.20, 25.00
Min, Max	12.5, 81.3	43.8, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Social Functioning				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	81.25 (21.13)	83.33 (18.82)		
Median	87.50	87.50		
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00		
Min, Max	50.0, 100.0	62.5, 100.0		
Week 12				
m	8	6		
n	8	6	8	6
Mean (SD/SE)	78.13 (27.35)	79.17 (28.14)	-3.13 (6.14)	-4.17 (7.68)
Median	87.50	93.75	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-18.75, 6.25	-25.00, 0.00
Min, Max	25.0, 100.0	37.5, 100.0	-25.0, 25.0	-25.0, 25.0
Week 36				
m	7	6		
n	7	5	7	5
Mean (SD/SE)	87.50 (16.14)	87.50 (21.65)	1.79 (8.38)	0.00 (7.91)
Median	100.00	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	-12.50, 25.00	0.00, 0.00
Min, Max	62.5, 100.0	50.0, 100.0	-37.5, 25.0	-25.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Role Emotional				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	79.16 (20.89)	68.07 (31.79)		
Median	79.15	70.85		
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	16.7, 100.0		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	82.30 (35.20)	81.95 (24.96)	3.14 (8.33)	13.88 (6.33)
Median	100.00	95.85	8.35	12.50
IQR: Q1, Q3	79.20, 100.00	50.00, 100.00	0.00, 16.70	0.00, 25.00
Min, Max	0.0, 100.0	50.0, 100.0	-50.0, 25.0	0.0, 33.3
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	89.29 (13.36)	85.00 (22.36)	5.96 (5.05)	6.66 (4.86)
Median	100.00	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 8.30
Min, Max	75.0, 100.0	50.0, 100.0	-8.3, 25.0	0.0, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Mental Health				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	81.88 (14.38)	56.67 (23.17)		
Median	82.50	47.50		
IQR: Q1, Q3	72.50, 92.50	45.00, 80.00		
Min, Max	60.0, 100.0	30.0, 90.0		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	75.00 (16.26)	68.33 (24.83)	-6.88 (3.13)	11.67 (3.57)
Median	82.50	67.50	-5.00	12.50
IQR: Q1, Q3	60.00, 85.00	55.00, 95.00	-15.00, 0.00	5.00, 15.00
Min, Max	50.0, 95.0	30.0, 95.0	-20.0, 5.0	0.0, 25.0
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	84.29 (13.67)	71.00 (20.74)	-0.71 (4.81)	9.00 (9.80)
Median	85.00	60.00	0	10.00
IQR: Q1, Q3	70.00, 100.00	60.00, 85.00	-15.00, 10.00	0.00, 15.00
Min, Max	65.0, 100.0	50.0, 100.0	-20.0, 15.0	-20.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Mental Component Score				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	52.31 (8.33)	44.27 (13.08)		
Median	52.80	41.40		
IQR: Q1, Q3	45.25, 60.45	34.20, 58.30		
Min, Max	40.6, 60.9	29.1, 61.2		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	50.39 (11.03)	48.17 (10.08)	-1.93 (1.96)	3.90 (1.89)
Median	53.45	48.30	0.40	3.85
IQR: Q1, Q3	44.90, 58.15	41.10, 58.00	-5.65, 1.85	-0.30, 6.20
Min, Max	28.4, 61.7	33.6, 59.7	-12.3, 3.7	-1.5, 11.3
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	54.50 (5.28)	50.02 (10.13)	0.51 (2.99)	2.72 (4.02)
Median	56.50	52.00	-1.00	2.80
IQR: Q1, Q3	51.50, 59.00	45.50, 56.40	-8.10, 7.00	-2.80, 11.30
Min, Max	44.4, 59.6	35.1, 61.1	-8.8, 13.0	-9.2, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=6)	MGL-3196 (N=8)	Placebo (N=6)
Physical Component Score				
Baseline				
m	8	6		
n	8	6		
Mean (SD)	46.54 (8.37)	50.22 (7.36)		
Median	44.90	49.70		
IQR: Q1, Q3	40.60, 53.15	46.60, 57.20		
Min, Max	35.2, 59.8	38.9, 59.2		
Week 12				
m	8	6		
n	8	6		
Mean (SD/SE)	47.13 (10.36)	49.78 (9.24)	0.59 (1.43)	-0.43 (2.29)
Median	48.55	52.00	1.15	-1.60
IQR: Q1, Q3	40.15, 55.80	43.90, 57.90	-1.95, 3.25	-5.10, 3.30
Min, Max	28.8, 59.2	34.5, 58.4	-6.4, 6.2	-5.8, 8.2
Week 36				
m	7	6		
n	7	5		
Mean (SD/SE)	47.23 (10.36)	54.52 (6.32)	0.59 (1.13)	2.04 (3.73)
Median	47.20	53.50	0.70	-2.30
IQR: Q1, Q3	38.60, 56.50	52.60, 54.90	-1.10, 3.20	-2.60, 6.00
Min, Max	30.7, 58.7	47.1, 64.5	-4.5, 4.8	-5.7, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Physical Functioning				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	80.0 (26.5)	57.1 (32.8)		
Median	90.0	55.0		
IQR: Q1, Q3	50.0, 100.0	30.0, 95.0		
Min, Max	50, 100	10, 95		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	86.7 (14.4)	67.9 (31.9)	6.7 (7.3)	10.7 (9.3)
Median	95.0	85.0	5.0	10.0
IQR: Q1, Q3	70.0, 95.0	55.0, 85.0	-5.0, 20.0	-10.0, 30.0
Min, Max	70, 95	5, 100	-5, 20	-25, 50
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	97.5 (3.5)	69.2 (34.1)	2.5 (2.5)	7.5 (4.4)
Median	97.5	80.0	2.5	5.0
IQR: Q1, Q3	95.0, 100.0	60.0, 95.0	0.0, 5.0	0.0, 20.0
Min, Max	95, 100	5, 95	0, 5	-5, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Role Physical				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	77.10 (25.26)	41.97 (40.61)		
Median	81.30	18.80		
IQR: Q1, Q3	50.00, 100.00	12.50, 87.50		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	87.50 (21.65)	50.90 (31.54)	10.40 (5.50)	8.93 (8.61)
Median	100.00	50.00	12.50	12.50
IQR: Q1, Q3	62.50, 100.00	31.30, 75.00	0.00, 18.70	-12.50, 31.20
Min, Max	62.5, 100.0	0.0, 100.0	0.0, 18.7	-25.0, 37.5
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	100.00 (0.00)	58.33 (37.64)	9.35 (9.35)	11.45 (7.97)
Median	100.00	50.00	9.35	6.25
IQR: Q1, Q3	100.00, 100.00	50.00, 100.00	0.00, 18.70	0.00, 31.20
Min, Max	100.0, 100.0	0.0, 100.0	0.0, 18.7	-12.5, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Bodily Pain				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	73.3 (11.0)	52.1 (34.2)		
Median	74.0	54.0		
IQR: Q1, Q3	62.0, 84.0	22.0, 74.0		
Min, Max	62, 84	0, 100		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	71.7 (36.1)	61.1 (35.2)	-1.7 (20.7)	9.0 (7.2)
Median	84.0	62.0	16.0	8.0
IQR: Q1, Q3	31.0, 100.0	41.0, 100.0	-43.0, 22.0	0.0, 26.0
Min, Max	31, 100	0, 100	-43, 22	-23, 33
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	100.0 (0.0)	57.0 (37.8)	27.0 (11.0)	5.2 (5.6)
Median	100.0	73.0	27.0	0
IQR: Q1, Q3	100.0, 100.0	22.0, 74.0	16.0, 38.0	0.0, 0.0
Min, Max	100, 100	0, 100	16, 38	-2, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
General Health				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	69.7 (6.8)	60.0 (18.7)		
Median	72.0	57.0		
IQR: Q1, Q3	62.0, 75.0	45.0, 77.0		
Min, Max	62, 75	35, 82		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	62.0 (13.2)	60.0 (23.3)	-7.7 (3.7)	0.0 (3.8)
Median	67.0	72.0	-5.0	-5.0
IQR: Q1, Q3	47.0, 72.0	35.0, 82.0	-15.0, -3.0	-5.0, 5.0
Min, Max	47, 72	30, 82	-15, -3	-10, 20
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	68.5 (4.9)	51.8 (19.0)	-5.0 (5.0)	-10.7 (4.5)
Median	68.5	53.5	-5.0	-13.5
IQR: Q1, Q3	65.0, 72.0	40.0, 57.0	-10.0, 0.0	-20.0, 0.0
Min, Max	65, 72	25, 82	-10, 0	-22, 5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Vitality				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	68.80 (12.50)	41.99 (22.16)		
Median	68.80	31.30		
IQR: Q1, Q3	56.30, 81.30	25.00, 62.50		
Min, Max	56.3, 81.3	12.5, 68.8		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	52.10 (3.64)	41.99 (23.86)	-16.70 (7.52)	0.00 (8.07)
Median	50.00	43.80	-12.50	0
IQR: Q1, Q3	50.00, 56.30	25.00, 56.30	-31.30, -6.30	-18.70, 18.70
Min, Max	50.0, 56.3	0.0, 75.0	-31.3, -6.3	-31.3, 31.3
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	68.80 (0.00)	46.90 (28.72)	-6.25 (6.25)	2.08 (8.50)
Median	68.80	50.00	-6.25	9.35
IQR: Q1, Q3	68.80, 68.80	31.30, 68.80	-12.50, 0.00	-12.50, 18.80
Min, Max	68.8, 68.8	0.0, 81.3	-12.5, 0.0	-31.3, 18.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Social Functioning				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	75.00 (25.00)	60.71 (25.44)		
Median	75.00	62.50		
IQR: Q1, Q3	50.00, 100.00	37.50, 87.50		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	83.33 (28.87)	55.36 (35.25)	8.33 (8.33)	-5.36 (7.65)
Median	100.00	50.00	0	0
IQR: Q1, Q3	50.00, 100.00	37.50, 100.00	0.00, 25.00	-25.00, 12.50
Min, Max	50.0, 100.0	0.0, 100.0	0.0, 25.0	-37.5, 12.5
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	100.00 (0.00)	64.58 (37.43)	12.50 (12.50)	4.17 (8.94)
Median	100.00	68.75	12.50	12.50
IQR: Q1, Q3	100.00, 100.00	50.00, 100.00	0.00, 25.00	0.00, 12.50
Min, Max	100.0, 100.0	0.0, 100.0	0.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Role Emotional				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	75.00 (25.00)	46.43 (39.63)		
Median	75.00	33.30		
IQR: Q1, Q3	50.00, 100.00	16.70, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	3	7		
n	3	7	3	7
Mean (SD/SE)	88.90 (19.23)	59.53 (34.50)	13.90 (7.35)	13.10 (6.26)
Median	100.00	50.00	16.70	0
IQR: Q1, Q3	66.70, 100.00	50.00, 100.00	0.00, 25.00	0.00, 33.30
Min, Max	66.7, 100.0	0.0, 100.0	0.0, 25.0	0.0, 33.4
Week 36				
m	2	7		
n	2	6	2	6
Mean (SD/SE)	100.00 (0.00)	63.88 (37.52)	12.50 (12.50)	12.50 (7.06)
Median	100.00	66.65	12.50	4.15
IQR: Q1, Q3	100.00, 100.00	50.00, 100.00	0.00, 25.00	0.00, 25.00
Min, Max	100.0, 100.0	0.0, 100.0	0.0, 25.0	0.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Mental Health				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	80.00 (20.00)	54.29 (24.40)		
Median	80.00	45.00		
IQR: Q1, Q3	60.00, 100.00	30.00, 85.00		
Min, Max	60.0, 100.0	30.0, 90.0		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	73.33 (16.07)	55.00 (27.99)	-6.67 (4.41)	0.71 (5.82)
Median	80.00	55.00	-5.00	0
IQR: Q1, Q3	55.00, 85.00	30.00, 90.00	-15.00, 0.00	0.00, 10.00
Min, Max	55.0, 85.0	15.0, 90.0	-15.0, 0.0	-30.0, 20.0
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	95.00 (7.07)	57.50 (33.28)	5.00 (5.00)	-0.83 (9.26)
Median	95.00	57.50	5.00	5.00
IQR: Q1, Q3	90.00, 100.00	50.00, 85.00	0.00, 10.00	0.00, 10.00
Min, Max	90.0, 100.0	0.0, 95.0	0.0, 10.0	-45.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Mental Component Score				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	50.43 (10.16)	38.64 (12.30)		
Median	49.80	32.40		
IQR: Q1, Q3	40.60, 60.90	29.10, 54.70		
Min, Max	40.6, 60.9	26.9, 57.0		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	49.33 (7.13)	38.93 (15.81)	-1.10 (3.33)	0.29 (3.73)
Median	53.40	34.40	0.50	2.30
IQR: Q1, Q3	41.10, 53.50	33.60, 57.00	-7.50, 3.70	-4.80, 7.50
Min, Max	41.1, 53.5	12.9, 59.2	-7.5, 3.7	-19.5, 9.8
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	57.90 (1.56)	41.68 (16.41)	2.55 (4.45)	1.45 (4.30)
Median	57.90	41.75	2.55	3.05
IQR: Q1, Q3	56.80, 59.00	36.60, 55.60	-1.90, 7.00	0.90, 9.70
Min, Max	56.8, 59.0	13.9, 60.5	-1.9, 7.0	-18.5, 10.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=3)	Placebo (N=7)	MGL-3196 (N=3)	Placebo (N=7)
Physical Component Score				
Baseline				
m	3	7		
n	3	7		
Mean (SD)	50.70 (4.48)	43.66 (11.46)		
Median	51.70	41.10		
IQR: Q1, Q3	45.80, 54.60	35.50, 54.30		
Min, Max	45.8, 54.6	25.8, 56.1		
Week 12				
m	3	7		
n	3	7		
Mean (SD/SE)	51.37 (7.74)	46.57 (9.24)	0.67 (2.00)	2.91 (2.63)
Median	54.80	46.50	2.20	2.50
IQR: Q1, Q3	42.50, 56.80	36.50, 56.40	-3.30, 3.10	-4.40, 9.10
Min, Max	42.5, 56.8	34.5, 58.6	-3.3, 3.1	-7.8, 10.7
Week 36				
m	2	7		
n	2	6		
Mean (SD/SE)	55.90 (0.85)	45.60 (10.62)	2.75 (2.05)	1.15 (1.76)
Median	55.90	49.75	2.75	0.15
IQR: Q1, Q3	55.30, 56.50	36.40, 53.70	0.70, 4.80	-0.80, 2.90
Min, Max	55.3, 56.5	28.7, 55.3	0.7, 4.8	-4.1, 8.6

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Physical Functioning				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	71.4 (26.1)	75.8 (24.8)		
Median	77.5	80.0		
IQR: Q1, Q3	75.0, 85.0	67.5, 97.5		
Min, Max	5, 100	30, 100		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	68.9 (29.5)	79.2 (20.7)	-2.5 (3.2)	3.3 (8.1)
Median	80.0	87.5	0	0
IQR: Q1, Q3	45.0, 90.0	65.0, 95.0	-5.0, 5.0	-7.5, 7.5
Min, Max	5, 100	40, 100	-30, 15	-50, 70
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	74.2 (22.4)	82.5 (20.5)	3.8 (4.4)	6.7 (6.4)
Median	80.0	92.5	5.0	2.5
IQR: Q1, Q3	65.0, 85.0	67.5, 100.0	0.0, 5.0	0.0, 5.0
Min, Max	30, 100	45, 100	-20, 40	-20, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Role Physical				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	74.58 (35.81)	76.05 (29.04)		
Median	93.80	87.50		
IQR: Q1, Q3	62.50, 100.00	56.25, 100.00		
Min, Max	0.0, 100.0	6.3, 100.0		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	75.92 (29.81)	77.10 (21.20)	1.34 (4.25)	1.05 (5.80)
Median	93.80	84.40	0	0
IQR: Q1, Q3	56.30, 93.80	56.25, 96.90	-6.20, 12.50	-12.50, 15.65
Min, Max	12.5, 100.0	43.8, 100.0	-25.0, 31.3	-31.2, 37.5
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	76.46 (19.79)	77.62 (24.20)	3.36 (8.30)	1.57 (7.10)
Median	75.00	84.40	0	0
IQR: Q1, Q3	56.30, 93.80	53.15, 100.00	-6.30, 12.50	-18.75, 15.65
Min, Max	50.0, 100.0	37.5, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Bodily Pain				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	53.2 (30.0)	76.9 (23.7)		
Median	61.5	84.0		
IQR: Q1, Q3	31.0, 74.0	57.5, 100.0		
Min, Max	0, 100	41, 100		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	66.6 (25.3)	67.9 (31.1)	13.4 (7.9)	-9.0 (6.1)
Median	67.0	72.0	5.0	-4.5
IQR: Q1, Q3	51.0, 84.0	51.5, 100.0	0.0, 26.0	-25.0, 0.0
Min, Max	22, 100	0, 100	-22, 100	-41, 31
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	60.1 (22.9)	72.3 (26.2)	9.2 (8.2)	-4.6 (8.2)
Median	62.0	79.0	0	0
IQR: Q1, Q3	42.0, 74.0	46.0, 100.0	-10.0, 26.0	-21.5, 13.0
Min, Max	22, 100	31, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
General Health				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	58.1 (18.0)	66.1 (17.8)		
Median	54.5	72.0		
IQR: Q1, Q3	47.0, 70.0	51.0, 78.5		
Min, Max	30, 92	30, 92		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	59.0 (16.4)	64.7 (18.6)	0.9 (3.8)	-1.4 (3.7)
Median	58.5	69.5	0	-2.5
IQR: Q1, Q3	55.0, 67.0	51.0, 76.0	-5.0, 5.0	-7.5, 2.5
Min, Max	25, 82	30, 97	-25, 35	-23, 30
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	63.9 (20.5)	71.9 (21.8)	8.5 (5.4)	5.8 (3.7)
Median	67.0	72.0	5.0	1.0
IQR: Q1, Q3	45.0, 77.0	59.5, 89.5	-5.0, 20.0	-5.0, 16.0
Min, Max	35, 100	25, 100	-25, 48	-10, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Vitality				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	60.30 (19.85)	60.97 (17.91)		
Median	59.40	53.15		
IQR: Q1, Q3	43.80, 75.00	46.90, 81.30		
Min, Max	31.3, 100.0	37.5, 87.5		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	62.96 (21.71)	60.97 (16.23)	2.66 (5.35)	0.00 (3.69)
Median	62.50	56.30	6.20	3.10
IQR: Q1, Q3	43.80, 81.30	50.00, 75.05	0.00, 18.70	-9.35, 6.25
Min, Max	31.3, 100.0	43.8, 87.5	-37.5, 31.2	-25.0, 25.0
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	62.52 (22.10)	64.08 (22.31)	3.35 (5.23)	3.12 (6.32)
Median	62.50	65.65	6.30	9.40
IQR: Q1, Q3	50.00, 75.00	46.90, 75.00	0.00, 18.70	-15.60, 21.85
Min, Max	12.5, 100.0	25.0, 100.0	-43.8, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Social Functioning				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	86.61 (21.07)	86.46 (20.96)		
Median	100.00	100.00		
IQR: Q1, Q3	87.50, 100.00	68.75, 100.00		
Min, Max	37.5, 100.0	50.0, 100.0		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	82.14 (22.85)	82.29 (24.11)	-4.46 (4.06)	-4.17 (5.18)
Median	87.50	100.00	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-12.50, 0.00	0.00, 0.00
Min, Max	25.0, 100.0	50.0, 100.0	-25.0, 25.0	-50.0, 25.0
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	76.92 (22.15)	83.33 (20.18)	-8.65 (8.88)	-3.13 (5.36)
Median	75.00	93.75	0	0
IQR: Q1, Q3	75.00, 100.00	68.75, 100.00	-25.00, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	50.0, 100.0	-75.0, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Role Emotional				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	82.14 (29.75)	82.64 (22.33)		
Median	100.00	91.70		
IQR: Q1, Q3	75.00, 100.00	70.85, 100.00		
Min, Max	0.0, 100.0	33.3, 100.0		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	81.56 (33.84)	83.33 (20.41)	-0.59 (4.41)	0.69 (3.90)
Median	100.00	87.50	0	0
IQR: Q1, Q3	91.70, 100.00	75.00, 100.00	0.00, 8.30	-8.40, 4.20
Min, Max	0.0, 100.0	41.7, 100.0	-50.0, 16.7	-16.7, 25.0
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	80.77 (17.48)	78.48 (25.98)	0.00 (6.74)	-4.17 (4.75)
Median	75.00	87.50	0	0
IQR: Q1, Q3	75.00, 100.00	58.35, 100.00	-8.30, 0.00	-16.65, 4.15
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 50.0	-33.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Mental Health				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	79.82 (15.21)	69.58 (20.83)		
Median	82.50	72.50		
IQR: Q1, Q3	80.00, 90.00	47.50, 87.50		
Min, Max	45.0, 100.0	45.0, 100.0		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	80.00 (13.73)	70.42 (24.16)	0.18 (2.88)	0.83 (5.80)
Median	82.50	72.50	0	7.50
IQR: Q1, Q3	75.00, 90.00	50.00, 95.00	-5.00, 5.00	-10.00, 15.00
Min, Max	50.0, 100.0	35.0, 100.0	-20.0, 20.0	-50.0, 25.0
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	76.54 (18.41)	75.42 (23.01)	-2.50 (4.60)	5.83 (4.76)
Median	80.00	72.50	0	10.00
IQR: Q1, Q3	70.00, 85.00	55.00, 100.00	-15.00, 5.00	-2.50, 15.00
Min, Max	35.0, 100.0	45.0, 100.0	-30.0, 25.0	-20.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Mental Component Score				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	53.72 (8.81)	49.83 (10.38)		
Median	57.45	50.55		
IQR: Q1, Q3	52.50, 59.20	40.45, 57.85		
Min, Max	32.2, 62.3	34.2, 65.3		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	53.11 (9.44)	49.75 (10.03)	-0.61 (1.48)	-0.08 (1.92)
Median	54.40	49.50	0.70	0.15
IQR: Q1, Q3	48.70, 60.60	40.25, 58.85	-4.80, 2.60	-2.55, 3.65
Min, Max	28.4, 63.1	36.2, 66.1	-12.3, 9.9	-15.9, 11.3
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	51.20 (6.76)	50.06 (11.58)	-2.11 (2.29)	0.23 (2.25)
Median	53.10	54.20	-3.30	0.70
IQR: Q1, Q3	51.00, 56.40	37.95, 59.95	-6.10, 3.40	-4.60, 5.05
Min, Max	37.5, 59.6	32.7, 64.0	-18.2, 13.0	-14.6, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=14)	Placebo (N=12)	MGL-3196 (N=14)	Placebo (N=12)
Physical Component Score				
Baseline				
m	14	12		
n	14	12		
Mean (SD)	44.36 (9.21)	50.39 (7.98)		
Median	43.75	50.20		
IQR: Q1, Q3	37.70, 50.20	46.85, 56.40		
Min, Max	27.0, 59.8	34.3, 60.5		
Week 12				
m	14	12		
n	14	12	14	12
Mean (SD/SE)	46.04 (9.60)	49.60 (8.27)	1.68 (1.06)	-0.79 (1.37)
Median	49.35	50.75	2.20	0.35
IQR: Q1, Q3	37.80, 51.90	42.60, 57.95	0.10, 4.40	-5.45, 2.20
Min, Max	27.2, 59.2	35.4, 58.6	-6.4, 7.0	-8.0, 8.2
Week 36				
m	13	12		
n	13	12	13	12
Mean (SD/SE)	47.18 (7.86)	51.49 (9.25)	3.61 (2.02)	1.10 (2.36)
Median	47.20	53.05	3.20	1.10
IQR: Q1, Q3	42.90, 53.20	46.05, 58.25	0.00, 5.70	-3.65, 6.70
Min, Max	30.7, 58.7	31.5, 64.5	-9.6, 15.9	-15.6, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Physical Functioning				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	78.8 (21.2)	65.6 (37.0)		
Median	85.0	90.0		
IQR: Q1, Q3	62.5, 95.0	30.0, 95.0		
Min, Max	45, 100	10, 100		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	77.5 (22.5)	80.6 (22.7)	-1.3 (4.4)	15.0 (9.1)
Median	80.0	95.0	0	5.0
IQR: Q1, Q3	70.0, 95.0	60.0, 95.0	-10.0, 5.0	-5.0, 15.0
Min, Max	30, 100	40, 100	-20, 20	-10, 70
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	83.6 (23.0)	77.8 (33.1)	0.7 (2.0)	12.2 (7.8)
Median	95.0	95.0	0	0
IQR: Q1, Q3	80.0, 100.0	60.0, 100.0	0.0, 5.0	0.0, 20.0
Min, Max	35, 100	5, 100	-10, 5	-5, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Role Physical				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	86.74 (17.49)	64.60 (43.18)		
Median	90.65	87.50		
IQR: Q1, Q3	81.30, 100.00	18.80, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	84.39 (17.67)	71.54 (34.25)	-2.35 (6.01)	6.94 (6.70)
Median	90.65	81.30	0	0
IQR: Q1, Q3	68.75, 100.00	50.00, 100.00	-18.75, 12.50	0.00, 18.80
Min, Max	56.3, 100.0	0.0, 100.0	-25.0, 18.7	-25.0, 37.5
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	88.40 (19.24)	73.62 (34.91)	-3.59 (6.94)	9.02 (6.75)
Median	100.00	93.80	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	-25.00, 12.50	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-31.3, 18.7	-25.0, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Bodily Pain				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	63.3 (29.7)	69.0 (38.5)		
Median	68.0	84.0		
IQR: Q1, Q3	56.0, 79.0	41.0, 100.0		
Min, Max	0, 100	0, 100		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	81.3 (26.4)	65.8 (43.8)	18.0 (14.1)	-3.2 (6.2)
Median	92.0	100.0	19.0	0
IQR: Q1, Q3	67.5, 100.0	41.0, 100.0	0.0, 24.5	0.0, 0.0
Min, Max	31, 100	0, 100	-43, 100	-41, 19
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	76.1 (29.9)	67.4 (37.4)	14.4 (9.6)	-1.6 (6.5)
Median	100.0	72.0	16.0	0
IQR: Q1, Q3	42.0, 100.0	51.0, 100.0	-10.0, 38.0	0.0, 0.0
Min, Max	41, 100	0, 100	-19, 50	-49, 21

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
General Health				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	60.6 (16.6)	64.9 (18.8)		
Median	62.0	67.0		
IQR: Q1, Q3	51.0, 73.5	50.0, 77.0		
Min, Max	30, 82	35, 92		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	57.1 (17.9)	70.0 (21.7)	-3.5 (2.1)	5.1 (4.4)
Median	59.5	80.0	-4.0	5.0
IQR: Q1, Q3	46.0, 69.5	55.0, 82.0	-5.0, 0.0	-5.0, 8.0
Min, Max	25, 82	30, 97	-15, 5	-12, 30
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	68.0 (22.2)	65.2 (23.9)	7.6 (7.7)	0.3 (5.1)
Median	72.0	72.0	0	0
IQR: Q1, Q3	45.0, 82.0	52.0, 82.0	-5.0, 20.0	-10.0, 8.0
Min, Max	35, 100	25, 100	-10, 48	-20, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Vitality				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	71.13 (14.53)	53.51 (23.00)		
Median	68.80	56.30		
IQR: Q1, Q3	59.40, 78.15	43.80, 68.80		
Min, Max	56.3, 100.0	12.5, 81.3		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	65.64 (21.13)	56.97 (27.32)	-5.49 (5.47)	3.46 (6.26)
Median	62.55	56.30	-3.15	6.20
IQR: Q1, Q3	50.00, 81.25	43.80, 75.00	-15.65, 3.15	-6.20, 6.20
Min, Max	37.5, 100.0	0.0, 87.5	-31.3, 18.7	-31.3, 31.3
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	67.89 (26.87)	59.06 (34.39)	-5.36 (6.89)	5.54 (7.33)
Median	68.80	68.80	0	18.70
IQR: Q1, Q3	68.80, 81.30	31.30, 81.30	-12.50, 6.30	0.00, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-43.8, 6.3	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Social Functioning				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	87.50 (17.68)	75.00 (27.95)		
Median	93.75	87.50		
IQR: Q1, Q3	81.25, 100.00	50.00, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	87.50 (17.68)	76.39 (35.60)	0.00 (5.28)	1.39 (5.68)
Median	93.75	100.00	0	0
IQR: Q1, Q3	81.25, 100.00	50.00, 100.00	-6.25, 6.25	0.00, 12.50
Min, Max	50.0, 100.0	0.0, 100.0	-25.0, 25.0	-37.5, 25.0
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	85.71 (28.35)	76.39 (33.33)	-7.14 (12.16)	1.39 (7.05)
Median	100.00	87.50	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Role Emotional				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	88.54 (18.33)	69.44 (38.20)		
Median	100.00	91.70		
IQR: Q1, Q3	79.15, 100.00	33.30, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	95.84 (11.77)	75.93 (34.72)	7.30 (3.68)	6.49 (4.57)
Median	100.00	91.70	0	0
IQR: Q1, Q3	100.00, 100.00	66.70, 100.00	0.00, 16.70	0.00, 8.40
Min, Max	66.7, 100.0	0.0, 100.0	0.0, 25.0	-8.4, 33.4
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	92.86 (12.20)	71.30 (36.35)	-1.19 (5.58)	1.86 (5.86)
Median	100.00	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 0.00
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 25.0	-25.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Mental Health				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	84.06 (12.81)	65.00 (20.16)		
Median	82.50	65.00		
IQR: Q1, Q3	80.00, 93.75	45.00, 85.00		
Min, Max	60.0, 100.0	45.0, 90.0		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	80.63 (11.48)	67.78 (29.59)	-3.44 (2.16)	2.78 (4.87)
Median	82.50	75.00	-2.50	10.00
IQR: Q1, Q3	80.00, 85.00	55.00, 90.00	-6.25, 0.00	0.00, 10.00
Min, Max	55.0, 95.0	15.0, 100.0	-15.0, 5.0	-30.0, 15.0
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	88.57 (13.14)	62.22 (30.12)	1.07 (4.81)	-2.78 (7.03)
Median	90.00	60.00	0	5.00
IQR: Q1, Q3	80.00, 100.00	55.00, 85.00	-7.50, 10.00	-20.00, 15.00
Min, Max	65.0, 100.0	0.0, 100.0	-20.0, 20.0	-45.0, 15.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Mental Component Score				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	55.69 (7.47)	45.92 (12.00)		
Median	59.10	47.30		
IQR: Q1, Q3	51.45, 60.75	34.20, 57.00		
Min, Max	40.6, 62.3	31.9, 61.2		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	55.04 (6.73)	46.82 (15.51)	-0.65 (1.33)	0.90 (2.95)
Median	54.60	47.90	0.40	2.20
IQR: Q1, Q3	53.25, 60.90	41.70, 59.20	-2.95, 1.85	-1.20, 4.10
Min, Max	41.1, 61.7	12.9, 61.3	-7.5, 3.7	-19.5, 11.3
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	56.00 (3.12)	44.91 (15.24)	-1.84 (2.11)	-1.01 (3.56)
Median	56.50	45.50	-1.90	1.90
IQR: Q1, Q3	52.10, 59.00	39.30, 55.60	-5.80, 3.40	-9.20, 5.10
Min, Max	51.5, 59.6	13.9, 62.3	-8.8, 7.0	-18.5, 11.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=9)	MGL-3196 (N=8)	Placebo (N=9)
Physical Component Score				
Baseline				
m	8	9		
n	8	9		
Mean (SD)	47.81 (7.78)	47.64 (12.45)		
Median	47.80	54.30		
IQR: Q1, Q3	42.80, 53.15	35.50, 56.10		
Min, Max	35.2, 59.8	25.8, 60.5		
Week 12				
m	8	9		
n	8	9		
Mean (SD/SE)	48.93 (9.80)	50.36 (9.98)	1.11 (1.52)	2.71 (1.91)
Median	51.20	57.90	2.65	2.50
IQR: Q1, Q3	44.70, 55.80	43.30, 58.40	-1.95, 3.45	1.10, 7.80
Min, Max	28.8, 59.2	35.4, 58.6	-6.4, 7.0	-7.8, 10.7
Week 36				
m	7	9		
n	7	9		
Mean (SD/SE)	50.43 (9.96)	50.84 (11.82)	2.33 (1.91)	3.20 (1.92)
Median	55.30	54.90	0.70	0.90
IQR: Q1, Q3	43.60, 56.50	45.00, 58.40	-1.10, 5.50	-0.60, 3.00
Min, Max	30.7, 58.7	28.7, 64.5	-4.5, 10.8	-2.3, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Physical Functioning				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	67.8 (29.2)	72.0 (20.0)		
Median	75.0	72.5		
IQR: Q1, Q3	75.0, 80.0	65.0, 85.0		
Min, Max	5, 100	30, 100		
Week 12				
m	9	10		
n	9	10	9	10
Mean (SD/SE)	67.2 (32.6)	70.0 (27.3)	-0.6 (4.2)	-2.0 (7.6)
Median	80.0	77.5	0	0
IQR: Q1, Q3	45.0, 90.0	60.0, 85.0	0.0, 5.0	-10.0, 10.0
Min, Max	5, 100	5, 100	-30, 15	-50, 30
Week 36				
m	8	10		
n	8	9	8	9
Mean (SD/SE)	71.9 (21.7)	78.3 (17.3)	6.3 (6.9)	1.7 (3.8)
Median	77.5	80.0	5.0	5.0
IQR: Q1, Q3	60.0, 85.0	75.0, 90.0	-7.5, 17.5	0.0, 5.0
Min, Max	30, 100	45, 100	-20, 40	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Role Physical				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	64.61 (41.46)	62.50 (32.27)		
Median	93.80	62.50		
IQR: Q1, Q3	31.30, 93.80	50.00, 87.50		
Min, Max	0.0, 100.0	12.5, 100.0		
Week 12				
m	9	10		
n	9	10	9	10
Mean (SD/SE)	72.26 (35.38)	63.76 (21.80)	7.64 (4.14)	1.26 (7.02)
Median	93.80	56.25	6.20	0
IQR: Q1, Q3	50.00, 93.80	50.00, 87.50	0.00, 12.50	-12.50, 18.80
Min, Max	12.5, 100.0	31.3, 100.0	-6.2, 31.3	-31.2, 37.5
Week 36				
m	8	10		
n	8	9	8	9
Mean (SD/SE)	71.90 (18.61)	68.76 (25.38)	10.94 (12.09)	0.70 (8.62)
Median	71.90	56.30	6.25	0
IQR: Q1, Q3	53.15, 90.65	50.00, 100.00	-6.25, 43.75	-12.50, 12.50
Min, Max	50.0, 93.8	37.5, 100.0	-50.0, 50.0	-37.5, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Bodily Pain				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	51.0 (27.7)	66.7 (21.1)		
Median	62.0	74.0		
IQR: Q1, Q3	31.0, 72.0	41.0, 84.0		
Min, Max	10, 84	41, 100		
Week 12				
m	9	10		
n	9	10		
Mean (SD/SE)	55.3 (20.2)	65.1 (18.1)	4.3 (5.8)	-1.6 (7.9)
Median	62.0	67.0	0	-4.5
IQR: Q1, Q3	51.0, 72.0	52.0, 74.0	-9.0, 12.0	-22.0, 26.0
Min, Max	22, 74	32, 100	-22, 29	-33, 33
Week 36				
m	8	10		
n	8	9		
Mean (SD/SE)	56.0 (17.6)	67.0 (23.6)	9.1 (11.4)	-1.1 (9.9)
Median	62.0	74.0	5.0	0
IQR: Q1, Q3	46.0, 68.0	41.0, 84.0	-10.0, 29.5	-10.0, 10.0
Min, Max	22, 74	31, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
General Health				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	59.7 (18.5)	62.9 (17.9)		
Median	57.0	72.0		
IQR: Q1, Q3	47.0, 70.0	47.0, 77.0		
Min, Max	35, 92	30, 82		
Week 12				
m	9	10		
n	9	10		
Mean (SD/SE)	61.7 (13.8)	56.6 (16.8)	2.0 (5.9)	-6.3 (2.2)
Median	60.0	62.0	0	-5.0
IQR: Q1, Q3	55.0, 67.0	42.0, 72.0	-10.0, 15.0	-10.0, 0.0
Min, Max	35, 82	30, 72	-25, 35	-23, 0
Week 36				
m	8	10		
n	8	9		
Mean (SD/SE)	61.5 (17.0)	65.2 (22.6)	5.9 (6.7)	0.3 (4.7)
Median	67.0	67.0	2.5	0
IQR: Q1, Q3	46.0, 74.5	52.0, 72.0	-5.0, 23.5	-5.0, 5.0
Min, Max	35, 82	25, 100	-25, 30	-22, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Vitality				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	53.51 (18.78)	54.39 (20.64)		
Median	56.30	50.00		
IQR: Q1, Q3	37.50, 68.80	37.50, 68.80		
Min, Max	31.3, 81.3	25.0, 87.5		
Week 12				
m	9	10		
n	9	10	9	10
Mean (SD/SE)	56.97 (19.37)	51.28 (14.08)	3.46 (7.86)	-3.11 (4.08)
Median	62.50	50.00	6.20	0
IQR: Q1, Q3	43.80, 62.50	43.80, 56.30	0.00, 18.70	-12.50, 6.30
Min, Max	31.3, 87.5	25.0, 81.3	-37.5, 31.2	-25.0, 18.7
Week 36				
m	8	10		
n	8	9	8	9
Mean (SD/SE)	59.40 (13.77)	57.66 (12.79)	8.58 (5.65)	0.00 (6.91)
Median	59.40	50.00	12.50	0
IQR: Q1, Q3	46.90, 68.75	50.00, 68.80	3.10, 18.70	-12.50, 18.70
Min, Max	43.8, 81.3	43.8, 75.0	-25.0, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Social Functioning				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	81.94 (25.09)	78.75 (24.33)		
Median	100.00	87.50		
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00		
Min, Max	37.5, 100.0	37.5, 100.0		
Week 12				
m	9	10		
n	9	10	9	10
Mean (SD/SE)	77.78 (27.08)	68.75 (27.16)	-4.17 (5.51)	-10.00 (5.83)
Median	87.50	50.00	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-12.50, 0.00	-25.00, 0.00
Min, Max	25.0, 100.0	37.5, 100.0	-25.0, 25.0	-50.0, 12.5
Week 36				
m	8	10		
n	8	9	8	9
Mean (SD/SE)	75.00 (14.94)	77.78 (22.34)	-4.69 (11.31)	-2.78 (6.17)
Median	75.00	75.00	-12.50	0
IQR: Q1, Q3	68.75, 81.25	62.50, 100.00	-31.25, 18.75	0.00, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	-37.5, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Role Emotional				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	74.08 (34.72)	69.17 (31.68)		
Median	91.70	79.15		
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00		
Min, Max	0.0, 100.0	16.7, 100.0		
Week 12				
m	9	10		
n	9	10	9	10
Mean (SD/SE)	71.31 (39.11)	73.33 (22.49)	-2.77 (6.66)	4.16 (5.59)
Median	91.70	75.00	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-8.30, 8.30	-8.40, 25.00
Min, Max	0.0, 100.0	50.0, 100.0	-50.0, 16.7	-16.7, 33.3
Week 36				
m	8	10		
n	8	9	8	9
Mean (SD/SE)	75.00 (17.82)	75.92 (24.10)	4.16 (10.57)	0.92 (6.58)
Median	75.00	75.00	0	0
IQR: Q1, Q3	62.50, 87.50	50.00, 100.00	-8.35, 25.00	0.00, 8.30
Min, Max	50.0, 100.0	50.0, 100.0	-50.0, 50.0	-33.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Mental Health				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	76.11 (17.28)	63.00 (26.06)		
Median	80.00	55.00		
IQR: Q1, Q3	65.00, 90.00	45.00, 90.00		
Min, Max	45.0, 95.0	30.0, 100.0		
Week 12				
m	9	10		
n	9	10		
Mean (SD/SE)	77.22 (16.22)	62.00 (23.59)	1.11 (4.39)	-1.00 (6.74)
Median	80.00	60.00	0	0
IQR: Q1, Q3	65.00, 90.00	45.00, 75.00	-5.00, 10.00	-10.00, 15.00
Min, Max	50.0, 100.0	30.0, 100.0	-20.0, 20.0	-50.0, 25.0
Week 36				
m	8	10		
n	8	9		
Mean (SD/SE)	70.63 (18.79)	76.67 (23.58)	-3.75 (6.53)	10.00 (4.49)
Median	77.50	85.00	-5.00	10.00
IQR: Q1, Q3	60.00, 82.50	50.00, 100.00	-17.50, 10.00	0.00, 10.00
Min, Max	35.0, 90.0	50.0, 100.0	-30.0, 25.0	-5.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Mental Component Score				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	50.88 (9.71)	45.51 (12.89)		
Median	55.70	43.95		
IQR: Q1, Q3	43.60, 57.60	37.90, 57.40		
Min, Max	32.2, 59.2	26.9, 65.3		
Week 12				
m	9	10		
n	9	10		
Mean (SD/SE)	50.14 (10.48)	44.81 (11.44)	-0.73 (2.26)	-0.70 (2.19)
Median	50.50	40.25	1.20	0.25
IQR: Q1, Q3	47.80, 58.80	34.40, 52.80	-5.20, 3.90	-4.60, 4.50
Min, Max	28.4, 63.1	33.6, 66.1	-12.3, 9.9	-15.9, 7.5
Week 36				
m	8	10		
n	8	9		
Mean (SD/SE)	48.68 (7.26)	49.62 (11.96)	-1.18 (3.56)	2.29 (1.93)
Median	52.05	56.40	-2.25	2.60
IQR: Q1, Q3	41.85, 53.85	36.60, 58.80	-7.10, 7.25	-1.30, 5.00
Min, Max	37.5, 56.4	35.1, 64.0	-18.2, 13.0	-6.4, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=10)	MGL-3196 (N=9)	Placebo (N=10)
Physical Component Score				
Baseline				
m	9	10		
n	9	10		
Mean (SD)	43.40 (9.60)	48.15 (7.05)		
Median	44.00	48.40		
IQR: Q1, Q3	37.70, 50.20	41.10, 53.90		
Min, Max	27.0, 54.5	38.7, 59.2		
Week 12				
m	9	10		
n	9	10		
Mean (SD/SE)	45.24 (9.08)	46.80 (7.06)	1.84 (1.16)	-1.35 (1.70)
Median	49.60	48.75	1.00	-2.30
IQR: Q1, Q3	37.80, 51.20	41.30, 51.60	0.10, 4.40	-5.80, 2.50
Min, Max	27.2, 54.5	34.5, 56.4	-4.9, 6.2	-8.0, 9.1
Week 36				
m	8	10		
n	8	9		
Mean (SD/SE)	46.53 (5.62)	48.21 (7.86)	4.51 (2.91)	-0.97 (2.59)
Median	47.10	49.80	4.15	-2.60
IQR: Q1, Q3	41.75, 50.75	47.10, 52.60	0.45, 10.30	-4.70, 6.00
Min, Max	38.6, 54.4	31.5, 58.1	-9.6, 15.9	-15.6, 8.6

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; HA = Hyaluronic Acid.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Physical Functioning				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	74.4 (21.8)	65.5 (33.4)		
Median	77.5	75.0		
IQR: Q1, Q3	62.5, 90.0	30.0, 95.0		
Min, Max	35, 100	10, 100		
Week 12				
m	8	11		
n	8	11	8	11
Mean (SD/SE)	70.6 (23.1)	78.2 (28.6)	-3.8 (5.5)	12.7 (8.3)
Median	72.5	85.0	-2.5	5.0
IQR: Q1, Q3	57.5, 90.0	60.0, 95.0	-12.5, 5.0	-5.0, 30.0
Min, Max	30, 95	5, 100	-30, 20	-25, 70
Week 36				
m	7	11		
n	7	10	7	10
Mean (SD/SE)	82.9 (15.5)	81.0 (29.7)	5.0 (6.7)	12.0 (7.0)
Median	80.0	95.0	5.0	2.5
IQR: Q1, Q3	75.0, 95.0	75.0, 100.0	0.0, 5.0	0.0, 20.0
Min, Max	55, 100	5, 100	-20, 40	-5, 70

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Role Physical				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	67.99 (37.26)	60.24 (40.91)		
Median	81.30	75.00		
IQR: Q1, Q3	40.65, 100.00	12.50, 100.00		
Min, Max	0.0, 100.0	0.0, 100.0		
Week 12				
m	8	11		
n	8	11	8	11
Mean (SD/SE)	72.66 (30.25)	66.49 (32.99)	4.68 (5.63)	6.25 (5.84)
Median	81.25	75.00	12.50	0
IQR: Q1, Q3	56.25, 96.90	50.00, 100.00	-6.25, 15.60	-12.50, 18.80
Min, Max	12.5, 100.0	0.0, 100.0	-25.0, 18.7	-25.0, 37.5
Week 36				
m	7	11		
n	7	10	7	10
Mean (SD/SE)	83.94 (19.71)	71.26 (33.75)	13.39 (9.49)	6.25 (6.04)
Median	93.80	81.30	12.50	0
IQR: Q1, Q3	68.80, 100.00	50.00, 100.00	0.00, 37.50	0.00, 18.80
Min, Max	50.0, 100.0	0.0, 100.0	-25.0, 50.0	-25.0, 37.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Bodily Pain				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	51.0 (29.8)	68.1 (34.8)		
Median	61.5	74.0		
IQR: Q1, Q3	26.5, 74.0	41.0, 100.0		
Min, Max	0, 84	0, 100		
Week 12				
m	8	11		
n	8	11	8	11
Mean (SD/SE)	71.5 (32.2)	75.3 (33.6)	20.5 (14.2)	7.2 (4.7)
Median	84.0	100.0	22.5	0
IQR: Q1, Q3	41.0, 100.0	51.0, 100.0	3.5, 27.5	0.0, 19.0
Min, Max	22, 100	0, 100	-43, 100	-23, 33
Week 36				
m	7	11		
n	7	10	7	10
Mean (SD/SE)	70.7 (28.2)	69.3 (35.3)	23.0 (8.8)	-0.2 (6.5)
Median	62.0	74.0	26.0	0
IQR: Q1, Q3	42.0, 100.0	51.0, 100.0	10.0, 40.0	0.0, 0.0
Min, Max	41, 100	0, 100	-19, 50	-49, 33

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
General Health				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	60.0 (11.9)	63.9 (18.6)		
Median	62.0	67.0		
IQR: Q1, Q3	51.0, 69.5	47.0, 77.0		
Min, Max	40, 75	35, 92		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	57.5 (9.3)	66.7 (22.4)	-2.5 (3.3)	2.8 (3.9)
Median	56.0	77.0	-4.0	0
IQR: Q1, Q3	51.0, 64.5	42.0, 82.0	-8.5, 2.5	-5.0, 8.0
Min, Max	45, 72	30, 97	-15, 15	-12, 30
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	71.1 (16.9)	64.2 (22.7)	11.4 (7.9)	-1.6 (5.1)
Median	67.0	64.5	0	-2.5
IQR: Q1, Q3	65.0, 82.0	52.0, 82.0	-5.0, 27.0	-17.0, 8.0
Min, Max	45, 100	25, 100	-10, 48	-22, 25

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Vitality				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	64.10 (21.31)	50.60 (23.30)		
Median	65.65	56.30		
IQR: Q1, Q3	50.05, 75.05	31.30, 68.80		
Min, Max	31.3, 100.0	12.5, 81.3		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	64.08 (20.80)	52.86 (26.42)	-0.03 (5.91)	2.26 (5.67)
Median	59.40	50.00	3.10	6.20
IQR: Q1, Q3	50.00, 78.15	43.80, 75.00	-9.40, 12.50	-12.50, 18.70
Min, Max	37.5, 100.0	0.0, 87.5	-31.3, 18.7	-31.3, 31.3
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	71.46 (13.89)	57.52 (32.65)	6.24 (4.72)	4.36 (6.92)
Median	68.80	59.40	6.20	18.70
IQR: Q1, Q3	62.50, 75.00	31.30, 81.30	0.00, 18.70	-12.50, 18.80
Min, Max	56.3, 100.0	0.0, 100.0	-12.5, 25.0	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Social Functioning				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	79.69 (23.09)	71.59 (26.86)		
Median	87.50	62.50		
IQR: Q1, Q3	56.25, 100.00	37.50, 100.00		
Min, Max	50.0, 100.0	37.5, 100.0		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	73.44 (28.69)	70.45 (34.58)	-6.25 (5.79)	-1.14 (5.45)
Median	81.25	87.50	-6.25	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	-18.75, 0.00	-12.50, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-25.0, 25.0	-37.5, 25.0
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	82.14 (27.82)	75.00 (31.73)	-1.79 (12.92)	2.50 (6.40)
Median	100.00	81.25	0	6.25
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	0.00, 25.00	0.00, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	-75.0, 25.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Role Emotional				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	76.04 (23.33)	62.13 (38.62)		
Median	79.15	66.70		
IQR: Q1, Q3	50.00, 100.00	25.00, 100.00		
Min, Max	50.0, 100.0	0.0, 100.0		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	77.09 (36.66)	71.97 (32.12)	1.05 (8.10)	9.85 (4.75)
Median	100.00	83.30	0	0
IQR: Q1, Q3	58.35, 100.00	50.00, 100.00	0.00, 16.70	0.00, 25.00
Min, Max	0.0, 100.0	0.0, 100.0	-50.0, 25.0	-8.4, 33.4
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	85.71 (13.36)	72.50 (31.68)	5.96 (7.43)	5.83 (5.56)
Median	75.00	75.00	0	0
IQR: Q1, Q3	75.00, 100.00	58.30, 100.00	-8.30, 25.00	0.00, 8.30
Min, Max	75.0, 100.0	0.0, 100.0	-25.0, 25.0	-25.0, 41.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Mental Health				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	78.44 (17.27)	59.55 (22.52)		
Median	80.00	55.00		
IQR: Q1, Q3	62.50, 93.75	45.00, 85.00		
Min, Max	55.0, 100.0	30.0, 90.0		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	75.00 (15.12)	64.55 (27.79)	-3.44 (3.92)	5.00 (4.05)
Median	80.00	55.00	-5.00	10.00
IQR: Q1, Q3	65.00, 82.50	50.00, 90.00	-11.25, 0.00	0.00, 15.00
Min, Max	50.0, 95.0	15.0, 100.0	-15.0, 20.0	-30.0, 20.0
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	90.00 (10.00)	61.00 (28.66)	8.93 (4.49)	-1.50 (6.50)
Median	90.00	60.00	10.00	5.00
IQR: Q1, Q3	80.00, 100.00	50.00, 85.00	0.00, 20.00	-20.00, 15.00
Min, Max	80.0, 100.0	0.0, 100.0	-7.5, 25.0	-45.0, 20.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Mental Component Score				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	52.05 (9.46)	42.76 (12.92)		
Median	53.85	38.50		
IQR: Q1, Q3	42.15, 60.75	31.90, 57.00		
Min, Max	40.6, 62.3	26.9, 61.2		
Week 12				
m	8	11		
n	8	11		
Mean (SD/SE)	50.03 (11.00)	44.26 (14.97)	-2.03 (2.03)	1.50 (2.54)
Median	53.25	45.50	-0.30	2.30
IQR: Q1, Q3	44.45, 57.35	33.70, 59.20	-6.15, 2.40	-1.50, 7.50
Min, Max	28.4, 61.7	12.9, 61.3	-12.3, 4.2	-19.5, 11.3
Week 36				
m	7	11		
n	7	10		
Mean (SD/SE)	55.53 (3.34)	44.26 (14.56)	1.84 (2.76)	0.13 (3.36)
Median	56.50	43.95	-1.00	3.05
IQR: Q1, Q3	52.10, 59.00	36.60, 55.60	-5.80, 7.40	-9.20, 9.70
Min, Max	51.0, 59.6	13.9, 62.3	-5.8, 13.0	-18.5, 11.3

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=8)	Placebo (N=11)	MGL-3196 (N=8)	Placebo (N=11)
Physical Component Score				
Baseline				
m	8	11		
n	8	11		
Mean (SD)	44.66 (7.47)	48.04 (11.04)		
Median	44.65	53.90		
IQR: Q1, Q3	39.90, 50.75	38.90, 56.10		
Min, Max	32.1, 54.6	25.8, 60.5		
Week 12				
m	8	11		
n	8	11	8	11
Mean (SD/SE)	47.30 (7.57)	50.81 (9.26)	2.64 (1.11)	2.77 (1.79)
Median	48.00	56.40	3.25	2.50
IQR: Q1, Q3	40.15, 54.05	43.30, 58.40	1.15, 4.30	-2.50, 8.20
Min, Max	37.2, 56.8	34.5, 58.6	-3.3, 7.0	-7.8, 10.7
Week 36				
m	7	11		
n	7	10	7	10
Mean (SD/SE)	49.89 (6.91)	51.21 (10.98)	5.39 (2.13)	2.26 (1.77)
Median	52.90	54.30	4.80	0.55
IQR: Q1, Q3	43.60, 55.30	49.70, 58.40	0.70, 10.80	-0.80, 3.00
Min, Max	38.6, 56.5	28.7, 64.5	0.1, 14.9	-4.1, 14.8

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Physical Functioning				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	71.7 (29.8)	73.8 (21.7)		
Median	80.0	72.5		
IQR: Q1, Q3	75.0, 85.0	67.5, 90.0		
Min, Max	5, 100	30, 100		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	73.3 (33.1)	70.6 (20.4)	1.7 (2.8)	-3.1 (8.1)
Median	85.0	70.0	0	0
IQR: Q1, Q3	80.0, 90.0	55.0, 87.5	0.0, 5.0	-10.0, 7.5
Min, Max	5, 100	40, 100	-15, 15	-50, 30
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	72.5 (27.1)	74.4 (20.8)	2.5 (4.3)	0.6 (4.2)
Median	82.5	77.5	2.5	2.5
IQR: Q1, Q3	50.0, 92.5	55.0, 92.5	-5.0, 7.5	-5.0, 5.0
Min, Max	30, 100	45, 100	-15, 25	-20, 20

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Role Physical				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	81.28 (30.61)	67.98 (32.28)		
Median	93.80	75.00		
IQR: Q1, Q3	81.30, 100.00	50.00, 93.75		
Min, Max	6.3, 100.0	6.3, 100.0		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	82.68 (27.37)	68.76 (20.85)	1.40 (5.08)	0.79 (8.38)
Median	93.80	65.65	0	0
IQR: Q1, Q3	93.80, 93.80	50.00, 87.50	-6.20, 6.20	-18.75, 18.75
Min, Max	18.8, 100.0	43.8, 100.0	-25.0, 31.3	-31.2, 37.5
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	75.80 (20.99)	71.10 (26.07)	-3.91 (10.43)	3.13 (10.02)
Median	81.25	65.65	-3.10	3.15
IQR: Q1, Q3	53.15, 93.80	50.00, 100.00	-18.80, 6.25	-18.75, 25.00
Min, Max	50.0, 100.0	37.5, 100.0	-50.0, 50.0	-37.5, 43.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Bodily Pain				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	61.9 (27.9)	67.4 (23.3)		
Median	62.0	74.0		
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0		
Min, Max	10, 100	41, 100		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	64.0 (20.8)	51.9 (25.3)	2.1 (4.8)	-15.5 (8.1)
Median	62.0	57.0	0	-22.0
IQR: Q1, Q3	61.0, 72.0	41.5, 72.0	0.0, 10.0	-30.5, -4.5
Min, Max	22, 100	0, 74	-22, 29	-41, 31
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	60.8 (23.5)	64.6 (24.9)	1.6 (10.6)	-2.8 (10.6)
Median	62.0	68.0	-5.0	0
IQR: Q1, Q3	46.0, 74.0	41.0, 84.0	-10.0, 9.5	-21.5, 15.5
Min, Max	22, 100	31, 100	-40, 64	-53, 43

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
General Health				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	60.2 (21.4)	63.8 (18.0)		
Median	57.0	72.0		
IQR: Q1, Q3	47.0, 77.0	51.0, 76.0		
Min, Max	30, 92	30, 82		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	61.3 (20.0)	57.8 (15.8)	1.1 (5.5)	-6.0 (2.7)
Median	67.0	62.0	0	-5.0
IQR: Q1, Q3	57.0, 77.0	46.0, 72.0	-5.0, 0.0	-7.5, 0.0
Min, Max	25, 82	30, 72	-25, 35	-23, 0
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	58.8 (20.1)	66.5 (23.8)	2.5 (6.1)	2.8 (4.3)
Median	59.5	69.5	2.5	0
IQR: Q1, Q3	40.0, 77.0	52.0, 82.0	-7.5, 12.5	-5.0, 7.0
Min, Max	35, 82	25, 100	-25, 30	-10, 28

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: >=17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Vitality				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	59.76 (17.14)	58.61 (18.29)		
Median	56.30	50.00		
IQR: Q1, Q3	56.30, 75.00	46.90, 75.05		
Min, Max	31.3, 81.3	37.5, 87.5		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	58.36 (20.24)	55.50 (11.31)	-1.40 (7.91)	-3.11 (3.92)
Median	62.50	53.15	0	0
IQR: Q1, Q3	43.80, 75.00	50.00, 56.30	-18.80, 12.50	-9.35, 6.25
Min, Max	31.3, 87.5	43.8, 81.3	-37.5, 31.2	-25.0, 6.3
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	56.28 (23.63)	59.40 (12.92)	-1.58 (7.72)	0.79 (7.42)
Median	56.25	59.40	6.25	3.15
IQR: Q1, Q3	43.80, 78.15	46.90, 71.90	-12.50, 12.50	-15.60, 18.75
Min, Max	12.5, 81.3	43.8, 75.0	-43.8, 18.7	-31.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Social Functioning				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	88.89 (20.20)	84.38 (22.90)		
Median	100.00	100.00		
IQR: Q1, Q3	87.50, 100.00	62.50, 100.00		
Min, Max	37.5, 100.0	50.0, 100.0		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	90.28 (13.66)	75.00 (26.73)	1.39 (4.86)	-9.38 (6.58)
Median	100.00	75.00	0	0
IQR: Q1, Q3	87.50, 100.00	50.00, 100.00	0.00, 12.50	-12.50, 0.00
Min, Max	62.5, 100.0	50.0, 100.0	-25.0, 25.0	-50.0, 0.0
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	78.13 (17.36)	79.69 (23.09)	-9.38 (10.50)	-4.69 (6.66)
Median	75.00	87.50	-18.75	0
IQR: Q1, Q3	68.75, 93.75	56.25, 100.00	-31.25, 6.25	-12.50, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	-37.5, 50.0	-37.5, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Role Emotional				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	85.19 (33.01)	79.16 (25.21)		
Median	100.00	87.50		
IQR: Q1, Q3	91.70, 100.00	62.50, 100.00		
Min, Max	0.0, 100.0	33.3, 100.0		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	87.98 (27.03)	78.13 (23.11)	2.79 (3.11)	-1.04 (4.84)
Median	100.00	83.30	0	0
IQR: Q1, Q3	91.70, 100.00	58.35, 100.00	0.00, 8.30	-12.50, 4.20
Min, Max	16.7, 100.0	41.7, 100.0	-8.3, 16.7	-16.7, 25.0
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	81.25 (21.25)	75.00 (29.88)	-2.09 (9.55)	-4.16 (6.49)
Median	87.50	87.50	0	0
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	-8.35, 0.00	-16.65, 4.15
Min, Max	50.0, 100.0	25.0, 100.0	-50.0, 50.0	-33.3, 25.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: >=17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Mental Health				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	81.11 (14.53)	70.00 (23.30)		
Median	85.00	70.00		
IQR: Q1, Q3	80.00, 90.00	47.50, 90.00		
Min, Max	45.0, 95.0	45.0, 100.0		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	82.22 (12.53)	65.00 (25.21)	1.11 (3.31)	-5.00 (8.02)
Median	85.00	67.50	0	-5.00
IQR: Q1, Q3	80.00, 90.00	40.00, 85.00	0.00, 5.00	-12.50, 10.00
Min, Max	60.0, 100.0	35.0, 100.0	-20.0, 15.0	-50.0, 25.0
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	69.38 (18.98)	80.00 (22.83)	-10.63 (4.57)	10.00 (4.91)
Median	72.50	90.00	-12.50	10.00
IQR: Q1, Q3	57.50, 85.00	55.00, 100.00	-20.00, 2.50	0.00, 12.50
Min, Max	35.0, 90.0	50.0, 100.0	-30.0, 5.0	-5.0, 40.0

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Mental Component Score				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	54.11 (8.64)	49.75 (10.36)		
Median	57.30	49.35		
IQR: Q1, Q3	53.10, 59.10	40.45, 57.85		
Min, Max	32.2, 60.3	37.4, 65.3		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	54.60 (6.72)	47.83 (10.84)	0.49 (1.70)	-1.93 (2.35)
Median	55.70	46.10	1.20	-0.75
IQR: Q1, Q3	50.50, 59.30	38.65, 55.40	-3.80, 2.60	-4.10, 2.00
Min, Max	42.1, 63.1	36.2, 66.1	-6.5, 9.9	-15.9, 6.2
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	49.09 (7.62)	51.03 (11.91)	-4.40 (2.77)	1.28 (1.92)
Median	52.30	56.65	-4.70	0.70
IQR: Q1, Q3	41.85, 55.20	37.95, 59.95	-8.45, 1.10	-2.05, 3.90
Min, Max	37.5, 56.5	35.1, 64.0	-18.2, 7.1	-6.4, 11.5

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 20
Data Cut-off Date: 15MAY2018

AMNOG Table PRO2.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	Visit Result		Absolute Change from Baseline	
	MGL-3196 (N=9)	Placebo (N=8)	MGL-3196 (N=9)	Placebo (N=8)
Physical Component Score				
Baseline				
m	9	8		
n	9	8		
Mean (SD)	46.20 (10.26)	47.74 (8.19)		
Median	47.50	48.40		
IQR: Q1, Q3	43.20, 54.40	42.65, 53.15		
Min, Max	27.0, 59.8	34.3, 59.2		
Week 12				
m	9	8		
n	9	8		
Mean (SD/SE)	46.69 (11.10)	45.29 (6.61)	0.49 (1.40)	-2.45 (1.48)
Median	50.20	45.75	0.20	-2.65
IQR: Q1, Q3	47.60, 51.90	39.90, 50.75	-0.60, 4.40	-5.80, 1.00
Min, Max	27.2, 59.2	35.4, 54.1	-6.4, 6.2	-8.0, 3.3
Week 36				
m	8	8		
n	8	8		
Mean (SD/SE)	47.00 (8.91)	47.43 (8.41)	1.84 (2.70)	-0.31 (3.03)
Median	47.75	49.00	1.60	-0.30
IQR: Q1, Q3	41.75, 53.80	42.85, 53.05	-2.80, 5.40	-5.20, 6.70
Min, Max	30.7, 58.7	31.5, 58.1	-9.6, 15.9	-15.6, 10.7

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: SD is reported for observed values; SE is reported for absolute change from baseline values.

Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Absolute Change from Baseline" is the number of subjects with results at both baseline and the given visit.

Program: t-pro01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Physical Functioning		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	91.0 (12.4)	66.8 (34.6)
Analysis Visit Mean (SD)	84.0 (23.3)	73.2 (30.7)
LS Mean of Absolute Change from Baseline (SE)	0.87 (12.06)	1.71 (8.05)
95% CI	(-25.00, 26.73)	(-15.56, 18.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.84 (14.99)	
95% CI	(-32.99, 31.31)	
p-value	0.9561	
Corrected Hedge's g Statistics	-0.030	
95% CI	(-1.09, 1.03)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	91.0 (12.4)	70.5 (34.1)
Analysis Visit Mean (SD)	88.0 (19.6)	79.0 (31.4)
LS Mean of Absolute Change from Baseline (SE)	-0.17 (9.38)	5.44 (6.36)
95% CI	(-20.29, 19.94)	(-8.19, 19.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.62 (11.62)	
95% CI	(-30.53, 19.30)	
p-value	0.6363	
Corrected Hedge's g Statistics	-0.259	
95% CI	(-1.34, 0.82)	
Subgroup*Treatment Interaction p-value	0.7426	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Role Physical		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	77.52 (43.45)	67.62 (41.34)
Analysis Visit Mean (SD)	81.26 (38.53)	71.61 (33.11)
LS Mean of Absolute Change from Baseline (SE)	4.97 (6.87)	2.75 (4.65)
95% CI	(-9.76, 19.71)	(-7.22, 12.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.23 (8.32)	
95% CI	(-15.62, 20.08)	
p-value	0.7928	
Corrected Hedge's g Statistics	0.137	
95% CI	(-0.92, 1.20)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	77.52 (43.45)	73.13 (39.08)
Analysis Visit Mean (SD)	86.26 (20.92)	81.88 (33.13)
LS Mean of Absolute Change from Baseline (SE)	10.55 (6.97)	9.02 (4.82)
95% CI	(-4.40, 25.49)	(-1.31, 19.35)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.53 (8.48)	
95% CI	(-16.67, 19.72)	
p-value	0.8599	
Corrected Hedge's g Statistics	0.094	
95% CI	(-0.98, 1.17)	
Subgroup*Treatment Interaction p-value	0.7751	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Bodily Pain		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	63.8 (31.1)	68.4 (31.5)
Analysis Visit Mean (SD)	71.0 (32.3)	62.0 (35.5)
LS Mean of Absolute Change from Baseline (SE)	6.83 (9.38)	-6.26 (6.31)
95% CI	(-13.28, 26.95)	(-19.79, 7.28)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.09 (11.31)	
95% CI	(-11.17, 37.36)	
p-value	0.2665	
Corrected Hedge's g Statistics	0.591	
95% CI	(-0.49, 1.67)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	63.8 (31.1)	69.8 (32.8)
Analysis Visit Mean (SD)	70.8 (27.7)	72.7 (30.5)
LS Mean of Absolute Change from Baseline (SE)	5.97 (8.68)	3.95 (6.12)
95% CI	(-12.66, 24.59)	(-9.17, 17.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.02 (10.64)	
95% CI	(-20.81, 24.84)	
p-value	0.8525	
Corrected Hedge's g Statistics	0.098	
95% CI	(-0.98, 1.17)	
Subgroup*Treatment Interaction p-value	0.9817	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
General Health		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	70.6 (11.7)	65.8 (18.6)
Analysis Visit Mean (SD)	70.6 (10.4)	63.4 (20.8)
LS Mean of Absolute Change from Baseline (SE)	0.46 (5.66)	-2.85 (3.83)
95% CI	(-11.69, 12.61)	(-11.06, 5.36)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.32 (6.87)	
95% CI	(-11.42, 18.05)	
p-value	0.6368	
Corrected Hedge's g Statistics	0.247	
95% CI	(-0.81, 1.31)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	70.6 (11.7)	67.9 (18.3)
Analysis Visit Mean (SD)	72.6 (7.0)	75.4 (23.1)
LS Mean of Absolute Change from Baseline (SE)	2.18 (6.01)	6.94 (4.20)
95% CI	(-10.71, 15.07)	(-2.06, 15.94)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.76 (7.34)	
95% CI	(-20.50, 10.98)	
p-value	0.5272	
Corrected Hedge's g Statistics	-0.336	
95% CI	(-1.42, 0.74)	
Subgroup*Treatment Interaction p-value	0.9981	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Vitality		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	65.04 (21.46)	56.28 (20.16)
Analysis Visit Mean (SD)	61.26 (17.91)	53.43 (25.06)
LS Mean of Absolute Change from Baseline (SE)	-3.04 (7.20)	-3.43 (4.87)
95% CI	(-18.48, 12.40)	(-13.88, 7.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.39 (8.78)	
95% CI	(-18.45, 19.23)	
p-value	0.9649	
Corrected Hedge's g Statistics	0.023	
95% CI	(-1.03, 1.08)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	65.04 (21.46)	59.41 (18.23)
Analysis Visit Mean (SD)	70.04 (11.19)	67.52 (28.69)
LS Mean of Absolute Change from Baseline (SE)	5.98 (8.90)	7.78 (6.08)
95% CI	(-13.11, 25.06)	(-5.27, 20.83)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.81 (10.86)	
95% CI	(-25.11, 21.49)	
p-value	0.8704	
Corrected Hedge's g Statistics	-0.087	
95% CI	(-1.16, 0.99)	
Subgroup*Treatment Interaction p-value	0.9898	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Social Functioning		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	87.50 (21.65)	82.95 (24.54)
Analysis Visit Mean (SD)	85.00 (33.54)	75.00 (34.91)
LS Mean of Absolute Change from Baseline (SE)	-3.05 (8.61)	-7.47 (5.81)
95% CI	(-21.52, 15.43)	(-19.94, 5.00)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.42 (10.42)	
95% CI	(-17.91, 26.76)	
p-value	0.6774	
Corrected Hedge's g Statistics	0.217	
95% CI	(-0.84, 1.28)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	87.50 (21.65)	85.00 (24.86)
Analysis Visit Mean (SD)	90.00 (13.69)	86.25 (31.43)
LS Mean of Absolute Change from Baseline (SE)	2.76 (8.05)	0.75 (5.64)
95% CI	(-14.51, 20.03)	(-11.35, 12.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.01 (9.83)	
95% CI	(-19.08, 23.10)	
p-value	0.8409	
Corrected Hedge's g Statistics	0.106	
95% CI	(-0.97, 1.18)	
Subgroup*Treatment Interaction p-value	0.6397	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Role Emotional		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	88.34 (21.73)	71.22 (37.52)
Analysis Visit Mean (SD)	80.00 (44.72)	77.27 (32.93)
LS Mean of Absolute Change from Baseline (SE)	-7.81 (8.49)	5.66 (5.74)
95% CI	(-26.03, 10.41)	(-6.66, 17.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-13.47 (10.40)	
95% CI	(-35.79, 8.84)	
p-value	0.2163	
Corrected Hedge's g Statistics	-0.669	
95% CI	(-1.75, 0.41)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	88.34 (21.73)	76.67 (34.66)
Analysis Visit Mean (SD)	90.00 (10.87)	77.50 (36.23)
LS Mean of Absolute Change from Baseline (SE)	2.65 (5.98)	0.59 (4.15)
95% CI	(-10.18, 15.47)	(-8.32, 9.50)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.06 (7.31)	
95% CI	(-13.63, 17.74)	
p-value	0.7827	
Corrected Hedge's g Statistics	0.147	
95% CI	(-0.93, 1.22)	
Subgroup*Treatment Interaction p-value	0.3181	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Mental Health		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	83.00 (13.04)	66.36 (23.88)
Analysis Visit Mean (SD)	80.00 (16.96)	63.18 (30.60)
LS Mean of Absolute Change from Baseline (SE)	-2.04 (9.37)	-3.80 (6.30)
95% CI	(-22.14, 18.06)	(-17.32, 9.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.76 (11.66)	
95% CI	(-23.24, 26.77)	
p-value	0.8819	
Corrected Hedge's g Statistics	0.080	
95% CI	(-0.98, 1.14)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	83.00 (13.04)	70.00 (21.73)
Analysis Visit Mean (SD)	88.00 (7.58)	75.50 (31.75)
LS Mean of Absolute Change from Baseline (SE)	5.50 (9.40)	5.35 (6.37)
95% CI	(-14.65, 25.66)	(-8.32, 19.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.16 (11.58)	
95% CI	(-24.68, 25.00)	
p-value	0.9893	
Corrected Hedge's g Statistics	0.007	
95% CI	(-1.07, 1.08)	
Subgroup*Treatment Interaction p-value	0.5180	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Mental Component Score		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	53.92 (7.89)	47.54 (12.16)
Analysis Visit Mean (SD)	51.12 (12.93)	46.20 (14.91)
LS Mean of Absolute Change from Baseline (SE)	-2.95 (4.05)	-1.23 (2.74)
95% CI	(-11.63, 5.74)	(-7.10, 4.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.72 (4.98)	
95% CI	(-12.39, 8.96)	
p-value	0.7354	
Corrected Hedge's g Statistics	-0.179	
95% CI	(-1.24, 0.88)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	53.92 (7.89)	49.38 (11.08)
Analysis Visit Mean (SD)	55.92 (2.16)	50.67 (14.86)
LS Mean of Absolute Change from Baseline (SE)	2.54 (3.98)	1.48 (2.73)
95% CI	(-5.99, 11.07)	(-4.39, 7.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.06 (4.87)	
95% CI	(-9.39, 11.51)	
p-value	0.8305	
Corrected Hedge's g Statistics	0.115	
95% CI	(-0.96, 1.19)	
Subgroup*Treatment Interaction p-value	0.8694	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=11)
Physical Component Score		
Week 12		
m	5	11
n	5	11
Baseline Mean (SD)	49.94 (9.14)	47.97 (10.67)
Analysis Visit Mean (SD)	51.18 (8.64)	48.27 (9.20)
LS Mean of Absolute Change from Baseline (SE)	1.49 (2.17)	0.07 (1.46)
95% CI	(-3.16, 6.15)	(-3.07, 3.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.42 (2.62)	
95% CI	(-4.21, 7.05)	
p-value	0.5968	
Corrected Hedge's g Statistics	0.277	
95% CI	(-0.78, 1.34)	
Week 36		
m	5	11
n	5	10
Baseline Mean (SD)	49.94 (9.14)	48.88 (10.79)
Analysis Visit Mean (SD)	51.06 (7.91)	52.03 (9.67)
LS Mean of Absolute Change from Baseline (SE)	1.36 (2.40)	2.71 (1.67)
95% CI	(-3.80, 6.51)	(-0.88, 6.30)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.35 (2.93)	
95% CI	(-7.64, 4.94)	
p-value	0.6518	
Corrected Hedge's g Statistics	-0.239	
95% CI	(-1.32, 0.84)	
Subgroup*Treatment Interaction p-value	0.9942	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Physical Functioning		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	65.4 (26.2)	71.9 (19.6)
Analysis Visit Mean (SD)	67.1 (29.1)	77.5 (16.3)
LS Mean of Absolute Change from Baseline (SE)	1.46 (3.53)	5.93 (4.33)
95% CI	(-5.96, 8.88)	(-3.17, 15.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.48 (5.61)	
95% CI	(-16.27, 7.32)	
p-value	0.4358	
Corrected Hedge's g Statistics	-0.350	
95% CI	(-1.25, 0.55)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	65.0 (27.7)	71.9 (19.6)
Analysis Visit Mean (SD)	72.0 (22.6)	76.9 (17.9)
LS Mean of Absolute Change from Baseline (SE)	6.28 (4.03)	6.25 (4.52)
95% CI	(-2.19, 14.75)	(-3.25, 15.75)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.03 (6.09)	
95% CI	(-12.77, 12.83)	
p-value	0.9962	
Corrected Hedge's g Statistics	0.002	
95% CI	(-0.93, 0.93)	
Subgroup*Treatment Interaction p-value	0.7426	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Role Physical		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	73.98 (30.70)	57.83 (31.12)
Analysis Visit Mean (SD)	76.59 (24.88)	61.73 (19.03)
LS Mean of Absolute Change from Baseline (SE)	5.48 (4.35)	-0.16 (5.36)
95% CI	(-3.67, 14.62)	(-11.42, 11.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.64 (7.02)	
95% CI	(-9.11, 20.39)	
p-value	0.4325	
Corrected Hedge's g Statistics	0.357	
95% CI	(-0.54, 1.26)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	74.40 (32.32)	57.83 (31.12)
Analysis Visit Mean (SD)	76.27 (19.94)	57.83 (19.12)
LS Mean of Absolute Change from Baseline (SE)	7.39 (5.60)	-6.87 (6.46)
95% CI	(-4.38, 19.15)	(-20.43, 6.70)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	14.25 (8.69)	
95% CI	(-4.01, 32.52)	
p-value	0.1185	
Corrected Hedge's g Statistics	0.756	
95% CI	(-0.21, 1.72)	
Subgroup*Treatment Interaction p-value	0.7751	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Bodily Pain		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	53.8 (28.2)	67.0 (29.1)
Analysis Visit Mean (SD)	66.1 (24.7)	70.1 (27.7)
LS Mean of Absolute Change from Baseline (SE)	9.51 (7.16)	8.94 (8.89)
95% CI	(-5.53, 24.54)	(-9.73, 27.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.56 (11.55)	
95% CI	(-23.70, 24.82)	
p-value	0.9617	
Corrected Hedge's g Statistics	0.022	
95% CI	(-0.87, 0.92)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	48.8 (28.2)	67.0 (29.1)
Analysis Visit Mean (SD)	62.7 (25.3)	60.4 (30.7)
LS Mean of Absolute Change from Baseline (SE)	5.07 (8.52)	-0.68 (9.63)
95% CI	(-12.82, 22.96)	(-20.92, 19.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.74 (13.16)	
95% CI	(-21.91, 33.40)	
p-value	0.6677	
Corrected Hedge's g Statistics	0.202	
95% CI	(-0.73, 1.13)	
Subgroup*Treatment Interaction p-value	0.9817	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
General Health		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	55.8 (17.4)	61.1 (17.5)
Analysis Visit Mean (SD)	54.9 (15.3)	62.4 (20.0)
LS Mean of Absolute Change from Baseline (SE)	-1.16 (3.56)	2.46 (4.41)
95% CI	(-8.64, 6.32)	(-6.80, 11.73)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.63 (5.69)	
95% CI	(-15.59, 8.34)	
p-value	0.5323	
Corrected Hedge's g Statistics	-0.280	
95% CI	(-1.18, 0.62)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	51.5 (14.1)	61.1 (17.5)
Analysis Visit Mean (SD)	60.5 (22.2)	52.5 (14.8)
LS Mean of Absolute Change from Baseline (SE)	4.82 (5.56)	-6.59 (6.23)
95% CI	(-6.86, 16.51)	(-19.69, 6.50)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	11.42 (8.53)	
95% CI	(-6.50, 29.33)	
p-value	0.1974	
Corrected Hedge's g Statistics	0.617	
95% CI	(-0.33, 1.57)	
Subgroup*Treatment Interaction p-value	0.9981	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Vitality		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	60.45 (18.33)	50.80 (23.49)
Analysis Visit Mean (SD)	60.96 (21.66)	54.73 (15.21)
LS Mean of Absolute Change from Baseline (SE)	2.82 (5.09)	1.09 (6.24)
95% CI	(-7.88, 13.52)	(-12.01, 14.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.73 (8.16)	
95% CI	(-15.42, 18.89)	
p-value	0.8343	
Corrected Hedge's g Statistics	0.094	
95% CI	(-0.80, 0.99)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	59.41 (19.59)	50.80 (23.49)
Analysis Visit Mean (SD)	60.02 (23.79)	46.90 (14.56)
LS Mean of Absolute Change from Baseline (SE)	-0.28 (5.33)	-6.59 (6.30)
95% CI	(-11.48, 10.91)	(-19.82, 6.65)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.30 (8.35)	
95% CI	(-11.25, 23.86)	
p-value	0.4603	
Corrected Hedge's g Statistics	0.347	
95% CI	(-0.59, 1.28)	
Subgroup*Treatment Interaction p-value	0.9898	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Social Functioning		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	83.33 (22.19)	68.75 (25.88)
Analysis Visit Mean (SD)	81.25 (18.84)	68.75 (25.88)
LS Mean of Absolute Change from Baseline (SE)	-0.44 (4.21)	-2.56 (5.21)
95% CI	(-9.28, 8.41)	(-13.52, 8.39)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.13 (6.85)	
95% CI	(-12.27, 16.52)	
p-value	0.7599	
Corrected Hedge's g Statistics	0.139	
95% CI	(-0.76, 1.03)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	85.00 (21.08)	68.75 (25.88)
Analysis Visit Mean (SD)	75.00 (24.30)	65.63 (17.36)
LS Mean of Absolute Change from Baseline (SE)	-3.30 (7.22)	-11.49 (8.12)
95% CI	(-18.47, 11.88)	(-28.56, 5.57)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.20 (11.21)	
95% CI	(-15.34, 31.74)	
p-value	0.4738	
Corrected Hedge's g Statistics	0.341	
95% CI	(-0.60, 1.28)	
Subgroup*Treatment Interaction p-value	0.6397	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Role Emotional		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	77.78 (31.04)	66.66 (30.54)
Analysis Visit Mean (SD)	84.04 (26.45)	70.84 (21.36)
LS Mean of Absolute Change from Baseline (SE)	7.54 (3.16)	2.33 (3.88)
95% CI	(0.89, 14.18)	(-5.83, 10.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.20 (5.05)	
95% CI	(-5.40, 15.81)	
p-value	0.3164	
Corrected Hedge's g Statistics	0.454	
95% CI	(-0.45, 1.36)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	78.33 (32.20)	66.66 (30.54)
Analysis Visit Mean (SD)	80.00 (19.72)	68.75 (21.25)
LS Mean of Absolute Change from Baseline (SE)	4.50 (5.37)	-2.20 (6.17)
95% CI	(-6.77, 15.77)	(-15.16, 10.76)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.70 (8.25)	
95% CI	(-10.63, 24.03)	
p-value	0.4271	
Corrected Hedge's g Statistics	0.372	
95% CI	(-0.57, 1.31)	
Subgroup*Treatment Interaction p-value	0.3181	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Mental Health		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	78.54 (16.67)	60.63 (22.43)
Analysis Visit Mean (SD)	78.33 (13.20)	66.88 (19.81)
LS Mean of Absolute Change from Baseline (SE)	1.88 (2.63)	3.25 (3.28)
95% CI	(-3.66, 7.41)	(-3.64, 10.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.38 (4.42)	
95% CI	(-10.65, 7.90)	
p-value	0.7590	
Corrected Hedge's g Statistics	-0.143	
95% CI	(-1.04, 0.75)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	79.25 (16.92)	60.63 (22.43)
Analysis Visit Mean (SD)	74.50 (20.74)	61.88 (19.81)
LS Mean of Absolute Change from Baseline (SE)	-2.98 (5.02)	-1.59 (5.73)
95% CI	(-13.53, 7.57)	(-13.63, 10.46)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.39 (8.03)	
95% CI	(-18.26, 15.47)	
p-value	0.8642	
Corrected Hedge's g Statistics	-0.083	
95% CI	(-1.01, 0.85)	
Subgroup*Treatment Interaction p-value	0.5180	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Mental Component Score		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	52.82 (9.48)	43.19 (12.43)
Analysis Visit Mean (SD)	53.00 (7.48)	45.16 (11.31)
LS Mean of Absolute Change from Baseline (SE)	1.11 (1.28)	0.61 (1.60)
95% CI	(-1.59, 3.81)	(-2.76, 3.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.50 (2.15)	
95% CI	(-4.01, 5.01)	
p-value	0.8168	
Corrected Hedge's g Statistics	0.108	
95% CI	(-0.79, 1.00)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	53.41 (9.41)	43.19 (12.43)
Analysis Visit Mean (SD)	50.18 (7.45)	43.01 (11.05)
LS Mean of Absolute Change from Baseline (SE)	-2.05 (2.29)	-2.65 (2.67)
95% CI	(-6.85, 2.76)	(-8.26, 2.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.60 (3.69)	
95% CI	(-7.16, 8.36)	
p-value	0.8722	
Corrected Hedge's g Statistics	0.078	
95% CI	(-0.85, 1.01)	
Subgroup*Treatment Interaction p-value	0.8694	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.2
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Gender

(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=8)
Physical Component Score		
Week 12		
m	12	8
n	12	8
Baseline Mean (SD)	43.62 (8.35)	47.83 (8.87)
Analysis Visit Mean (SD)	45.23 (9.37)	48.78 (8.08)
LS Mean of Absolute Change from Baseline (SE)	1.43 (1.44)	1.30 (1.79)
95% CI	(-1.59, 4.45)	(-2.45, 5.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.13 (2.32)	
95% CI	(-4.75, 5.01)	
p-value	0.9555	
Corrected Hedge's g Statistics	0.025	
95% CI	(-0.87, 0.92)	
Week 36		
m	10	8
n	10	8
Baseline Mean (SD)	42.31 (8.35)	47.83 (8.87)
Analysis Visit Mean (SD)	46.99 (7.94)	46.40 (9.72)
LS Mean of Absolute Change from Baseline (SE)	2.73 (2.25)	-0.26 (2.59)
95% CI	(-2.00, 7.45)	(-5.69, 5.18)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.99 (3.51)	
95% CI	(-4.38, 10.35)	
p-value	0.4057	
Corrected Hedge's g Statistics	0.395	
95% CI	(-0.54, 1.33)	
Subgroup*Treatment Interaction p-value	0.9942	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Physical Functioning		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	66.1 (30.6)	63.8 (26.9)
Analysis Visit Mean (SD)	64.4 (31.9)	70.0 (28.4)
LS Mean of Absolute Change from Baseline (SE)	-1.63 (7.92)	5.49 (6.87)
95% CI	(-18.21, 14.95)	(-8.89, 19.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.12 (10.49)	
95% CI	(-29.07, 14.83)	
p-value	0.5052	
Corrected Hedge's g Statistics	-0.287	
95% CI	(-1.16, 0.58)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	68.1 (32.1)	66.8 (25.9)
Analysis Visit Mean (SD)	76.9 (23.7)	77.3 (20.8)
LS Mean of Absolute Change from Baseline (SE)	10.37 (5.96)	9.55 (5.09)
95% CI	(-2.09, 22.84)	(-1.11, 20.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.83 (7.83)	
95% CI	(-15.57, 17.22)	
p-value	0.9172	
Corrected Hedge's g Statistics	0.047	
95% CI	(-0.86, 0.96)	
Subgroup*Treatment Interaction p-value	0.9260	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Role Physical		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	60.44 (39.77)	60.95 (38.90)
Analysis Visit Mean (SD)	67.38 (34.06)	64.60 (22.82)
LS Mean of Absolute Change from Baseline (SE)	6.27 (4.74)	3.18 (4.10)
95% CI	(-3.65, 16.18)	(-5.41, 11.76)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.09 (6.26)	
95% CI	(-10.02, 16.20)	
p-value	0.6272	
Corrected Hedge's g Statistics	0.209	
95% CI	(-0.66, 1.08)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	61.75 (42.31)	65.35 (37.53)
Analysis Visit Mean (SD)	82.06 (20.44)	68.19 (22.09)
LS Mean of Absolute Change from Baseline (SE)	20.18 (4.27)	4.42 (3.67)
95% CI	(11.23, 29.12)	(-3.27, 12.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.76 (5.64)	
95% CI	(3.97, 27.56)	
p-value	0.0115	
Corrected Hedge's g Statistics	1.240	
95% CI	(0.25, 2.23)	
Subgroup*Treatment Interaction p-value	0.4358	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Bodily Pain		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	46.2 (30.8)	67.9 (27.2)
Analysis Visit Mean (SD)	60.0 (29.4)	65.5 (28.7)
LS Mean of Absolute Change from Baseline (SE)	6.18 (9.59)	3.58 (8.25)
95% CI	(-13.89, 26.25)	(-13.69, 20.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.60 (13.08)	
95% CI	(-24.78, 29.99)	
p-value	0.8444	
Corrected Hedge's g Statistics	0.087	
95% CI	(-0.78, 0.95)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	42.8 (31.0)	69.2 (28.2)
Analysis Visit Mean (SD)	63.1 (19.7)	69.3 (27.7)
LS Mean of Absolute Change from Baseline (SE)	9.05 (8.60)	7.22 (7.20)
95% CI	(-8.94, 27.04)	(-7.85, 22.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.83 (11.73)	
95% CI	(-22.72, 26.38)	
p-value	0.8777	
Corrected Hedge's g Statistics	0.073	
95% CI	(-0.84, 0.98)	
Subgroup*Treatment Interaction p-value	0.9940	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
General Health		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	55.8 (14.5)	66.9 (15.9)
Analysis Visit Mean (SD)	57.8 (15.2)	62.3 (16.4)
LS Mean of Absolute Change from Baseline (SE)	-0.05 (4.21)	-3.27 (3.57)
95% CI	(-8.86, 8.76)	(-10.75, 4.20)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.23 (5.69)	
95% CI	(-8.69, 15.14)	
p-value	0.5776	
Corrected Hedge's g Statistics	0.248	
95% CI	(-0.62, 1.12)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	55.0 (15.3)	68.9 (15.0)
Analysis Visit Mean (SD)	68.1 (20.5)	68.5 (20.9)
LS Mean of Absolute Change from Baseline (SE)	11.66 (6.24)	0.21 (5.31)
95% CI	(-1.40, 24.72)	(-10.90, 11.32)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	11.45 (8.60)	
95% CI	(-6.55, 29.44)	
p-value	0.1988	
Corrected Hedge's g Statistics	0.621	
95% CI	(-0.31, 1.55)	
Subgroup*Treatment Interaction p-value	0.1226	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Vitality		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	59.77 (22.76)	54.19 (23.59)
Analysis Visit Mean (SD)	67.38 (22.26)	53.68 (16.74)
LS Mean of Absolute Change from Baseline (SE)	8.49 (4.26)	-1.68 (3.70)
95% CI	(-0.44, 17.41)	(-9.44, 6.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	10.17 (5.67)	
95% CI	(-1.69, 22.04)	
p-value	0.0887	
Corrected Hedge's g Statistics	0.762	
95% CI	(-0.13, 1.66)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	60.20 (24.30)	56.85 (22.79)
Analysis Visit Mean (SD)	71.11 (15.64)	55.70 (20.81)
LS Mean of Absolute Change from Baseline (SE)	11.03 (5.08)	-1.93 (4.34)
95% CI	(0.40, 21.65)	(-11.01, 7.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.95 (6.69)	
95% CI	(-1.04, 26.95)	
p-value	0.0678	
Corrected Hedge's g Statistics	0.861	
95% CI	(-0.09, 1.81)	
Subgroup*Treatment Interaction p-value	0.0553	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Social Functioning		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	75.00 (25.77)	77.08 (26.02)
Analysis Visit Mean (SD)	75.00 (28.64)	69.79 (26.89)
LS Mean of Absolute Change from Baseline (SE)	-0.34 (5.81)	-7.31 (5.02)
95% CI	(-12.51, 11.82)	(-17.82, 3.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.96 (7.68)	
95% CI	(-9.11, 23.04)	
p-value	0.3760	
Corrected Hedge's g Statistics	0.384	
95% CI	(-0.49, 1.26)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	78.13 (25.66)	78.41 (26.86)
Analysis Visit Mean (SD)	79.69 (24.94)	77.27 (20.01)
LS Mean of Absolute Change from Baseline (SE)	2.24 (7.73)	-0.31 (6.59)
95% CI	(-13.93, 18.42)	(-14.10, 13.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.55 (10.15)	
95% CI	(-18.70, 23.80)	
p-value	0.8044	
Corrected Hedge's g Statistics	0.111	
95% CI	(-0.80, 1.02)	
Subgroup*Treatment Interaction p-value	0.3662	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Role Emotional		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	66.67 (32.54)	63.89 (32.44)
Analysis Visit Mean (SD)	70.38 (39.77)	71.53 (22.59)
LS Mean of Absolute Change from Baseline (SE)	3.71 (6.17)	7.01 (5.36)
95% CI	(-9.21, 16.63)	(-4.20, 18.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.30 (8.17)	
95% CI	(-20.41, 13.80)	
p-value	0.6907	
Corrected Hedge's g Statistics	-0.171	
95% CI	(-1.04, 0.69)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	68.75 (34.14)	68.18 (30.25)
Analysis Visit Mean (SD)	82.29 (17.50)	72.73 (25.58)
LS Mean of Absolute Change from Baseline (SE)	14.78 (5.29)	5.57 (4.51)
95% CI	(3.71, 25.85)	(-3.88, 15.02)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.21 (6.95)	
95% CI	(-5.33, 23.75)	
p-value	0.2007	
Corrected Hedge's g Statistics	0.588	
95% CI	(-0.34, 1.52)	
Subgroup*Treatment Interaction p-value	0.8748	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Mental Health		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	74.44 (19.11)	60.00 (23.65)
Analysis Visit Mean (SD)	76.11 (17.81)	61.67 (22.70)
LS Mean of Absolute Change from Baseline (SE)	4.14 (5.28)	-0.82 (4.61)
95% CI	(-6.91, 15.19)	(-10.48, 8.83)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.96 (7.20)	
95% CI	(-10.11, 20.04)	
p-value	0.4992	
Corrected Hedge's g Statistics	0.299	
95% CI	(-0.57, 1.17)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	76.25 (19.59)	62.73 (22.73)
Analysis Visit Mean (SD)	81.25 (20.83)	69.09 (21.43)
LS Mean of Absolute Change from Baseline (SE)	8.28 (5.66)	5.18 (4.72)
95% CI	(-3.56, 20.12)	(-4.69, 15.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.10 (7.53)	
95% CI	(-12.67, 18.86)	
p-value	0.6855	
Corrected Hedge's g Statistics	0.187	
95% CI	(-0.73, 1.10)	
Subgroup*Treatment Interaction p-value	0.6157	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Mental Component Score		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	49.62 (10.83)	44.30 (12.82)
Analysis Visit Mean (SD)	50.86 (11.89)	44.68 (10.83)
LS Mean of Absolute Change from Baseline (SE)	1.74 (2.09)	-0.21 (1.82)
95% CI	(-2.62, 6.10)	(-4.02, 3.60)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.95 (2.80)	
95% CI	(-3.92, 7.81)	
p-value	0.4957	
Corrected Hedge's g Statistics	0.297	
95% CI	(-0.57, 1.17)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	50.75 (10.99)	45.68 (12.47)
Analysis Visit Mean (SD)	53.30 (6.25)	46.85 (10.99)
LS Mean of Absolute Change from Baseline (SE)	4.05 (2.24)	0.55 (1.88)
95% CI	(-0.64, 8.74)	(-3.39, 4.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.51 (2.96)	
95% CI	(-2.68, 9.69)	
p-value	0.2503	
Corrected Hedge's g Statistics	0.533	
95% CI	(-0.39, 1.46)	
Subgroup*Treatment Interaction p-value	0.3187	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=12)
Physical Component Score		
Week 12		
m	9	12
n	9	12
Baseline Mean (SD)	42.42 (8.91)	48.02 (8.85)
Analysis Visit Mean (SD)	44.66 (9.28)	47.85 (8.25)
LS Mean of Absolute Change from Baseline (SE)	1.62 (1.69)	0.24 (1.45)
95% CI	(-1.92, 5.16)	(-2.79, 3.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.39 (2.28)	
95% CI	(-3.38, 6.15)	
p-value	0.5505	
Corrected Hedge's g Statistics	0.264	
95% CI	(-0.60, 1.13)	
Week 36		
m	8	12
n	8	11
Baseline Mean (SD)	42.00 (9.43)	48.85 (8.79)
Analysis Visit Mean (SD)	48.64 (6.50)	49.75 (9.82)
LS Mean of Absolute Change from Baseline (SE)	4.59 (2.59)	1.72 (2.20)
95% CI	(-0.82, 10.00)	(-2.89, 6.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.87 (3.50)	
95% CI	(-4.46, 10.21)	
p-value	0.4229	
Corrected Hedge's g Statistics	0.375	
95% CI	(-0.54, 1.29)	
Subgroup*Treatment Interaction p-value	0.3492	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Physical Functioning		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	80.6 (17.2)	77.9 (31.5)
Analysis Visit Mean (SD)	80.6 (21.6)	83.6 (16.8)
LS Mean of Absolute Change from Baseline (SE)	0.56 (4.38)	5.23 (4.68)
95% CI	(-8.90, 10.02)	(-4.88, 15.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.67 (6.42)	
95% CI	(-18.53, 9.19)	
p-value	0.4793	
Corrected Hedge's g Statistics	-0.355	
95% CI	(-1.38, 0.67)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	80.0 (18.5)	77.9 (31.5)
Analysis Visit Mean (SD)	77.9 (22.5)	79.3 (33.7)
LS Mean of Absolute Change from Baseline (SE)	-2.22 (2.17)	1.54 (2.17)
95% CI	(-6.92, 2.47)	(-3.15, 6.24)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.77 (3.08)	
95% CI	(-10.41, 2.88)	
p-value	0.2425	
Corrected Hedge's g Statistics	-0.613	
95% CI	(-1.69, 0.46)	
Subgroup*Treatment Interaction p-value	0.9260	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Role Physical		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	91.43 (13.33)	67.86 (35.25)
Analysis Visit Mean (SD)	89.88 (14.14)	72.33 (36.42)
LS Mean of Absolute Change from Baseline (SE)	0.25 (6.10)	2.56 (6.51)
95% CI	(-12.92, 13.43)	(-11.50, 16.63)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.31 (9.38)	
95% CI	(-22.58, 17.96)	
p-value	0.8094	
Corrected Hedge's g Statistics	-0.126	
95% CI	(-1.14, 0.89)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	91.09 (14.37)	67.86 (35.25)
Analysis Visit Mean (SD)	76.79 (20.95)	75.90 (40.58)
LS Mean of Absolute Change from Baseline (SE)	-13.64 (7.60)	7.58 (7.88)
95% CI	(-30.05, 2.77)	(-9.44, 24.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-21.22 (11.49)	
95% CI	(-46.05, 3.60)	
p-value	0.0877	
Corrected Hedge's g Statistics	-0.970	
95% CI	(-2.08, 0.14)	
Subgroup*Treatment Interaction p-value	0.4358	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Bodily Pain		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	68.6 (21.5)	67.6 (35.9)
Analysis Visit Mean (SD)	76.0 (20.7)	65.3 (39.3)
LS Mean of Absolute Change from Baseline (SE)	7.44 (5.31)	-2.29 (5.67)
95% CI	(-4.02, 18.91)	(-14.54, 9.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.73 (7.77)	
95% CI	(-7.05, 26.51)	
p-value	0.2325	
Corrected Hedge's g Statistics	0.610	
95% CI	(-0.43, 1.65)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	66.4 (22.2)	67.6 (35.9)
Analysis Visit Mean (SD)	68.0 (32.3)	64.0 (36.2)
LS Mean of Absolute Change from Baseline (SE)	-1.30 (8.62)	-3.57 (8.72)
95% CI	(-19.91, 17.32)	(-22.41, 15.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.28 (12.26)	
95% CI	(-24.20, 28.76)	
p-value	0.8555	
Corrected Hedge's g Statistics	0.093	
95% CI	(-0.96, 1.14)	
Subgroup*Treatment Interaction p-value	0.9940	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
General Health		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	65.0 (19.3)	58.6 (21.0)
Analysis Visit Mean (SD)	61.5 (16.7)	64.0 (26.4)
LS Mean of Absolute Change from Baseline (SE)	-3.19 (4.21)	5.24 (4.47)
95% CI	(-12.29, 5.91)	(-4.40, 14.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.43 (6.18)	
95% CI	(-21.79, 4.92)	
p-value	0.1956	
Corrected Hedge's g Statistics	-0.669	
95% CI	(-1.71, 0.37)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	61.1 (17.2)	58.6 (21.0)
Analysis Visit Mean (SD)	60.4 (18.1)	60.0 (25.7)
LS Mean of Absolute Change from Baseline (SE)	-3.78 (6.56)	0.60 (6.79)
95% CI	(-17.97, 10.40)	(-14.06, 15.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.38 (9.48)	
95% CI	(-24.86, 16.09)	
p-value	0.6513	
Corrected Hedge's g Statistics	-0.232	
95% CI	(-1.28, 0.82)	
Subgroup*Treatment Interaction p-value	0.1226	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Vitality		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	64.09 (14.08)	53.60 (18.00)
Analysis Visit Mean (SD)	53.93 (15.64)	54.49 (28.35)
LS Mean of Absolute Change from Baseline (SE)	-8.41 (7.47)	-0.74 (7.92)
95% CI	(-24.55, 7.72)	(-17.84, 16.37)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.68 (11.20)	
95% CI	(-31.87, 16.51)	
p-value	0.5049	
Corrected Hedge's g Statistics	-0.343	
95% CI	(-1.37, 0.68)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	62.53 (14.44)	53.60 (18.00)
Analysis Visit Mean (SD)	54.50 (23.04)	62.53 (32.28)
LS Mean of Absolute Change from Baseline (SE)	-10.71 (7.64)	9.77 (7.96)
95% CI	(-27.21, 5.80)	(-7.43, 26.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-20.48 (11.32)	
95% CI	(-44.92, 3.97)	
p-value	0.0936	
Corrected Hedge's g Statistics	-0.929	
95% CI	(-2.03, 0.17)	
Subgroup*Treatment Interaction p-value	0.0553	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Social Functioning		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	95.31 (6.47)	76.79 (26.45)
Analysis Visit Mean (SD)	90.63 (11.08)	76.79 (38.48)
LS Mean of Absolute Change from Baseline (SE)	-6.23 (6.56)	1.60 (6.99)
95% CI	(-20.41, 7.94)	(-13.49, 16.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.83 (10.16)	
95% CI	(-29.79, 14.13)	
p-value	0.4548	
Corrected Hedge's g Statistics	-0.398	
95% CI	(-1.42, 0.63)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	94.64 (6.68)	76.79 (26.45)
Analysis Visit Mean (SD)	80.36 (20.23)	76.79 (38.48)
LS Mean of Absolute Change from Baseline (SE)	-17.25 (7.58)	2.43 (7.79)
95% CI	(-33.62, -0.88)	(-14.41, 19.27)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-19.68 (11.48)	
95% CI	(-44.49, 5.12)	
p-value	0.1101	
Corrected Hedge's g Statistics	-0.906	
95% CI	(-2.01, 0.19)	
Subgroup*Treatment Interaction p-value	0.3662	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Role Emotional		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	96.88 (8.84)	78.57 (36.91)
Analysis Visit Mean (SD)	96.89 (4.30)	79.77 (37.22)
LS Mean of Absolute Change from Baseline (SE)	0.83 (3.72)	0.35 (3.97)
95% CI	(-7.20, 8.85)	(-8.22, 8.92)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.48 (5.61)	
95% CI	(-11.65, 12.61)	
p-value	0.9338	
Corrected Hedge's g Statistics	0.043	
95% CI	(-0.97, 1.06)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	96.43 (9.45)	78.57 (36.91)
Analysis Visit Mean (SD)	84.53 (18.90)	75.00 (38.19)
LS Mean of Absolute Change from Baseline (SE)	-12.57 (6.50)	-4.20 (6.69)
95% CI	(-26.61, 1.47)	(-18.66, 10.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.37 (9.62)	
95% CI	(-29.15, 12.40)	
p-value	0.3998	
Corrected Hedge's g Statistics	-0.449	
95% CI	(-1.51, 0.61)	
Subgroup*Treatment Interaction p-value	0.8748	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Mental Health		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	85.94 (6.81)	70.71 (21.30)
Analysis Visit Mean (SD)	81.88 (7.53)	70.00 (32.15)
LS Mean of Absolute Change from Baseline (SE)	-5.88 (4.75)	1.17 (5.06)
95% CI	(-16.15, 4.39)	(-9.77, 12.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.05 (7.36)	
95% CI	(-22.95, 8.86)	
p-value	0.3558	
Corrected Hedge's g Statistics	-0.494	
95% CI	(-1.52, 0.54)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	85.36 (7.13)	70.71 (21.30)
Analysis Visit Mean (SD)	76.43 (16.26)	70.00 (36.63)
LS Mean of Absolute Change from Baseline (SE)	-12.48 (6.30)	2.99 (6.52)
95% CI	(-26.08, 1.13)	(-11.10, 17.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-15.47 (9.58)	
95% CI	(-36.15, 5.22)	
p-value	0.1303	
Corrected Hedge's g Statistics	-0.854	
95% CI	(-1.95, 0.24)	
Subgroup*Treatment Interaction p-value	0.6157	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Mental Component Score		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	57.10 (3.13)	48.11 (11.37)
Analysis Visit Mean (SD)	54.24 (4.10)	47.61 (17.29)
LS Mean of Absolute Change from Baseline (SE)	-3.94 (2.73)	0.62 (2.90)
95% CI	(-9.84, 1.95)	(-5.65, 6.90)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.57 (4.28)	
95% CI	(-13.81, 4.67)	
p-value	0.3052	
Corrected Hedge's g Statistics	-0.558	
95% CI	(-1.59, 0.48)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	56.81 (3.26)	48.11 (11.37)
Analysis Visit Mean (SD)	50.71 (7.42)	47.93 (17.74)
LS Mean of Absolute Change from Baseline (SE)	-7.95 (3.16)	1.26 (3.30)
95% CI	(-14.77, -1.13)	(-5.87, 8.40)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.21 (4.89)	
95% CI	(-19.78, 1.36)	
p-value	0.0822	
Corrected Hedge's g Statistics	-1.009	
95% CI	(-2.12, 0.10)	
Subgroup*Treatment Interaction p-value	0.3187	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.3
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Ethnicity

(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=7)
Physical Component Score		
Week 12		
m	8	7
n	8	7
Baseline Mean (SD)	48.91 (7.83)	47.73 (11.73)
Analysis Visit Mean (SD)	49.59 (9.24)	49.57 (9.52)
LS Mean of Absolute Change from Baseline (SE)	0.81 (1.71)	1.77 (1.83)
95% CI	(-2.90, 4.51)	(-2.18, 5.72)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.96 (2.51)	
95% CI	(-6.38, 4.46)	
p-value	0.7070	
Corrected Hedge's g Statistics	-0.187	
95% CI	(-1.20, 0.83)	
Week 36		
m	7	7
n	7	7
Baseline Mean (SD)	48.11 (8.10)	47.73 (11.73)
Analysis Visit Mean (SD)	48.01 (9.80)	49.19 (10.64)
LS Mean of Absolute Change from Baseline (SE)	-0.39 (1.68)	1.42 (1.70)
95% CI	(-4.01, 3.23)	(-2.25, 5.09)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.81 (2.39)	
95% CI	(-6.96, 3.35)	
p-value	0.4622	
Corrected Hedge's g Statistics	-0.379	
95% CI	(-1.44, 0.68)	
Subgroup*Treatment Interaction p-value	0.3492	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Physical Functioning		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	73.1 (23.1)	66.2 (30.2)
Analysis Visit Mean (SD)	68.1 (28.9)	78.5 (26.6)
LS Mean of Absolute Change from Baseline (SE)	-3.85 (7.46)	11.07 (5.86)
95% CI	(-19.45, 11.76)	(-1.20, 23.35)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-14.92 (9.52)	
95% CI	(-34.86, 5.01)	
p-value	0.1337	
Corrected Hedge's g Statistics	-0.678	
95% CI	(-1.58, 0.23)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	73.1 (23.1)	69.2 (29.5)
Analysis Visit Mean (SD)	76.9 (22.2)	78.8 (27.2)
LS Mean of Absolute Change from Baseline (SE)	4.63 (6.73)	7.52 (5.43)
95% CI	(-9.46, 18.71)	(-3.84, 18.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.90 (8.66)	
95% CI	(-21.03, 15.23)	
p-value	0.7416	
Corrected Hedge's g Statistics	-0.147	
95% CI	(-1.04, 0.75)	
Subgroup*Treatment Interaction p-value	0.1687	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Role Physical		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	73.46 (37.46)	61.55 (38.26)
Analysis Visit Mean (SD)	75.03 (32.05)	65.40 (30.47)
LS Mean of Absolute Change from Baseline (SE)	3.28 (5.45)	2.20 (4.29)
95% CI	(-8.14, 14.69)	(-6.78, 11.18)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.08 (6.98)	
95% CI	(-13.54, 15.69)	
p-value	0.8792	
Corrected Hedge's g Statistics	0.067	
95% CI	(-0.81, 0.95)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	73.46 (37.46)	65.63 (36.88)
Analysis Visit Mean (SD)	80.49 (21.25)	70.33 (30.87)
LS Mean of Absolute Change from Baseline (SE)	9.50 (5.92)	4.05 (4.72)
95% CI	(-2.90, 21.89)	(-5.83, 13.93)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.45 (7.61)	
95% CI	(-10.47, 21.37)	
p-value	0.4826	
Corrected Hedge's g Statistics	0.316	
95% CI	(-0.58, 1.22)	
Subgroup*Treatment Interaction p-value	0.9989	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Bodily Pain		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	58.1 (29.0)	71.0 (33.0)
Analysis Visit Mean (SD)	67.9 (26.9)	69.5 (30.8)
LS Mean of Absolute Change from Baseline (SE)	7.70 (6.42)	-0.39 (5.00)
95% CI	(-5.74, 21.13)	(-10.86, 10.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.09 (8.22)	
95% CI	(-9.10, 25.29)	
p-value	0.3371	
Corrected Hedge's g Statistics	0.430	
95% CI	(-0.46, 1.32)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	58.1 (29.0)	72.4 (34.0)
Analysis Visit Mean (SD)	63.9 (25.1)	67.3 (33.0)
LS Mean of Absolute Change from Baseline (SE)	3.69 (6.63)	-3.42 (5.37)
95% CI	(-10.19, 17.57)	(-14.67, 7.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.11 (8.64)	
95% CI	(-10.97, 25.20)	
p-value	0.4204	
Corrected Hedge's g Statistics	0.365	
95% CI	(-0.54, 1.27)	
Subgroup*Treatment Interaction p-value	0.8405	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
General Health		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	55.4 (17.8)	65.4 (18.6)
Analysis Visit Mean (SD)	60.4 (19.5)	62.5 (19.1)
LS Mean of Absolute Change from Baseline (SE)	3.77 (4.56)	-2.21 (3.52)
95% CI	(-5.77, 13.32)	(-9.59, 5.16)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.99 (5.86)	
95% CI	(-6.28, 18.25)	
p-value	0.3199	
Corrected Hedge's g Statistics	0.450	
95% CI	(-0.44, 1.34)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	55.4 (17.8)	67.1 (18.3)
Analysis Visit Mean (SD)	63.1 (15.2)	64.3 (21.6)
LS Mean of Absolute Change from Baseline (SE)	6.10 (5.21)	-1.78 (4.23)
95% CI	(-4.80, 17.00)	(-10.63, 7.08)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.88 (6.88)	
95% CI	(-6.52, 22.28)	
p-value	0.2663	
Corrected Hedge's g Statistics	0.514	
95% CI	(-0.39, 1.42)	
Subgroup*Treatment Interaction p-value	0.0895	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Vitality		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	58.64 (16.34)	51.95 (21.87)
Analysis Visit Mean (SD)	62.50 (20.04)	50.99 (21.93)
LS Mean of Absolute Change from Baseline (SE)	5.29 (6.50)	-2.32 (5.11)
95% CI	(-8.31, 18.88)	(-13.02, 8.37)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.61 (8.32)	
95% CI	(-9.81, 25.04)	
p-value	0.3718	
Corrected Hedge's g Statistics	0.397	
95% CI	(-0.49, 1.29)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	58.64 (16.34)	54.20 (21.22)
Analysis Visit Mean (SD)	61.74 (21.51)	53.15 (26.86)
LS Mean of Absolute Change from Baseline (SE)	4.03 (7.61)	-2.10 (6.06)
95% CI	(-11.89, 19.94)	(-14.79, 10.59)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.12 (9.78)	
95% CI	(-14.34, 26.59)	
p-value	0.5385	
Corrected Hedge's g Statistics	0.277	
95% CI	(-0.62, 1.18)	
Subgroup*Treatment Interaction p-value	0.2414	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Social Functioning		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	85.94 (19.41)	74.04 (25.75)
Analysis Visit Mean (SD)	81.25 (28.35)	71.15 (33.22)
LS Mean of Absolute Change from Baseline (SE)	-5.86 (5.64)	-2.06 (4.41)
95% CI	(-17.66, 5.94)	(-11.28, 7.17)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.80 (7.27)	
95% CI	(-19.02, 11.41)	
p-value	0.6069	
Corrected Hedge's g Statistics	-0.229	
95% CI	(-1.11, 0.65)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	85.94 (19.41)	75.00 (26.65)
Analysis Visit Mean (SD)	84.38 (12.94)	75.00 (30.62)
LS Mean of Absolute Change from Baseline (SE)	0.21 (6.78)	-2.21 (5.42)
95% CI	(-13.99, 14.41)	(-13.56, 9.14)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.42 (8.80)	
95% CI	(-16.00, 20.84)	
p-value	0.7864	
Corrected Hedge's g Statistics	0.122	
95% CI	(-0.77, 1.02)	
Subgroup*Treatment Interaction p-value	0.7910	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Role Emotional		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	85.41 (22.60)	62.18 (35.62)
Analysis Visit Mean (SD)	81.25 (37.20)	71.15 (30.16)
LS Mean of Absolute Change from Baseline (SE)	-2.69 (6.57)	7.82 (5.16)
95% CI	(-16.45, 11.07)	(-2.97, 18.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-10.51 (8.62)	
95% CI	(-28.56, 7.54)	
p-value	0.2377	
Corrected Hedge's g Statistics	-0.543	
95% CI	(-1.44, 0.35)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	85.41 (22.60)	65.98 (34.36)
Analysis Visit Mean (SD)	89.59 (12.40)	70.83 (29.41)
LS Mean of Absolute Change from Baseline (SE)	8.84 (5.21)	3.03 (4.14)
95% CI	(-2.07, 19.76)	(-5.65, 11.70)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.82 (6.82)	
95% CI	(-8.45, 20.09)	
p-value	0.4042	
Corrected Hedge's g Statistics	0.384	
95% CI	(-0.52, 1.29)	
Subgroup*Treatment Interaction p-value	0.2962	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Mental Health		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	82.50 (16.26)	58.08 (21.65)
Analysis Visit Mean (SD)	83.13 (15.34)	63.08 (23.41)
LS Mean of Absolute Change from Baseline (SE)	3.36 (5.31)	3.04 (4.11)
95% CI	(-7.77, 14.48)	(-5.57, 11.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.32 (7.24)	
95% CI	(-14.82, 15.46)	
p-value	0.9651	
Corrected Hedge's g Statistics	0.021	
95% CI	(-0.86, 0.90)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	82.50 (16.26)	60.42 (20.83)
Analysis Visit Mean (SD)	83.75 (11.88)	62.08 (27.09)
LS Mean of Absolute Change from Baseline (SE)	5.68 (7.49)	-1.32 (5.79)
95% CI	(-10.00, 21.37)	(-13.43, 10.80)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.00 (10.11)	
95% CI	(-14.16, 28.16)	
p-value	0.4971	
Corrected Hedge's g Statistics	0.327	
95% CI	(-0.57, 1.23)	
Subgroup*Treatment Interaction p-value	0.8362	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Mental Component Score		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	54.46 (8.04)	42.57 (11.91)
Analysis Visit Mean (SD)	53.75 (11.40)	43.89 (13.16)
LS Mean of Absolute Change from Baseline (SE)	-0.43 (2.87)	1.12 (2.22)
95% CI	(-6.44, 5.58)	(-3.54, 5.77)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.54 (3.87)	
95% CI	(-9.65, 6.56)	
p-value	0.6944	
Corrected Hedge's g Statistics	-0.184	
95% CI	(-1.07, 0.70)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	54.46 (8.04)	43.69 (11.70)
Analysis Visit Mean (SD)	54.80 (3.24)	44.06 (13.39)
LS Mean of Absolute Change from Baseline (SE)	2.90 (3.28)	-0.93 (2.55)
95% CI	(-3.95, 9.76)	(-6.27, 4.41)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.84 (4.39)	
95% CI	(-5.36, 13.03)	
p-value	0.3931	
Corrected Hedge's g Statistics	0.408	
95% CI	(-0.50, 1.31)	
Subgroup*Treatment Interaction p-value	0.7966	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=13)
Physical Component Score		
Week 12		
m	8	13
n	8	13
Baseline Mean (SD)	44.20 (9.51)	49.04 (10.55)
Analysis Visit Mean (SD)	45.78 (10.48)	49.68 (8.42)
LS Mean of Absolute Change from Baseline (SE)	0.77 (1.94)	1.06 (1.50)
95% CI	(-3.30, 4.83)	(-2.09, 4.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.30 (2.49)	
95% CI	(-5.50, 4.91)	
p-value	0.9067	
Corrected Hedge's g Statistics	-0.052	
95% CI	(-0.93, 0.83)	
Week 36		
m	8	13
n	8	12
Baseline Mean (SD)	44.20 (9.51)	49.88 (10.55)
Analysis Visit Mean (SD)	46.93 (9.21)	50.43 (9.76)
LS Mean of Absolute Change from Baseline (SE)	2.09 (2.05)	0.63 (1.64)
95% CI	(-2.19, 6.38)	(-2.81, 4.06)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.47 (2.67)	
95% CI	(-4.12, 7.05)	
p-value	0.5887	
Corrected Hedge's g Statistics	0.246	
95% CI	(-0.65, 1.14)	
Subgroup*Treatment Interaction p-value	0.7600	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Physical Functioning		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	72.8 (29.0)	75.0 (26.5)
Analysis Visit Mean (SD)	75.6 (28.3)	67.5 (21.9)
LS Mean of Absolute Change from Baseline (SE)	2.47 (5.09)	-7.29 (6.23)
95% CI	(-8.53, 13.46)	(-20.75, 6.17)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.76 (8.05)	
95% CI	(-7.62, 27.15)	
p-value	0.2467	
Corrected Hedge's g Statistics	0.602	
95% CI	(-0.45, 1.66)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	74.3 (31.7)	75.0 (26.5)
Analysis Visit Mean (SD)	77.9 (24.3)	76.7 (24.4)
LS Mean of Absolute Change from Baseline (SE)	3.26 (3.90)	1.88 (4.25)
95% CI	(-5.16, 11.68)	(-7.31, 11.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.38 (5.77)	
95% CI	(-11.08, 13.85)	
p-value	0.8144	
Corrected Hedge's g Statistics	0.124	
95% CI	(-0.97, 1.22)	
Subgroup*Treatment Interaction p-value	0.1687	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Role Physical		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	76.41 (31.83)	67.72 (36.30)
Analysis Visit Mean (SD)	80.58 (26.22)	71.88 (22.95)
LS Mean of Absolute Change from Baseline (SE)	5.51 (5.07)	2.08 (6.23)
95% CI	(-5.45, 16.47)	(-11.37, 15.52)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.44 (8.06)	
95% CI	(-13.99, 20.86)	
p-value	0.6771	
Corrected Hedge's g Statistics	0.212	
95% CI	(-0.82, 1.25)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	77.70 (34.38)	67.72 (36.30)
Analysis Visit Mean (SD)	78.59 (20.36)	72.92 (30.02)
LS Mean of Absolute Change from Baseline (SE)	3.93 (8.33)	1.84 (9.21)
95% CI	(-14.07, 21.92)	(-18.06, 21.74)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.09 (12.49)	
95% CI	(-24.89, 29.06)	
p-value	0.8697	
Corrected Hedge's g Statistics	0.087	
95% CI	(-1.00, 1.18)	
Subgroup*Treatment Interaction p-value	0.9989	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Bodily Pain		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	55.6 (29.7)	60.8 (22.0)
Analysis Visit Mean (SD)	67.2 (27.1)	56.7 (35.4)
LS Mean of Absolute Change from Baseline (SE)	11.26 (10.22)	-0.90 (12.60)
95% CI	(-10.82, 33.34)	(-28.12, 26.32)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.16 (16.24)	
95% CI	(-22.93, 47.24)	
p-value	0.4674	
Corrected Hedge's g Statistics	0.372	
95% CI	(-0.67, 1.41)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	48.9 (30.5)	60.8 (22.0)
Analysis Visit Mean (SD)	67.1 (27.7)	67.0 (27.1)
LS Mean of Absolute Change from Baseline (SE)	9.60 (10.83)	10.25 (11.68)
95% CI	(-13.79, 32.99)	(-14.97, 35.48)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.66 (16.12)	
95% CI	(-35.48, 34.16)	
p-value	0.9681	
Corrected Hedge's g Statistics	-0.021	
95% CI	(-1.11, 1.07)	
Subgroup*Treatment Interaction p-value	0.8405	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
General Health		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	64.3 (16.2)	60.5 (17.2)
Analysis Visit Mean (SD)	58.8 (12.2)	63.8 (23.4)
LS Mean of Absolute Change from Baseline (SE)	-5.11 (3.75)	3.11 (4.57)
95% CI	(-13.22, 3.00)	(-6.75, 12.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.22 (5.93)	
95% CI	(-21.03, 4.59)	
p-value	0.1890	
Corrected Hedge's g Statistics	-0.689	
95% CI	(-1.75, 0.37)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	60.7 (14.3)	60.5 (17.2)
Analysis Visit Mean (SD)	66.1 (24.0)	67.2 (26.5)
LS Mean of Absolute Change from Baseline (SE)	1.73 (7.74)	6.45 (8.63)
95% CI	(-14.99, 18.45)	(-12.19, 25.09)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.72 (11.59)	
95% CI	(-29.75, 20.31)	
p-value	0.6903	
Corrected Hedge's g Statistics	-0.211	
95% CI	(-1.30, 0.88)	
Subgroup*Treatment Interaction p-value	0.0895	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Vitality		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	64.61 (21.19)	58.35 (20.80)
Analysis Visit Mean (SD)	59.76 (21.21)	60.43 (18.82)
LS Mean of Absolute Change from Baseline (SE)	-3.97 (5.05)	0.96 (6.18)
95% CI	(-14.87, 6.93)	(-12.40, 14.32)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.93 (8.03)	
95% CI	(-22.28, 12.42)	
p-value	0.5501	
Corrected Hedge's g Statistics	-0.306	
95% CI	(-1.35, 0.73)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	64.31 (23.86)	58.35 (20.80)
Analysis Visit Mean (SD)	65.21 (20.99)	68.77 (19.35)
LS Mean of Absolute Change from Baseline (SE)	-0.23 (5.45)	9.13 (6.09)
95% CI	(-12.00, 11.54)	(-4.04, 22.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.36 (8.22)	
95% CI	(-27.11, 8.39)	
p-value	0.2753	
Corrected Hedge's g Statistics	-0.594	
95% CI	(-1.71, 0.52)	
Subgroup*Treatment Interaction p-value	0.2414	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Social Functioning		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	83.33 (24.21)	83.33 (25.82)
Analysis Visit Mean (SD)	83.33 (18.75)	75.00 (27.39)
LS Mean of Absolute Change from Baseline (SE)	-0.24 (5.80)	-8.57 (7.11)
95% CI	(-12.78, 12.30)	(-23.93, 6.79)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.33 (9.18)	
95% CI	(-11.49, 28.16)	
p-value	0.3803	
Corrected Hedge's g Statistics	0.450	
95% CI	(-0.60, 1.50)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	85.71 (23.31)	83.33 (25.82)
Analysis Visit Mean (SD)	75.00 (29.76)	81.25 (22.01)
LS Mean of Absolute Change from Baseline (SE)	-8.91 (10.46)	-2.61 (11.29)
95% CI	(-31.51, 13.69)	(-26.99, 21.77)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.30 (15.40)	
95% CI	(-39.56, 26.96)	
p-value	0.6890	
Corrected Hedge's g Statistics	-0.212	
95% CI	(-1.31, 0.88)	
Subgroup*Treatment Interaction p-value	0.7910	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Role Emotional		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	76.86 (33.54)	84.72 (26.06)
Analysis Visit Mean (SD)	84.28 (27.45)	81.95 (23.80)
LS Mean of Absolute Change from Baseline (SE)	6.71 (3.09)	-1.87 (3.79)
95% CI	(0.02, 13.39)	(-10.06, 6.31)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.58 (4.91)	
95% CI	(-2.03, 19.19)	
p-value	0.1042	
Corrected Hedge's g Statistics	0.870	
95% CI	(-0.21, 1.95)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	77.39 (35.91)	84.72 (26.06)
Analysis Visit Mean (SD)	76.19 (20.65)	79.17 (33.23)
LS Mean of Absolute Change from Baseline (SE)	-4.26 (8.02)	-3.30 (9.08)
95% CI	(-21.59, 13.07)	(-22.91, 16.30)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.96 (12.16)	
95% CI	(-27.23, 25.31)	
p-value	0.9385	
Corrected Hedge's g Statistics	-0.041	
95% CI	(-1.13, 1.05)	
Subgroup*Treatment Interaction p-value	0.2962	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Mental Health		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	77.50 (15.21)	76.67 (21.60)
Analysis Visit Mean (SD)	75.00 (11.99)	68.33 (33.12)
LS Mean of Absolute Change from Baseline (SE)	-2.48 (5.42)	-8.39 (6.64)
95% CI	(-14.20, 9.23)	(-22.74, 5.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.91 (8.57)	
95% CI	(-12.61, 24.43)	
p-value	0.5028	
Corrected Hedge's g Statistics	0.342	
95% CI	(-0.70, 1.38)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	78.21 (15.19)	76.67 (21.60)
Analysis Visit Mean (SD)	73.57 (23.58)	84.17 (22.89)
LS Mean of Absolute Change from Baseline (SE)	-4.73 (5.29)	7.52 (5.72)
95% CI	(-16.16, 6.71)	(-4.83, 19.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-12.25 (7.80)	
95% CI	(-29.10, 4.59)	
p-value	0.1400	
Corrected Hedge's g Statistics	-0.814	
95% CI	(-1.95, 0.32)	
Subgroup*Treatment Interaction p-value	0.8362	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Mental Component Score		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	51.97 (9.77)	52.50 (10.39)
Analysis Visit Mean (SD)	51.29 (6.71)	49.82 (13.42)
LS Mean of Absolute Change from Baseline (SE)	-0.75 (1.95)	-2.65 (2.39)
95% CI	(-4.96, 3.46)	(-7.81, 2.50)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.90 (3.08)	
95% CI	(-4.76, 8.56)	
p-value	0.5478	
Corrected Hedge's g Statistics	0.306	
95% CI	(-0.73, 1.34)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	52.57 (9.84)	52.50 (10.39)
Analysis Visit Mean (SD)	49.00 (8.46)	53.68 (12.33)
LS Mean of Absolute Change from Baseline (SE)	-3.90 (2.64)	1.22 (2.90)
95% CI	(-9.60, 1.80)	(-5.05, 7.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.12 (3.92)	
95% CI	(-13.60, 3.35)	
p-value	0.2144	
Corrected Hedge's g Statistics	-0.677	
95% CI	(-1.80, 0.44)	
Subgroup*Treatment Interaction p-value	0.7966	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.4
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=6)
Physical Component Score		
Week 12		
m	9	6
n	9	6
Baseline Mean (SD)	46.61 (8.55)	45.47 (7.75)
Analysis Visit Mean (SD)	48.04 (8.65)	45.88 (8.90)
LS Mean of Absolute Change from Baseline (SE)	1.46 (1.30)	0.40 (1.59)
95% CI	(-1.34, 4.27)	(-3.03, 3.83)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.06 (2.05)	
95% CI	(-3.37, 5.50)	
p-value	0.6129	
Corrected Hedge's g Statistics	0.257	
95% CI	(-0.78, 1.29)	
Week 36		
m	7	6
n	7	6
Baseline Mean (SD)	45.60 (9.26)	45.47 (7.75)
Analysis Visit Mean (SD)	49.97 (6.39)	47.72 (10.63)
LS Mean of Absolute Change from Baseline (SE)	1.58 (3.07)	2.00 (3.55)
95% CI	(-5.05, 8.21)	(-5.66, 9.67)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.42 (4.69)	
95% CI	(-10.56, 9.72)	
p-value	0.9305	
Corrected Hedge's g Statistics	-0.046	
95% CI	(-1.14, 1.04)	
Subgroup*Treatment Interaction p-value	0.7600	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Physical Functioning		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	71.5 (26.7)	67.8 (25.8)
Analysis Visit Mean (SD)	76.5 (26.5)	72.8 (31.1)
LS Mean of Absolute Change from Baseline (SE)	5.02 (4.46)	4.88 (4.72)
95% CI	(-4.40, 14.43)	(-5.08, 14.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.14 (6.50)	
95% CI	(-13.58, 13.85)	
p-value	0.9837	
Corrected Hedge's g Statistics	0.009	
95% CI	(-0.89, 0.91)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	72.5 (28.7)	72.5 (23.0)
Analysis Visit Mean (SD)	77.5 (21.9)	75.0 (20.9)
LS Mean of Absolute Change from Baseline (SE)	5.33 (3.77)	3.23 (3.77)
95% CI	(-2.61, 13.28)	(-4.72, 11.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.10 (5.32)	
95% CI	(-9.13, 13.33)	
p-value	0.6982	
Corrected Hedge's g Statistics	0.186	
95% CI	(-0.80, 1.17)	
Subgroup*Treatment Interaction p-value	0.1802	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Role Physical		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	76.90 (30.05)	61.81 (40.07)
Analysis Visit Mean (SD)	84.41 (25.39)	64.60 (23.99)
LS Mean of Absolute Change from Baseline (SE)	9.88 (4.63)	-1.19 (4.94)
95% CI	(0.11, 19.65)	(-11.61, 9.22)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	11.08 (6.85)	
95% CI	(-3.37, 25.52)	
p-value	0.1241	
Corrected Hedge's g Statistics	0.719	
95% CI	(-0.21, 1.65)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	78.15 (31.86)	67.98 (38.00)
Analysis Visit Mean (SD)	82.05 (19.60)	71.88 (24.78)
LS Mean of Absolute Change from Baseline (SE)	7.58 (6.39)	1.53 (6.43)
95% CI	(-5.90, 21.06)	(-12.05, 15.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.06 (9.13)	
95% CI	(-13.20, 25.31)	
p-value	0.5159	
Corrected Hedge's g Statistics	0.316	
95% CI	(-0.67, 1.30)	
Subgroup*Treatment Interaction p-value	0.1592	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Bodily Pain		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	61.5 (24.0)	72.4 (22.7)
Analysis Visit Mean (SD)	65.2 (23.8)	63.6 (30.0)
LS Mean of Absolute Change from Baseline (SE)	1.79 (7.55)	-6.49 (8.00)
95% CI	(-14.13, 17.72)	(-23.36, 10.39)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.28 (11.16)	
95% CI	(-15.26, 31.82)	
p-value	0.4682	
Corrected Hedge's g Statistics	0.331	
95% CI	(-0.58, 1.24)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	57.1 (25.0)	74.8 (23.1)
Analysis Visit Mean (SD)	65.6 (27.2)	73.4 (21.9)
LS Mean of Absolute Change from Baseline (SE)	0.23 (9.06)	5.15 (9.01)
95% CI	(-18.88, 19.34)	(-13.87, 24.16)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.92 (13.22)	
95% CI	(-32.80, 22.96)	
p-value	0.7145	
Corrected Hedge's g Statistics	-0.182	
95% CI	(-1.16, 0.80)	
Subgroup*Treatment Interaction p-value	0.5769	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
General Health		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	61.2 (16.5)	68.0 (15.8)
Analysis Visit Mean (SD)	59.9 (14.2)	61.6 (17.6)
LS Mean of Absolute Change from Baseline (SE)	-2.37 (3.90)	-5.14 (4.12)
95% CI	(-10.59, 5.85)	(-13.84, 3.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.77 (5.74)	
95% CI	(-9.34, 14.88)	
p-value	0.6353	
Corrected Hedge's g Statistics	0.214	
95% CI	(-0.69, 1.12)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	57.3 (14.0)	70.9 (14.2)
Analysis Visit Mean (SD)	57.3 (16.0)	66.1 (14.9)
LS Mean of Absolute Change from Baseline (SE)	-5.19 (5.18)	-2.15 (5.20)
95% CI	(-16.13, 5.74)	(-13.12, 8.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.05 (7.71)	
95% CI	(-19.31, 13.22)	
p-value	0.6978	
Corrected Hedge's g Statistics	-0.196	
95% CI	(-1.18, 0.79)	
Subgroup*Treatment Interaction p-value	0.6533	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Vitality		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	60.04 (15.92)	59.06 (21.45)
Analysis Visit Mean (SD)	57.52 (18.34)	54.89 (16.48)
LS Mean of Absolute Change from Baseline (SE)	-2.64 (5.31)	-4.93 (5.60)
95% CI	(-13.84, 8.57)	(-16.75, 6.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.30 (7.72)	
95% CI	(-13.99, 18.58)	
p-value	0.7696	
Corrected Hedge's g Statistics	0.131	
95% CI	(-0.77, 1.03)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	58.64 (17.02)	63.31 (18.42)
Analysis Visit Mean (SD)	60.96 (13.25)	60.96 (11.47)
LS Mean of Absolute Change from Baseline (SE)	0.01 (4.06)	-1.11 (4.14)
95% CI	(-8.56, 8.58)	(-9.85, 7.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.13 (5.82)	
95% CI	(-11.15, 13.40)	
p-value	0.8486	
Corrected Hedge's g Statistics	0.092	
95% CI	(-0.89, 1.07)	
Subgroup*Treatment Interaction p-value	0.9535	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Social Functioning		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	85.00 (23.42)	77.78 (24.83)
Analysis Visit Mean (SD)	86.25 (18.11)	76.39 (28.26)
LS Mean of Absolute Change from Baseline (SE)	1.75 (4.35)	-2.33 (4.62)
95% CI	(-7.44, 10.93)	(-12.08, 7.42)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.08 (6.38)	
95% CI	(-9.39, 17.55)	
p-value	0.5315	
Corrected Hedge's g Statistics	0.282	
95% CI	(-0.62, 1.19)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	87.50 (22.16)	79.69 (25.82)
Analysis Visit Mean (SD)	81.25 (18.90)	84.38 (17.36)
LS Mean of Absolute Change from Baseline (SE)	-3.52 (6.52)	0.91 (6.52)
95% CI	(-17.28, 10.25)	(-12.84, 14.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.43 (9.28)	
95% CI	(-24.01, 15.16)	
p-value	0.6397	
Corrected Hedge's g Statistics	-0.227	
95% CI	(-1.21, 0.76)	
Subgroup*Treatment Interaction p-value	0.9061	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Role Emotional		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	78.33 (32.20)	66.67 (35.60)
Analysis Visit Mean (SD)	85.85 (26.36)	75.00 (26.35)
LS Mean of Absolute Change from Baseline (SE)	8.67 (3.39)	6.17 (3.61)
95% CI	(1.51, 15.83)	(-1.44, 13.78)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.50 (4.99)	
95% CI	(-8.02, 13.02)	
p-value	0.6227	
Corrected Hedge's g Statistics	0.222	
95% CI	(-0.68, 1.13)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	79.16 (33.92)	72.91 (32.36)
Analysis Visit Mean (SD)	80.21 (21.34)	76.04 (29.02)
LS Mean of Absolute Change from Baseline (SE)	2.48 (6.36)	3.76 (6.45)
95% CI	(-10.94, 15.89)	(-9.84, 17.36)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.28 (9.09)	
95% CI	(-20.45, 17.89)	
p-value	0.8894	
Corrected Hedge's g Statistics	-0.067	
95% CI	(-1.05, 0.91)	
Subgroup*Treatment Interaction p-value	0.8248	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Mental Health		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	81.50 (17.49)	63.33 (27.84)
Analysis Visit Mean (SD)	79.50 (14.99)	66.11 (25.10)
LS Mean of Absolute Change from Baseline (SE)	-0.24 (3.48)	0.27 (3.75)
95% CI	(-7.58, 7.10)	(-7.65, 8.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.51 (5.31)	
95% CI	(-11.72, 10.70)	
p-value	0.9247	
Corrected Hedge's g Statistics	-0.044	
95% CI	(-0.94, 0.86)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	83.13 (17.72)	67.50 (26.59)
Analysis Visit Mean (SD)	75.63 (23.37)	79.38 (19.90)
LS Mean of Absolute Change from Baseline (SE)	-5.92 (4.80)	10.29 (4.71)
95% CI	(-16.05, 4.20)	(0.36, 20.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-16.22 (6.93)	
95% CI	(-30.84, -1.60)	
p-value	0.0317	
Corrected Hedge's g Statistics	-1.140	
95% CI	(-2.20, -0.08)	
Subgroup*Treatment Interaction p-value	0.0901	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Mental Component Score		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	52.79 (9.53)	45.69 (13.60)
Analysis Visit Mean (SD)	52.60 (7.46)	47.12 (12.73)
LS Mean of Absolute Change from Baseline (SE)	0.38 (1.46)	0.57 (1.57)
95% CI	(-2.71, 3.46)	(-2.75, 3.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.19 (2.20)	
95% CI	(-4.83, 4.44)	
p-value	0.9310	
Corrected Hedge's g Statistics	-0.040	
95% CI	(-0.94, 0.86)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	53.53 (9.45)	47.76 (12.93)
Analysis Visit Mean (SD)	50.46 (8.83)	51.30 (10.60)
LS Mean of Absolute Change from Baseline (SE)	-2.61 (2.05)	2.84 (2.07)
95% CI	(-6.94, 1.71)	(-1.53, 7.20)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.45 (2.97)	
95% CI	(-11.71, 0.81)	
p-value	0.0838	
Corrected Hedge's g Statistics	-0.884	
95% CI	(-1.91, 0.14)	
Subgroup*Treatment Interaction p-value	0.2817	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=9)
Physical Component Score		
Week 12		
m	10	9
n	10	9
Baseline Mean (SD)	46.20 (8.01)	48.94 (8.90)
Analysis Visit Mean (SD)	47.87 (8.30)	47.18 (8.71)
LS Mean of Absolute Change from Baseline (SE)	1.46 (1.50)	-1.56 (1.58)
95% CI	(-1.71, 4.63)	(-4.90, 1.78)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.02 (2.20)	
95% CI	(-1.62, 7.66)	
p-value	0.1872	
Corrected Hedge's g Statistics	0.608	
95% CI	(-0.31, 1.53)	
Week 36		
m	8	9
n	8	8
Baseline Mean (SD)	45.21 (8.46)	50.20 (8.62)
Analysis Visit Mean (SD)	48.45 (6.00)	48.68 (7.64)
LS Mean of Absolute Change from Baseline (SE)	1.20 (2.19)	-0.24 (2.21)
95% CI	(-3.41, 5.81)	(-4.90, 4.42)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.44 (3.17)	
95% CI	(-5.25, 8.13)	
p-value	0.6552	
Corrected Hedge's g Statistics	0.219	
95% CI	(-0.76, 1.20)	
Subgroup*Treatment Interaction p-value	0.1433	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Physical Functioning		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	75.0 (25.8)	70.0 (32.4)
Analysis Visit Mean (SD)	65.7 (30.9)	77.0 (19.7)
LS Mean of Absolute Change from Baseline (SE)	-7.64 (8.24)	5.85 (6.89)
95% CI	(-25.20, 9.92)	(-8.83, 20.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-13.49 (10.76)	
95% CI	(-36.42, 9.44)	
p-value	0.2291	
Corrected Hedge's g Statistics	-0.588	
95% CI	(-1.57, 0.40)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	75.0 (25.8)	70.0 (32.4)
Analysis Visit Mean (SD)	77.1 (24.6)	80.5 (29.8)
LS Mean of Absolute Change from Baseline (SE)	3.04 (7.27)	9.87 (6.07)
95% CI	(-12.44, 18.53)	(-3.08, 22.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.82 (9.49)	
95% CI	(-27.05, 13.40)	
p-value	0.4831	
Corrected Hedge's g Statistics	-0.337	
95% CI	(-1.31, 0.64)	
Subgroup*Treatment Interaction p-value	0.1802	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Role Physical		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	72.34 (40.32)	65.01 (35.62)
Analysis Visit Mean (SD)	68.76 (31.66)	70.01 (31.98)
LS Mean of Absolute Change from Baseline (SE)	-2.58 (5.30)	4.30 (4.43)
95% CI	(-13.88, 8.71)	(-5.14, 13.74)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.88 (6.92)	
95% CI	(-21.64, 7.87)	
p-value	0.3358	
Corrected Hedge's g Statistics	-0.466	
95% CI	(-1.44, 0.51)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	72.34 (40.32)	65.01 (35.62)
Analysis Visit Mean (SD)	76.80 (21.87)	70.64 (34.49)
LS Mean of Absolute Change from Baseline (SE)	6.11 (7.52)	4.47 (6.29)
95% CI	(-9.92, 22.14)	(-8.92, 17.87)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.63 (9.83)	
95% CI	(-19.31, 22.58)	
p-value	0.8702	
Corrected Hedge's g Statistics	0.078	
95% CI	(-0.89, 1.04)	
Subgroup*Treatment Interaction p-value	0.1592	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Bodily Pain		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	50.0 (34.7)	63.6 (35.6)
Analysis Visit Mean (SD)	70.9 (30.9)	67.1 (35.0)
LS Mean of Absolute Change from Baseline (SE)	18.19 (9.43)	5.37 (7.86)
95% CI	(-1.90, 38.28)	(-11.38, 22.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.82 (12.39)	
95% CI	(-13.59, 39.23)	
p-value	0.3172	
Corrected Hedge's g Statistics	0.489	
95% CI	(-0.49, 1.47)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	50.0 (34.7)	63.6 (35.6)
Analysis Visit Mean (SD)	65.1 (25.3)	62.3 (36.1)
LS Mean of Absolute Change from Baseline (SE)	12.53 (8.65)	0.53 (7.21)
95% CI	(-5.91, 30.96)	(-14.84, 15.90)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.00 (11.37)	
95% CI	(-12.24, 36.23)	
p-value	0.3081	
Corrected Hedge's g Statistics	0.499	
95% CI	(-0.48, 1.48)	
Subgroup*Treatment Interaction p-value	0.5769	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
General Health		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	58.6 (19.0)	60.1 (19.5)
Analysis Visit Mean (SD)	59.0 (18.5)	64.2 (22.7)
LS Mean of Absolute Change from Baseline (SE)	0.37 (4.30)	4.14 (3.60)
95% CI	(-8.79, 9.53)	(-3.52, 11.81)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.77 (5.61)	
95% CI	(-15.72, 8.18)	
p-value	0.5115	
Corrected Hedge's g Statistics	-0.315	
95% CI	(-1.29, 0.66)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	58.6 (19.0)	60.1 (19.5)
Analysis Visit Mean (SD)	72.9 (20.1)	64.5 (28.0)
LS Mean of Absolute Change from Baseline (SE)	14.26 (6.55)	4.42 (5.48)
95% CI	(0.31, 28.21)	(-7.25, 16.09)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.85 (8.54)	
95% CI	(-8.35, 28.04)	
p-value	0.2668	
Corrected Hedge's g Statistics	0.540	
95% CI	(-0.44, 1.52)	
Subgroup*Treatment Interaction p-value	0.6533	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Vitality		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	64.31 (23.29)	49.40 (20.94)
Analysis Visit Mean (SD)	66.09 (22.79)	53.15 (25.21)
LS Mean of Absolute Change from Baseline (SE)	2.92 (6.10)	2.95 (5.05)
95% CI	(-10.09, 15.92)	(-7.82, 13.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.03 (8.15)	
95% CI	(-17.39, 17.33)	
p-value	0.9968	
Corrected Hedge's g Statistics	-0.002	
95% CI	(-0.97, 0.96)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	64.31 (23.29)	49.40 (20.94)
Analysis Visit Mean (SD)	66.10 (27.69)	56.27 (32.93)
LS Mean of Absolute Change from Baseline (SE)	1.96 (9.03)	6.75 (7.48)
95% CI	(-17.30, 21.21)	(-9.19, 22.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.79 (12.06)	
95% CI	(-30.50, 20.92)	
p-value	0.6967	
Corrected Hedge's g Statistics	-0.192	
95% CI	(-1.16, 0.78)	
Subgroup*Treatment Interaction p-value	0.9535	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Social Functioning		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	83.93 (20.04)	76.25 (27.29)
Analysis Visit Mean (SD)	76.79 (29.25)	68.75 (33.98)
LS Mean of Absolute Change from Baseline (SE)	-7.26 (7.85)	-7.42 (6.55)
95% CI	(-23.99, 9.48)	(-21.39, 6.55)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.17 (10.29)	
95% CI	(-21.77, 22.11)	
p-value	0.9874	
Corrected Hedge's g Statistics	0.008	
95% CI	(-0.96, 0.97)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	83.93 (20.04)	76.25 (27.29)
Analysis Visit Mean (SD)	78.57 (26.73)	71.25 (33.36)
LS Mean of Absolute Change from Baseline (SE)	-4.24 (9.74)	-5.78 (8.13)
95% CI	(-24.99, 16.51)	(-23.11, 11.54)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.55 (12.76)	
95% CI	(-25.66, 28.75)	
p-value	0.9052	
Corrected Hedge's g Statistics	0.057	
95% CI	(-0.91, 1.02)	
Subgroup*Treatment Interaction p-value	0.9061	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Role Emotional		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	84.53 (23.78)	71.67 (34.07)
Analysis Visit Mean (SD)	78.57 (39.34)	74.17 (31.04)
LS Mean of Absolute Change from Baseline (SE)	-5.88 (6.81)	2.44 (5.67)
95% CI	(-20.38, 8.63)	(-9.65, 14.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.32 (8.96)	
95% CI	(-27.42, 10.79)	
p-value	0.3680	
Corrected Hedge's g Statistics	-0.439	
95% CI	(-1.42, 0.54)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	84.53 (23.78)	71.67 (34.07)
Analysis Visit Mean (SD)	86.90 (12.60)	71.67 (32.20)
LS Mean of Absolute Change from Baseline (SE)	4.85 (6.50)	-1.74 (5.42)
95% CI	(-9.01, 18.71)	(-13.29, 9.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.59 (8.56)	
95% CI	(-11.67, 24.84)	
p-value	0.4538	
Corrected Hedge's g Statistics	0.364	
95% CI	(-0.61, 1.34)	
Subgroup*Treatment Interaction p-value	0.8248	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Mental Health		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	77.50 (12.83)	64.50 (18.77)
Analysis Visit Mean (SD)	77.86 (13.18)	63.50 (28.09)
LS Mean of Absolute Change from Baseline (SE)	1.47 (7.57)	-1.78 (6.24)
95% CI	(-14.66, 17.60)	(-15.09, 11.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.25 (10.17)	
95% CI	(-18.43, 24.92)	
p-value	0.7539	
Corrected Hedge's g Statistics	0.155	
95% CI	(-0.81, 1.12)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	77.50 (12.83)	64.50 (18.77)
Analysis Visit Mean (SD)	82.86 (10.75)	61.50 (30.65)
LS Mean of Absolute Change from Baseline (SE)	5.41 (7.52)	-3.04 (6.20)
95% CI	(-10.61, 21.43)	(-16.26, 10.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.44 (10.10)	
95% CI	(-13.09, 29.98)	
p-value	0.4164	
Corrected Hedge's g Statistics	0.406	
95% CI	(-0.57, 1.38)	
Subgroup*Treatment Interaction p-value	0.0901	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF

(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Mental Component Score		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	53.64 (8.38)	45.72 (11.39)
Analysis Visit Mean (SD)	52.23 (11.50)	44.54 (14.12)
LS Mean of Absolute Change from Baseline (SE)	-1.31 (3.46)	-1.25 (2.86)
95% CI	(-8.69, 6.07)	(-7.35, 4.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.05 (4.65)	
95% CI	(-9.97, 9.86)	
p-value	0.9909	
Corrected Hedge's g Statistics	-0.006	
95% CI	(-0.97, 0.96)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	53.64 (8.38)	45.72 (11.39)
Analysis Visit Mean (SD)	53.96 (2.49)	44.04 (15.21)
LS Mean of Absolute Change from Baseline (SE)	1.50 (3.72)	-2.51 (3.07)
95% CI	(-6.42, 9.42)	(-9.05, 4.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.01 (4.99)	
95% CI	(-6.63, 14.65)	
p-value	0.4348	
Corrected Hedge's g Statistics	0.390	
95% CI	(-0.58, 1.36)	
Subgroup*Treatment Interaction p-value	0.2817	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.5
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=10)
Physical Component Score		
Week 12		
m	7	10
n	7	10
Baseline Mean (SD)	44.44 (10.43)	46.98 (10.73)
Analysis Visit Mean (SD)	45.70 (11.17)	49.66 (8.62)
LS Mean of Absolute Change from Baseline (SE)	0.98 (1.74)	2.87 (1.45)
95% CI	(-2.73, 4.69)	(-0.23, 5.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.89 (2.28)	
95% CI	(-6.74, 2.96)	
p-value	0.4196	
Corrected Hedge's g Statistics	-0.390	
95% CI	(-1.36, 0.59)	
Week 36		
m	7	10
n	7	10
Baseline Mean (SD)	44.44 (10.43)	46.98 (10.73)
Analysis Visit Mean (SD)	48.23 (10.17)	50.21 (11.67)
LS Mean of Absolute Change from Baseline (SE)	3.62 (2.29)	3.35 (1.91)
95% CI	(-1.26, 8.51)	(-0.74, 7.43)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.28 (3.00)	
95% CI	(-6.11, 6.66)	
p-value	0.9280	
Corrected Hedge's g Statistics	0.043	
95% CI	(-0.92, 1.01)	
Subgroup*Treatment Interaction p-value	0.1433	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; NASH = Non-alcoholic steatohepatitis.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Physical Functioning		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	83.8 (11.1)	72.5 (30.5)
Analysis Visit Mean (SD)	83.8 (8.5)	68.3 (33.9)
LS Mean of Absolute Change from Baseline (SE)	0.07 (6.37)	-4.29 (5.31)
95% CI	(-14.61, 14.76)	(-16.53, 7.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.36 (8.41)	
95% CI	(-15.02, 23.75)	
p-value	0.6178	
Corrected Hedge's g Statistics	0.305	
95% CI	(-0.97, 1.58)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	83.8 (11.1)	81.0 (24.8)
Analysis Visit Mean (SD)	86.3 (9.5)	87.0 (16.0)
LS Mean of Absolute Change from Baseline (SE)	3.70 (1.42)	5.84 (1.23)
95% CI	(0.43, 6.96)	(3.01, 8.67)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.15 (1.88)	
95% CI	(-6.48, 2.19)	
p-value	0.2864	
Corrected Hedge's g Statistics	-0.685	
95% CI	(-2.04, 0.67)	
Subgroup*Treatment Interaction p-value	0.4551	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Role Physical		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	93.78 (8.82)	64.60 (40.44)
Analysis Visit Mean (SD)	93.78 (5.10)	59.40 (18.86)
LS Mean of Absolute Change from Baseline (SE)	8.36 (4.20)	-14.08 (3.53)
95% CI	(-1.31, 18.04)	(-22.22, -5.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	22.45 (5.77)	
95% CI	(9.14, 35.75)	
p-value	0.0046	
Corrected Hedge's g Statistics	2.372	
95% CI	(0.73, 4.01)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	93.78 (8.82)	75.02 (35.06)
Analysis Visit Mean (SD)	89.08 (10.68)	68.76 (20.73)
LS Mean of Absolute Change from Baseline (SE)	2.40 (7.51)	-9.91 (6.31)
95% CI	(-14.92, 19.71)	(-24.47, 4.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.31 (10.14)	
95% CI	(-11.08, 35.69)	
p-value	0.2594	
Corrected Hedge's g Statistics	0.754	
95% CI	(-0.61, 2.11)	
Subgroup*Treatment Interaction p-value	0.1642	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Bodily Pain		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	62.8 (22.6)	68.0 (27.1)
Analysis Visit Mean (SD)	86.3 (18.4)	67.5 (26.0)
LS Mean of Absolute Change from Baseline (SE)	22.19 (8.89)	0.01 (7.23)
95% CI	(1.69, 42.70)	(-16.66, 16.68)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	22.18 (11.49)	
95% CI	(-4.31, 48.68)	
p-value	0.0896	
Corrected Hedge's g Statistics	1.130	
95% CI	(-0.23, 2.49)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	62.8 (22.6)	70.8 (29.3)
Analysis Visit Mean (SD)	73.3 (31.1)	68.4 (28.4)
LS Mean of Absolute Change from Baseline (SE)	10.45 (7.34)	-2.21 (6.56)
95% CI	(-6.48, 27.37)	(-17.33, 12.91)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.66 (9.91)	
95% CI	(-10.20, 35.51)	
p-value	0.2373	
Corrected Hedge's g Statistics	0.767	
95% CI	(-0.59, 2.13)	
Subgroup*Treatment Interaction p-value	0.4393	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
General Health		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	59.8 (11.4)	70.0 (15.4)
Analysis Visit Mean (SD)	61.5 (11.7)	70.0 (17.7)
LS Mean of Absolute Change from Baseline (SE)	0.63 (5.90)	0.46 (4.60)
95% CI	(-12.97, 14.23)	(-10.14, 11.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.16 (7.70)	
95% CI	(-17.60, 17.93)	
p-value	0.9835	
Corrected Hedge's g Statistics	0.013	
95% CI	(-1.25, 1.28)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	59.8 (11.4)	75.0 (10.4)
Analysis Visit Mean (SD)	66.0 (15.6)	64.2 (16.6)
LS Mean of Absolute Change from Baseline (SE)	8.10 (7.81)	-14.46 (7.12)
95% CI	(-9.91, 26.11)	(-30.88, 1.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	22.56 (11.62)	
95% CI	(-4.23, 49.35)	
p-value	0.0881	
Corrected Hedge's g Statistics	1.270	
95% CI	(-0.17, 2.71)	
Subgroup*Treatment Interaction p-value	0.7016	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Vitality		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	67.23 (10.68)	47.93 (23.29)
Analysis Visit Mean (SD)	67.20 (15.63)	44.83 (11.49)
LS Mean of Absolute Change from Baseline (SE)	7.63 (7.04)	-10.27 (5.85)
95% CI	(-8.61, 23.86)	(-23.76, 3.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	17.90 (9.72)	
95% CI	(-4.52, 40.31)	
p-value	0.1029	
Corrected Hedge's g Statistics	1.135	
95% CI	(-0.22, 2.49)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	67.23 (10.68)	52.52 (22.80)
Analysis Visit Mean (SD)	68.78 (5.10)	51.28 (23.98)
LS Mean of Absolute Change from Baseline (SE)	4.76 (9.04)	-4.88 (7.62)
95% CI	(-16.07, 25.60)	(-22.44, 12.68)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.64 (12.36)	
95% CI	(-18.86, 38.14)	
p-value	0.4577	
Corrected Hedge's g Statistics	0.490	
95% CI	(-0.84, 1.82)	
Subgroup*Treatment Interaction p-value	0.3457	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Social Functioning		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	100.00 (0.00)	77.08 (26.71)
Analysis Visit Mean (SD)	90.63 (11.97)	72.92 (30.02)
LS Mean of Absolute Change from Baseline (SE)	-9.56 (7.28)	-4.01 (5.96)
95% CI	(-26.34, 7.23)	(-17.76, 9.73)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.54 (10.08)	
95% CI	(-28.80, 17.71)	
p-value	0.5975	
Corrected Hedge's g Statistics	-0.343	
95% CI	(-1.62, 0.93)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	100.00 (0.00)	80.00 (28.78)
Analysis Visit Mean (SD)	93.75 (12.50)	80.00 (20.92)
LS Mean of Absolute Change from Baseline (SE)	-0.86 (7.11)	-1.20 (6.02)
95% CI	(-17.26, 15.54)	(-15.07, 12.68)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.34 (9.86)	
95% CI	(-22.40, 23.07)	
p-value	0.9737	
Corrected Hedge's g Statistics	0.022	
95% CI	(-1.29, 1.34)	
Subgroup*Treatment Interaction p-value	0.7812	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Role Emotional		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	95.83 (8.35)	65.28 (36.67)
Analysis Visit Mean (SD)	100.00 (0.00)	72.22 (20.18)
LS Mean of Absolute Change from Baseline (SE)	12.24 (4.60)	-1.29 (3.88)
95% CI	(1.63, 22.85)	(-10.23, 7.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.52 (6.42)	
95% CI	(-1.28, 28.33)	
p-value	0.0683	
Corrected Hedge's g Statistics	1.301	
95% CI	(-0.09, 2.69)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	95.83 (8.35)	75.00 (31.20)
Analysis Visit Mean (SD)	85.43 (12.51)	75.00 (15.59)
LS Mean of Absolute Change from Baseline (SE)	0.84 (7.40)	-4.15 (6.14)
95% CI	(-16.22, 17.90)	(-18.32, 10.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.99 (10.08)	
95% CI	(-18.26, 28.24)	
p-value	0.6338	
Corrected Hedge's g Statistics	0.312	
95% CI	(-1.01, 1.64)	
Subgroup*Treatment Interaction p-value	0.9385	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Mental Health		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	91.88 (9.87)	62.50 (24.24)
Analysis Visit Mean (SD)	87.50 (6.45)	63.33 (21.13)
LS Mean of Absolute Change from Baseline (SE)	-0.53 (5.02)	-2.70 (4.22)
95% CI	(-12.11, 11.04)	(-12.44, 7.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.17 (7.31)	
95% CI	(-14.69, 19.02)	
p-value	0.7744	
Corrected Hedge's g Statistics	0.191	
95% CI	(-1.08, 1.46)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	91.88 (9.87)	69.00 (20.43)
Analysis Visit Mean (SD)	91.25 (10.31)	71.00 (24.85)
LS Mean of Absolute Change from Baseline (SE)	-0.09 (6.61)	2.39 (5.24)
95% CI	(-15.35, 15.16)	(-9.69, 14.47)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.48 (9.25)	
95% CI	(-23.80, 18.84)	
p-value	0.7953	
Corrected Hedge's g Statistics	-0.178	
95% CI	(-1.50, 1.14)	
Subgroup*Treatment Interaction p-value	0.8623	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Mental Component Score		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	59.18 (1.84)	43.53 (12.30)
Analysis Visit Mean (SD)	56.88 (4.30)	44.82 (10.38)
LS Mean of Absolute Change from Baseline (SE)	-0.18 (2.87)	-0.59 (2.39)
95% CI	(-6.79, 6.43)	(-6.11, 4.93)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.41 (4.22)	
95% CI	(-9.32, 10.13)	
p-value	0.9253	
Corrected Hedge's g Statistics	0.063	
95% CI	(-1.20, 1.33)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	59.18 (1.84)	46.42 (11.26)
Analysis Visit Mean (SD)	56.18 (3.70)	46.72 (11.62)
LS Mean of Absolute Change from Baseline (SE)	-0.71 (4.45)	-0.96 (3.52)
95% CI	(-10.96, 9.54)	(-9.08, 7.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.25 (6.30)	
95% CI	(-14.26, 14.77)	
p-value	0.9689	
Corrected Hedge's g Statistics	0.027	
95% CI	(-1.29, 1.34)	
Subgroup*Treatment Interaction p-value	0.7628	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Visit Statistic	MGL-3196 (N=4)	Placebo (N=6)
Physical Component Score		
Week 12		
m	4	6
n	4	6
Baseline Mean (SD)	47.78 (5.47)	49.78 (10.08)
Analysis Visit Mean (SD)	51.15 (4.73)	47.72 (8.68)
LS Mean of Absolute Change from Baseline (SE)	2.87 (2.29)	-1.99 (1.85)
95% CI	(-2.40, 8.14)	(-6.25, 2.28)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.86 (2.95)	
95% CI	(-1.94, 11.65)	
p-value	0.1380	
Corrected Hedge's g Statistics	0.965	
95% CI	(-0.37, 2.30)	
Week 36		
m	4	6
n	4	5
Baseline Mean (SD)	47.78 (5.47)	51.96 (9.57)
Analysis Visit Mean (SD)	50.63 (5.73)	50.30 (8.85)
LS Mean of Absolute Change from Baseline (SE)	2.70 (1.40)	-1.55 (1.27)
95% CI	(-0.54, 5.93)	(-4.48, 1.39)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.24 (1.93)	
95% CI	(-0.21, 8.69)	
p-value	0.0592	
Corrected Hedge's g Statistics	1.333	
95% CI	(-0.12, 2.78)	
Subgroup*Treatment Interaction p-value	0.0912	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Physical Functioning		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	69.6 (28.1)	67.3 (28.9)
Analysis Visit Mean (SD)	68.5 (31.1)	78.1 (20.9)
LS Mean of Absolute Change from Baseline (SE)	-0.71 (5.71)	10.29 (5.71)
95% CI	(-12.50, 11.08)	(-1.50, 22.08)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-11.00 (8.08)	
95% CI	(-27.68, 5.68)	
p-value	0.1860	
Corrected Hedge's g Statistics	-0.517	
95% CI	(-1.30, 0.26)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	70.0 (29.7)	67.3 (28.9)
Analysis Visit Mean (SD)	74.1 (25.1)	74.6 (28.2)
LS Mean of Absolute Change from Baseline (SE)	5.03 (5.38)	6.94 (4.98)
95% CI	(-6.07, 16.12)	(-3.33, 17.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.91 (7.33)	
95% CI	(-17.04, 13.22)	
p-value	0.7963	
Corrected Hedge's g Statistics	-0.103	
95% CI	(-0.91, 0.70)	
Subgroup*Treatment Interaction p-value	0.4551	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Role Physical		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	69.25 (36.39)	62.98 (36.66)
Analysis Visit Mean (SD)	73.10 (30.87)	71.16 (31.10)
LS Mean of Absolute Change from Baseline (SE)	4.70 (4.20)	7.44 (4.20)
95% CI	(-3.97, 13.38)	(-1.23, 16.11)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.73 (5.95)	
95% CI	(-15.02, 9.56)	
p-value	0.6503	
Corrected Hedge's g Statistics	-0.175	
95% CI	(-0.94, 0.60)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	68.77 (38.62)	62.98 (36.66)
Analysis Visit Mean (SD)	76.15 (21.98)	72.12 (33.23)
LS Mean of Absolute Change from Baseline (SE)	9.20 (5.98)	7.80 (5.68)
95% CI	(-3.15, 21.54)	(-3.93, 19.52)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.40 (8.26)	
95% CI	(-15.65, 18.46)	
p-value	0.8667	
Corrected Hedge's g Statistics	0.067	
95% CI	(-0.74, 0.87)	
Subgroup*Treatment Interaction p-value	0.1642	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Bodily Pain		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	54.9 (30.6)	67.7 (31.9)
Analysis Visit Mean (SD)	61.8 (26.0)	64.5 (35.2)
LS Mean of Absolute Change from Baseline (SE)	4.47 (7.16)	-0.26 (7.19)
95% CI	(-10.30, 19.25)	(-15.11, 14.58)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.74 (10.26)	
95% CI	(-16.44, 25.91)	
p-value	0.6485	
Corrected Hedge's g Statistics	0.177	
95% CI	(-0.59, 0.95)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	50.5 (31.3)	67.7 (31.9)
Analysis Visit Mean (SD)	62.5 (24.1)	66.8 (32.1)
LS Mean of Absolute Change from Baseline (SE)	4.14 (7.80)	3.12 (7.21)
95% CI	(-11.96, 20.24)	(-11.75, 18.00)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.02 (10.80)	
95% CI	(-21.28, 23.31)	
p-value	0.9259	
Corrected Hedge's g Statistics	0.038	
95% CI	(-0.77, 0.84)	
Subgroup*Treatment Interaction p-value	0.4393	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
General Health		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	60.2 (18.8)	61.0 (18.7)
Analysis Visit Mean (SD)	58.9 (16.9)	59.7 (20.7)
LS Mean of Absolute Change from Baseline (SE)	-1.24 (3.58)	-1.05 (3.58)
95% CI	(-8.62, 6.14)	(-8.43, 6.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.19 (5.06)	
95% CI	(-10.64, 10.25)	
p-value	0.9698	
Corrected Hedge's g Statistics	-0.015	
95% CI	(-0.78, 0.75)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	57.2 (17.7)	61.0 (18.7)
Analysis Visit Mean (SD)	64.0 (20.9)	65.6 (25.1)
LS Mean of Absolute Change from Baseline (SE)	4.66 (5.24)	4.81 (4.88)
95% CI	(-6.15, 15.47)	(-5.26, 14.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.15 (7.17)	
95% CI	(-14.96, 14.65)	
p-value	0.9833	
Corrected Hedge's g Statistics	-0.008	
95% CI	(-0.81, 0.79)	
Subgroup*Treatment Interaction p-value	0.7016	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Vitality		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	60.13 (20.65)	56.76 (20.49)
Analysis Visit Mean (SD)	59.15 (21.43)	58.19 (23.30)
LS Mean of Absolute Change from Baseline (SE)	-0.39 (4.85)	1.02 (4.84)
95% CI	(-10.40, 9.61)	(-8.98, 11.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.41 (6.87)	
95% CI	(-15.58, 12.76)	
p-value	0.8389	
Corrected Hedge's g Statistics	-0.078	
95% CI	(-0.85, 0.69)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	59.13 (22.06)	56.76 (20.49)
Analysis Visit Mean (SD)	61.39 (23.85)	61.08 (26.04)
LS Mean of Absolute Change from Baseline (SE)	-0.06 (5.99)	3.86 (5.77)
95% CI	(-12.42, 12.30)	(-8.05, 15.76)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.91 (8.33)	
95% CI	(-21.10, 13.27)	
p-value	0.6425	
Corrected Hedge's g Statistics	-0.185	
95% CI	(-0.99, 0.62)	
Subgroup*Treatment Interaction p-value	0.3457	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Social Functioning		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	79.81 (22.56)	76.92 (25.94)
Analysis Visit Mean (SD)	79.81 (25.28)	72.12 (32.34)
LS Mean of Absolute Change from Baseline (SE)	0.10 (5.24)	-4.93 (5.24)
95% CI	(-10.71, 10.92)	(-15.76, 5.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.04 (7.42)	
95% CI	(-10.28, 20.35)	
p-value	0.5038	
Corrected Hedge's g Statistics	0.258	
95% CI	(-0.51, 1.03)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	80.68 (21.91)	76.92 (25.94)
Analysis Visit Mean (SD)	75.00 (23.05)	75.96 (30.39)
LS Mean of Absolute Change from Baseline (SE)	-5.06 (7.69)	-1.88 (7.15)
95% CI	(-20.92, 10.80)	(-16.64, 12.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.18 (10.51)	
95% CI	(-24.88, 18.52)	
p-value	0.7650	
Corrected Hedge's g Statistics	-0.120	
95% CI	(-0.92, 0.68)	
Subgroup*Treatment Interaction p-value	0.7812	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Role Emotional		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	76.28 (30.97)	71.15 (33.96)
Analysis Visit Mean (SD)	77.58 (34.42)	75.65 (31.81)
LS Mean of Absolute Change from Baseline (SE)	1.56 (4.46)	4.24 (4.45)
95% CI	(-7.64, 10.75)	(-4.96, 13.43)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.68 (6.31)	
95% CI	(-15.70, 10.35)	
p-value	0.6751	
Corrected Hedge's g Statistics	-0.161	
95% CI	(-0.93, 0.61)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	76.52 (32.02)	71.15 (33.96)
Analysis Visit Mean (SD)	82.57 (19.53)	73.08 (34.55)
LS Mean of Absolute Change from Baseline (SE)	7.11 (5.37)	1.12 (4.96)
95% CI	(-3.97, 18.18)	(-9.12, 11.36)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.98 (7.32)	
95% CI	(-9.13, 21.09)	
p-value	0.4218	
Corrected Hedge's g Statistics	0.324	
95% CI	(-0.48, 1.13)	
Subgroup*Treatment Interaction p-value	0.9385	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Mental Health		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	76.15 (15.16)	64.62 (23.14)
Analysis Visit Mean (SD)	76.15 (14.60)	65.38 (28.76)
LS Mean of Absolute Change from Baseline (SE)	1.13 (4.76)	-0.29 (4.75)
95% CI	(-8.70, 10.96)	(-10.10, 9.51)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.43 (6.88)	
95% CI	(-12.77, 15.62)	
p-value	0.8375	
Corrected Hedge's g Statistics	0.080	
95% CI	(-0.69, 0.85)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	76.36 (15.18)	64.62 (23.14)
Analysis Visit Mean (SD)	74.55 (18.90)	68.85 (29.09)
LS Mean of Absolute Change from Baseline (SE)	-0.96 (6.00)	3.15 (5.56)
95% CI	(-13.35, 11.43)	(-8.32, 14.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.11 (8.36)	
95% CI	(-21.36, 13.15)	
p-value	0.6277	
Corrected Hedge's g Statistics	-0.199	
95% CI	(-1.00, 0.61)	
Subgroup*Treatment Interaction p-value	0.8623	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Mental Component Score		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	51.28 (9.32)	46.71 (12.41)
Analysis Visit Mean (SD)	51.08 (9.74)	46.20 (14.65)
LS Mean of Absolute Change from Baseline (SE)	-0.01 (2.09)	-0.69 (2.09)
95% CI	(-4.32, 4.30)	(-4.99, 3.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.68 (2.98)	
95% CI	(-5.48, 6.84)	
p-value	0.8222	
Corrected Hedge's g Statistics	0.087	
95% CI	(-0.68, 0.86)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	51.55 (9.31)	46.71 (12.41)
Analysis Visit Mean (SD)	50.61 (7.04)	47.48 (14.61)
LS Mean of Absolute Change from Baseline (SE)	-0.52 (2.59)	0.16 (2.41)
95% CI	(-5.86, 4.82)	(-4.82, 5.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.68 (3.58)	
95% CI	(-8.07, 6.71)	
p-value	0.8509	
Corrected Hedge's g Statistics	-0.076	
95% CI	(-0.88, 0.73)	
Subgroup*Treatment Interaction p-value	0.7628	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.6
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Visit Statistic	MGL-3196 (N=13)	Placebo (N=13)
Physical Component Score		
Week 12		
m	13	13
n	13	13
Baseline Mean (SD)	44.77 (9.68)	47.05 (9.79)
Analysis Visit Mean (SD)	45.69 (10.13)	48.84 (8.77)
LS Mean of Absolute Change from Baseline (SE)	0.78 (1.30)	1.99 (1.31)
95% CI	(-1.91, 3.47)	(-0.71, 4.68)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.21 (1.85)	
95% CI	(-5.03, 2.62)	
p-value	0.5207	
Corrected Hedge's g Statistics	-0.248	
95% CI	(-1.02, 0.52)	
Week 36		
m	11	13
n	11	13
Baseline Mean (SD)	43.79 (10.09)	47.05 (9.79)
Analysis Visit Mean (SD)	47.52 (8.64)	49.23 (10.51)
LS Mean of Absolute Change from Baseline (SE)	2.32 (2.16)	2.66 (2.03)
95% CI	(-2.13, 6.77)	(-1.54, 6.85)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.34 (2.98)	
95% CI	(-6.49, 5.81)	
p-value	0.9103	
Corrected Hedge's g Statistics	-0.045	
95% CI	(-0.85, 0.76)	
Subgroup*Treatment Interaction p-value	0.0912	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Physical Functioning		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	73.2 (20.8)	72.9 (23.4)
Analysis Visit Mean (SD)	73.6 (23.6)	79.3 (19.5)
LS Mean of Absolute Change from Baseline (SE)	0.43 (3.55)	6.36 (4.45)
95% CI	(-7.10, 7.95)	(-3.07, 15.79)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.93 (5.69)	
95% CI	(-18.00, 6.13)	
p-value	0.3128	
Corrected Hedge's g Statistics	-0.480	
95% CI	(-1.44, 0.48)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	74.4 (21.3)	72.9 (23.4)
Analysis Visit Mean (SD)	78.3 (19.7)	81.4 (15.7)
LS Mean of Absolute Change from Baseline (SE)	4.42 (3.63)	8.39 (4.12)
95% CI	(-3.28, 12.12)	(-0.34, 17.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.97 (5.49)	
95% CI	(-15.61, 7.67)	
p-value	0.4798	
Corrected Hedge's g Statistics	-0.345	
95% CI	(-1.34, 0.65)	
Subgroup*Treatment Interaction p-value	0.8867	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Role Physical		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	79.57 (22.72)	54.47 (35.11)
Analysis Visit Mean (SD)	82.41 (18.30)	64.30 (21.86)
LS Mean of Absolute Change from Baseline (SE)	8.26 (4.90)	1.48 (6.27)
95% CI	(-2.14, 18.65)	(-11.81, 14.77)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.78 (8.32)	
95% CI	(-10.86, 24.41)	
p-value	0.4271	
Corrected Hedge's g Statistics	0.394	
95% CI	(-0.56, 1.35)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	81.28 (22.52)	54.47 (35.11)
Analysis Visit Mean (SD)	78.49 (19.80)	68.76 (23.10)
LS Mean of Absolute Change from Baseline (SE)	4.71 (6.55)	4.27 (7.82)
95% CI	(-9.18, 18.59)	(-12.32, 20.85)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.44 (10.71)	
95% CI	(-22.27, 23.15)	
p-value	0.9675	
Corrected Hedge's g Statistics	0.021	
95% CI	(-0.97, 1.01)	
Subgroup*Treatment Interaction p-value	0.6947	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Bodily Pain		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	56.7 (24.8)	69.7 (21.7)
Analysis Visit Mean (SD)	69.9 (21.4)	64.4 (34.6)
LS Mean of Absolute Change from Baseline (SE)	9.79 (8.45)	2.24 (10.81)
95% CI	(-8.12, 27.70)	(-20.67, 25.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.55 (13.94)	
95% CI	(-22.01, 37.10)	
p-value	0.5957	
Corrected Hedge's g Statistics	0.255	
95% CI	(-0.70, 1.21)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	51.8 (24.7)	69.7 (21.7)
Analysis Visit Mean (SD)	60.1 (26.1)	72.7 (18.2)
LS Mean of Absolute Change from Baseline (SE)	-0.33 (7.86)	9.75 (8.97)
95% CI	(-16.99, 16.32)	(-9.27, 28.76)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-10.08 (12.34)	
95% CI	(-36.23, 16.07)	
p-value	0.4258	
Corrected Hedge's g Statistics	-0.403	
95% CI	(-1.40, 0.59)	
Subgroup*Treatment Interaction p-value	0.6783	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
General Health		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	60.4 (17.4)	65.3 (15.0)
Analysis Visit Mean (SD)	56.3 (13.8)	61.7 (16.4)
LS Mean of Absolute Change from Baseline (SE)	-4.34 (2.44)	-2.65 (3.09)
95% CI	(-9.51, 0.82)	(-9.19, 3.90)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.70 (3.95)	
95% CI	(-10.06, 6.67)	
p-value	0.6732	
Corrected Hedge's g Statistics	-0.199	
95% CI	(-1.15, 0.75)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	56.7 (15.5)	65.3 (15.0)
Analysis Visit Mean (SD)	63.9 (22.0)	58.9 (9.2)
LS Mean of Absolute Change from Baseline (SE)	0.22 (5.89)	-3.59 (6.86)
95% CI	(-12.27, 12.70)	(-18.13, 10.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.81 (9.18)	
95% CI	(-15.65, 23.27)	
p-value	0.6839	
Corrected Hedge's g Statistics	0.201	
95% CI	(-0.79, 1.19)	
Subgroup*Treatment Interaction p-value	0.7696	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Vitality		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	65.37 (17.31)	53.60 (13.91)
Analysis Visit Mean (SD)	61.95 (21.36)	54.49 (10.02)
LS Mean of Absolute Change from Baseline (SE)	-1.01 (5.14)	-2.54 (6.50)
95% CI	(-11.91, 9.90)	(-16.32, 11.24)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.53 (8.55)	
95% CI	(-16.60, 19.67)	
p-value	0.8600	
Corrected Hedge's g Statistics	0.085	
95% CI	(-0.86, 1.03)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	65.31 (18.78)	53.60 (13.91)
Analysis Visit Mean (SD)	61.83 (25.47)	58.96 (11.89)
LS Mean of Absolute Change from Baseline (SE)	-4.68 (5.62)	3.45 (6.78)
95% CI	(-16.60, 7.24)	(-10.93, 17.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.13 (9.08)	
95% CI	(-27.38, 11.12)	
p-value	0.3841	
Corrected Hedge's g Statistics	-0.443	
95% CI	(-1.44, 0.56)	
Subgroup*Treatment Interaction p-value	0.4487	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Social Functioning		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	87.50 (17.68)	73.21 (24.40)
Analysis Visit Mean (SD)	82.95 (18.77)	71.43 (26.73)
LS Mean of Absolute Change from Baseline (SE)	-3.69 (4.47)	-3.31 (5.72)
95% CI	(-13.16, 5.79)	(-15.43, 8.81)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.38 (7.46)	
95% CI	(-16.19, 15.43)	
p-value	0.9601	
Corrected Hedge's g Statistics	-0.024	
95% CI	(-0.97, 0.92)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	90.28 (13.66)	73.21 (24.40)
Analysis Visit Mean (SD)	76.39 (26.84)	80.36 (20.23)
LS Mean of Absolute Change from Baseline (SE)	-9.20 (8.39)	1.45 (9.56)
95% CI	(-26.99, 8.59)	(-18.82, 21.73)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-10.65 (13.35)	
95% CI	(-38.94, 17.64)	
p-value	0.4365	
Corrected Hedge's g Statistics	-0.399	
95% CI	(-1.40, 0.60)	
Subgroup*Treatment Interaction p-value	0.1866	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Role Emotional		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	84.09 (19.53)	65.47 (33.49)
Analysis Visit Mean (SD)	90.16 (16.59)	67.86 (25.64)
LS Mean of Absolute Change from Baseline (SE)	8.12 (2.92)	-0.91 (3.71)
95% CI	(1.94, 14.30)	(-8.78, 6.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.02 (4.87)	
95% CI	(-1.29, 19.34)	
p-value	0.0822	
Corrected Hedge's g Statistics	0.883	
95% CI	(-0.11, 1.87)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	86.11 (17.18)	65.47 (33.49)
Analysis Visit Mean (SD)	81.48 (16.55)	65.47 (27.82)
LS Mean of Absolute Change from Baseline (SE)	-1.30 (5.90)	-5.21 (6.88)
95% CI	(-13.81, 11.20)	(-19.79, 9.37)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.90 (9.41)	
95% CI	(-16.05, 23.86)	
p-value	0.6840	
Corrected Hedge's g Statistics	0.206	
95% CI	(-0.78, 1.20)	
Subgroup*Treatment Interaction p-value	0.2477	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Mental Health		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	81.14 (13.10)	63.57 (24.45)
Analysis Visit Mean (SD)	79.09 (11.14)	66.43 (21.74)
LS Mean of Absolute Change from Baseline (SE)	-0.07 (3.04)	-0.22 (3.90)
95% CI	(-6.51, 6.38)	(-8.49, 8.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.16 (5.20)	
95% CI	(-10.86, 11.18)	
p-value	0.9765	
Corrected Hedge's g Statistics	0.015	
95% CI	(-0.93, 0.96)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	82.50 (12.12)	63.57 (24.45)
Analysis Visit Mean (SD)	80.56 (16.67)	72.14 (22.33)
LS Mean of Absolute Change from Baseline (SE)	-0.16 (5.04)	5.84 (5.84)
95% CI	(-10.84, 10.53)	(-6.54, 18.22)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.00 (8.18)	
95% CI	(-23.35, 11.35)	
p-value	0.4743	
Corrected Hedge's g Statistics	-0.371	
95% CI	(-1.37, 0.62)	
Subgroup*Treatment Interaction p-value	0.4643	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Mental Component Score		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	54.55 (7.17)	44.44 (12.25)
Analysis Visit Mean (SD)	53.60 (6.51)	44.74 (10.85)
LS Mean of Absolute Change from Baseline (SE)	-0.21 (1.16)	-0.87 (1.50)
95% CI	(-2.67, 2.25)	(-4.06, 2.31)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.66 (2.02)	
95% CI	(-3.61, 4.93)	
p-value	0.7478	
Corrected Hedge's g Statistics	0.161	
95% CI	(-0.79, 1.11)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	55.59 (6.01)	44.44 (12.25)
Analysis Visit Mean (SD)	51.76 (6.97)	46.53 (10.90)
LS Mean of Absolute Change from Baseline (SE)	-3.08 (2.17)	0.28 (2.60)
95% CI	(-7.67, 1.52)	(-5.23, 5.79)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.36 (3.63)	
95% CI	(-11.06, 4.35)	
p-value	0.3696	
Corrected Hedge's g Statistics	-0.476	
95% CI	(-1.48, 0.53)	
Subgroup*Treatment Interaction p-value	0.5804	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Visit Statistic	MGL-3196 (N=11)	Placebo (N=7)
Physical Component Score		
Week 12		
m	11	7
n	11	7
Baseline Mean (SD)	45.75 (7.36)	48.19 (8.15)
Analysis Visit Mean (SD)	47.10 (8.02)	48.86 (7.77)
LS Mean of Absolute Change from Baseline (SE)	1.21 (1.51)	0.98 (1.91)
95% CI	(-1.99, 4.42)	(-3.07, 5.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.23 (2.45)	
95% CI	(-4.96, 5.43)	
p-value	0.9252	
Corrected Hedge's g Statistics	0.044	
95% CI	(-0.90, 0.99)	
Week 36		
m	9	7
n	9	7
Baseline Mean (SD)	44.78 (7.56)	48.19 (8.15)
Analysis Visit Mean (SD)	47.58 (8.40)	50.06 (3.40)
LS Mean of Absolute Change from Baseline (SE)	1.01 (1.90)	2.85 (2.25)
95% CI	(-3.03, 5.04)	(-1.92, 7.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.84 (2.98)	
95% CI	(-8.15, 4.47)	
p-value	0.5451	
Corrected Hedge's g Statistics	-0.299	
95% CI	(-1.29, 0.69)	
Subgroup*Treatment Interaction p-value	0.6980	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Physical Functioning		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	72.5 (35.0)	66.7 (32.1)
Analysis Visit Mean (SD)	69.2 (37.1)	72.5 (28.4)
LS Mean of Absolute Change from Baseline (SE)	-2.19 (10.39)	4.58 (7.36)
95% CI	(-24.21, 19.83)	(-11.02, 20.18)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.77 (12.75)	
95% CI	(-33.81, 20.26)	
p-value	0.6027	
Corrected Hedge's g Statistics	-0.253	
95% CI	(-1.24, 0.73)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	72.5 (35.0)	70.0 (31.4)
Analysis Visit Mean (SD)	75.8 (27.8)	75.9 (30.9)
LS Mean of Absolute Change from Baseline (SE)	4.02 (8.08)	4.60 (5.92)
95% CI	(-13.11, 21.16)	(-7.95, 17.14)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.57 (10.02)	
95% CI	(-21.81, 20.66)	
p-value	0.9551	
Corrected Hedge's g Statistics	-0.028	
95% CI	(-1.02, 0.97)	
Subgroup*Treatment Interaction p-value	0.8867	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Role Physical		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	66.68 (49.31)	68.76 (38.15)
Analysis Visit Mean (SD)	69.82 (42.10)	69.28 (31.58)
LS Mean of Absolute Change from Baseline (SE)	2.50 (5.17)	0.33 (3.66)
95% CI	(-8.47, 13.47)	(-7.42, 8.08)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.17 (6.33)	
95% CI	(-11.26, 15.59)	
p-value	0.7368	
Corrected Hedge's g Statistics	0.163	
95% CI	(-0.82, 1.14)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	66.68 (49.31)	73.87 (35.44)
Analysis Visit Mean (SD)	81.27 (22.36)	72.74 (34.27)
LS Mean of Absolute Change from Baseline (SE)	13.47 (7.02)	0.92 (5.11)
95% CI	(-1.41, 28.34)	(-9.91, 11.75)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.54 (8.69)	
95% CI	(-5.88, 30.96)	
p-value	0.1681	
Corrected Hedge's g Statistics	0.699	
95% CI	(-0.32, 1.72)	
Subgroup*Treatment Interaction p-value	0.6947	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Bodily Pain		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	56.8 (36.9)	66.7 (34.4)
Analysis Visit Mean (SD)	63.2 (35.3)	66.0 (31.8)
LS Mean of Absolute Change from Baseline (SE)	5.09 (6.75)	-0.12 (4.75)
95% CI	(-9.21, 19.39)	(-10.19, 9.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.21 (8.29)	
95% CI	(-12.35, 22.78)	
p-value	0.5382	
Corrected Hedge's g Statistics	0.301	
95% CI	(-0.68, 1.29)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	56.8 (36.9)	67.8 (35.8)
Analysis Visit Mean (SD)	73.3 (24.4)	63.7 (36.5)
LS Mean of Absolute Change from Baseline (SE)	14.08 (9.77)	-2.26 (7.14)
95% CI	(-6.62, 34.79)	(-17.40, 12.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	16.34 (12.16)	
95% CI	(-9.44, 42.13)	
p-value	0.1978	
Corrected Hedge's g Statistics	0.653	
95% CI	(-0.37, 1.67)	
Subgroup*Treatment Interaction p-value	0.6783	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
General Health		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	59.7 (18.0)	63.0 (19.9)
Analysis Visit Mean (SD)	65.5 (18.1)	63.7 (22.4)
LS Mean of Absolute Change from Baseline (SE)	5.28 (6.13)	0.79 (4.32)
95% CI	(-7.71, 18.28)	(-8.37, 9.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.49 (7.51)	
95% CI	(-11.43, 20.41)	
p-value	0.5584	
Corrected Hedge's g Statistics	0.285	
95% CI	(-0.70, 1.27)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	59.7 (18.0)	64.6 (20.0)
Analysis Visit Mean (SD)	65.5 (15.7)	69.3 (27.7)
LS Mean of Absolute Change from Baseline (SE)	5.85 (6.45)	4.12 (4.74)
95% CI	(-7.82, 19.52)	(-5.92, 14.17)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.73 (8.03)	
95% CI	(-15.30, 18.75)	
p-value	0.8326	
Corrected Hedge's g Statistics	0.104	
95% CI	(-0.89, 1.10)	
Subgroup*Treatment Interaction p-value	0.7696	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Vitality		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	55.25 (21.06)	54.19 (25.06)
Analysis Visit Mean (SD)	59.38 (19.26)	53.68 (25.77)
LS Mean of Absolute Change from Baseline (SE)	4.09 (7.29)	-0.88 (5.16)
95% CI	(-11.36, 19.54)	(-11.82, 10.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.98 (8.93)	
95% CI	(-13.95, 23.90)	
p-value	0.5850	
Corrected Hedge's g Statistics	0.265	
95% CI	(-0.72, 1.25)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	55.25 (21.06)	56.85 (24.45)
Analysis Visit Mean (SD)	65.65 (11.70)	57.97 (31.51)
LS Mean of Absolute Change from Baseline (SE)	10.36 (8.66)	0.85 (6.26)
95% CI	(-8.00, 28.72)	(-12.43, 14.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.52 (10.69)	
95% CI	(-13.14, 32.17)	
p-value	0.3865	
Corrected Hedge's g Statistics	0.432	
95% CI	(-0.57, 1.44)	
Subgroup*Treatment Interaction p-value	0.4487	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Social Functioning		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	79.17 (28.14)	79.17 (26.83)
Analysis Visit Mean (SD)	81.25 (31.37)	72.92 (34.06)
LS Mean of Absolute Change from Baseline (SE)	2.07 (8.31)	-6.26 (5.88)
95% CI	(-15.55, 19.70)	(-18.72, 6.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.33 (10.18)	
95% CI	(-13.25, 29.92)	
p-value	0.4251	
Corrected Hedge's g Statistics	0.390	
95% CI	(-0.60, 1.38)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	79.17 (28.14)	80.68 (27.59)
Analysis Visit Mean (SD)	85.42 (12.29)	75.00 (32.11)
LS Mean of Absolute Change from Baseline (SE)	6.08 (8.82)	-6.02 (6.48)
95% CI	(-12.62, 24.78)	(-19.75, 7.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.10 (10.95)	
95% CI	(-11.11, 35.30)	
p-value	0.2854	
Corrected Hedge's g Statistics	0.533	
95% CI	(-0.48, 1.54)	
Subgroup*Treatment Interaction p-value	0.1866	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Role Emotional		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	75.00 (41.83)	71.53 (35.44)
Analysis Visit Mean (SD)	69.45 (47.62)	78.48 (29.82)
LS Mean of Absolute Change from Baseline (SE)	-5.43 (7.68)	6.49 (5.44)
95% CI	(-21.72, 10.85)	(-5.04, 18.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-11.93 (9.42)	
95% CI	(-31.89, 8.03)	
p-value	0.2234	
Corrected Hedge's g Statistics	-0.603	
95% CI	(-1.60, 0.40)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	75.00 (41.83)	76.52 (32.46)
Analysis Visit Mean (SD)	86.12 (20.19)	78.79 (31.48)
LS Mean of Absolute Change from Baseline (SE)	11.39 (6.99)	3.77 (5.13)
95% CI	(-3.44, 26.22)	(-7.10, 14.65)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.62 (8.67)	
95% CI	(-10.77, 26.00)	
p-value	0.3927	
Corrected Hedge's g Statistics	0.424	
95% CI	(-0.58, 1.43)	
Subgroup*Treatment Interaction p-value	0.2477	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Mental Health		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	77.50 (20.19)	64.17 (22.95)
Analysis Visit Mean (SD)	78.33 (19.15)	63.75 (29.09)
LS Mean of Absolute Change from Baseline (SE)	2.02 (8.01)	-1.26 (5.66)
95% CI	(-14.95, 18.99)	(-13.27, 10.74)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.28 (10.01)	
95% CI	(-17.94, 24.50)	
p-value	0.7475	
Corrected Hedge's g Statistics	0.159	
95% CI	(-0.82, 1.14)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	77.50 (20.19)	67.27 (21.26)
Analysis Visit Mean (SD)	76.67 (22.06)	67.73 (30.93)
LS Mean of Absolute Change from Baseline (SE)	-0.62 (8.58)	0.27 (6.19)
95% CI	(-18.81, 17.57)	(-12.85, 13.40)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.90 (10.70)	
95% CI	(-23.58, 21.79)	
p-value	0.9342	
Corrected Hedge's g Statistics	-0.041	
95% CI	(-1.04, 0.95)	
Subgroup*Treatment Interaction p-value	0.4643	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Mental Component Score		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	50.57 (11.56)	46.44 (12.54)
Analysis Visit Mean (SD)	50.33 (12.89)	46.36 (14.79)
LS Mean of Absolute Change from Baseline (SE)	-0.03 (3.77)	-0.26 (2.67)
95% CI	(-8.02, 7.96)	(-5.93, 5.41)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.23 (4.65)	
95% CI	(-9.63, 10.10)	
p-value	0.9607	
Corrected Hedge's g Statistics	0.024	
95% CI	(-0.96, 1.00)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	50.57 (11.56)	48.02 (11.84)
Analysis Visit Mean (SD)	52.60 (6.88)	47.74 (15.44)
LS Mean of Absolute Change from Baseline (SE)	2.50 (3.93)	-0.24 (2.87)
95% CI	(-5.83, 10.83)	(-6.32, 5.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.74 (4.88)	
95% CI	(-7.60, 13.07)	
p-value	0.5821	
Corrected Hedge's g Statistics	0.272	
95% CI	(-0.73, 1.27)	
Subgroup*Treatment Interaction p-value	0.5804	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.7
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Visit Statistic	MGL-3196 (N=6)	Placebo (N=12)
Physical Component Score		
Week 12		
m	6	12
n	6	12
Baseline Mean (SD)	44.97 (11.82)	47.75 (10.83)
Analysis Visit Mean (SD)	46.75 (12.21)	48.27 (9.25)
LS Mean of Absolute Change from Baseline (SE)	1.40 (2.01)	0.64 (1.41)
95% CI	(-2.85, 5.66)	(-2.35, 3.63)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.76 (2.46)	
95% CI	(-4.45, 5.97)	
p-value	0.7611	
Corrected Hedge's g Statistics	0.148	
95% CI	(-0.83, 1.13)	
Week 36		
m	6	12
n	6	11
Baseline Mean (SD)	44.97 (11.82)	48.55 (10.97)
Analysis Visit Mean (SD)	49.50 (7.69)	49.19 (12.53)
LS Mean of Absolute Change from Baseline (SE)	4.14 (2.89)	0.52 (2.11)
95% CI	(-1.98, 10.26)	(-3.95, 4.99)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.62 (3.60)	
95% CI	(-4.00, 11.25)	
p-value	0.3286	
Corrected Hedge's g Statistics	0.490	
95% CI	(-0.52, 1.50)	
Subgroup*Treatment Interaction p-value	0.6980	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; ALT = Alanine aminotransferase.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Physical Functioning		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	77.5 (19.7)	70.0 (23.9)
Analysis Visit Mean (SD)	75.0 (25.8)	78.2 (20.5)
LS Mean of Absolute Change from Baseline (SE)	-0.73 (5.69)	6.87 (5.25)
95% CI	(-12.47, 11.02)	(-3.97, 17.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.60 (7.80)	
95% CI	(-23.70, 8.51)	
p-value	0.3401	
Corrected Hedge's g Statistics	-0.374	
95% CI	(-1.15, 0.40)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	76.8 (20.5)	70.0 (23.9)
Analysis Visit Mean (SD)	78.6 (20.4)	79.3 (19.1)
LS Mean of Absolute Change from Baseline (SE)	3.64 (4.77)	7.79 (4.26)
95% CI	(-6.20, 13.49)	(-0.99, 16.57)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.14 (6.43)	
95% CI	(-17.42, 9.13)	
p-value	0.5254	
Corrected Hedge's g Statistics	-0.252	
95% CI	(-1.05, 0.54)	
Subgroup*Treatment Interaction p-value	0.2116	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Role Physical		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	78.67 (32.25)	64.29 (32.92)
Analysis Visit Mean (SD)	79.71 (27.07)	73.22 (23.82)
LS Mean of Absolute Change from Baseline (SE)	3.98 (4.30)	6.71 (3.96)
95% CI	(-4.90, 12.86)	(-1.47, 14.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.73 (5.92)	
95% CI	(-14.95, 9.49)	
p-value	0.6494	
Corrected Hedge's g Statistics	-0.178	
95% CI	(-0.95, 0.59)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	77.29 (33.45)	64.29 (32.92)
Analysis Visit Mean (SD)	77.85 (20.99)	74.11 (26.27)
LS Mean of Absolute Change from Baseline (SE)	4.54 (5.67)	6.51 (5.11)
95% CI	(-7.16, 16.25)	(-4.03, 17.04)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.96 (7.71)	
95% CI	(-17.88, 13.96)	
p-value	0.8015	
Corrected Hedge's g Statistics	-0.100	
95% CI	(-0.89, 0.69)	
Subgroup*Treatment Interaction p-value	0.0284	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Bodily Pain		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	58.7 (28.7)	69.7 (27.3)
Analysis Visit Mean (SD)	70.8 (23.5)	69.9 (30.5)
LS Mean of Absolute Change from Baseline (SE)	9.43 (7.02)	2.91 (6.50)
95% CI	(-5.05, 23.91)	(-10.52, 16.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.53 (9.66)	
95% CI	(-13.42, 26.47)	
p-value	0.5059	
Corrected Hedge's g Statistics	0.260	
95% CI	(-0.51, 1.03)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	56.4 (28.9)	69.7 (27.3)
Analysis Visit Mean (SD)	64.9 (26.5)	68.9 (27.6)
LS Mean of Absolute Change from Baseline (SE)	3.57 (7.31)	2.03 (6.49)
95% CI	(-11.51, 18.65)	(-11.36, 15.42)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.54 (9.90)	
95% CI	(-18.90, 21.98)	
p-value	0.8777	
Corrected Hedge's g Statistics	0.061	
95% CI	(-0.73, 0.85)	
Subgroup*Treatment Interaction p-value	0.6961	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
General Health		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	62.3 (18.0)	63.7 (16.9)
Analysis Visit Mean (SD)	62.2 (15.4)	63.9 (18.5)
LS Mean of Absolute Change from Baseline (SE)	-0.22 (3.70)	0.61 (3.43)
95% CI	(-7.87, 7.42)	(-6.48, 7.70)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.84 (5.05)	
95% CI	(-11.27, 9.59)	
p-value	0.8699	
Corrected Hedge's g Statistics	-0.063	
95% CI	(-0.83, 0.71)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	59.6 (16.2)	63.7 (16.9)
Analysis Visit Mean (SD)	68.3 (19.1)	65.9 (22.6)
LS Mean of Absolute Change from Baseline (SE)	7.22 (5.41)	2.59 (4.79)
95% CI	(-3.95, 18.39)	(-7.30, 12.47)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.63 (7.25)	
95% CI	(-10.33, 19.59)	
p-value	0.5288	
Corrected Hedge's g Statistics	0.250	
95% CI	(-0.54, 1.04)	
Subgroup*Treatment Interaction p-value	0.9595	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Vitality		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	63.05 (19.48)	55.83 (22.13)
Analysis Visit Mean (SD)	62.00 (21.72)	60.29 (16.37)
LS Mean of Absolute Change from Baseline (SE)	0.88 (4.55)	3.07 (4.19)
95% CI	(-8.50, 10.27)	(-5.58, 11.73)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.19 (6.23)	
95% CI	(-15.06, 10.67)	
p-value	0.7279	
Corrected Hedge's g Statistics	-0.135	
95% CI	(-0.91, 0.64)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	61.96 (20.04)	55.83 (22.13)
Analysis Visit Mean (SD)	63.10 (23.63)	62.52 (20.35)
LS Mean of Absolute Change from Baseline (SE)	0.63 (5.44)	5.45 (4.91)
95% CI	(-10.59, 11.85)	(-4.69, 15.58)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.82 (7.37)	
95% CI	(-20.04, 10.40)	
p-value	0.5196	
Corrected Hedge's g Statistics	-0.256	
95% CI	(-1.05, 0.54)	
Subgroup*Treatment Interaction p-value	0.0989	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Social Functioning		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	87.50 (16.85)	75.89 (25.22)
Analysis Visit Mean (SD)	83.33 (24.03)	74.11 (25.22)
LS Mean of Absolute Change from Baseline (SE)	-3.00 (5.11)	-2.67 (4.70)
95% CI	(-13.55, 7.55)	(-12.36, 7.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.33 (7.07)	
95% CI	(-14.92, 14.25)	
p-value	0.9626	
Corrected Hedge's g Statistics	-0.018	
95% CI	(-0.79, 0.75)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	86.36 (17.19)	75.89 (25.22)
Analysis Visit Mean (SD)	76.14 (24.01)	79.46 (21.15)
LS Mean of Absolute Change from Baseline (SE)	-7.00 (6.45)	0.57 (5.72)
95% CI	(-20.31, 6.31)	(-11.24, 12.38)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.57 (8.75)	
95% CI	(-25.62, 10.48)	
p-value	0.3954	
Corrected Hedge's g Statistics	-0.342	
95% CI	(-1.14, 0.45)	
Subgroup*Treatment Interaction p-value	0.0826	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Role Emotional		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	86.81 (19.61)	72.02 (28.62)
Analysis Visit Mean (SD)	85.43 (30.39)	78.58 (23.27)
LS Mean of Absolute Change from Baseline (SE)	-0.24 (4.84)	5.68 (4.44)
95% CI	(-10.22, 9.75)	(-3.48, 14.84)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.92 (6.71)	
95% CI	(-19.77, 7.93)	
p-value	0.3867	
Corrected Hedge's g Statistics	-0.344	
95% CI	(-1.12, 0.43)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	85.61 (20.10)	72.02 (28.62)
Analysis Visit Mean (SD)	84.85 (16.59)	77.38 (26.24)
LS Mean of Absolute Change from Baseline (SE)	2.05 (5.29)	2.73 (4.70)
95% CI	(-8.87, 12.98)	(-6.98, 12.43)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.67 (7.21)	
95% CI	(-15.56, 14.21)	
p-value	0.9267	
Corrected Hedge's g Statistics	-0.037	
95% CI	(-0.83, 0.75)	
Subgroup*Treatment Interaction p-value	0.1042	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Mental Health		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	81.04 (11.15)	63.93 (22.38)
Analysis Visit Mean (SD)	79.58 (12.52)	67.50 (24.08)
LS Mean of Absolute Change from Baseline (SE)	1.10 (4.56)	1.55 (4.15)
95% CI	(-8.31, 10.52)	(-7.01, 10.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.45 (6.48)	
95% CI	(-13.83, 12.93)	
p-value	0.9456	
Corrected Hedge's g Statistics	-0.028	
95% CI	(-0.80, 0.74)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	80.23 (11.32)	63.93 (22.38)
Analysis Visit Mean (SD)	78.64 (13.62)	72.14 (20.64)
LS Mean of Absolute Change from Baseline (SE)	1.89 (4.57)	5.21 (4.04)
95% CI	(-7.55, 11.33)	(-3.14, 13.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.32 (6.39)	
95% CI	(-16.50, 9.87)	
p-value	0.6085	
Corrected Hedge's g Statistics	-0.212	
95% CI	(-1.00, 0.58)	
Subgroup*Treatment Interaction p-value	0.1242	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Mental Component Score		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	54.32 (6.72)	46.09 (12.17)
Analysis Visit Mean (SD)	52.83 (9.17)	47.36 (11.18)
LS Mean of Absolute Change from Baseline (SE)	-0.74 (1.84)	0.69 (1.68)
95% CI	(-4.54, 3.06)	(-2.77, 4.16)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.43 (2.59)	
95% CI	(-6.78, 3.92)	
p-value	0.5854	
Corrected Hedge's g Statistics	-0.219	
95% CI	(-0.99, 0.55)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	53.88 (6.87)	46.09 (12.17)
Analysis Visit Mean (SD)	51.77 (5.96)	49.06 (10.61)
LS Mean of Absolute Change from Baseline (SE)	-0.48 (2.08)	1.50 (1.84)
95% CI	(-4.77, 3.81)	(-2.30, 5.30)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.98 (2.87)	
95% CI	(-7.91, 3.95)	
p-value	0.4969	
Corrected Hedge's g Statistics	-0.278	
95% CI	(-1.07, 0.52)	
Subgroup*Treatment Interaction p-value	0.0607	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Visit Statistic	MGL-3196 (N=12)	Placebo (N=14)
Physical Component Score		
Week 12		
m	12	14
n	12	14
Baseline Mean (SD)	46.58 (8.50)	48.23 (8.13)
Analysis Visit Mean (SD)	48.13 (8.87)	49.86 (8.06)
LS Mean of Absolute Change from Baseline (SE)	1.45 (1.30)	1.75 (1.21)
95% CI	(-1.24, 4.14)	(-0.74, 4.25)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.30 (1.78)	
95% CI	(-3.98, 3.37)	
p-value	0.8658	
Corrected Hedge's g Statistics	-0.065	
95% CI	(-0.84, 0.71)	
Week 36		
m	11	14
n	11	14
Baseline Mean (SD)	45.86 (8.52)	48.23 (8.13)
Analysis Visit Mean (SD)	48.65 (8.78)	49.82 (9.05)
LS Mean of Absolute Change from Baseline (SE)	1.74 (2.10)	1.90 (1.90)
95% CI	(-2.60, 6.08)	(-2.02, 5.83)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.16 (2.85)	
95% CI	(-6.04, 5.71)	
p-value	0.9552	
Corrected Hedge's g Statistics	-0.022	
95% CI	(-0.81, 0.77)	
Subgroup*Treatment Interaction p-value	0.3193	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Physical Functioning		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	62.0 (36.5)	66.0 (42.6)
Analysis Visit Mean (SD)	65.0 (34.8)	66.0 (36.5)
LS Mean of Absolute Change from Baseline (SE)	1.86 (9.26)	-0.16 (9.22)
95% CI	(-19.50, 23.22)	(-21.43, 21.11)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.02 (13.06)	
95% CI	(-28.10, 32.15)	
p-value	0.8808	
Corrected Hedge's g Statistics	0.088	
95% CI	(-1.15, 1.33)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	65.0 (41.4)	75.0 (43.4)
Analysis Visit Mean (SD)	73.8 (30.4)	73.8 (45.9)
LS Mean of Absolute Change from Baseline (SE)	6.77 (4.60)	4.19 (4.58)
95% CI	(-3.83, 17.37)	(-6.37, 14.75)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.58 (6.48)	
95% CI	(-12.37, 17.54)	
p-value	0.7011	
Corrected Hedge's g Statistics	0.245	
95% CI	(-1.15, 1.64)	
Subgroup*Treatment Interaction p-value	0.2116	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Role Physical		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	66.28 (38.67)	61.26 (50.47)
Analysis Visit Mean (SD)	73.78 (34.06)	51.28 (34.64)
LS Mean of Absolute Change from Baseline (SE)	7.21 (4.38)	-11.60 (4.41)
95% CI	(-2.90, 17.32)	(-21.76, -1.43)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	18.80 (6.21)	
95% CI	(4.48, 33.13)	
p-value	0.0164	
Corrected Hedge's g Statistics	1.728	
95% CI	(0.28, 3.18)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	70.35 (43.40)	73.45 (49.05)
Analysis Visit Mean (SD)	84.40 (19.42)	60.95 (42.81)
LS Mean of Absolute Change from Baseline (SE)	14.83 (7.32)	-12.94 (7.36)
95% CI	(-2.05, 31.72)	(-29.90, 4.02)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	27.77 (10.35)	
95% CI	(3.90, 51.64)	
p-value	0.0278	
Corrected Hedge's g Statistics	1.645	
95% CI	(0.04, 3.25)	
Subgroup*Treatment Interaction p-value	0.0284	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Bodily Pain		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	52.2 (30.6)	62.4 (38.7)
Analysis Visit Mean (SD)	59.6 (33.4)	52.8 (35.7)
LS Mean of Absolute Change from Baseline (SE)	6.34 (10.73)	-8.18 (10.77)
95% CI	(-18.40, 31.09)	(-33.02, 16.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	14.52 (15.30)	
95% CI	(-20.77, 49.81)	
p-value	0.3705	
Corrected Hedge's g Statistics	0.546	
95% CI	(-0.72, 1.81)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	46.8 (32.4)	64.5 (44.3)
Analysis Visit Mean (SD)	66.8 (25.9)	61.5 (42.9)
LS Mean of Absolute Change from Baseline (SE)	23.84 (12.87)	-3.41 (12.80)
95% CI	(-5.84, 53.51)	(-32.94, 26.11)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	27.25 (18.42)	
95% CI	(-15.22, 69.72)	
p-value	0.1773	
Corrected Hedge's g Statistics	0.923	
95% CI	(-0.53, 2.38)	
Subgroup*Treatment Interaction p-value	0.6961	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
General Health		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	54.8 (14.9)	64.2 (22.5)
Analysis Visit Mean (SD)	53.2 (15.7)	60.2 (25.7)
LS Mean of Absolute Change from Baseline (SE)	-1.53 (4.38)	-4.05 (4.34)
95% CI	(-11.64, 8.58)	(-14.06, 5.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.52 (6.28)	
95% CI	(-11.95, 17.00)	
p-value	0.6985	
Corrected Hedge's g Statistics	0.234	
95% CI	(-1.01, 1.48)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	53.0 (16.5)	69.0 (22.8)
Analysis Visit Mean (SD)	54.3 (17.2)	62.8 (25.6)
LS Mean of Absolute Change from Baseline (SE)	-2.57 (5.54)	-7.70 (5.52)
95% CI	(-15.34, 10.20)	(-20.43, 5.04)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.12 (8.02)	
95% CI	(-13.36, 23.61)	
p-value	0.5406	
Corrected Hedge's g Statistics	0.403	
95% CI	(-1.00, 1.80)	
Subgroup*Treatment Interaction p-value	0.9595	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Vitality		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	58.80 (18.54)	48.78 (19.47)
Analysis Visit Mean (SD)	58.76 (17.44)	36.28 (23.99)
LS Mean of Absolute Change from Baseline (SE)	0.87 (7.49)	-14.16 (7.67)
95% CI	(-16.40, 18.15)	(-31.86, 3.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.03 (10.93)	
95% CI	(-10.16, 40.23)	
p-value	0.2061	
Corrected Hedge's g Statistics	0.801	
95% CI	(-0.49, 2.09)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	59.43 (21.35)	54.73 (16.43)
Analysis Visit Mean (SD)	64.08 (10.68)	43.78 (37.87)
LS Mean of Absolute Change from Baseline (SE)	3.48 (10.00)	-9.78 (9.97)
95% CI	(-19.57, 26.53)	(-32.76, 13.20)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.26 (14.22)	
95% CI	(-19.53, 46.05)	
p-value	0.3785	
Corrected Hedge's g Statistics	0.577	
95% CI	(-0.84, 1.99)	
Subgroup*Treatment Interaction p-value	0.0989	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Social Functioning		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	77.50 (31.12)	80.00 (28.78)
Analysis Visit Mean (SD)	80.00 (22.71)	67.50 (46.44)
LS Mean of Absolute Change from Baseline (SE)	2.89 (7.45)	-12.37 (7.41)
95% CI	(-14.28, 20.06)	(-29.47, 4.73)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.26 (10.49)	
95% CI	(-8.93, 39.45)	
p-value	0.1838	
Corrected Hedge's g Statistics	0.830	
95% CI	(-0.46, 2.12)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	84.38 (31.25)	84.38 (31.25)
Analysis Visit Mean (SD)	90.63 (11.97)	68.75 (47.32)
LS Mean of Absolute Change from Baseline (SE)	6.95 (11.82)	-18.17 (11.80)
95% CI	(-20.32, 34.22)	(-45.38, 9.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	25.12 (16.66)	
95% CI	(-13.30, 63.55)	
p-value	0.1701	
Corrected Hedge's g Statistics	0.925	
95% CI	(-0.53, 2.38)	
Subgroup*Treatment Interaction p-value	0.0826	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Role Emotional		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	66.66 (42.49)	61.68 (49.16)
Analysis Visit Mean (SD)	76.68 (36.50)	63.32 (39.78)
LS Mean of Absolute Change from Baseline (SE)	9.83 (5.48)	0.41 (5.51)
95% CI	(-2.82, 22.47)	(-12.30, 13.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.41 (7.77)	
95% CI	(-8.50, 27.33)	
p-value	0.2603	
Corrected Hedge's g Statistics	0.691	
95% CI	(-0.58, 1.97)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	70.83 (47.87)	72.93 (48.77)
Analysis Visit Mean (SD)	79.18 (22.05)	60.43 (42.70)
LS Mean of Absolute Change from Baseline (SE)	10.13 (7.98)	-7.20 (8.01)
95% CI	(-8.28, 28.54)	(-25.67, 11.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	17.33 (11.28)	
95% CI	(-8.69, 43.35)	
p-value	0.1631	
Corrected Hedge's g Statistics	0.942	
95% CI	(-0.52, 2.40)	
Subgroup*Treatment Interaction p-value	0.1042	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Mental Health		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	77.00 (24.39)	64.00 (26.79)
Analysis Visit Mean (SD)	77.00 (18.23)	57.00 (32.52)
LS Mean of Absolute Change from Baseline (SE)	0.44 (6.60)	-8.13 (6.82)
95% CI	(-14.77, 15.65)	(-23.86, 7.60)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.57 (9.63)	
95% CI	(-13.64, 30.79)	
p-value	0.3995	
Corrected Hedge's g Statistics	0.516	
95% CI	(-0.74, 1.78)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	81.25 (25.94)	72.50 (21.79)
Analysis Visit Mean (SD)	80.00 (30.82)	60.00 (47.08)
LS Mean of Absolute Change from Baseline (SE)	-6.79 (6.19)	-11.64 (6.11)
95% CI	(-21.07, 7.49)	(-25.73, 2.44)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.85 (8.76)	
95% CI	(-15.35, 25.06)	
p-value	0.5947	
Corrected Hedge's g Statistics	0.343	
95% CI	(-1.05, 1.74)	
Subgroup*Treatment Interaction p-value	0.1242	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Mental Component Score		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	50.32 (13.13)	44.64 (13.36)
Analysis Visit Mean (SD)	51.52 (9.55)	41.28 (18.45)
LS Mean of Absolute Change from Baseline (SE)	1.30 (3.85)	-3.66 (3.96)
95% CI	(-7.58, 10.19)	(-12.79, 5.47)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.96 (5.58)	
95% CI	(-7.91, 17.84)	
p-value	0.4000	
Corrected Hedge's g Statistics	0.513	
95% CI	(-0.75, 1.77)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	52.75 (13.80)	48.53 (11.72)
Analysis Visit Mean (SD)	52.98 (9.46)	41.00 (21.88)
LS Mean of Absolute Change from Baseline (SE)	-0.33 (4.13)	-6.46 (4.09)
95% CI	(-9.85, 9.19)	(-15.89, 2.96)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.13 (5.84)	
95% CI	(-7.33, 19.60)	
p-value	0.3244	
Corrected Hedge's g Statistics	0.649	
95% CI	(-0.77, 2.07)	
Subgroup*Treatment Interaction p-value	0.0607	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.8
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Visit Statistic	MGL-3196 (N=5)	Placebo (N=5)
Physical Component Score		
Week 12		
m	5	5
n	5	5
Baseline Mean (SD)	42.82 (9.98)	47.02 (14.36)
Analysis Visit Mean (SD)	44.20 (10.83)	44.62 (9.48)
LS Mean of Absolute Change from Baseline (SE)	0.73 (2.31)	-1.91 (2.30)
95% CI	(-4.59, 6.05)	(-7.20, 3.39)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.63 (3.29)	
95% CI	(-4.94, 10.21)	
p-value	0.4458	
Corrected Hedge's g Statistics	0.462	
95% CI	(-0.79, 1.72)	
Week 36		
m	4	5
n	4	4
Baseline Mean (SD)	42.08 (11.36)	49.05 (15.73)
Analysis Visit Mean (SD)	47.53 (5.71)	48.50 (13.83)
LS Mean of Absolute Change from Baseline (SE)	4.91 (2.17)	1.01 (2.19)
95% CI	(-0.10, 9.91)	(-4.03, 6.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.89 (3.14)	
95% CI	(-3.34, 11.13)	
p-value	0.2497	
Corrected Hedge's g Statistics	0.777	
95% CI	(-0.66, 2.21)	
Subgroup*Treatment Interaction p-value	0.3193	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; LDL = low density lipoprotein.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Physical Functioning		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	65.7 (33.6)	68.6 (30.5)
Analysis Visit Mean (SD)	67.9 (36.2)	72.9 (34.3)
LS Mean of Absolute Change from Baseline (SE)	1.38 (10.43)	4.30 (10.41)
95% CI	(-21.36, 24.11)	(-18.38, 26.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.92 (14.74)	
95% CI	(-35.04, 29.20)	
p-value	0.8462	
Corrected Hedge's g Statistics	-0.099	
95% CI	(-1.15, 0.95)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	65.7 (33.6)	75.0 (27.7)
Analysis Visit Mean (SD)	78.6 (23.0)	91.7 (9.8)
LS Mean of Absolute Change from Baseline (SE)	11.42 (5.01)	18.02 (5.29)
95% CI	(0.50, 22.34)	(6.49, 29.55)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.60 (7.31)	
95% CI	(-22.53, 9.34)	
p-value	0.3847	
Corrected Hedge's g Statistics	-0.468	
95% CI	(-1.57, 0.64)	
Subgroup*Treatment Interaction p-value	0.9779	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Role Physical		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	69.69 (36.15)	67.86 (40.09)
Analysis Visit Mean (SD)	78.60 (31.63)	69.66 (27.09)
LS Mean of Absolute Change from Baseline (SE)	8.55 (5.16)	0.87 (5.17)
95% CI	(-2.68, 19.79)	(-10.38, 12.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.68 (7.29)	
95% CI	(-8.21, 23.57)	
p-value	0.3132	
Corrected Hedge's g Statistics	0.526	
95% CI	(-0.54, 1.59)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	69.69 (36.15)	77.08 (34.84)
Analysis Visit Mean (SD)	84.86 (16.07)	79.17 (24.58)
LS Mean of Absolute Change from Baseline (SE)	14.56 (4.37)	5.33 (4.58)
95% CI	(5.04, 24.08)	(-4.66, 15.31)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.23 (6.34)	
95% CI	(-4.57, 23.04)	
p-value	0.1708	
Corrected Hedge's g Statistics	0.753	
95% CI	(-0.38, 1.88)	
Subgroup*Treatment Interaction p-value	0.3698	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Bodily Pain		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	49.0 (27.7)	70.6 (25.7)
Analysis Visit Mean (SD)	64.0 (22.0)	79.9 (20.3)
LS Mean of Absolute Change from Baseline (SE)	9.97 (6.38)	14.12 (6.36)
95% CI	(-3.93, 23.87)	(0.27, 27.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.15 (9.39)	
95% CI	(-24.61, 16.31)	
p-value	0.6664	
Corrected Hedge's g Statistics	-0.231	
95% CI	(-1.28, 0.82)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	49.0 (27.7)	73.3 (26.9)
Analysis Visit Mean (SD)	66.4 (18.8)	84.3 (12.7)
LS Mean of Absolute Change from Baseline (SE)	8.38 (6.49)	21.95 (7.09)
95% CI	(-5.75, 22.51)	(6.51, 37.40)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-13.58 (10.09)	
95% CI	(-35.56, 8.41)	
p-value	0.2033	
Corrected Hedge's g Statistics	-0.732	
95% CI	(-1.86, 0.39)	
Subgroup*Treatment Interaction p-value	0.2482	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
General Health		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	53.3 (15.7)	70.3 (17.7)
Analysis Visit Mean (SD)	61.1 (17.0)	65.0 (18.7)
LS Mean of Absolute Change from Baseline (SE)	6.43 (4.68)	-4.06 (4.59)
95% CI	(-3.75, 16.62)	(-14.05, 5.94)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	10.49 (6.96)	
95% CI	(-4.68, 25.66)	
p-value	0.1578	
Corrected Hedge's g Statistics	0.801	
95% CI	(-0.29, 1.89)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	53.3 (15.7)	74.5 (15.1)
Analysis Visit Mean (SD)	64.3 (17.5)	72.7 (22.3)
LS Mean of Absolute Change from Baseline (SE)	9.24 (7.06)	-0.53 (7.75)
95% CI	(-6.14, 24.62)	(-17.42, 16.36)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.77 (11.47)	
95% CI	(-15.21, 34.75)	
p-value	0.4108	
Corrected Hedge's g Statistics	0.483	
95% CI	(-0.62, 1.59)	
Subgroup*Treatment Interaction p-value	0.0437	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Vitality		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	58.09 (16.81)	55.39 (20.87)
Analysis Visit Mean (SD)	68.77 (16.91)	55.37 (20.54)
LS Mean of Absolute Change from Baseline (SE)	10.73 (4.93)	-0.66 (4.96)
95% CI	(-0.01, 21.47)	(-11.46, 10.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	11.39 (6.99)	
95% CI	(-3.84, 26.63)	
p-value	0.1291	
Corrected Hedge's g Statistics	0.816	
95% CI	(-0.27, 1.91)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	58.09 (16.81)	60.45 (17.53)
Analysis Visit Mean (SD)	67.87 (10.49)	68.77 (18.54)
LS Mean of Absolute Change from Baseline (SE)	9.84 (3.90)	8.50 (4.12)
95% CI	(1.34, 18.35)	(-0.48, 17.47)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.35 (5.67)	
95% CI	(-11.01, 13.71)	
p-value	0.8164	
Corrected Hedge's g Statistics	0.123	
95% CI	(-0.97, 1.21)	
Subgroup*Treatment Interaction p-value	0.2013	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Social Functioning		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	82.14 (24.85)	78.57 (24.70)
Analysis Visit Mean (SD)	85.71 (20.95)	69.64 (28.74)
LS Mean of Absolute Change from Baseline (SE)	3.90 (7.11)	-9.64 (7.12)
95% CI	(-11.59, 19.39)	(-25.16, 5.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.54 (10.08)	
95% CI	(-8.42, 35.49)	
p-value	0.2039	
Corrected Hedge's g Statistics	0.673	
95% CI	(-0.40, 1.75)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	82.14 (24.85)	81.25 (25.92)
Analysis Visit Mean (SD)	87.50 (12.50)	89.58 (16.61)
LS Mean of Absolute Change from Baseline (SE)	6.11 (4.78)	7.92 (5.14)
95% CI	(-4.30, 16.52)	(-3.27, 19.11)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.81 (7.01)	
95% CI	(-17.10, 13.47)	
p-value	0.8005	
Corrected Hedge's g Statistics	-0.134	
95% CI	(-1.23, 0.96)	
Subgroup*Treatment Interaction p-value	0.2648	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Role Emotional		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	71.43 (35.96)	69.06 (37.48)
Analysis Visit Mean (SD)	80.96 (33.91)	73.80 (23.28)
LS Mean of Absolute Change from Baseline (SE)	9.32 (4.27)	3.90 (4.28)
95% CI	(0.01, 18.63)	(-5.43, 13.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.41 (6.05)	
95% CI	(-7.76, 18.59)	
p-value	0.3882	
Corrected Hedge's g Statistics	0.448	
95% CI	(-0.61, 1.51)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	71.43 (35.96)	77.78 (32.35)
Analysis Visit Mean (SD)	82.14 (17.63)	80.55 (22.78)
LS Mean of Absolute Change from Baseline (SE)	10.30 (4.21)	6.16 (4.56)
95% CI	(1.13, 19.47)	(-3.77, 16.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.14 (6.21)	
95% CI	(-9.39, 17.68)	
p-value	0.5174	
Corrected Hedge's g Statistics	0.346	
95% CI	(-0.75, 1.44)	
Subgroup*Treatment Interaction p-value	0.3994	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Mental Health		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	77.86 (20.59)	65.00 (26.46)
Analysis Visit Mean (SD)	84.29 (13.67)	61.43 (25.77)
LS Mean of Absolute Change from Baseline (SE)	8.39 (5.98)	-6.76 (6.10)
95% CI	(-4.64, 21.42)	(-20.05, 6.52)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.16 (8.71)	
95% CI	(-3.81, 34.12)	
p-value	0.1073	
Corrected Hedge's g Statistics	0.888	
95% CI	(-0.21, 1.99)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	77.86 (20.59)	70.83 (23.54)
Analysis Visit Mean (SD)	79.29 (21.10)	75.00 (20.98)
LS Mean of Absolute Change from Baseline (SE)	2.76 (5.19)	4.17 (5.50)
95% CI	(-8.55, 14.06)	(-7.82, 16.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.41 (7.62)	
95% CI	(-18.02, 15.20)	
p-value	0.8563	
Corrected Hedge's g Statistics	-0.096	
95% CI	(-1.19, 0.99)	
Subgroup*Treatment Interaction p-value	0.1223	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Mental Component Score		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	51.47 (10.41)	45.94 (14.17)
Analysis Visit Mean (SD)	55.19 (7.79)	44.16 (11.81)
LS Mean of Absolute Change from Baseline (SE)	4.30 (1.85)	-2.79 (1.88)
95% CI	(0.27, 8.33)	(-6.88, 1.30)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.09 (2.67)	
95% CI	(1.27, 12.91)	
p-value	0.0210	
Corrected Hedge's g Statistics	1.346	
95% CI	(0.19, 2.51)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	51.47 (10.41)	48.75 (13.22)
Analysis Visit Mean (SD)	52.89 (6.61)	50.17 (9.15)
LS Mean of Absolute Change from Baseline (SE)	2.23 (1.42)	1.06 (1.51)
95% CI	(-0.87, 5.32)	(-2.22, 4.35)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.16 (2.08)	
95% CI	(-3.37, 5.69)	
p-value	0.5867	
Corrected Hedge's g Statistics	0.290	
95% CI	(-0.81, 1.39)	
Subgroup*Treatment Interaction p-value	0.0608	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=7)	Placebo (N=7)
Physical Component Score		
Week 12		
m	7	7
n	7	7
Baseline Mean (SD)	42.77 (10.01)	49.43 (6.89)
Analysis Visit Mean (SD)	45.73 (10.15)	50.97 (8.36)
LS Mean of Absolute Change from Baseline (SE)	2.75 (1.90)	1.72 (1.87)
95% CI	(-1.39, 6.89)	(-2.36, 5.80)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.03 (2.77)	
95% CI	(-5.01, 7.07)	
p-value	0.7169	
Corrected Hedge's g Statistics	0.193	
95% CI	(-0.86, 1.24)	
Week 36		
m	7	7
n	7	6
Baseline Mean (SD)	42.77 (10.01)	51.18 (5.57)
Analysis Visit Mean (SD)	49.41 (5.37)	54.72 (5.86)
LS Mean of Absolute Change from Baseline (SE)	4.54 (2.03)	5.78 (2.19)
95% CI	(0.12, 8.95)	(1.00, 10.55)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.24 (3.16)	
95% CI	(-8.12, 5.63)	
p-value	0.7007	
Corrected Hedge's g Statistics	-0.215	
95% CI	(-1.31, 0.88)	
Subgroup*Treatment Interaction p-value	0.9731	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Physical Functioning		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	78.0 (18.4)	69.2 (28.9)
Analysis Visit Mean (SD)	75.0 (22.2)	76.3 (19.7)
LS Mean of Absolute Change from Baseline (SE)	-1.32 (4.52)	5.50 (4.13)
95% CI	(-10.76, 8.11)	(-3.11, 14.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.83 (6.18)	
95% CI	(-19.71, 6.05)	
p-value	0.2819	
Corrected Hedge's g Statistics	-0.459	
95% CI	(-1.31, 0.39)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	80.6 (17.6)	69.2 (28.9)
Analysis Visit Mean (SD)	76.3 (23.3)	71.3 (28.6)
LS Mean of Absolute Change from Baseline (SE)	-4.30 (3.89)	1.98 (3.15)
95% CI	(-12.41, 3.82)	(-4.59, 8.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.28 (5.07)	
95% CI	(-16.85, 4.30)	
p-value	0.2299	
Corrected Hedge's g Statistics	-0.549	
95% CI	(-1.46, 0.36)	
Subgroup*Treatment Interaction p-value	0.9779	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Role Physical		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	78.76 (32.97)	60.95 (36.25)
Analysis Visit Mean (SD)	77.52 (27.52)	66.16 (29.37)
LS Mean of Absolute Change from Baseline (SE)	1.86 (5.19)	2.70 (4.72)
95% CI	(-8.96, 12.68)	(-7.13, 12.54)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.85 (7.13)	
95% CI	(-15.72, 14.03)	
p-value	0.9067	
Corrected Hedge's g Statistics	-0.050	
95% CI	(-0.89, 0.79)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	80.48 (35.27)	60.95 (36.25)
Analysis Visit Mean (SD)	75.00 (23.15)	67.20 (32.22)
LS Mean of Absolute Change from Baseline (SE)	0.89 (7.55)	2.61 (6.36)
95% CI	(-14.85, 16.63)	(-10.66, 15.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.72 (10.05)	
95% CI	(-22.68, 19.23)	
p-value	0.8656	
Corrected Hedge's g Statistics	-0.076	
95% CI	(-0.97, 0.82)	
Subgroup*Treatment Interaction p-value	0.3698	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline

(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Bodily Pain		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	62.2 (29.1)	66.2 (32.8)
Analysis Visit Mean (SD)	70.0 (29.7)	57.0 (35.1)
LS Mean of Absolute Change from Baseline (SE)	7.25 (8.52)	-8.23 (7.79)
95% CI	(-10.52, 25.03)	(-24.48, 8.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.49 (11.56)	
95% CI	(-8.62, 39.60)	
p-value	0.1952	
Corrected Hedge's g Statistics	0.553	
95% CI	(-0.30, 1.41)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	58.0 (31.3)	66.2 (32.8)
Analysis Visit Mean (SD)	64.5 (31.4)	58.7 (33.3)
LS Mean of Absolute Change from Baseline (SE)	1.99 (8.48)	-6.71 (6.98)
95% CI	(-15.70, 19.67)	(-21.28, 7.85)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.70 (11.02)	
95% CI	(-14.29, 31.69)	
p-value	0.4390	
Corrected Hedge's g Statistics	0.346	
95% CI	(-0.56, 1.25)	
Subgroup*Treatment Interaction p-value	0.2482	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
General Health		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	64.9 (17.1)	60.1 (17.5)
Analysis Visit Mean (SD)	58.4 (15.2)	61.8 (21.3)
LS Mean of Absolute Change from Baseline (SE)	-6.05 (3.74)	1.47 (3.39)
95% CI	(-13.85, 1.74)	(-5.60, 8.54)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.52 (5.07)	
95% CI	(-18.09, 3.05)	
p-value	0.1535	
Corrected Hedge's g Statistics	-0.614	
95% CI	(-1.47, 0.24)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	61.9 (16.1)	60.1 (17.5)
Analysis Visit Mean (SD)	64.8 (21.7)	61.5 (22.7)
LS Mean of Absolute Change from Baseline (SE)	1.94 (6.07)	1.18 (4.99)
95% CI	(-10.72, 14.59)	(-9.23, 11.59)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.76 (7.86)	
95% CI	(-15.64, 17.15)	
p-value	0.9241	
Corrected Hedge's g Statistics	0.042	
95% CI	(-0.85, 0.94)	
Subgroup*Treatment Interaction p-value	0.0437	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Vitality		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	64.40 (20.42)	53.15 (22.22)
Analysis Visit Mean (SD)	55.64 (21.13)	53.16 (22.06)
LS Mean of Absolute Change from Baseline (SE)	-6.25 (5.71)	-1.83 (5.17)
95% CI	(-18.15, 5.65)	(-12.61, 8.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.42 (7.83)	
95% CI	(-20.76, 11.92)	
p-value	0.5789	
Corrected Hedge's g Statistics	-0.237	
95% CI	(-1.08, 0.61)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	64.09 (22.59)	53.15 (22.22)
Analysis Visit Mean (SD)	59.41 (26.73)	53.15 (27.11)
LS Mean of Absolute Change from Baseline (SE)	-4.85 (7.61)	-1.49 (6.52)
95% CI	(-20.72, 11.02)	(-15.08, 12.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.36 (10.18)	
95% CI	(-24.60, 17.88)	
p-value	0.7448	
Corrected Hedge's g Statistics	-0.145	
95% CI	(-1.04, 0.75)	
Subgroup*Treatment Interaction p-value	0.2013	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Social Functioning		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	86.25 (19.94)	76.04 (26.89)
Analysis Visit Mean (SD)	80.00 (25.14)	73.96 (33.05)
LS Mean of Absolute Change from Baseline (SE)	-6.58 (5.02)	-1.77 (4.58)
95% CI	(-17.05, 3.88)	(-11.33, 7.78)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.81 (6.87)	
95% CI	(-19.15, 9.53)	
p-value	0.4920	
Corrected Hedge's g Statistics	-0.292	
95% CI	(-1.14, 0.55)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	89.06 (16.95)	76.04 (26.89)
Analysis Visit Mean (SD)	73.44 (27.09)	70.83 (30.31)
LS Mean of Absolute Change from Baseline (SE)	-12.40 (9.19)	-7.11 (7.50)
95% CI	(-31.57, 6.77)	(-22.74, 8.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.29 (12.07)	
95% CI	(-30.47, 19.88)	
p-value	0.6656	
Corrected Hedge's g Statistics	-0.195	
95% CI	(-1.09, 0.70)	
Subgroup*Treatment Interaction p-value	0.2648	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Role Emotional		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	87.50 (21.25)	69.44 (33.40)
Analysis Visit Mean (SD)	84.18 (31.29)	75.01 (31.58)
LS Mean of Absolute Change from Baseline (SE)	-2.71 (5.50)	5.04 (5.00)
95% CI	(-14.18, 8.76)	(-5.39, 15.48)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.75 (7.62)	
95% CI	(-23.65, 8.15)	
p-value	0.3212	
Corrected Hedge's g Statistics	-0.430	
95% CI	(-1.28, 0.42)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	90.63 (18.60)	69.44 (33.40)
Analysis Visit Mean (SD)	84.38 (18.60)	70.14 (33.42)
LS Mean of Absolute Change from Baseline (SE)	-2.10 (7.23)	-1.62 (5.87)
95% CI	(-17.17, 12.98)	(-13.86, 10.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.48 (9.60)	
95% CI	(-20.51, 19.55)	
p-value	0.9608	
Corrected Hedge's g Statistics	-0.022	
95% CI	(-0.92, 0.87)	
Subgroup*Treatment Interaction p-value	0.3994	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Mental Health		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	81.25 (11.62)	63.33 (21.67)
Analysis Visit Mean (SD)	75.00 (13.33)	66.67 (27.08)
LS Mean of Absolute Change from Baseline (SE)	-6.50 (4.24)	3.54 (3.81)
95% CI	(-15.34, 2.33)	(-4.41, 11.48)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-10.04 (6.03)	
95% CI	(-22.61, 2.53)	
p-value	0.1112	
Corrected Hedge's g Statistics	-0.727	
95% CI	(-1.59, 0.14)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	82.81 (9.77)	63.33 (21.67)
Analysis Visit Mean (SD)	78.75 (17.06)	66.67 (30.40)
LS Mean of Absolute Change from Baseline (SE)	-3.18 (7.41)	2.92 (6.09)
95% CI	(-18.64, 12.27)	(-9.78, 15.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.11 (10.18)	
95% CI	(-27.35, 15.13)	
p-value	0.5555	
Corrected Hedge's g Statistics	-0.278	
95% CI	(-1.18, 0.62)	
Subgroup*Treatment Interaction p-value	0.1223	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Mental Component Score		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	54.31 (7.88)	45.57 (11.45)
Analysis Visit Mean (SD)	50.53 (9.68)	46.70 (14.33)
LS Mean of Absolute Change from Baseline (SE)	-4.07 (2.23)	1.38 (2.02)
95% CI	(-8.72, 0.57)	(-2.83, 5.58)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.45 (3.14)	
95% CI	(-12.00, 1.10)	
p-value	0.0982	
Corrected Hedge's g Statistics	-0.748	
95% CI	(-1.62, 0.12)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	55.43 (6.95)	45.57 (11.45)
Analysis Visit Mean (SD)	51.40 (7.15)	45.82 (15.40)
LS Mean of Absolute Change from Baseline (SE)	-2.89 (3.53)	-0.38 (2.91)
95% CI	(-10.26, 4.48)	(-6.45, 5.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.51 (4.82)	
95% CI	(-12.56, 7.54)	
p-value	0.6080	
Corrected Hedge's g Statistics	-0.239	
95% CI	(-1.14, 0.66)	
Subgroup*Treatment Interaction p-value	0.0608	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.9
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Visit Statistic	MGL-3196 (N=10)	Placebo (N=12)
Physical Component Score		
Week 12		
m	10	12
n	10	12
Baseline Mean (SD)	47.37 (7.85)	47.03 (11.19)
Analysis Visit Mean (SD)	47.85 (9.14)	47.03 (8.62)
LS Mean of Absolute Change from Baseline (SE)	0.56 (1.51)	0.00 (1.38)
95% CI	(-2.60, 3.71)	(-2.87, 2.88)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.55 (2.05)	
95% CI	(-3.72, 4.82)	
p-value	0.7900	
Corrected Hedge's g Statistics	0.111	
95% CI	(-0.73, 0.95)	
Week 36		
m	8	12
n	8	12
Baseline Mean (SD)	46.68 (8.43)	47.03 (11.19)
Analysis Visit Mean (SD)	47.41 (9.89)	46.93 (10.57)
LS Mean of Absolute Change from Baseline (SE)	0.01 (2.15)	-0.09 (1.80)
95% CI	(-4.48, 4.49)	(-3.85, 3.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.10 (2.80)	
95% CI	(-5.75, 5.95)	
p-value	0.9719	
Corrected Hedge's g Statistics	0.015	
95% CI	(-0.88, 0.91)	
Subgroup*Treatment Interaction p-value	0.9731	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Physical Functioning		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	70.0 (30.2)	71.5 (30.2)
Analysis Visit Mean (SD)	70.6 (31.8)	74.2 (19.5)
LS Mean of Absolute Change from Baseline (SE)	0.35 (5.45)	3.03 (4.54)
95% CI	(-11.02, 11.72)	(-6.43, 12.50)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.69 (7.09)	
95% CI	(-17.48, 12.11)	
p-value	0.7089	
Corrected Hedge's g Statistics	-0.158	
95% CI	(-1.01, 0.69)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	68.1 (31.7)	71.5 (30.2)
Analysis Visit Mean (SD)	76.9 (21.9)	75.4 (28.6)
LS Mean of Absolute Change from Baseline (SE)	8.04 (4.20)	4.07 (3.31)
95% CI	(-0.73, 16.80)	(-2.84, 10.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.97 (5.35)	
95% CI	(-7.20, 15.13)	
p-value	0.4671	
Corrected Hedge's g Statistics	0.320	
95% CI	(-0.57, 1.21)	
Subgroup*Treatment Interaction p-value	0.1696	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Role Physical		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	79.89 (35.31)	62.99 (40.29)
Analysis Visit Mean (SD)	78.50 (27.08)	62.99 (27.18)
LS Mean of Absolute Change from Baseline (SE)	2.68 (4.68)	-2.45 (3.87)
95% CI	(-7.09, 12.45)	(-10.52, 5.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.13 (6.15)	
95% CI	(-7.69, 17.95)	
p-value	0.4134	
Corrected Hedge's g Statistics	0.353	
95% CI	(-0.50, 1.21)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	78.15 (37.33)	62.99 (40.29)
Analysis Visit Mean (SD)	78.15 (18.60)	63.95 (30.42)
LS Mean of Absolute Change from Baseline (SE)	5.11 (6.78)	-2.32 (5.37)
95% CI	(-9.03, 19.24)	(-13.52, 8.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.42 (8.73)	
95% CI	(-10.79, 25.64)	
p-value	0.4053	
Corrected Hedge's g Statistics	0.369	
95% CI	(-0.52, 1.26)	
Subgroup*Treatment Interaction p-value	0.3854	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Bodily Pain		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	48.9 (33.0)	60.5 (31.4)
Analysis Visit Mean (SD)	68.2 (24.0)	60.2 (35.6)
LS Mean of Absolute Change from Baseline (SE)	16.67 (8.86)	2.09 (7.38)
95% CI	(-1.82, 35.16)	(-13.30, 17.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	14.58 (11.63)	
95% CI	(-9.69, 38.84)	
p-value	0.2247	
Corrected Hedge's g Statistics	0.527	
95% CI	(-0.34, 1.39)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	44.5 (32.4)	60.5 (31.4)
Analysis Visit Mean (SD)	61.9 (22.7)	64.2 (31.8)
LS Mean of Absolute Change from Baseline (SE)	10.94 (8.68)	6.39 (6.79)
95% CI	(-7.17, 29.06)	(-7.78, 20.55)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.56 (11.17)	
95% CI	(-18.75, 27.86)	
p-value	0.6877	
Corrected Hedge's g Statistics	0.178	
95% CI	(-0.70, 1.06)	
Subgroup*Treatment Interaction p-value	0.6103	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
General Health		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	58.6 (18.4)	63.5 (17.8)
Analysis Visit Mean (SD)	62.4 (13.6)	65.4 (21.5)
LS Mean of Absolute Change from Baseline (SE)	3.33 (4.47)	2.61 (3.74)
95% CI	(-5.99, 12.66)	(-5.18, 10.40)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.72 (5.85)	
95% CI	(-11.49, 12.93)	
p-value	0.9029	
Corrected Hedge's g Statistics	0.052	
95% CI	(-0.80, 0.90)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	54.4 (14.5)	63.5 (17.8)
Analysis Visit Mean (SD)	70.0 (21.0)	60.5 (22.7)
LS Mean of Absolute Change from Baseline (SE)	12.37 (6.51)	-2.25 (5.08)
95% CI	(-1.21, 25.95)	(-12.84, 8.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	14.62 (8.37)	
95% CI	(-2.83, 32.08)	
p-value	0.0958	
Corrected Hedge's g Statistics	0.765	
95% CI	(-0.15, 1.68)	
Subgroup*Treatment Interaction p-value	0.3193	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Vitality		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	63.92 (20.42)	53.39 (21.59)
Analysis Visit Mean (SD)	64.61 (22.52)	52.43 (21.73)
LS Mean of Absolute Change from Baseline (SE)	3.04 (6.05)	-2.35 (4.98)
95% CI	(-9.59, 15.67)	(-12.74, 8.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.38 (7.96)	
95% CI	(-11.22, 21.98)	
p-value	0.5065	
Corrected Hedge's g Statistics	0.287	
95% CI	(-0.57, 1.14)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	62.54 (21.38)	53.39 (21.59)
Analysis Visit Mean (SD)	67.99 (17.81)	54.83 (26.17)
LS Mean of Absolute Change from Baseline (SE)	4.27 (6.44)	0.25 (5.19)
95% CI	(-9.15, 17.70)	(-10.58, 11.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.03 (8.38)	
95% CI	(-13.45, 21.50)	
p-value	0.6359	
Corrected Hedge's g Statistics	0.209	
95% CI	(-0.67, 1.09)	
Subgroup*Treatment Interaction p-value	0.4294	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Social Functioning		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	87.50 (22.53)	74.04 (28.17)
Analysis Visit Mean (SD)	86.11 (19.21)	69.23 (32.52)
LS Mean of Absolute Change from Baseline (SE)	-0.19 (5.88)	-5.52 (4.84)
95% CI	(-12.46, 12.09)	(-15.63, 4.58)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.34 (7.74)	
95% CI	(-10.81, 21.49)	
p-value	0.4986	
Corrected Hedge's g Statistics	0.293	
95% CI	(-0.56, 1.15)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	85.94 (23.56)	74.04 (28.17)
Analysis Visit Mean (SD)	73.44 (25.39)	73.08 (29.25)
LS Mean of Absolute Change from Baseline (SE)	-9.36 (9.02)	-3.50 (7.08)
95% CI	(-28.17, 9.46)	(-18.26, 11.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.86 (11.61)	
95% CI	(-30.07, 18.36)	
p-value	0.6194	
Corrected Hedge's g Statistics	-0.220	
95% CI	(-1.10, 0.66)	
Subgroup*Treatment Interaction p-value	0.9921	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Role Emotional		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	82.41 (34.97)	69.87 (36.10)
Analysis Visit Mean (SD)	83.34 (29.75)	71.15 (29.77)
LS Mean of Absolute Change from Baseline (SE)	2.61 (3.32)	0.33 (2.75)
95% CI	(-4.32, 9.54)	(-5.40, 6.06)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.28 (4.34)	
95% CI	(-6.78, 11.34)	
p-value	0.6051	
Corrected Hedge's g Statistics	0.221	
95% CI	(-0.63, 1.07)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	80.21 (36.72)	69.87 (36.10)
Analysis Visit Mean (SD)	78.13 (19.89)	69.23 (32.17)
LS Mean of Absolute Change from Baseline (SE)	-0.42 (6.75)	-2.58 (5.39)
95% CI	(-14.50, 13.66)	(-13.83, 8.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.16 (8.69)	
95% CI	(-15.96, 20.28)	
p-value	0.8061	
Corrected Hedge's g Statistics	0.107	
95% CI	(-0.77, 0.99)	
Subgroup*Treatment Interaction p-value	0.4297	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Mental Health		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	78.06 (16.95)	67.31 (22.79)
Analysis Visit Mean (SD)	82.22 (11.21)	63.08 (27.35)
LS Mean of Absolute Change from Baseline (SE)	5.62 (5.38)	-5.08 (4.43)
95% CI	(-5.60, 16.85)	(-14.32, 4.15)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	10.71 (7.08)	
95% CI	(-4.06, 25.47)	
p-value	0.1461	
Corrected Hedge's g Statistics	0.642	
95% CI	(-0.23, 1.51)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	76.56 (17.47)	67.31 (22.79)
Analysis Visit Mean (SD)	74.38 (21.45)	68.85 (30.15)
LS Mean of Absolute Change from Baseline (SE)	-2.35 (6.55)	1.45 (5.15)
95% CI	(-16.01, 11.30)	(-9.30, 12.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.80 (8.43)	
95% CI	(-21.39, 13.79)	
p-value	0.6572	
Corrected Hedge's g Statistics	-0.197	
95% CI	(-1.08, 0.69)	
Subgroup*Treatment Interaction p-value	0.0407	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Mental Component Score		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	53.88 (9.66)	46.37 (12.16)
Analysis Visit Mean (SD)	54.28 (6.89)	44.65 (14.62)
LS Mean of Absolute Change from Baseline (SE)	0.99 (2.54)	-2.08 (2.08)
95% CI	(-4.30, 6.28)	(-6.41, 2.25)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.06 (3.36)	
95% CI	(-3.95, 10.08)	
p-value	0.3730	
Corrected Hedge's g Statistics	0.391	
95% CI	(-0.47, 1.25)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	53.23 (10.12)	46.37 (12.16)
Analysis Visit Mean (SD)	49.99 (7.42)	46.21 (14.83)
LS Mean of Absolute Change from Baseline (SE)	-3.08 (3.00)	-0.65 (2.38)
95% CI	(-9.34, 3.19)	(-5.63, 4.32)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.43 (3.92)	
95% CI	(-10.61, 5.76)	
p-value	0.5433	
Corrected Hedge's g Statistics	-0.272	
95% CI	(-1.16, 0.61)	
Subgroup*Treatment Interaction p-value	0.2351	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=13)
Physical Component Score		
Week 12		
m	9	13
n	9	13
Baseline Mean (SD)	44.53 (9.59)	46.85 (10.69)
Analysis Visit Mean (SD)	46.84 (8.92)	47.88 (8.48)
LS Mean of Absolute Change from Baseline (SE)	1.99 (1.50)	1.35 (1.25)
95% CI	(-1.13, 5.12)	(-1.25, 3.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.65 (1.96)	
95% CI	(-3.44, 4.73)	
p-value	0.7449	
Corrected Hedge's g Statistics	0.138	
95% CI	(-0.71, 0.99)	
Week 36		
m	8	13
n	8	13
Baseline Mean (SD)	43.29 (9.44)	46.85 (10.69)
Analysis Visit Mean (SD)	49.33 (5.52)	47.61 (10.45)
LS Mean of Absolute Change from Baseline (SE)	4.91 (2.29)	1.20 (1.79)
95% CI	(0.14, 9.69)	(-2.53, 4.93)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.71 (2.93)	
95% CI	(-2.39, 9.82)	
p-value	0.2190	
Corrected Hedge's g Statistics	0.551	
95% CI	(-0.34, 1.45)	
Subgroup*Treatment Interaction p-value	0.5839	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Physical Functioning		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	76.3 (20.7)	63.3 (26.8)
Analysis Visit Mean (SD)	73.8 (25.0)	76.7 (36.8)
LS Mean of Absolute Change from Baseline (SE)	-1.92 (8.82)	11.57 (10.56)
95% CI	(-21.15, 17.30)	(-11.43, 34.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-13.49 (13.97)	
95% CI	(-43.92, 16.94)	
p-value	0.3531	
Corrected Hedge's g Statistics	-0.499	
95% CI	(-1.57, 0.58)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	80.0 (19.1)	70.0 (23.7)
Analysis Visit Mean (SD)	77.9 (24.6)	85.0 (15.8)
LS Mean of Absolute Change from Baseline (SE)	1.65 (8.20)	7.50 (9.67)
95% CI	(-16.22, 19.52)	(-13.57, 28.57)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.85 (12.87)	
95% CI	(-33.88, 22.18)	
p-value	0.6576	
Corrected Hedge's g Statistics	-0.249	
95% CI	(-1.40, 0.90)	
Subgroup*Treatment Interaction p-value	0.1696	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Role Physical		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	69.55 (32.81)	64.58 (31.04)
Analysis Visit Mean (SD)	77.36 (31.51)	77.10 (29.22)
LS Mean of Absolute Change from Baseline (SE)	7.72 (5.02)	11.69 (5.84)
95% CI	(-3.22, 18.66)	(-1.03, 24.42)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.98 (7.69)	
95% CI	(-20.74, 12.79)	
p-value	0.6147	
Corrected Hedge's g Statistics	-0.261	
95% CI	(-1.32, 0.80)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	72.34 (34.40)	75.00 (19.76)
Analysis Visit Mean (SD)	81.26 (23.11)	90.02 (19.04)
LS Mean of Absolute Change from Baseline (SE)	10.16 (5.56)	17.11 (6.53)
95% CI	(-1.95, 22.27)	(2.88, 31.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.95 (8.56)	
95% CI	(-25.59, 11.69)	
p-value	0.4325	
Corrected Hedge's g Statistics	-0.437	
95% CI	(-1.60, 0.72)	
Subgroup*Treatment Interaction p-value	0.3854	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Bodily Pain		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	65.6 (20.9)	83.7 (19.3)
Analysis Visit Mean (SD)	66.8 (30.1)	76.7 (19.7)
LS Mean of Absolute Change from Baseline (SE)	0.40 (7.29)	-6.18 (8.40)
95% CI	(-15.49, 16.28)	(-24.48, 12.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.57 (11.68)	
95% CI	(-18.86, 32.01)	
p-value	0.5837	
Corrected Hedge's g Statistics	0.299	
95% CI	(-0.77, 1.36)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	64.4 (22.2)	89.6 (14.2)
Analysis Visit Mean (SD)	69.4 (29.5)	75.2 (27.7)
LS Mean of Absolute Change from Baseline (SE)	3.21 (9.33)	-12.97 (11.69)
95% CI	(-17.13, 23.55)	(-38.45, 12.50)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	16.18 (16.27)	
95% CI	(-19.26, 51.62)	
p-value	0.3394	
Corrected Hedge's g Statistics	0.591	
95% CI	(-0.58, 1.76)	
Subgroup*Treatment Interaction p-value	0.6103	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
General Health		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	61.9 (16.4)	64.7 (19.5)
Analysis Visit Mean (SD)	56.3 (17.8)	57.7 (16.4)
LS Mean of Absolute Change from Baseline (SE)	-5.88 (2.84)	-6.89 (3.26)
95% CI	(-12.06, 0.30)	(-14.00, 0.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.01 (4.33)	
95% CI	(-8.43, 10.45)	
p-value	0.8198	
Corrected Hedge's g Statistics	0.118	
95% CI	(-0.94, 1.18)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	61.9 (17.7)	68.6 (18.9)
Analysis Visit Mean (SD)	58.3 (15.8)	77.6 (18.9)
LS Mean of Absolute Change from Baseline (SE)	-3.76 (2.93)	9.83 (3.52)
95% CI	(-10.15, 2.63)	(2.17, 17.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-13.59 (4.62)	
95% CI	(-23.65, -3.53)	
p-value	0.0123	
Corrected Hedge's g Statistics	-1.608	
95% CI	(-2.92, -0.29)	
Subgroup*Treatment Interaction p-value	0.3193	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Vitality		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	59.41 (17.68)	55.23 (22.17)
Analysis Visit Mean (SD)	57.04 (17.50)	57.32 (20.70)
LS Mean of Absolute Change from Baseline (SE)	-2.16 (5.71)	0.43 (6.65)
95% CI	(-14.60, 10.28)	(-14.06, 14.92)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.59 (8.78)	
95% CI	(-21.71, 16.54)	
p-value	0.7731	
Corrected Hedge's g Statistics	-0.149	
95% CI	(-1.21, 0.91)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	59.86 (19.05)	61.28 (18.45)
Analysis Visit Mean (SD)	58.07 (23.59)	67.52 (22.26)
LS Mean of Absolute Change from Baseline (SE)	-2.07 (8.10)	4.55 (9.56)
95% CI	(-19.72, 15.58)	(-16.27, 25.37)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.62 (12.52)	
95% CI	(-33.89, 20.65)	
p-value	0.6066	
Corrected Hedge's g Statistics	-0.285	
95% CI	(-1.44, 0.87)	
Subgroup*Treatment Interaction p-value	0.4294	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Social Functioning		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	81.25 (21.13)	83.33 (18.82)
Analysis Visit Mean (SD)	78.13 (27.35)	79.17 (28.14)
LS Mean of Absolute Change from Baseline (SE)	-3.00 (6.68)	-4.13 (7.66)
95% CI	(-17.55, 11.55)	(-20.83, 12.56)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.13 (10.15)	
95% CI	(-20.98, 23.24)	
p-value	0.9131	
Corrected Hedge's g Statistics	0.056	
95% CI	(-1.00, 1.11)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	85.71 (18.30)	87.50 (17.68)
Analysis Visit Mean (SD)	87.50 (16.14)	87.50 (21.65)
LS Mean of Absolute Change from Baseline (SE)	3.08 (6.57)	-0.87 (7.69)
95% CI	(-11.24, 17.40)	(-17.63, 15.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.95 (10.09)	
95% CI	(-18.02, 25.93)	
p-value	0.7020	
Corrected Hedge's g Statistics	0.211	
95% CI	(-0.94, 1.36)	
Subgroup*Treatment Interaction p-value	0.9921	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Role Emotional		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	79.16 (20.89)	68.07 (31.79)
Analysis Visit Mean (SD)	82.30 (35.20)	81.95 (24.96)
LS Mean of Absolute Change from Baseline (SE)	3.28 (7.57)	13.06 (9.01)
95% CI	(-13.21, 19.76)	(-6.58, 32.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.78 (11.84)	
95% CI	(-35.58, 16.01)	
p-value	0.4248	
Corrected Hedge's g Statistics	-0.422	
95% CI	(-1.49, 0.65)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	83.33 (18.63)	78.34 (21.73)
Analysis Visit Mean (SD)	89.29 (13.36)	85.00 (22.36)
LS Mean of Absolute Change from Baseline (SE)	7.71 (4.43)	6.88 (5.09)
95% CI	(-1.94, 17.36)	(-4.22, 17.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.83 (6.73)	
95% CI	(-13.83, 15.49)	
p-value	0.9039	
Corrected Hedge's g Statistics	0.066	
95% CI	(-1.08, 1.21)	
Subgroup*Treatment Interaction p-value	0.4297	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Mental Health		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	81.88 (14.38)	56.67 (23.17)
Analysis Visit Mean (SD)	75.00 (16.26)	68.33 (24.83)
LS Mean of Absolute Change from Baseline (SE)	-6.74 (3.48)	11.41 (4.43)
95% CI	(-14.33, 0.85)	(1.77, 21.06)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-18.15 (6.13)	
95% CI	(-31.52, -4.79)	
p-value	0.0119	
Corrected Hedge's g Statistics	-1.654	
95% CI	(-2.88, -0.43)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	85.00 (12.25)	62.00 (21.39)
Analysis Visit Mean (SD)	84.29 (13.67)	71.00 (20.74)
LS Mean of Absolute Change from Baseline (SE)	5.11 (6.87)	3.17 (7.71)
95% CI	(-9.86, 20.07)	(-13.63, 19.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.94 (11.40)	
95% CI	(-22.90, 26.78)	
p-value	0.8678	
Corrected Hedge's g Statistics	0.101	
95% CI	(-1.05, 1.25)	
Subgroup*Treatment Interaction p-value	0.0407	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Mental Component Score		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	52.31 (8.33)	44.27 (13.08)
Analysis Visit Mean (SD)	50.39 (11.03)	48.17 (10.08)
LS Mean of Absolute Change from Baseline (SE)	-1.66 (1.89)	3.26 (2.30)
95% CI	(-5.78, 2.47)	(-1.75, 8.27)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.91 (3.07)	
95% CI	(-11.60, 1.77)	
p-value	0.1354	
Corrected Hedge's g Statistics	-0.841	
95% CI	(-1.94, 0.26)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	53.99 (7.40)	47.30 (12.04)
Analysis Visit Mean (SD)	54.50 (5.28)	50.02 (10.13)
LS Mean of Absolute Change from Baseline (SE)	2.81 (2.70)	1.21 (3.06)
95% CI	(-3.06, 8.69)	(-5.46, 7.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.60 (4.21)	
95% CI	(-7.57, 10.77)	
p-value	0.7108	
Corrected Hedge's g Statistics	0.210	
95% CI	(-0.94, 1.36)	
Subgroup*Treatment Interaction p-value	0.2351	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.10
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=6)
Physical Component Score		
Week 12		
m	8	6
n	8	6
Baseline Mean (SD)	46.54 (8.37)	50.22 (7.36)
Analysis Visit Mean (SD)	47.13 (10.36)	49.78 (9.24)
LS Mean of Absolute Change from Baseline (SE)	0.78 (1.77)	-0.59 (2.02)
95% CI	(-3.08, 4.64)	(-5.00, 3.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.37 (2.73)	
95% CI	(-4.57, 7.32)	
p-value	0.6236	
Corrected Hedge's g Statistics	0.258	
95% CI	(-0.80, 1.32)	
Week 36		
m	7	6
n	7	5
Baseline Mean (SD)	46.64 (9.03)	52.48 (5.42)
Analysis Visit Mean (SD)	47.23 (10.36)	54.52 (6.32)
LS Mean of Absolute Change from Baseline (SE)	-0.05 (2.14)	1.60 (2.50)
95% CI	(-4.71, 4.61)	(-3.83, 7.04)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.66 (3.35)	
95% CI	(-8.96, 5.64)	
p-value	0.6296	
Corrected Hedge's g Statistics	-0.272	
95% CI	(-1.42, 0.88)	
Subgroup*Treatment Interaction p-value	0.5839	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Physical Functioning		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	80.0 (26.5)	57.1 (32.8)
Analysis Visit Mean (SD)	86.7 (14.4)	67.9 (31.9)
LS Mean of Absolute Change from Baseline (SE)	11.19 (12.53)	7.48 (8.25)
95% CI	(-17.70, 40.08)	(-11.54, 26.51)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.71 (15.47)	
95% CI	(-31.96, 39.38)	
p-value	0.8166	
Corrected Hedge's g Statistics	0.154	
95% CI	(-1.20, 1.51)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	95.0 (7.1)	61.7 (33.4)
Analysis Visit Mean (SD)	97.5 (3.5)	69.2 (34.1)
LS Mean of Absolute Change from Baseline (SE)	4.52 (8.98)	8.64 (4.75)
95% CI	(-16.19, 25.22)	(-2.32, 19.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.13 (10.47)	
95% CI	(-28.27, 20.02)	
p-value	0.7038	
Corrected Hedge's g Statistics	-0.303	
95% CI	(-1.91, 1.30)	
Subgroup*Treatment Interaction p-value	0.3257	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Role Physical		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	77.10 (25.26)	41.97 (40.61)
Analysis Visit Mean (SD)	87.50 (21.65)	50.90 (31.54)
LS Mean of Absolute Change from Baseline (SE)	17.92 (10.42)	4.56 (6.74)
95% CI	(-6.12, 41.96)	(-10.98, 20.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.36 (12.99)	
95% CI	(-16.61, 43.32)	
p-value	0.3341	
Corrected Hedge's g Statistics	0.675	
95% CI	(-0.71, 2.06)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	90.65 (13.22)	46.88 (42.15)
Analysis Visit Mean (SD)	100.00 (0.00)	58.33 (37.64)
LS Mean of Absolute Change from Baseline (SE)	13.44 (10.55)	9.86 (6.43)
95% CI	(-10.89, 37.77)	(-4.96, 24.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.58 (12.90)	
95% CI	(-26.17, 33.33)	
p-value	0.7885	
Corrected Hedge's g Statistics	0.199	
95% CI	(-1.40, 1.80)	
Subgroup*Treatment Interaction p-value	0.2489	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Bodily Pain		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	73.3 (11.0)	52.1 (34.2)
Analysis Visit Mean (SD)	71.7 (36.1)	61.1 (35.2)
LS Mean of Absolute Change from Baseline (SE)	0.40 (15.52)	8.23 (9.85)
95% CI	(-35.39, 36.18)	(-14.47, 30.94)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.84 (18.81)	
95% CI	(-51.22, 35.55)	
p-value	0.6880	
Corrected Hedge's g Statistics	-0.270	
95% CI	(-1.63, 1.09)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	73.0 (15.6)	51.8 (37.4)
Analysis Visit Mean (SD)	100.0 (0.0)	57.0 (37.8)
LS Mean of Absolute Change from Baseline (SE)	19.99 (11.07)	4.56 (6.54)
95% CI	(-5.54, 45.52)	(-10.52, 19.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.43 (13.11)	
95% CI	(-14.81, 45.67)	
p-value	0.2733	
Corrected Hedge's g Statistics	0.840	
95% CI	(-0.81, 2.49)	
Subgroup*Treatment Interaction p-value	0.9843	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11

Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP

(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
General Health		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	69.7 (6.8)	60.0 (18.7)
Analysis Visit Mean (SD)	62.0 (13.2)	60.0 (23.3)
LS Mean of Absolute Change from Baseline (SE)	-8.63 (5.56)	0.66 (3.65)
95% CI	(-21.45, 4.19)	(-7.75, 9.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.29 (6.78)	
95% CI	(-24.94, 6.35)	
p-value	0.2080	
Corrected Hedge's g Statistics	-0.870	
95% CI	(-2.28, 0.53)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	73.5 (2.1)	62.5 (19.1)
Analysis Visit Mean (SD)	68.5 (4.9)	51.8 (19.0)
LS Mean of Absolute Change from Baseline (SE)	-1.66 (7.95)	-10.50 (4.46)
95% CI	(-19.98, 16.66)	(-20.78, -0.22)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	8.84 (9.21)	
95% CI	(-12.41, 30.08)	
p-value	0.3654	
Corrected Hedge's g Statistics	0.701	
95% CI	(-0.94, 2.34)	
Subgroup*Treatment Interaction p-value	0.8372	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Vitality		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	68.80 (12.50)	41.99 (22.16)
Analysis Visit Mean (SD)	52.10 (3.64)	41.99 (23.86)
LS Mean of Absolute Change from Baseline (SE)	-8.84 (12.22)	-4.03 (7.65)
95% CI	(-37.03, 19.35)	(-21.66, 13.60)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.81 (15.56)	
95% CI	(-40.70, 31.08)	
p-value	0.7652	
Corrected Hedge's g Statistics	-0.212	
95% CI	(-1.57, 1.14)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	75.05 (8.84)	44.82 (22.85)
Analysis Visit Mean (SD)	68.80 (0.00)	46.90 (28.72)
LS Mean of Absolute Change from Baseline (SE)	-1.04 (13.47)	0.20 (7.79)
95% CI	(-32.11, 30.03)	(-17.76, 18.16)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.24 (16.68)	
95% CI	(-39.71, 37.24)	
p-value	0.9427	
Corrected Hedge's g Statistics	-0.056	
95% CI	(-1.66, 1.54)	
Subgroup*Treatment Interaction p-value	0.6559	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Social Functioning		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	75.00 (25.00)	60.71 (25.44)
Analysis Visit Mean (SD)	83.33 (28.87)	55.36 (35.25)
LS Mean of Absolute Change from Baseline (SE)	7.35 (11.84)	-4.79 (7.72)
95% CI	(-19.96, 34.66)	(-22.58, 13.01)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.14 (14.39)	
95% CI	(-21.06, 45.33)	
p-value	0.4236	
Corrected Hedge's g Statistics	0.536	
95% CI	(-0.84, 1.91)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	87.50 (17.68)	60.42 (27.86)
Analysis Visit Mean (SD)	100.00 (0.00)	64.58 (37.43)
LS Mean of Absolute Change from Baseline (SE)	8.65 (14.06)	1.24 (8.65)
95% CI	(-23.77, 41.08)	(-18.72, 21.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.42 (16.90)	
95% CI	(-31.56, 46.40)	
p-value	0.6724	
Corrected Hedge's g Statistics	0.307	
95% CI	(-1.30, 1.91)	
Subgroup*Treatment Interaction p-value	0.1548	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Role Emotional		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	75.00 (25.00)	46.43 (39.63)
Analysis Visit Mean (SD)	88.90 (19.23)	59.53 (34.50)
LS Mean of Absolute Change from Baseline (SE)	17.83 (8.64)	10.65 (5.63)
95% CI	(-2.09, 37.74)	(-2.34, 23.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.18 (10.67)	
95% CI	(-17.42, 31.77)	
p-value	0.5201	
Corrected Hedge's g Statistics	0.434	
95% CI	(-0.93, 1.80)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	87.50 (17.68)	51.38 (40.97)
Analysis Visit Mean (SD)	100.00 (0.00)	63.88 (37.52)
LS Mean of Absolute Change from Baseline (SE)	18.38 (9.78)	13.45 (6.27)
95% CI	(-4.18, 40.94)	(-1.00, 27.90)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.93 (12.01)	
95% CI	(-22.77, 32.62)	
p-value	0.6925	
Corrected Hedge's g Statistics	0.283	
95% CI	(-1.32, 1.89)	
Subgroup*Treatment Interaction p-value	0.4996	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11

Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP

(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Mental Health		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	80.00 (20.00)	54.29 (24.40)
Analysis Visit Mean (SD)	73.33 (16.07)	55.00 (27.99)
LS Mean of Absolute Change from Baseline (SE)	-5.39 (9.21)	-0.05 (5.95)
95% CI	(-26.62, 15.84)	(-13.76, 13.67)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.34 (11.64)	
95% CI	(-32.18, 21.49)	
p-value	0.6583	
Corrected Hedge's g Statistics	-0.306	
95% CI	(-1.66, 1.05)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	90.00 (14.14)	58.33 (24.01)
Analysis Visit Mean (SD)	95.00 (7.07)	57.50 (33.28)
LS Mean of Absolute Change from Baseline (SE)	4.76 (12.71)	-1.34 (7.97)
95% CI	(-24.55, 34.07)	(-19.72, 17.05)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.10 (15.91)	
95% CI	(-30.59, 42.78)	
p-value	0.7115	
Corrected Hedge's g Statistics	0.275	
95% CI	(-1.33, 1.88)	
Subgroup*Treatment Interaction p-value	0.7415	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Mental Component Score		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	50.43 (10.16)	38.64 (12.30)
Analysis Visit Mean (SD)	49.33 (7.13)	38.93 (15.81)
LS Mean of Absolute Change from Baseline (SE)	-0.55 (5.94)	-0.04 (3.84)
95% CI	(-14.25, 13.16)	(-8.89, 8.82)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.51 (7.45)	
95% CI	(-17.68, 16.66)	
p-value	0.9474	
Corrected Hedge's g Statistics	-0.045	
95% CI	(-1.40, 1.31)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	55.35 (7.85)	40.23 (12.66)
Analysis Visit Mean (SD)	57.90 (1.56)	41.68 (16.41)
LS Mean of Absolute Change from Baseline (SE)	4.42 (6.04)	1.67 (3.79)
95% CI	(-9.52, 18.36)	(-7.07, 10.41)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.75 (7.50)	
95% CI	(-14.54, 20.05)	
p-value	0.7230	
Corrected Hedge's g Statistics	0.261	
95% CI	(-1.34, 1.87)	
Subgroup*Treatment Interaction p-value	0.6881	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Visit Statistic	MGL-3196 (N=3)	Placebo (N=7)
Physical Component Score		
Week 12		
m	3	7
n	3	7
Baseline Mean (SD)	50.70 (4.48)	43.66 (11.46)
Analysis Visit Mean (SD)	51.37 (7.74)	46.57 (9.24)
LS Mean of Absolute Change from Baseline (SE)	2.07 (3.48)	2.14 (2.25)
95% CI	(-5.95, 10.10)	(-3.05, 7.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.07 (4.26)	
95% CI	(-9.89, 9.74)	
p-value	0.9866	
Corrected Hedge's g Statistics	-0.011	
95% CI	(-1.36, 1.34)	
Week 36		
m	2	7
n	2	6
Baseline Mean (SD)	53.15 (2.05)	44.45 (12.34)
Analysis Visit Mean (SD)	55.90 (0.85)	45.60 (10.62)
LS Mean of Absolute Change from Baseline (SE)	3.43 (2.86)	0.57 (1.59)
95% CI	(-3.16, 10.02)	(-3.10, 4.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.86 (3.34)	
95% CI	(-4.83, 10.56)	
p-value	0.4158	
Corrected Hedge's g Statistics	0.636	
95% CI	(-0.99, 2.27)	
Subgroup*Treatment Interaction p-value	0.6793	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Physical Functioning		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	71.4 (26.1)	75.8 (24.8)
Analysis Visit Mean (SD)	68.9 (29.5)	79.2 (20.7)
LS Mean of Absolute Change from Baseline (SE)	-3.08 (5.24)	4.17 (5.67)
95% CI	(-13.90, 7.73)	(-7.53, 15.87)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.26 (7.73)	
95% CI	(-23.22, 8.71)	
p-value	0.3575	
Corrected Hedge's g Statistics	-0.358	
95% CI	(-1.14, 0.42)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	70.4 (26.9)	75.8 (24.8)
Analysis Visit Mean (SD)	74.2 (22.4)	82.5 (20.5)
LS Mean of Absolute Change from Baseline (SE)	2.82 (4.38)	7.76 (4.58)
95% CI	(-6.22, 11.85)	(-1.69, 17.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.95 (6.35)	
95% CI	(-18.06, 8.16)	
p-value	0.4435	
Corrected Hedge's g Statistics	-0.303	
95% CI	(-1.09, 0.49)	
Subgroup*Treatment Interaction p-value	0.3257	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Role Physical		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	74.58 (35.81)	76.05 (29.04)
Analysis Visit Mean (SD)	75.92 (29.81)	77.10 (21.20)
LS Mean of Absolute Change from Baseline (SE)	1.24 (3.90)	1.43 (4.21)
95% CI	(-6.80, 9.28)	(-7.26, 10.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.19 (5.74)	
95% CI	(-12.03, 11.65)	
p-value	0.9733	
Corrected Hedge's g Statistics	-0.013	
95% CI	(-0.78, 0.76)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	73.10 (36.83)	76.05 (29.04)
Analysis Visit Mean (SD)	76.46 (19.79)	77.62 (24.20)
LS Mean of Absolute Change from Baseline (SE)	2.54 (5.02)	2.28 (5.29)
95% CI	(-7.83, 12.91)	(-8.65, 13.21)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.26 (7.30)	
95% CI	(-14.81, 15.33)	
p-value	0.9722	
Corrected Hedge's g Statistics	0.014	
95% CI	(-0.77, 0.80)	
Subgroup*Treatment Interaction p-value	0.2489	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Bodily Pain		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	53.2 (30.0)	76.9 (23.7)
Analysis Visit Mean (SD)	66.6 (25.3)	67.9 (31.1)
LS Mean of Absolute Change from Baseline (SE)	8.99 (6.62)	-3.47 (7.24)
95% CI	(-4.66, 22.65)	(-18.41, 11.47)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.46 (10.24)	
95% CI	(-8.68, 33.61)	
p-value	0.2355	
Corrected Hedge's g Statistics	0.485	
95% CI	(-0.30, 1.27)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	50.8 (29.8)	76.9 (23.7)
Analysis Visit Mean (SD)	60.1 (22.9)	72.3 (26.2)
LS Mean of Absolute Change from Baseline (SE)	0.01 (6.82)	4.28 (7.12)
95% CI	(-14.07, 14.09)	(-10.40, 18.97)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.27 (10.39)	
95% CI	(-25.71, 17.16)	
p-value	0.6844	
Corrected Hedge's g Statistics	-0.168	
95% CI	(-0.95, 0.62)	
Subgroup*Treatment Interaction p-value	0.9843	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
General Health		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	58.1 (18.0)	66.1 (17.8)
Analysis Visit Mean (SD)	59.0 (16.4)	64.7 (18.6)
LS Mean of Absolute Change from Baseline (SE)	-0.05 (3.40)	0.12 (3.71)
95% CI	(-7.07, 6.98)	(-7.54, 7.78)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.17 (5.10)	
95% CI	(-10.69, 10.35)	
p-value	0.9741	
Corrected Hedge's g Statistics	-0.013	
95% CI	(-0.78, 0.76)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	55.5 (15.8)	66.1 (17.8)
Analysis Visit Mean (SD)	63.9 (20.5)	71.9 (21.8)
LS Mean of Absolute Change from Baseline (SE)	6.20 (4.74)	7.10 (4.96)
95% CI	(-3.59, 15.99)	(-3.13, 17.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.90 (7.01)	
95% CI	(-15.38, 13.58)	
p-value	0.8990	
Corrected Hedge's g Statistics	-0.051	
95% CI	(-0.84, 0.73)	
Subgroup*Treatment Interaction p-value	0.8372	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Vitality		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	60.30 (19.85)	60.97 (17.91)
Analysis Visit Mean (SD)	62.96 (21.71)	60.97 (16.23)
LS Mean of Absolute Change from Baseline (SE)	2.65 (4.22)	0.25 (4.56)
95% CI	(-6.05, 11.36)	(-9.16, 9.65)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.41 (6.21)	
95% CI	(-10.41, 15.23)	
p-value	0.7015	
Corrected Hedge's g Statistics	0.148	
95% CI	(-0.62, 0.92)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	59.17 (20.18)	60.97 (17.91)
Analysis Visit Mean (SD)	62.52 (22.10)	64.08 (22.31)
LS Mean of Absolute Change from Baseline (SE)	0.88 (5.43)	3.40 (5.76)
95% CI	(-10.33, 12.10)	(-8.49, 15.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.52 (7.92)	
95% CI	(-18.86, 13.83)	
p-value	0.7535	
Corrected Hedge's g Statistics	-0.123	
95% CI	(-0.91, 0.66)	
Subgroup*Treatment Interaction p-value	0.6559	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Social Functioning		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	86.61 (21.07)	86.46 (20.96)
Analysis Visit Mean (SD)	82.14 (22.85)	82.29 (24.11)
LS Mean of Absolute Change from Baseline (SE)	-4.40 (4.38)	-4.13 (4.73)
95% CI	(-13.44, 4.64)	(-13.89, 5.63)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.27 (6.44)	
95% CI	(-13.57, 13.03)	
p-value	0.9670	
Corrected Hedge's g Statistics	-0.016	
95% CI	(-0.79, 0.76)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	85.58 (21.56)	86.46 (20.96)
Analysis Visit Mean (SD)	76.92 (22.15)	83.33 (20.18)
LS Mean of Absolute Change from Baseline (SE)	-9.22 (5.87)	-2.98 (6.11)
95% CI	(-21.33, 2.89)	(-15.58, 9.62)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.23 (8.47)	
95% CI	(-23.71, 11.25)	
p-value	0.4688	
Corrected Hedge's g Statistics	-0.285	
95% CI	(-1.07, 0.50)	
Subgroup*Treatment Interaction p-value	0.1548	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Role Emotional		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	82.14 (29.75)	82.64 (22.33)
Analysis Visit Mean (SD)	81.56 (33.84)	83.33 (20.41)
LS Mean of Absolute Change from Baseline (SE)	-0.58 (4.10)	0.75 (4.43)
95% CI	(-9.03, 7.88)	(-8.39, 9.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.32 (6.03)	
95% CI	(-13.77, 11.13)	
p-value	0.8283	
Corrected Hedge's g Statistics	-0.084	
95% CI	(-0.85, 0.69)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	80.77 (30.50)	82.64 (22.33)
Analysis Visit Mean (SD)	80.77 (17.48)	78.48 (25.98)
LS Mean of Absolute Change from Baseline (SE)	-0.68 (4.72)	-3.88 (4.92)
95% CI	(-10.44, 9.07)	(-14.03, 6.28)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.19 (6.82)	
95% CI	(-10.89, 17.28)	
p-value	0.6440	
Corrected Hedge's g Statistics	0.181	
95% CI	(-0.60, 0.97)	
Subgroup*Treatment Interaction p-value	0.4996	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: ≥ 229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Mental Health		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	79.82 (15.21)	69.58 (20.83)
Analysis Visit Mean (SD)	80.00 (13.73)	70.42 (24.16)
LS Mean of Absolute Change from Baseline (SE)	1.74 (4.10)	-0.80 (4.43)
95% CI	(-6.73, 10.22)	(-9.93, 8.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.54 (6.16)	
95% CI	(-10.18, 15.26)	
p-value	0.6839	
Corrected Hedge's g Statistics	0.160	
95% CI	(-0.61, 0.93)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	79.04 (15.53)	69.58 (20.83)
Analysis Visit Mean (SD)	76.54 (18.41)	75.42 (23.01)
LS Mean of Absolute Change from Baseline (SE)	-1.38 (4.55)	4.45 (4.77)
95% CI	(-10.77, 8.02)	(-5.39, 14.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.82 (6.70)	
95% CI	(-19.66, 8.01)	
p-value	0.3936	
Corrected Hedge's g Statistics	-0.342	
95% CI	(-1.13, 0.45)	
Subgroup*Treatment Interaction p-value	0.7415	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Mental Component Score		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	53.72 (8.81)	49.83 (10.38)
Analysis Visit Mean (SD)	53.11 (9.44)	49.75 (10.03)
LS Mean of Absolute Change from Baseline (SE)	-0.25 (1.60)	-0.44 (1.73)
95% CI	(-3.56, 3.06)	(-4.01, 3.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.19 (2.38)	
95% CI	(-4.73, 5.11)	
p-value	0.9372	
Corrected Hedge's g Statistics	0.031	
95% CI	(-0.74, 0.80)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	53.31 (9.03)	49.83 (10.38)
Analysis Visit Mean (SD)	51.20 (6.76)	50.06 (11.58)
LS Mean of Absolute Change from Baseline (SE)	-1.57 (2.05)	-0.51 (2.14)
95% CI	(-5.80, 2.65)	(-4.92, 3.91)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.07 (2.99)	
95% CI	(-7.23, 5.10)	
p-value	0.7242	
Corrected Hedge's g Statistics	-0.139	
95% CI	(-0.92, 0.65)	
Subgroup*Treatment Interaction p-value	0.6881	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.11
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Visit Statistic	MGL-3196 (N=14)	Placebo (N=12)
Physical Component Score		
Week 12		
m	14	12
n	14	12
Baseline Mean (SD)	44.36 (9.21)	50.39 (7.98)
Analysis Visit Mean (SD)	46.04 (9.60)	49.60 (8.27)
LS Mean of Absolute Change from Baseline (SE)	1.46 (1.20)	-0.51 (1.31)
95% CI	(-1.01, 3.93)	(-3.21, 2.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.96 (1.83)	
95% CI	(-1.80, 5.73)	
p-value	0.2926	
Corrected Hedge's g Statistics	0.422	
95% CI	(-0.36, 1.20)	
Week 36		
m	13	12
n	13	12
Baseline Mean (SD)	43.58 (9.09)	50.39 (7.98)
Analysis Visit Mean (SD)	47.18 (7.86)	51.49 (9.25)
LS Mean of Absolute Change from Baseline (SE)	1.54 (2.00)	2.63 (2.13)
95% CI	(-2.59, 5.68)	(-1.77, 7.04)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.09 (3.03)	
95% CI	(-7.34, 5.15)	
p-value	0.7213	
Corrected Hedge's g Statistics	-0.145	
95% CI	(-0.93, 0.64)	
Subgroup*Treatment Interaction p-value	0.6793	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; HA = Hyaluronic Acid.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Physical Functioning		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	78.8 (21.2)	65.6 (37.0)
Analysis Visit Mean (SD)	77.5 (22.5)	80.6 (22.7)
LS Mean of Absolute Change from Baseline (SE)	1.76 (5.89)	11.73 (5.57)
95% CI	(-10.79, 14.30)	(-0.14, 23.60)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.97 (8.21)	
95% CI	(-27.46, 7.52)	
p-value	0.2430	
Corrected Hedge's g Statistics	-0.567	
95% CI	(-1.54, 0.40)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	82.9 (19.1)	65.6 (37.0)
Analysis Visit Mean (SD)	83.6 (23.0)	77.8 (33.1)
LS Mean of Absolute Change from Baseline (SE)	3.80 (6.52)	10.63 (5.83)
95% CI	(-10.09, 17.70)	(-1.81, 23.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.83 (8.90)	
95% CI	(-25.81, 12.15)	
p-value	0.4551	
Corrected Hedge's g Statistics	-0.371	
95% CI	(-1.37, 0.62)	
Subgroup*Treatment Interaction p-value	0.2806	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Role Physical		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	86.74 (17.49)	64.60 (43.18)
Analysis Visit Mean (SD)	84.39 (17.67)	71.54 (34.25)
LS Mean of Absolute Change from Baseline (SE)	1.10 (5.80)	3.42 (5.49)
95% CI	(-11.26, 13.47)	(-8.29, 15.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.32 (8.22)	
95% CI	(-19.83, 15.19)	
p-value	0.7815	
Corrected Hedge's g Statistics	-0.134	
95% CI	(-1.09, 0.82)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	91.99 (10.00)	64.60 (43.18)
Analysis Visit Mean (SD)	88.40 (19.24)	73.62 (34.91)
LS Mean of Absolute Change from Baseline (SE)	1.55 (6.52)	5.75 (5.95)
95% CI	(-12.35, 15.46)	(-6.92, 18.43)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.20 (9.12)	
95% CI	(-23.64, 15.25)	
p-value	0.6520	
Corrected Hedge's g Statistics	-0.226	
95% CI	(-1.22, 0.77)	
Subgroup*Treatment Interaction p-value	0.3879	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Bodily Pain		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	63.3 (29.7)	69.0 (38.5)
Analysis Visit Mean (SD)	81.3 (26.4)	65.8 (43.8)
LS Mean of Absolute Change from Baseline (SE)	17.08 (10.38)	-2.26 (9.79)
95% CI	(-5.04, 39.20)	(-23.13, 18.60)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	19.35 (14.29)	
95% CI	(-11.12, 49.81)	
p-value	0.1959	
Corrected Hedge's g Statistics	0.625	
95% CI	(-0.35, 1.60)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	61.7 (31.7)	69.0 (38.5)
Analysis Visit Mean (SD)	76.1 (29.9)	67.4 (37.4)
LS Mean of Absolute Change from Baseline (SE)	11.54 (8.20)	-0.85 (7.26)
95% CI	(-5.93, 29.02)	(-16.32, 14.63)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.39 (10.98)	
95% CI	(-11.02, 35.79)	
p-value	0.2769	
Corrected Hedge's g Statistics	0.539	
95% CI	(-0.47, 1.54)	
Subgroup*Treatment Interaction p-value	0.2505	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
General Health		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	60.6 (16.6)	64.9 (18.8)
Analysis Visit Mean (SD)	57.1 (17.9)	70.0 (21.7)
LS Mean of Absolute Change from Baseline (SE)	-3.58 (3.80)	5.18 (3.58)
95% CI	(-11.68, 4.51)	(-2.44, 12.81)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-8.77 (5.24)	
95% CI	(-19.94, 2.40)	
p-value	0.1150	
Corrected Hedge's g Statistics	-0.775	
95% CI	(-1.76, 0.21)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	60.4 (17.9)	64.9 (18.8)
Analysis Visit Mean (SD)	68.0 (22.2)	65.2 (23.9)
LS Mean of Absolute Change from Baseline (SE)	6.46 (6.84)	0.68 (6.05)
95% CI	(-8.12, 21.04)	(-12.22, 13.57)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.78 (9.17)	
95% CI	(-13.76, 25.32)	
p-value	0.5376	
Corrected Hedge's g Statistics	0.302	
95% CI	(-0.69, 1.29)	
Subgroup*Treatment Interaction p-value	0.0711	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Vitality		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	71.13 (14.53)	53.51 (23.00)
Analysis Visit Mean (SD)	65.64 (21.13)	56.97 (27.32)
LS Mean of Absolute Change from Baseline (SE)	-4.59 (6.66)	2.63 (6.27)
95% CI	(-18.79, 9.61)	(-10.73, 15.99)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.22 (9.61)	
95% CI	(-27.70, 13.25)	
p-value	0.4638	
Corrected Hedge's g Statistics	-0.364	
95% CI	(-1.32, 0.60)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	73.24 (14.29)	53.51 (23.00)
Analysis Visit Mean (SD)	67.89 (26.87)	59.06 (34.39)
LS Mean of Absolute Change from Baseline (SE)	-8.27 (7.86)	7.52 (7.13)
95% CI	(-25.02, 8.48)	(-7.69, 22.72)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-15.78 (11.18)	
95% CI	(-39.62, 8.05)	
p-value	0.1785	
Corrected Hedge's g Statistics	-0.706	
95% CI	(-1.72, 0.31)	
Subgroup*Treatment Interaction p-value	0.4211	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Social Functioning		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	87.50 (17.68)	75.00 (27.95)
Analysis Visit Mean (SD)	87.50 (17.68)	76.39 (35.60)
LS Mean of Absolute Change from Baseline (SE)	0.00 (5.98)	1.39 (5.69)
95% CI	(-12.75, 12.75)	(-10.74, 13.52)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.39 (8.41)	
95% CI	(-19.31, 16.54)	
p-value	0.8710	
Corrected Hedge's g Statistics	-0.078	
95% CI	(-1.03, 0.88)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	92.86 (9.83)	75.00 (27.95)
Analysis Visit Mean (SD)	85.71 (28.35)	76.39 (33.33)
LS Mean of Absolute Change from Baseline (SE)	-4.80 (10.45)	-0.06 (9.17)
95% CI	(-27.08, 17.48)	(-19.60, 19.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.74 (14.38)	
95% CI	(-35.39, 25.91)	
p-value	0.7463	
Corrected Hedge's g Statistics	-0.162	
95% CI	(-1.15, 0.83)	
Subgroup*Treatment Interaction p-value	0.6991	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Role Emotional		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	88.54 (18.33)	69.44 (38.20)
Analysis Visit Mean (SD)	95.84 (11.77)	75.93 (34.72)
LS Mean of Absolute Change from Baseline (SE)	9.17 (3.97)	4.50 (3.77)
95% CI	(0.70, 17.64)	(-3.54, 12.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.67 (5.62)	
95% CI	(-7.30, 16.65)	
p-value	0.4187	
Corrected Hedge's g Statistics	0.393	
95% CI	(-0.57, 1.35)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	94.04 (10.45)	69.44 (38.20)
Analysis Visit Mean (SD)	92.86 (12.20)	71.30 (36.35)
LS Mean of Absolute Change from Baseline (SE)	1.91 (6.01)	-0.06 (5.42)
95% CI	(-10.89, 14.72)	(-11.61, 11.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.97 (8.37)	
95% CI	(-15.86, 19.80)	
p-value	0.8170	
Corrected Hedge's g Statistics	0.116	
95% CI	(-0.87, 1.10)	
Subgroup*Treatment Interaction p-value	0.2923	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Mental Health		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	84.06 (12.81)	65.00 (20.16)
Analysis Visit Mean (SD)	80.63 (11.48)	67.78 (29.59)
LS Mean of Absolute Change from Baseline (SE)	-5.15 (4.37)	4.44 (4.14)
95% CI	(-14.47, 4.16)	(-4.38, 13.27)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-9.60 (6.45)	
95% CI	(-23.35, 4.16)	
p-value	0.1576	
Corrected Hedge's g Statistics	-0.735	
95% CI	(-1.72, 0.25)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	87.50 (9.01)	65.00 (20.16)
Analysis Visit Mean (SD)	88.57 (13.14)	62.22 (30.12)
LS Mean of Absolute Change from Baseline (SE)	1.51 (7.86)	-2.88 (6.78)
95% CI	(-15.24, 18.26)	(-17.34, 11.57)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.39 (11.34)	
95% CI	(-19.78, 28.56)	
p-value	0.7040	
Corrected Hedge's g Statistics	0.202	
95% CI	(-0.79, 1.19)	
Subgroup*Treatment Interaction p-value	0.7232	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Mental Component Score		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	55.69 (7.47)	45.92 (12.00)
Analysis Visit Mean (SD)	55.04 (6.73)	46.82 (15.51)
LS Mean of Absolute Change from Baseline (SE)	-0.61 (2.70)	0.86 (2.56)
95% CI	(-6.36, 5.15)	(-4.61, 6.32)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.46 (3.93)	
95% CI	(-9.85, 6.92)	
p-value	0.7148	
Corrected Hedge's g Statistics	-0.181	
95% CI	(-1.14, 0.77)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	57.84 (4.66)	45.92 (12.00)
Analysis Visit Mean (SD)	56.00 (3.12)	44.91 (15.24)
LS Mean of Absolute Change from Baseline (SE)	-0.34 (3.47)	-1.96 (3.15)
95% CI	(-7.75, 7.06)	(-8.67, 4.75)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.62 (5.00)	
95% CI	(-9.05, 12.28)	
p-value	0.7512	
Corrected Hedge's g Statistics	0.164	
95% CI	(-0.83, 1.15)	
Subgroup*Treatment Interaction p-value	0.7461	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=9)
Physical Component Score		
Week 12		
m	8	9
n	8	9
Baseline Mean (SD)	47.81 (7.78)	47.64 (12.45)
Analysis Visit Mean (SD)	48.93 (9.80)	50.36 (9.98)
LS Mean of Absolute Change from Baseline (SE)	1.12 (1.74)	2.69 (1.64)
95% CI	(-2.60, 4.83)	(-0.82, 6.19)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.57 (2.40)	
95% CI	(-6.68, 3.54)	
p-value	0.5225	
Corrected Hedge's g Statistics	-0.302	
95% CI	(-1.26, 0.66)	
Week 36		
m	7	9
n	7	9
Baseline Mean (SD)	48.10 (8.35)	47.64 (12.45)
Analysis Visit Mean (SD)	50.43 (9.96)	50.84 (11.82)
LS Mean of Absolute Change from Baseline (SE)	1.97 (2.06)	3.19 (1.85)
95% CI	(-2.43, 6.37)	(-0.76, 7.13)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-1.22 (2.77)	
95% CI	(-7.12, 4.69)	
p-value	0.6671	
Corrected Hedge's g Statistics	-0.209	
95% CI	(-1.20, 0.78)	
Subgroup*Treatment Interaction p-value	0.1893	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Physical Functioning		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	67.8 (29.2)	72.0 (20.0)
Analysis Visit Mean (SD)	67.2 (32.6)	70.0 (27.3)
LS Mean of Absolute Change from Baseline (SE)	-0.80 (6.72)	-1.89 (6.36)
95% CI	(-14.98, 13.38)	(-15.31, 11.53)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.09 (9.27)	
95% CI	(-18.47, 20.65)	
p-value	0.9077	
Corrected Hedge's g Statistics	0.052	
95% CI	(-0.85, 0.95)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	65.6 (30.4)	76.7 (14.4)
Analysis Visit Mean (SD)	71.9 (21.7)	78.3 (17.3)
LS Mean of Absolute Change from Baseline (SE)	4.32 (4.85)	3.96 (4.60)
95% CI	(-5.91, 14.55)	(-5.75, 13.68)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.35 (6.79)	
95% CI	(-13.97, 14.68)	
p-value	0.9589	
Corrected Hedge's g Statistics	0.024	
95% CI	(-0.93, 0.98)	
Subgroup*Treatment Interaction p-value	0.2806	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Role Physical		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	64.61 (41.46)	62.50 (32.27)
Analysis Visit Mean (SD)	72.26 (35.38)	63.76 (21.80)
LS Mean of Absolute Change from Baseline (SE)	7.81 (4.86)	0.77 (4.61)
95% CI	(-2.43, 18.06)	(-8.96, 10.49)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.05 (6.70)	
95% CI	(-7.08, 21.17)	
p-value	0.3073	
Corrected Hedge's g Statistics	0.462	
95% CI	(-0.45, 1.37)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	60.96 (42.75)	68.06 (28.72)
Analysis Visit Mean (SD)	71.90 (18.61)	68.76 (25.38)
LS Mean of Absolute Change from Baseline (SE)	9.03 (6.61)	3.45 (6.25)
95% CI	(-4.92, 22.98)	(-9.74, 16.65)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.58 (9.12)	
95% CI	(-13.66, 24.81)	
p-value	0.5491	
Corrected Hedge's g Statistics	0.282	
95% CI	(-0.67, 1.24)	
Subgroup*Treatment Interaction p-value	0.3879	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Bodily Pain		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	51.0 (27.7)	66.7 (21.1)
Analysis Visit Mean (SD)	55.3 (20.2)	65.1 (18.1)
LS Mean of Absolute Change from Baseline (SE)	-0.24 (5.76)	3.13 (5.49)
95% CI	(-12.40, 11.91)	(-8.46, 14.71)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.37 (8.17)	
95% CI	(-20.62, 13.87)	
p-value	0.6848	
Corrected Hedge's g Statistics	-0.186	
95% CI	(-1.09, 0.72)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	46.9 (26.5)	68.1 (21.9)
Analysis Visit Mean (SD)	56.0 (17.6)	67.0 (23.6)
LS Mean of Absolute Change from Baseline (SE)	-2.43 (8.06)	7.89 (7.49)
95% CI	(-19.44, 14.58)	(-7.90, 23.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-10.32 (11.51)	
95% CI	(-34.60, 13.96)	
p-value	0.3824	
Corrected Hedge's g Statistics	-0.433	
95% CI	(-1.40, 0.53)	
Subgroup*Treatment Interaction p-value	0.2505	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
General Health		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	59.7 (18.5)	62.9 (17.9)
Analysis Visit Mean (SD)	61.7 (13.8)	56.6 (16.8)
LS Mean of Absolute Change from Baseline (SE)	1.48 (3.77)	-5.53 (3.59)
95% CI	(-6.48, 9.44)	(-13.10, 2.04)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.01 (5.22)	
95% CI	(-4.00, 18.02)	
p-value	0.1968	
Corrected Hedge's g Statistics	0.591	
95% CI	(-0.33, 1.51)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	55.6 (14.9)	64.9 (17.8)
Analysis Visit Mean (SD)	61.5 (17.0)	65.2 (22.6)
LS Mean of Absolute Change from Baseline (SE)	2.77 (5.92)	0.57 (5.56)
95% CI	(-9.73, 15.27)	(-11.16, 12.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.20 (8.25)	
95% CI	(-15.20, 19.60)	
p-value	0.7929	
Corrected Hedge's g Statistics	0.125	
95% CI	(-0.83, 1.08)	
Subgroup*Treatment Interaction p-value	0.0711	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Vitality		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	53.51 (18.78)	54.39 (20.64)
Analysis Visit Mean (SD)	56.97 (19.37)	51.28 (14.08)
LS Mean of Absolute Change from Baseline (SE)	3.05 (5.04)	-3.00 (4.78)
95% CI	(-7.58, 13.69)	(-13.08, 7.09)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.05 (6.95)	
95% CI	(-8.61, 20.70)	
p-value	0.3960	
Corrected Hedge's g Statistics	0.382	
95% CI	(-0.53, 1.29)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	50.83 (18.13)	57.66 (18.95)
Analysis Visit Mean (SD)	59.40 (13.77)	57.66 (12.79)
LS Mean of Absolute Change from Baseline (SE)	4.87 (4.57)	1.96 (4.32)
95% CI	(-4.77, 14.51)	(-7.16, 11.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.92 (6.33)	
95% CI	(-10.45, 16.28)	
p-value	0.6510	
Corrected Hedge's g Statistics	0.214	
95% CI	(-0.74, 1.17)	
Subgroup*Treatment Interaction p-value	0.4211	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Social Functioning		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	81.94 (25.09)	78.75 (24.33)
Analysis Visit Mean (SD)	77.78 (27.08)	68.75 (27.16)
LS Mean of Absolute Change from Baseline (SE)	-3.91 (5.91)	-10.22 (5.61)
95% CI	(-16.38, 8.56)	(-22.05, 1.61)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.31 (8.16)	
95% CI	(-10.89, 23.52)	
p-value	0.4496	
Corrected Hedge's g Statistics	0.340	
95% CI	(-0.57, 1.25)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	79.69 (25.82)	80.56 (25.09)
Analysis Visit Mean (SD)	75.00 (14.94)	77.78 (22.34)
LS Mean of Absolute Change from Baseline (SE)	-5.09 (6.56)	-2.61 (6.18)
95% CI	(-18.93, 8.74)	(-15.65, 10.44)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.49 (9.02)	
95% CI	(-21.51, 16.53)	
p-value	0.7861	
Corrected Hedge's g Statistics	-0.127	
95% CI	(-1.08, 0.83)	
Subgroup*Treatment Interaction p-value	0.6991	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Role Emotional		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	74.08 (34.72)	69.17 (31.68)
Analysis Visit Mean (SD)	71.31 (39.11)	73.33 (22.49)
LS Mean of Absolute Change from Baseline (SE)	-2.38 (6.00)	3.51 (5.70)
95% CI	(-15.03, 10.28)	(-8.51, 15.54)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.89 (8.29)	
95% CI	(-23.37, 11.59)	
p-value	0.4868	
Corrected Hedge's g Statistics	-0.312	
95% CI	(-1.22, 0.59)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	70.84 (35.64)	75.00 (27.32)
Analysis Visit Mean (SD)	75.00 (17.82)	75.92 (24.10)
LS Mean of Absolute Change from Baseline (SE)	3.33 (6.18)	2.97 (5.84)
95% CI	(-9.70, 16.36)	(-9.34, 15.28)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.36 (8.51)	
95% CI	(-17.59, 18.31)	
p-value	0.9668	
Corrected Hedge's g Statistics	0.019	
95% CI	(-0.93, 0.97)	
Subgroup*Treatment Interaction p-value	0.2923	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Mental Health		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	76.11 (17.28)	63.00 (26.06)
Analysis Visit Mean (SD)	77.22 (16.22)	62.00 (23.59)
LS Mean of Absolute Change from Baseline (SE)	3.69 (5.45)	-3.71 (5.19)
95% CI	(-7.80, 15.18)	(-14.66, 7.24)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.40 (7.69)	
95% CI	(-8.83, 23.63)	
p-value	0.3493	
Corrected Hedge's g Statistics	0.432	
95% CI	(-0.48, 1.34)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	74.38 (17.61)	66.67 (24.75)
Analysis Visit Mean (SD)	70.63 (18.79)	76.67 (23.58)
LS Mean of Absolute Change from Baseline (SE)	-2.48 (5.47)	9.00 (5.12)
95% CI	(-14.01, 9.05)	(-1.81, 19.81)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-11.48 (7.55)	
95% CI	(-27.42, 4.46)	
p-value	0.1469	
Corrected Hedge's g Statistics	-0.707	
95% CI	(-1.69, 0.27)	
Subgroup*Treatment Interaction p-value	0.7232	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Mental Component Score		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	50.88 (9.71)	45.51 (12.89)
Analysis Visit Mean (SD)	50.14 (10.48)	44.81 (11.44)
LS Mean of Absolute Change from Baseline (SE)	-0.16 (2.22)	-1.31 (2.11)
95% CI	(-4.84, 4.52)	(-5.76, 3.14)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.15 (3.10)	
95% CI	(-5.40, 7.70)	
p-value	0.7161	
Corrected Hedge's g Statistics	0.165	
95% CI	(-0.74, 1.07)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	49.85 (9.85)	47.33 (12.22)
Analysis Visit Mean (SD)	48.68 (7.26)	49.62 (11.96)
LS Mean of Absolute Change from Baseline (SE)	-0.61 (2.58)	1.95 (2.43)
95% CI	(-6.06, 4.84)	(-3.17, 7.08)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.57 (3.56)	
95% CI	(-10.07, 4.94)	
p-value	0.4802	
Corrected Hedge's g Statistics	-0.334	
95% CI	(-1.29, 0.62)	
Subgroup*Treatment Interaction p-value	0.7461	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.12
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=10)
Physical Component Score		
Week 12		
m	9	10
n	9	10
Baseline Mean (SD)	43.40 (9.60)	48.15 (7.05)
Analysis Visit Mean (SD)	45.24 (9.08)	46.80 (7.06)
LS Mean of Absolute Change from Baseline (SE)	1.40 (1.52)	-0.93 (1.44)
95% CI	(-1.81, 4.60)	(-3.97, 2.11)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.33 (2.14)	
95% CI	(-2.18, 6.84)	
p-value	0.2911	
Corrected Hedge's g Statistics	0.488	
95% CI	(-0.43, 1.40)	
Week 36		
m	8	10
n	8	9
Baseline Mean (SD)	42.01 (9.24)	49.18 (6.64)
Analysis Visit Mean (SD)	46.53 (5.62)	48.21 (7.86)
LS Mean of Absolute Change from Baseline (SE)	1.64 (2.38)	0.76 (2.23)
95% CI	(-3.37, 6.66)	(-3.94, 5.46)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.89 (3.40)	
95% CI	(-6.28, 8.06)	
p-value	0.7969	
Corrected Hedge's g Statistics	0.126	
95% CI	(-0.83, 1.08)	
Subgroup*Treatment Interaction p-value	0.1893	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QoL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.

Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value and visit as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.

Note: The subgroup*treatment interaction p-values were obtained using the MMRM above with the subgroup and subgroup*treatment interaction term included additionally. For the MMRM and subgroup interaction tests, the covariance structure will be tested in the sequence of UN (Unstructure) and CS (Compound Symmetry). If both fail to converge, the result will be presented as NE (Not Estimable).

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Physical Functioning		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	74.4 (21.8)	65.5 (33.4)
Analysis Visit Mean (SD)	70.6 (23.1)	78.2 (28.6)
LS Mean of Absolute Change from Baseline (SE)	-2.29 (7.36)	10.51 (6.32)
95% CI	(-17.82, 13.24)	(-2.83, 23.85)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-12.80 (9.76)	
95% CI	(-33.39, 7.80)	
p-value	0.2074	
Corrected Hedge's g Statistics	-0.585	
95% CI	(-1.51, 0.34)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	77.9 (21.0)	69.0 (33.0)
Analysis Visit Mean (SD)	82.9 (15.5)	81.0 (29.7)
LS Mean of Absolute Change from Baseline (SE)	8.15 (7.23)	8.82 (6.03)
95% CI	(-7.09, 23.40)	(-3.91, 21.55)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.67 (9.46)	
95% CI	(-20.62, 19.29)	
p-value	0.9444	
Corrected Hedge's g Statistics	-0.033	
95% CI	(-1.00, 0.93)	
Subgroup*Treatment Interaction p-value	0.3219	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Role Physical		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	67.99 (37.26)	60.24 (40.91)
Analysis Visit Mean (SD)	72.66 (30.25)	66.49 (32.99)
LS Mean of Absolute Change from Baseline (SE)	5.42 (5.22)	4.85 (4.47)
95% CI	(-5.59, 16.44)	(-4.58, 14.29)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.57 (6.89)	
95% CI	(-13.97, 15.11)	
p-value	0.9347	
Corrected Hedge's g Statistics	0.037	
95% CI	(-0.87, 0.95)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	70.56 (39.48)	65.01 (39.77)
Analysis Visit Mean (SD)	83.94 (19.71)	71.26 (33.75)
LS Mean of Absolute Change from Baseline (SE)	15.68 (5.76)	6.09 (4.85)
95% CI	(3.52, 27.83)	(-4.14, 16.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	9.59 (7.54)	
95% CI	(-6.32, 25.49)	
p-value	0.2207	
Corrected Hedge's g Statistics	0.595	
95% CI	(-0.39, 1.58)	
Subgroup*Treatment Interaction p-value	0.9376	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Bodily Pain		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	51.0 (29.8)	68.1 (34.8)
Analysis Visit Mean (SD)	71.5 (32.2)	75.3 (33.6)
LS Mean of Absolute Change from Baseline (SE)	16.91 (9.57)	9.90 (8.13)
95% CI	(-3.29, 37.10)	(-7.25, 27.06)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	7.00 (12.78)	
95% CI	(-19.95, 33.96)	
p-value	0.5907	
Corrected Hedge's g Statistics	0.248	
95% CI	(-0.67, 1.16)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	47.7 (30.6)	69.5 (36.3)
Analysis Visit Mean (SD)	70.7 (28.2)	69.3 (35.3)
LS Mean of Absolute Change from Baseline (SE)	16.59 (8.12)	2.02 (6.75)
95% CI	(-0.55, 33.72)	(-12.23, 16.27)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	14.57 (10.81)	
95% CI	(-8.24, 37.38)	
p-value	0.1956	
Corrected Hedge's g Statistics	0.646	
95% CI	(-0.34, 1.64)	
Subgroup*Treatment Interaction p-value	0.9875	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
General Health		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	60.0 (11.9)	63.9 (18.6)
Analysis Visit Mean (SD)	57.5 (9.3)	66.7 (22.4)
LS Mean of Absolute Change from Baseline (SE)	-2.84 (4.18)	2.96 (3.55)
95% CI	(-11.66, 5.98)	(-4.52, 10.44)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.80 (5.50)	
95% CI	(-17.40, 5.81)	
p-value	0.3068	
Corrected Hedge's g Statistics	-0.470	
95% CI	(-1.39, 0.45)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	59.7 (12.8)	65.8 (18.4)
Analysis Visit Mean (SD)	71.1 (16.9)	64.2 (22.7)
LS Mean of Absolute Change from Baseline (SE)	9.59 (6.87)	-1.49 (5.77)
95% CI	(-4.90, 24.09)	(-13.67, 10.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	11.08 (9.05)	
95% CI	(-8.01, 30.18)	
p-value	0.2373	
Corrected Hedge's g Statistics	0.577	
95% CI	(-0.41, 1.56)	
Subgroup*Treatment Interaction p-value	0.3678	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Vitality		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	64.10 (21.31)	50.60 (23.30)
Analysis Visit Mean (SD)	64.08 (20.80)	52.86 (26.42)
LS Mean of Absolute Change from Baseline (SE)	1.63 (6.39)	0.71 (5.48)
95% CI	(-11.86, 15.11)	(-10.85, 12.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.92 (8.61)	
95% CI	(-17.25, 19.09)	
p-value	0.9162	
Corrected Hedge's g Statistics	0.048	
95% CI	(-0.86, 0.96)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	65.21 (22.77)	53.16 (22.87)
Analysis Visit Mean (SD)	71.46 (13.89)	57.52 (32.65)
LS Mean of Absolute Change from Baseline (SE)	6.25 (6.89)	3.23 (5.80)
95% CI	(-8.29, 20.79)	(-9.00, 15.46)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.02 (9.18)	
95% CI	(-16.35, 22.40)	
p-value	0.7461	
Corrected Hedge's g Statistics	0.157	
95% CI	(-0.81, 1.12)	
Subgroup*Treatment Interaction p-value	0.7670	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Social Functioning		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	79.69 (23.09)	71.59 (26.86)
Analysis Visit Mean (SD)	73.44 (28.69)	70.45 (34.58)
LS Mean of Absolute Change from Baseline (SE)	-6.52 (6.33)	-0.80 (5.43)
95% CI	(-19.88, 6.84)	(-12.25, 10.64)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.72 (8.39)	
95% CI	(-23.43, 11.99)	
p-value	0.5050	
Corrected Hedge's g Statistics	-0.304	
95% CI	(-1.22, 0.61)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	83.93 (21.30)	72.50 (28.14)
Analysis Visit Mean (SD)	82.14 (27.82)	75.00 (31.73)
LS Mean of Absolute Change from Baseline (SE)	1.66 (9.96)	-0.05 (8.25)
95% CI	(-19.34, 22.67)	(-17.45, 17.34)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.72 (13.06)	
95% CI	(-25.85, 29.28)	
p-value	0.8969	
Corrected Hedge's g Statistics	0.062	
95% CI	(-0.90, 1.03)	
Subgroup*Treatment Interaction p-value	0.3652	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Role Emotional		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	76.04 (23.33)	62.13 (38.62)
Analysis Visit Mean (SD)	77.09 (36.66)	71.97 (32.12)
LS Mean of Absolute Change from Baseline (SE)	1.89 (6.78)	8.78 (5.84)
95% CI	(-12.42, 16.21)	(-3.55, 21.10)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-6.88 (9.05)	
95% CI	(-25.99, 12.22)	
p-value	0.4576	
Corrected Hedge's g Statistics	-0.341	
95% CI	(-1.26, 0.58)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	79.76 (22.49)	66.67 (37.48)
Analysis Visit Mean (SD)	85.71 (13.36)	72.50 (31.68)
LS Mean of Absolute Change from Baseline (SE)	9.77 (5.89)	5.00 (4.85)
95% CI	(-2.65, 22.20)	(-5.24, 15.23)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.77 (7.69)	
95% CI	(-11.46, 21.00)	
p-value	0.5432	
Corrected Hedge's g Statistics	0.293	
95% CI	(-0.68, 1.26)	
Subgroup*Treatment Interaction p-value	0.4876	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Mental Health		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	78.44 (17.27)	59.55 (22.52)
Analysis Visit Mean (SD)	75.00 (15.12)	64.55 (27.79)
LS Mean of Absolute Change from Baseline (SE)	-3.10 (4.79)	4.68 (4.13)
95% CI	(-13.20, 7.00)	(-4.03, 13.39)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-7.78 (6.64)	
95% CI	(-21.79, 6.23)	
p-value	0.2574	
Corrected Hedge's g Statistics	-0.545	
95% CI	(-1.47, 0.38)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	81.07 (16.82)	62.50 (21.38)
Analysis Visit Mean (SD)	90.00 (10.00)	61.00 (28.66)
LS Mean of Absolute Change from Baseline (SE)	10.83 (6.83)	-3.12 (5.60)
95% CI	(-3.58, 25.24)	(-14.94, 8.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	13.96 (9.26)	
95% CI	(-5.58, 33.49)	
p-value	0.1501	
Corrected Hedge's g Statistics	0.742	
95% CI	(-0.26, 1.74)	
Subgroup*Treatment Interaction p-value	0.5162	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Mental Component Score		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	52.05 (9.46)	42.76 (12.92)
Analysis Visit Mean (SD)	50.03 (11.00)	44.26 (14.97)
LS Mean of Absolute Change from Baseline (SE)	-1.87 (2.81)	1.35 (2.42)
95% CI	(-7.80, 4.06)	(-3.76, 6.46)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.22 (3.85)	
95% CI	(-11.36, 4.91)	
p-value	0.4144	
Corrected Hedge's g Statistics	-0.385	
95% CI	(-1.30, 0.53)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	53.69 (8.92)	44.13 (12.75)
Analysis Visit Mean (SD)	55.53 (3.34)	44.26 (14.56)
LS Mean of Absolute Change from Baseline (SE)	4.36 (3.40)	-0.84 (2.80)
95% CI	(-2.82, 11.54)	(-6.76, 5.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.20 (4.58)	
95% CI	(-4.46, 14.86)	
p-value	0.2719	
Corrected Hedge's g Statistics	0.553	
95% CI	(-0.43, 1.54)	
Subgroup*Treatment Interaction p-value	0.9110	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=8)	Placebo (N=11)
Physical Component Score		
Week 12		
m	8	11
n	8	11
Baseline Mean (SD)	44.66 (7.47)	48.04 (11.04)
Analysis Visit Mean (SD)	47.30 (7.57)	50.81 (9.26)
LS Mean of Absolute Change from Baseline (SE)	2.11 (1.62)	3.06 (1.37)
95% CI	(-1.30, 5.53)	(0.16, 5.95)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-0.94 (2.14)	
95% CI	(-5.45, 3.57)	
p-value	0.6653	
Corrected Hedge's g Statistics	-0.197	
95% CI	(-1.11, 0.72)	
Week 36		
m	7	11
n	7	10
Baseline Mean (SD)	44.50 (8.05)	48.95 (11.19)
Analysis Visit Mean (SD)	49.89 (6.91)	51.21 (10.98)
LS Mean of Absolute Change from Baseline (SE)	4.47 (2.14)	2.01 (1.79)
95% CI	(-0.03, 8.98)	(-1.78, 5.79)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.47 (2.82)	
95% CI	(-3.49, 8.42)	
p-value	0.3945	
Corrected Hedge's g Statistics	0.413	
95% CI	(-0.56, 1.39)	
Subgroup*Treatment Interaction p-value	0.3474	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Physical Functioning		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	71.7 (29.8)	73.8 (21.7)
Analysis Visit Mean (SD)	73.3 (33.1)	70.6 (20.4)
LS Mean of Absolute Change from Baseline (SE)	1.58 (5.66)	-2.91 (6.01)
95% CI	(-10.48, 13.64)	(-15.72, 9.89)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	4.49 (8.26)	
95% CI	(-13.10, 22.09)	
p-value	0.5942	
Corrected Hedge's g Statistics	0.251	
95% CI	(-0.70, 1.21)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	70.0 (31.4)	73.8 (21.7)
Analysis Visit Mean (SD)	72.5 (27.1)	74.4 (20.8)
LS Mean of Absolute Change from Baseline (SE)	2.05 (3.95)	0.92 (3.95)
95% CI	(-6.37, 10.46)	(-7.50, 9.33)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	1.13 (5.59)	
95% CI	(-10.79, 13.05)	
p-value	0.8427	
Corrected Hedge's g Statistics	0.096	
95% CI	(-0.88, 1.08)	
Subgroup*Treatment Interaction p-value	0.3219	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Role Physical		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	81.28 (30.61)	67.98 (32.28)
Analysis Visit Mean (SD)	82.68 (27.37)	68.76 (20.85)
LS Mean of Absolute Change from Baseline (SE)	4.07 (5.38)	-1.74 (5.69)
95% CI	(-7.39, 15.53)	(-13.86, 10.38)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.81 (7.92)	
95% CI	(-11.08, 22.69)	
p-value	0.4750	
Corrected Hedge's g Statistics	0.342	
95% CI	(-0.62, 1.30)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	79.71 (32.34)	67.98 (32.28)
Analysis Visit Mean (SD)	75.80 (20.99)	71.10 (26.07)
LS Mean of Absolute Change from Baseline (SE)	-0.23 (7.30)	-0.95 (7.48)
95% CI	(-15.79, 15.33)	(-16.90, 15.00)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.72 (10.56)	
95% CI	(-21.80, 23.24)	
p-value	0.9464	
Corrected Hedge's g Statistics	0.033	
95% CI	(-0.95, 1.01)	
Subgroup*Treatment Interaction p-value	0.9376	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Bodily Pain		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	61.9 (27.9)	67.4 (23.3)
Analysis Visit Mean (SD)	64.0 (20.8)	51.9 (25.3)
LS Mean of Absolute Change from Baseline (SE)	1.38 (5.59)	-14.22 (5.95)
95% CI	(-10.54, 13.31)	(-26.91, -1.54)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	15.60 (8.19)	
95% CI	(-1.86, 33.06)	
p-value	0.0762	
Corrected Hedge's g Statistics	0.881	
95% CI	(-0.12, 1.88)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	59.1 (28.5)	67.4 (23.3)
Analysis Visit Mean (SD)	60.8 (23.5)	64.6 (24.9)
LS Mean of Absolute Change from Baseline (SE)	-2.50 (8.58)	-0.14 (8.57)
95% CI	(-20.80, 15.79)	(-18.40, 18.12)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.36 (12.21)	
95% CI	(-28.39, 23.66)	
p-value	0.8491	
Corrected Hedge's g Statistics	-0.092	
95% CI	(-1.07, 0.89)	
Subgroup*Treatment Interaction p-value	0.9875	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
General Health		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	60.2 (21.4)	63.8 (18.0)
Analysis Visit Mean (SD)	61.3 (20.0)	57.8 (15.8)
LS Mean of Absolute Change from Baseline (SE)	0.88 (4.05)	-5.16 (4.31)
95% CI	(-7.74, 9.51)	(-14.35, 4.03)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	6.04 (5.92)	
95% CI	(-6.58, 18.66)	
p-value	0.3237	
Corrected Hedge's g Statistics	0.471	
95% CI	(-0.49, 1.44)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	56.3 (19.0)	63.8 (18.0)
Analysis Visit Mean (SD)	58.8 (20.1)	66.5 (23.8)
LS Mean of Absolute Change from Baseline (SE)	-0.16 (5.46)	3.33 (5.55)
95% CI	(-11.79, 11.47)	(-8.50, 15.16)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-3.49 (7.84)	
95% CI	(-20.20, 13.22)	
p-value	0.6625	
Corrected Hedge's g Statistics	-0.212	
95% CI	(-1.19, 0.77)	
Subgroup*Treatment Interaction p-value	0.3678	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Vitality		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	59.76 (17.14)	58.61 (18.29)
Analysis Visit Mean (SD)	58.36 (20.24)	55.50 (11.31)
LS Mean of Absolute Change from Baseline (SE)	-0.76 (5.29)	-3.19 (5.61)
95% CI	(-12.04, 10.52)	(-15.14, 8.76)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.43 (7.71)	
95% CI	(-14.01, 18.87)	
p-value	0.7570	
Corrected Hedge's g Statistics	0.145	
95% CI	(-0.81, 1.10)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	57.85 (17.28)	58.61 (18.29)
Analysis Visit Mean (SD)	56.28 (23.63)	59.40 (12.92)
LS Mean of Absolute Change from Baseline (SE)	-4.08 (6.56)	0.70 (6.70)
95% CI	(-18.07, 9.90)	(-13.59, 14.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-4.78 (9.38)	
95% CI	(-24.77, 15.21)	
p-value	0.6176	
Corrected Hedge's g Statistics	-0.241	
95% CI	(-1.22, 0.74)	
Subgroup*Treatment Interaction p-value	0.7670	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Social Functioning		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	88.89 (20.20)	84.38 (22.90)
Analysis Visit Mean (SD)	90.28 (13.66)	75.00 (26.73)
LS Mean of Absolute Change from Baseline (SE)	2.22 (5.19)	-10.03 (5.50)
95% CI	(-8.85, 13.29)	(-21.75, 1.69)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	12.25 (7.59)	
95% CI	(-3.92, 28.42)	
p-value	0.1272	
Corrected Hedge's g Statistics	0.747	
95% CI	(-0.24, 1.73)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	87.50 (21.13)	84.38 (22.90)
Analysis Visit Mean (SD)	78.13 (17.36)	79.69 (23.09)
LS Mean of Absolute Change from Baseline (SE)	-8.92 (7.09)	-6.10 (7.12)
95% CI	(-24.03, 6.20)	(-21.28, 9.07)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-2.81 (10.06)	
95% CI	(-24.26, 18.63)	
p-value	0.7836	
Corrected Hedge's g Statistics	-0.132	
95% CI	(-1.11, 0.85)	
Subgroup*Treatment Interaction p-value	0.3652	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Role Emotional		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	85.19 (33.01)	79.16 (25.21)
Analysis Visit Mean (SD)	87.98 (27.03)	78.13 (23.11)
LS Mean of Absolute Change from Baseline (SE)	3.50 (3.36)	-1.60 (3.56)
95% CI	(-3.66, 10.67)	(-9.19, 5.98)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	5.11 (4.91)	
95% CI	(-5.36, 15.57)	
p-value	0.3148	
Corrected Hedge's g Statistics	0.481	
95% CI	(-0.49, 1.45)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	83.34 (34.79)	79.16 (25.21)
Analysis Visit Mean (SD)	81.25 (21.25)	75.00 (29.88)
LS Mean of Absolute Change from Baseline (SE)	-2.58 (6.87)	-5.32 (7.01)
95% CI	(-17.23, 12.07)	(-20.27, 9.63)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.74 (9.84)	
95% CI	(-18.23, 23.71)	
p-value	0.7844	
Corrected Hedge's g Statistics	0.132	
95% CI	(-0.85, 1.11)	
Subgroup*Treatment Interaction p-value	0.4876	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Mental Health		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	81.11 (14.53)	70.00 (23.30)
Analysis Visit Mean (SD)	82.22 (12.53)	65.00 (25.21)
LS Mean of Absolute Change from Baseline (SE)	3.26 (5.48)	-7.07 (5.79)
95% CI	(-8.42, 14.94)	(-19.41, 5.26)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	10.33 (8.15)	
95% CI	(-7.04, 27.71)	
p-value	0.2241	
Corrected Hedge's g Statistics	0.598	
95% CI	(-0.38, 1.57)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	80.00 (15.12)	70.00 (23.30)
Analysis Visit Mean (SD)	69.38 (18.98)	80.00 (22.83)
LS Mean of Absolute Change from Baseline (SE)	-9.95 (4.84)	9.11 (4.88)
95% CI	(-20.26, 0.36)	(-1.29, 19.51)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-19.06 (6.99)	
95% CI	(-33.96, -4.15)	
p-value	0.0156	
Corrected Hedge's g Statistics	-1.311	
95% CI	(-2.39, -0.23)	
Subgroup*Treatment Interaction p-value	0.5162	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Mental Component Score		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	54.11 (8.64)	49.75 (10.36)
Analysis Visit Mean (SD)	54.60 (6.72)	47.83 (10.84)
LS Mean of Absolute Change from Baseline (SE)	1.06 (1.88)	-2.45 (1.98)
95% CI	(-2.94, 5.06)	(-6.68, 1.77)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	3.51 (2.77)	
95% CI	(-2.39, 9.42)	
p-value	0.2239	
Corrected Hedge's g Statistics	0.593	
95% CI	(-0.38, 1.57)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	53.49 (9.02)	49.75 (10.36)
Analysis Visit Mean (SD)	49.09 (7.62)	51.03 (11.91)
LS Mean of Absolute Change from Baseline (SE)	-4.36 (2.36)	0.81 (2.39)
95% CI	(-9.40, 0.68)	(-4.29, 5.91)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	-5.17 (3.40)	
95% CI	(-12.41, 2.08)	
p-value	0.1492	
Corrected Hedge's g Statistics	-0.727	
95% CI	(-1.74, 0.29)	
Subgroup*Treatment Interaction p-value	0.9110	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO4.13
Summary of Absolute Change in HR-QOL SF-36 Score by Domain/Component - MMRM Model
by Baseline PRO-C3

(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Visit Statistic	MGL-3196 (N=9)	Placebo (N=8)
Physical Component Score		
Week 12		
m	9	8
n	9	8
Baseline Mean (SD)	46.20 (10.26)	47.74 (8.19)
Analysis Visit Mean (SD)	46.69 (11.10)	45.29 (6.61)
LS Mean of Absolute Change from Baseline (SE)	0.44 (1.40)	-2.34 (1.49)
95% CI	(-2.56, 3.43)	(-5.52, 0.85)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	2.77 (2.05)	
95% CI	(-1.61, 7.15)	
p-value	0.1971	
Corrected Hedge's g Statistics	0.624	
95% CI	(-0.35, 1.60)	
Week 36		
m	8	8
n	8	8
Baseline Mean (SD)	45.16 (10.45)	47.74 (8.19)
Analysis Visit Mean (SD)	47.00 (8.91)	47.43 (8.41)
LS Mean of Absolute Change from Baseline (SE)	0.50 (2.52)	0.19 (2.57)
95% CI	(-4.86, 5.87)	(-5.28, 5.66)
LS Mean of Absolute Change from Baseline Compared to Placebo (SE)	0.31 (3.61)	
95% CI	(-7.38, 8.01)	
p-value	0.9322	
Corrected Hedge's g Statistics	0.041	
95% CI	(-0.94, 1.02)	
Subgroup*Treatment Interaction p-value	0.3474	

Program: t-pro03-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (18.2)
No	5 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.89	
95% CI of the inverse odds ratio	(0.12, 71.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.14, 44.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-44.39, 19.39)	
p-value	0.5023	
p-value of Breslow-Day Test for Homogeneity [3]	0.4420	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	4 (36.4)
No	4 (80.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse odds ratio	(0.19, 28.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	
95% CI of the inverse risk ratio	(0.27, 12.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.36	
95% CI of the absolute risk difference	(-61.50, 28.77)	
p-value	0.5128	
p-value of Breslow-Day Test for Homogeneity [3]	0.6800	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	3 (27.3)
No	4 (80.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.12, 19.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	
95% CI of the inverse risk ratio	(0.18, 10.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.27	
95% CI of the absolute risk difference	(-51.11, 36.57)	
p-value	0.7555	
p-value of Breslow-Day Test for Homogeneity [3]	0.8089	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	4 (36.4)
No	4 (80.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse odds ratio	(0.19, 28.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	
95% CI of the inverse risk ratio	(0.27, 12.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.36	
95% CI of the absolute risk difference	(-61.50, 28.77)	
p-value	0.5128	
p-value of Breslow-Day Test for Homogeneity [3]	0.7553	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (40.0)	3 (27.3)
No	3 (60.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse odds ratio	(0.06, 5.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	
95% CI of the inverse risk ratio	(0.16, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.73	
95% CI of the absolute risk difference	(-37.64, 63.09)	
p-value	0.6107	
p-value of Breslow-Day Test for Homogeneity [3]	0.5311	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	4 (36.4)
No	2 (40.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	
95% CI of the inverse odds ratio	(0.04, 3.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	
95% CI of the inverse risk ratio	(0.21, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.64	
95% CI of the absolute risk difference	(-27.86, 75.13)	
p-value	0.3770	
p-value of Breslow-Day Test for Homogeneity [3]	0.6941	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	3 (27.3)
No	4 (80.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.12, 19.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	
95% CI of the inverse risk ratio	(0.18, 10.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.27	
95% CI of the absolute risk difference	(-51.11, 36.57)	
p-value	0.7555	
p-value of Breslow-Day Test for Homogeneity [3]	0.1036	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (40.0)	5 (45.5)
No	3 (60.0)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.15, 10.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse risk ratio	(0.32, 3.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.45	
95% CI of the absolute risk difference	(-57.51, 46.60)	
p-value	0.8385	
p-value of Breslow-Day Test for Homogeneity [3]	0.2544	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	6 (54.5)
No	4 (80.0)	5 (45.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	
95% CI of the inverse odds ratio	(0.40, 58.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.73	
95% CI of the inverse risk ratio	(0.44, 17.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-34.55	
95% CI of the absolute risk difference	(-80.32, 11.23)	
p-value	0.1967	
p-value of Breslow-Day Test for Homogeneity [3]	0.3354	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	7 (63.6)
No	2 (40.0)	4 (36.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse odds ratio	(0.13, 10.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	
95% CI of the inverse risk ratio	(0.46, 2.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.64	
95% CI of the absolute risk difference	(-55.13, 47.86)	
p-value	0.8892	
p-value of Breslow-Day Test for Homogeneity [3]	0.6451	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	2 (18.2)
No	4 (80.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse odds ratio	(0.06, 12.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	
95% CI of the inverse risk ratio	(0.11, 7.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.82	
95% CI of the absolute risk difference	(-40.00, 43.64)	
p-value	0.9312	
p-value of Breslow-Day Test for Homogeneity [3]	0.9082	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (40.0)	2 (18.2)
No	3 (60.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.03, 3.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse risk ratio	(0.09, 2.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.82	
95% CI of the absolute risk difference	(-26.80, 70.43)	
p-value	0.3502	
p-value of Breslow-Day Test for Homogeneity [3]	0.1454	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	1 (9.1)
No	4 (80.0)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.02, 8.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse risk ratio	(0.04, 5.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.91	
95% CI of the absolute risk difference	(-28.05, 49.87)	
p-value	0.5408	
p-value of Breslow-Day Test for Homogeneity [3]	0.6194	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	3 (27.3)
No	4 (80.0)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.12, 19.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	
95% CI of the inverse risk ratio	(0.18, 10.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.27	
95% CI of the absolute risk difference	(-51.11, 36.57)	
p-value	0.7555	
p-value of Breslow-Day Test for Homogeneity [3]	0.9114	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	4 (36.4)
No	4 (80.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse odds ratio	(0.19, 28.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	
95% CI of the inverse risk ratio	(0.27, 12.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.36	
95% CI of the absolute risk difference	(-61.50, 28.77)	
p-value	0.5128	
p-value of Breslow-Day Test for Homogeneity [3]	0.5236	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	8 (72.7)
No	2 (40.0)	3 (27.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse odds ratio	(0.19, 16.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	
95% CI of the inverse risk ratio	(0.54, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.73	
95% CI of the absolute risk difference	(-63.09, 37.64)	
p-value	0.6107	
p-value of Breslow-Day Test for Homogeneity [3]	0.9934	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	2 (18.2)
No	4 (80.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse odds ratio	(0.06, 12.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	
95% CI of the inverse risk ratio	(0.11, 7.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.82	
95% CI of the absolute risk difference	(-40.00, 43.64)	
p-value	0.9312	
p-value of Breslow-Day Test for Homogeneity [3]	0.1462	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (40.0)	5 (45.5)
No	3 (60.0)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.15, 10.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse risk ratio	(0.32, 3.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.45	
95% CI of the absolute risk difference	(-57.51, 46.60)	
p-value	0.8385	
p-value of Breslow-Day Test for Homogeneity [3]	0.8833	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Male

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=11)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (18.2)
No	5 (100)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.89	
95% CI of the inverse odds ratio	(0.12, 71.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.14, 44.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-44.39, 19.39)	
p-value	0.5023	
p-value of Breslow-Day Test for Homogeneity [3]	0.0748	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	4 (36.4)
No	4 (80.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse odds ratio	(0.19, 28.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	
95% CI of the inverse risk ratio	(0.27, 12.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.36	
95% CI of the absolute risk difference	(-61.50, 28.77)	
p-value	0.5128	
p-value of Breslow-Day Test for Homogeneity [3]	0.0654	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (16.7)	2 (25.0)
No	10 (83.3)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.18, 15.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.26, 8.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-45.01, 28.34)	
p-value	0.6481	
p-value of Breslow-Day Test for Homogeneity [3]	0.4420	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	7 (58.3)	5 (62.5)
No	5 (41.7)	3 (37.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	
95% CI of the inverse odds ratio	(0.19, 7.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	
95% CI of the inverse risk ratio	(0.52, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	
95% CI of the absolute risk difference	(-47.80, 39.46)	
p-value	0.8522	
p-value of Breslow-Day Test for Homogeneity [3]	0.6800	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	2 (25.0)
No	9 (75.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.13, 7.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.21, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-38.74, 38.74)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8089	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	4 (50.0)
No	7 (58.3)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse odds ratio	(0.23, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse risk ratio	(0.46, 3.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-52.81, 36.15)	
p-value	0.7136	
p-value of Breslow-Day Test for Homogeneity [3]	0.7553	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (41.7)	1 (12.5)
No	7 (58.3)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse risk ratio	(0.04, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.17	
95% CI of the absolute risk difference	(-6.93, 65.27)	
p-value	0.1632	
p-value of Breslow-Day Test for Homogeneity [3]	0.5311	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	1 (12.5)
No	7 (58.3)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse risk ratio	(0.04, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.17	
95% CI of the absolute risk difference	(-6.93, 65.27)	
p-value	0.1632	
p-value of Breslow-Day Test for Homogeneity [3]	0.6941	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (33.3)	0
No	8 (66.7)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	
95% CI of the inverse odds ratio	(0.01, 2.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.16	
95% CI of the inverse risk ratio	(0.01, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.06	
95% CI of the absolute risk difference	(-0.82, 58.94)	
p-value	0.1098	
p-value of Breslow-Day Test for Homogeneity [3]	0.1036	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	1 (12.5)
No	7 (58.3)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse risk ratio	(0.04, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.17	
95% CI of the absolute risk difference	(-6.93, 65.27)	
p-value	0.1632	
p-value of Breslow-Day Test for Homogeneity [3]	0.2544	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	2 (25.0)
No	9 (75.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.13, 7.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.21, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-38.74, 38.74)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.3354	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (50.0)	3 (37.5)
No	6 (50.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.10, 3.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.26, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.50	
95% CI of the absolute risk difference	(-31.38, 56.38)	
p-value	0.5820	
p-value of Breslow-Day Test for Homogeneity [3]	0.6451	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (16.7)	1 (12.5)
No	10 (83.3)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	
95% CI of the inverse odds ratio	(0.05, 9.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.08, 6.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	
95% CI of the absolute risk difference	(-26.98, 35.31)	
p-value	0.7982	
p-value of Breslow-Day Test for Homogeneity [3]	0.9082	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (25.0)	4 (50.0)
No	9 (75.0)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.45, 20.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse risk ratio	(0.60, 6.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	
95% CI of the absolute risk difference	(-67.43, 17.43)	
p-value	0.2508	
p-value of Breslow-Day Test for Homogeneity [3]	0.1454	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	2 (25.0)
No	9 (75.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.13, 7.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.21, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-38.74, 38.74)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.6194	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (25.0)	3 (37.5)
No	9 (75.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.26, 12.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.40, 5.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-54.04, 29.04)	
p-value	0.5501	
p-value of Breslow-Day Test for Homogeneity [3]	0.9114	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (16.7)	1 (12.5)
No	10 (83.3)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	
95% CI of the inverse odds ratio	(0.05, 9.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.08, 6.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	
95% CI of the absolute risk difference	(-26.98, 35.31)	
p-value	0.7982	
p-value of Breslow-Day Test for Homogeneity [3]	0.5236	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (25.0)	3 (37.5)
No	9 (75.0)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.26, 12.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.40, 5.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-54.04, 29.04)	
p-value	0.5501	
p-value of Breslow-Day Test for Homogeneity [3]	0.9934	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (25.0)
No	12 (100)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.62	
95% CI of the inverse odds ratio	(0.40, 231.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.22	
95% CI of the inverse risk ratio	(0.39, 133.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.93	
95% CI of the absolute risk difference	(-55.01, 7.14)	
p-value	0.1078	
p-value of Breslow-Day Test for Homogeneity [3]	0.1462	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (25.0)	2 (25.0)
No	9 (75.0)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.13, 7.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.21, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-38.74, 38.74)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8833	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.2
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Gender
(Label Population based on Modified Intent-to-Treat Population)

Gender: Female

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=8)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	0
No	9 (75.0)	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.16	
95% CI of the inverse odds ratio	(0.01, 3.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.01, 3.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.37	
95% CI of the absolute risk difference	(-7.01, 49.75)	
p-value	0.2014	
p-value of Breslow-Day Test for Homogeneity [3]	0.0748	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	7 (58.3)	1 (12.5)
No	5 (41.7)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	
95% CI of the inverse odds ratio	(0.01, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.03, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	45.83	
95% CI of the absolute risk difference	(9.73, 81.93)	
p-value	0.0404	
p-value of Breslow-Day Test for Homogeneity [3]	0.0654	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21

Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	4 (33.3)
No	7 (77.8)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.24, 12.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.35, 6.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	
95% CI of the absolute risk difference	(-49.18, 26.96)	
p-value	0.5770	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (66.7)	6 (50.0)
No	3 (33.3)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.08, 2.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.36, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-25.15, 58.49)	
p-value	0.4450	
p-value of Breslow-Day Test for Homogeneity [3]	0.2933	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	3 (25.0)
No	5 (55.6)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.07, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.17, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.44	
95% CI of the absolute risk difference	(-21.23, 60.12)	
p-value	0.3496	
p-value of Breslow-Day Test for Homogeneity [3]	0.0611	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	5 (41.7)
No	4 (44.4)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	
95% CI of the inverse odds ratio	(0.10, 3.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.31, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.89	
95% CI of the absolute risk difference	(-28.91, 56.69)	
p-value	0.5283	
p-value of Breslow-Day Test for Homogeneity [3]	0.1503	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	3 (25.0)
No	5 (55.6)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.07, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.17, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.44	
95% CI of the absolute risk difference	(-21.23, 60.12)	
p-value	0.3496	
p-value of Breslow-Day Test for Homogeneity [3]	0.8009	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	3 (25.0)
No	4 (44.4)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.04, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse risk ratio	(0.14, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.56	
95% CI of the absolute risk difference	(-10.12, 71.23)	
p-value	0.1536	
p-value of Breslow-Day Test for Homogeneity [3]	0.5285	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	1 (8.3)
No	6 (66.7)	11 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	
95% CI of the inverse odds ratio	(0.02, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	
95% CI of the inverse risk ratio	(0.03, 2.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.00	
95% CI of the absolute risk difference	(-9.54, 59.54)	
p-value	0.1488	
p-value of Breslow-Day Test for Homogeneity [3]	0.2631	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (33.3)
No	5 (55.6)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.11, 3.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.25, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	
95% CI of the absolute risk difference	(-30.90, 53.13)	
p-value	0.6038	
p-value of Breslow-Day Test for Homogeneity [3]	0.9641	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	4 (33.3)
No	5 (55.6)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.11, 3.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.25, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	
95% CI of the absolute risk difference	(-30.90, 53.13)	
p-value	0.6038	
p-value of Breslow-Day Test for Homogeneity [3]	0.0196	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	5 (41.7)
No	4 (44.4)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	
95% CI of the inverse odds ratio	(0.10, 3.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.31, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.89	
95% CI of the absolute risk difference	(-28.91, 56.69)	
p-value	0.5283	
p-value of Breslow-Day Test for Homogeneity [3]	0.2923	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	2 (16.7)
No	6 (66.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.05, 3.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.10, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-20.66, 53.99)	
p-value	0.3749	
p-value of Breslow-Day Test for Homogeneity [3]	0.1620	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (33.3)
No	5 (55.6)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.11, 3.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.25, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	
95% CI of the absolute risk difference	(-30.90, 53.13)	
p-value	0.6038	
p-value of Breslow-Day Test for Homogeneity [3]	0.3506	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	3 (25.0)
No	5 (55.6)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.07, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.17, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.44	
95% CI of the absolute risk difference	(-21.23, 60.12)	
p-value	0.3496	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	5 (41.7)
No	5 (55.6)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse odds ratio	(0.16, 5.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	
95% CI of the inverse risk ratio	(0.35, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.78	
95% CI of the absolute risk difference	(-40.02, 45.58)	
p-value	0.8987	
p-value of Breslow-Day Test for Homogeneity [3]	0.2863	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	3 (25.0)
No	6 (66.7)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.10, 4.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.20, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-31.02, 47.69)	
p-value	0.6757	
p-value of Breslow-Day Test for Homogeneity [3]	0.1091	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	7 (58.3)
No	5 (55.6)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.31, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	
95% CI of the inverse risk ratio	(0.55, 3.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	
95% CI of the absolute risk difference	(-56.69, 28.91)	
p-value	0.5283	
p-value of Breslow-Day Test for Homogeneity [3]	0.5621	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	3 (25.0)
No	8 (88.9)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.23, 31.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse risk ratio	(0.28, 18.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	
95% CI of the absolute risk difference	(-45.85, 18.08)	
p-value	0.4225	
p-value of Breslow-Day Test for Homogeneity [3]	0.5125	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (33.3)
No	5 (55.6)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.11, 3.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.25, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.11	
95% CI of the absolute risk difference	(-30.90, 53.13)	
p-value	0.6038	
p-value of Breslow-Day Test for Homogeneity [3]	0.1713	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=12)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	2 (16.7)
No	6 (66.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.05, 3.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.10, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-20.66, 53.99)	
p-value	0.3749	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	4 (33.3)
No	4 (44.4)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.07, 2.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.22, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.22	
95% CI of the absolute risk difference	(-19.79, 64.24)	
p-value	0.3085	
p-value of Breslow-Day Test for Homogeneity [3]	0.8182	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	8 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	3 (42.9)
No	6 (75.0)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse odds ratio	(0.25, 20.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	
95% CI of the inverse risk ratio	(0.39, 7.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.86	
95% CI of the absolute risk difference	(-65.23, 29.52)	
p-value	0.4642	
p-value of Breslow-Day Test for Homogeneity [3]	0.2933	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (28.6)
No	8 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.73	
95% CI of the inverse odds ratio	(0.31, 193.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.63	
95% CI of the inverse risk ratio	(0.31, 100.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.69	
95% CI of the absolute risk difference	(-61.13, 9.74)	
p-value	0.1654	
p-value of Breslow-Day Test for Homogeneity [3]	0.0611	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (12.5)	3 (42.9)
No	7 (87.5)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.25	
95% CI of the inverse odds ratio	(0.40, 68.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.43	
95% CI of the inverse risk ratio	(0.45, 25.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.36	
95% CI of the absolute risk difference	(-73.59, 12.88)	
p-value	0.1847	
p-value of Breslow-Day Test for Homogeneity [3]	0.1503	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	1 (14.3)
No	5 (62.5)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse odds ratio	(0.02, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	
95% CI of the inverse risk ratio	(0.05, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.21	
95% CI of the absolute risk difference	(-19.18, 65.61)	
p-value	0.3104	
p-value of Breslow-Day Test for Homogeneity [3]	0.8009	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	2 (28.6)
No	5 (62.5)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.08, 5.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	
95% CI of the inverse risk ratio	(0.17, 3.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.93	
95% CI of the absolute risk difference	(-38.46, 56.31)	
p-value	0.7144	
p-value of Breslow-Day Test for Homogeneity [3]	0.5285	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	2 (28.6)
No	6 (75.0)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.12, 11.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse risk ratio	(0.21, 6.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.57	
95% CI of the absolute risk difference	(-48.52, 41.38)	
p-value	0.8760	
p-value of Breslow-Day Test for Homogeneity [3]	0.2631	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	2 (28.6)
No	5 (62.5)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.08, 5.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	
95% CI of the inverse risk ratio	(0.17, 3.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.93	
95% CI of the absolute risk difference	(-38.46, 56.31)	
p-value	0.7144	
p-value of Breslow-Day Test for Homogeneity [3]	0.9641	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	4 (57.1)
No	8 (100)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	21.86	
95% CI of the inverse odds ratio	(0.91, 523.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	10.13	
95% CI of the inverse risk ratio	(0.64, 160.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-50.69	
95% CI of the absolute risk difference	(-88.19, -13.20)	
p-value	0.0220	
p-value of Breslow-Day Test for Homogeneity [3]	0.0196	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	5 (71.4)
No	4 (50.0)	2 (28.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse odds ratio	(0.29, 21.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	
95% CI of the inverse risk ratio	(0.62, 3.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.43	
95% CI of the absolute risk difference	(-69.60, 26.74)	
p-value	0.3980	
p-value of Breslow-Day Test for Homogeneity [3]	0.2923	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (14.3)
No	8 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.92	
95% CI of the inverse odds ratio	(0.14, 112.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.38	
95% CI of the inverse risk ratio	(0.16, 71.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	
95% CI of the absolute risk difference	(-44.11, 17.72)	
p-value	0.3993	
p-value of Breslow-Day Test for Homogeneity [3]	0.1620	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (12.5)	2 (28.6)
No	7 (87.5)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	
95% CI of the inverse odds ratio	(0.20, 40.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse risk ratio	(0.26, 20.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.07	
95% CI of the absolute risk difference	(-56.63, 24.49)	
p-value	0.4376	
p-value of Breslow-Day Test for Homogeneity [3]	0.3506	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	8 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	1 (14.3)
No	8 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.92	
95% CI of the inverse odds ratio	(0.14, 112.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.38	
95% CI of the inverse risk ratio	(0.16, 71.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	
95% CI of the absolute risk difference	(-44.11, 17.72)	
p-value	0.3993	
p-value of Breslow-Day Test for Homogeneity [3]	0.2863	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (28.6)
No	8 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.73	
95% CI of the inverse odds ratio	(0.31, 193.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.63	
95% CI of the inverse risk ratio	(0.31, 100.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.69	
95% CI of the absolute risk difference	(-61.13, 9.74)	
p-value	0.1654	
p-value of Breslow-Day Test for Homogeneity [3]	0.1091	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	4 (57.1)
No	6 (75.0)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.45, 35.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	
95% CI of the inverse risk ratio	(0.59, 8.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-32.14	
95% CI of the absolute risk difference	(-79.52, 15.23)	
p-value	0.2049	
p-value of Breslow-Day Test for Homogeneity [3]	0.5621	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (14.3)
No	8 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.92	
95% CI of the inverse odds ratio	(0.14, 112.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.38	
95% CI of the inverse risk ratio	(0.16, 71.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.19	
95% CI of the absolute risk difference	(-44.11, 17.72)	
p-value	0.3993	
p-value of Breslow-Day Test for Homogeneity [3]	0.5125	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (12.5)	3 (42.9)
No	7 (87.5)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.25	
95% CI of the inverse odds ratio	(0.40, 68.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.43	
95% CI of the inverse risk ratio	(0.45, 25.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.36	
95% CI of the absolute risk difference	(-73.59, 12.88)	
p-value	0.1847	
p-value of Breslow-Day Test for Homogeneity [3]	0.1713	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.3
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Ethnicity
(Label Population based on Modified Intent-to-Treat Population)

Ethnicity: Not Hispanic or Latino

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=7)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	8 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	1 (14.3)
No	5 (62.5)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse odds ratio	(0.02, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	
95% CI of the inverse risk ratio	(0.05, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.21	
95% CI of the absolute risk difference	(-19.18, 65.61)	
p-value	0.3104	
p-value of Breslow-Day Test for Homogeneity [3]	0.8182	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (23.1)
No	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	
95% CI of the inverse odds ratio	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	
95% CI of the inverse risk ratio	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.58	
95% CI of the absolute risk difference	(-42.98, 21.82)	
p-value	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.8903	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	6 (46.2)
No	4 (50.0)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse odds ratio	(0.15, 5.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	
95% CI of the inverse risk ratio	(0.37, 2.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.85	
95% CI of the absolute risk difference	(-40.14, 47.83)	
p-value	0.8639	
p-value of Breslow-Day Test for Homogeneity [3]	0.7856	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	3 (23.1)
No	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse odds ratio	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	
95% CI of the inverse risk ratio	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.92	
95% CI of the absolute risk difference	(-35.82, 39.67)	
p-value	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.6730	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	6 (46.2)
No	5 (62.5)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	
95% CI of the inverse odds ratio	(0.24, 8.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	
95% CI of the inverse risk ratio	(0.42, 3.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.65	
95% CI of the absolute risk difference	(-51.78, 34.47)	
p-value	0.6972	
p-value of Breslow-Day Test for Homogeneity [3]	0.8052	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	1 (7.7)
No	5 (62.5)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse odds ratio	(0.01, 1.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.03, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.81	
95% CI of the absolute risk difference	(-6.73, 66.35)	
p-value	0.0912	
p-value of Breslow-Day Test for Homogeneity [3]	0.1729	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	1 (7.7)
No	4 (50.0)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.01, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	
95% CI of the inverse risk ratio	(0.02, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.31	
95% CI of the absolute risk difference	(4.75, 79.86)	
p-value	0.0271	
p-value of Breslow-Day Test for Homogeneity [3]	0.0323	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	1 (7.7)
No	5 (62.5)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse odds ratio	(0.01, 1.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.03, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	29.81	
95% CI of the absolute risk difference	(-6.73, 66.35)	
p-value	0.0912	
p-value of Breslow-Day Test for Homogeneity [3]	0.1309	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	4 (30.8)
No	4 (50.0)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse odds ratio	(0.07, 2.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	
95% CI of the inverse risk ratio	(0.21, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.23	
95% CI of the absolute risk difference	(-23.55, 62.01)	
p-value	0.3782	
p-value of Breslow-Day Test for Homogeneity [3]	0.5757	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	5 (38.5)
No	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse odds ratio	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	
95% CI of the inverse risk ratio	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.96	
95% CI of the absolute risk difference	(-43.68, 41.76)	
p-value	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.2000	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (75.0)	5 (38.5)
No	2 (25.0)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse odds ratio	(0.03, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	
95% CI of the inverse risk ratio	(0.23, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	36.54	
95% CI of the absolute risk difference	(-3.46, 76.54)	
p-value	0.1035	
p-value of Breslow-Day Test for Homogeneity [3]	0.0123	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	2 (15.4)
No	7 (87.5)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	
95% CI of the inverse odds ratio	(0.10, 16.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	
95% CI of the inverse risk ratio	(0.13, 11.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.88	
95% CI of the absolute risk difference	(-33.05, 27.28)	
p-value	0.8544	
p-value of Breslow-Day Test for Homogeneity [3]	0.7514	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	5 (38.5)
No	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse odds ratio	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	
95% CI of the inverse risk ratio	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.96	
95% CI of the absolute risk difference	(-43.68, 41.76)	
p-value	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.8086	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	3 (23.1)
No	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse odds ratio	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	
95% CI of the inverse risk ratio	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.92	
95% CI of the absolute risk difference	(-35.82, 39.67)	
p-value	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.2854	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	5 (38.5)
No	6 (75.0)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.88	
95% CI of the inverse odds ratio	(0.27, 13.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	
95% CI of the inverse risk ratio	(0.39, 6.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.46	
95% CI of the absolute risk difference	(-53.46, 26.54)	
p-value	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	0.5557	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	3 (23.1)
No	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse odds ratio	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	
95% CI of the inverse risk ratio	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.92	
95% CI of the absolute risk difference	(-35.82, 39.67)	
p-value	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.3805	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	7 (53.8)
No	4 (50.0)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse odds ratio	(0.20, 6.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	
95% CI of the inverse risk ratio	(0.46, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.85	
95% CI of the absolute risk difference	(-47.83, 40.14)	
p-value	0.8639	
p-value of Breslow-Day Test for Homogeneity [3]	0.2223	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	4 (30.8)
No	7 (87.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.11	
95% CI of the inverse odds ratio	(0.28, 34.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.46	
95% CI of the inverse risk ratio	(0.33, 18.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.27	
95% CI of the absolute risk difference	(-52.25, 15.71)	
p-value	0.3398	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	5 (38.5)
No	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse odds ratio	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	
95% CI of the inverse risk ratio	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.96	
95% CI of the absolute risk difference	(-43.68, 41.76)	
p-value	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.7292	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 2

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=13)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	1 (7.7)
No	7 (87.5)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	
95% CI of the inverse odds ratio	(0.03, 10.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	
95% CI of the inverse risk ratio	(0.04, 8.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.81	
95% CI of the absolute risk difference	(-22.30, 31.92)	
p-value	0.7155	
p-value of Breslow-Day Test for Homogeneity [3]	0.9279	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	2 (15.4)
No	5 (62.5)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.04, 2.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	
95% CI of the inverse risk ratio	(0.09, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.12	
95% CI of the absolute risk difference	(-16.74, 60.98)	
p-value	0.2479	
p-value of Breslow-Day Test for Homogeneity [3]	0.5152	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	1 (16.7)
No	8 (88.9)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	
95% CI of the inverse odds ratio	(0.08, 31.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.11, 19.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	
95% CI of the absolute risk difference	(-41.76, 30.65)	
p-value	0.7565	
p-value of Breslow-Day Test for Homogeneity [3]	0.8903	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	3 (50.0)
No	5 (55.6)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.16, 9.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.38, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	
95% CI of the absolute risk difference	(-57.08, 45.97)	
p-value	0.8327	
p-value of Breslow-Day Test for Homogeneity [3]	0.7856	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (33.3)
No	7 (77.8)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.17, 17.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.28, 7.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	
95% CI of the absolute risk difference	(-57.59, 35.37)	
p-value	0.6336	
p-value of Breslow-Day Test for Homogeneity [3]	0.6730	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	2 (33.3)
No	6 (66.7)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.11, 8.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.23, 4.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-48.70, 48.70)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8052	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	3 (50.0)
No	5 (55.6)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.16, 9.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.38, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	
95% CI of the absolute risk difference	(-57.08, 45.97)	
p-value	0.8327	
p-value of Breslow-Day Test for Homogeneity [3]	0.1729	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (66.7)
No	5 (55.6)	2 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse odds ratio	(0.29, 21.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.60, 3.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.22	
95% CI of the absolute risk difference	(-71.99, 27.54)	
p-value	0.3980	
p-value of Breslow-Day Test for Homogeneity [3]	0.0323	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (33.3)
No	7 (77.8)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.17, 17.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.28, 7.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	
95% CI of the absolute risk difference	(-57.59, 35.37)	
p-value	0.6336	
p-value of Breslow-Day Test for Homogeneity [3]	0.1309	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	2 (33.3)
No	6 (66.7)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.11, 8.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.23, 4.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-48.70, 48.70)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.5757	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	3 (50.0)
No	8 (88.9)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.00	
95% CI of the inverse odds ratio	(0.58, 110.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	
95% CI of the inverse risk ratio	(0.60, 33.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-38.89	
95% CI of the absolute risk difference	(-83.86, 6.08)	
p-value	0.0952	
p-value of Breslow-Day Test for Homogeneity [3]	0.2000	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	5 (83.3)
No	6 (66.7)	1 (16.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	10.00	
95% CI of the inverse odds ratio	(0.78, 128.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.93, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-50.00	
95% CI of the absolute risk difference	(-92.87, -7.13)	
p-value	0.0572	
p-value of Breslow-Day Test for Homogeneity [3]	0.0123	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	1 (16.7)
No	7 (77.8)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse odds ratio	(0.05, 10.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.09, 6.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-34.78, 45.89)	
p-value	0.7921	
p-value of Breslow-Day Test for Homogeneity [3]	0.7514	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	1 (16.7)
No	7 (77.8)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse odds ratio	(0.05, 10.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.09, 6.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-34.78, 45.89)	
p-value	0.7921	
p-value of Breslow-Day Test for Homogeneity [3]	0.8086	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	0
No	7 (77.8)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	
95% CI of the inverse odds ratio	(0.01, 5.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	
95% CI of the inverse risk ratio	(0.02, 5.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.86	
95% CI of the absolute risk difference	(-15.07, 50.79)	
p-value	0.3418	
p-value of Breslow-Day Test for Homogeneity [3]	0.2854	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	1 (16.7)
No	7 (77.8)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse odds ratio	(0.05, 10.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.09, 6.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-34.78, 45.89)	
p-value	0.7921	
p-value of Breslow-Day Test for Homogeneity [3]	0.5557	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	2 (33.3)
No	8 (88.9)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.27, 58.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse risk ratio	(0.34, 26.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.22	
95% CI of the absolute risk difference	(-65.17, 20.72)	
p-value	0.2918	
p-value of Breslow-Day Test for Homogeneity [3]	0.3805	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	4 (66.7)
No	7 (77.8)	2 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.00	
95% CI of the inverse odds ratio	(0.69, 70.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse risk ratio	(0.78, 11.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-44.44	
95% CI of the absolute risk difference	(-90.93, 2.04)	
p-value	0.0852	
p-value of Breslow-Day Test for Homogeneity [3]	0.2223	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	9 (100)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	2 (33.3)
No	7 (77.8)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.17, 17.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.28, 7.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.11	
95% CI of the absolute risk difference	(-57.59, 35.37)	
p-value	0.6336	
p-value of Breslow-Day Test for Homogeneity [3]	0.7292	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.4
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Fibrosis Stage at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Fibrosis Stage at Baseline: 3

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=6)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	1 (16.7)
No	7 (77.8)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse odds ratio	(0.05, 10.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.09, 6.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-34.78, 45.89)	
p-value	0.7921	
p-value of Breslow-Day Test for Homogeneity [3]	0.9279	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	3 (50.0)
No	4 (44.4)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.10, 6.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.33, 2.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-45.97, 57.08)	
p-value	0.8327	
p-value of Breslow-Day Test for Homogeneity [3]	0.5152	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; MRI-PDFF = Proton density fat fraction magnetic resonance imaging; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	2 (22.2)
No	9 (90.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.57	
95% CI of the inverse odds ratio	(0.19, 34.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	
95% CI of the inverse risk ratio	(0.24, 20.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.22	
95% CI of the absolute risk difference	(-45.14, 20.69)	
p-value	0.4657	
p-value of Breslow-Day Test for Homogeneity [3]	0.7743	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (60.0)	3 (33.3)
No	4 (40.0)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.05, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.19, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.67	
95% CI of the absolute risk difference	(-16.58, 69.92)	
p-value	0.2451	
p-value of Breslow-Day Test for Homogeneity [3]	0.0841	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	2 (22.2)
No	8 (80.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.13, 10.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.19, 6.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	
95% CI of the absolute risk difference	(-39.00, 34.55)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.9671	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (40.0)	4 (44.4)
No	6 (60.0)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.19, 7.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.39, 3.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.44	
95% CI of the absolute risk difference	(-48.89, 40.01)	
p-value	0.8447	
p-value of Breslow-Day Test for Homogeneity [3]	0.8155	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (40.0)	2 (22.2)
No	6 (60.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	
95% CI of the inverse odds ratio	(0.06, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.13, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.78	
95% CI of the absolute risk difference	(-22.96, 58.52)	
p-value	0.4052	
p-value of Breslow-Day Test for Homogeneity [3]	0.8674	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (40.0)	2 (22.2)
No	6 (60.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	
95% CI of the inverse odds ratio	(0.06, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.13, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.78	
95% CI of the absolute risk difference	(-22.96, 58.52)	
p-value	0.4052	
p-value of Breslow-Day Test for Homogeneity [3]	0.8433	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	0
No	8 (80.0)	9 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	
95% CI of the inverse odds ratio	(0.01, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse risk ratio	(0.01, 4.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.73	
95% CI of the absolute risk difference	(-10.48, 45.94)	
p-value	0.2463	
p-value of Breslow-Day Test for Homogeneity [3]	0.3142	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	2 (22.2)
No	8 (80.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.13, 10.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.19, 6.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	
95% CI of the absolute risk difference	(-39.00, 34.55)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.3413	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	2 (22.2)
No	8 (80.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.13, 10.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.19, 6.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	
95% CI of the absolute risk difference	(-39.00, 34.55)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.4387	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (50.0)	3 (33.3)
No	5 (50.0)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.08, 3.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.22, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-27.02, 60.36)	
p-value	0.4625	
p-value of Breslow-Day Test for Homogeneity [3]	0.3684	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	2 (22.2)
No	8 (80.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.13, 10.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.19, 6.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	
95% CI of the absolute risk difference	(-39.00, 34.55)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.7741	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	4 (44.4)
No	8 (80.0)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.20	
95% CI of the inverse odds ratio	(0.42, 24.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	
95% CI of the inverse risk ratio	(0.53, 9.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.44	
95% CI of the absolute risk difference	(-65.29, 16.40)	
p-value	0.2524	
p-value of Breslow-Day Test for Homogeneity [3]	0.1269	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	2 (22.2)
No	8 (80.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.13, 10.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.19, 6.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	
95% CI of the absolute risk difference	(-39.00, 34.55)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.4144	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	3 (33.3)
No	8 (80.0)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.25, 15.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.36, 7.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.33	
95% CI of the absolute risk difference	(-52.87, 26.20)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.6802	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	3 (33.3)
No	10 (100)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	11.31	
95% CI of the inverse odds ratio	(0.50, 256.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.70	
95% CI of the inverse risk ratio	(0.45, 131.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.45	
95% CI of the absolute risk difference	(-62.48, 1.57)	
p-value	0.0759	
p-value of Breslow-Day Test for Homogeneity [3]	0.0283	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	6 (66.7)
No	8 (80.0)	3 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.00	
95% CI of the inverse odds ratio	(1.00, 63.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	
95% CI of the inverse risk ratio	(0.89, 12.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-46.67	
95% CI of the absolute risk difference	(-86.20, -7.13)	
p-value	0.0397	
p-value of Breslow-Day Test for Homogeneity [3]	0.0976	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (22.2)
No	10 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.00	
95% CI of the inverse odds ratio	(0.29, 167.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.50	
95% CI of the inverse risk ratio	(0.30, 101.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.45	
95% CI of the absolute risk difference	(-49.98, 9.07)	
p-value	0.1810	
p-value of Breslow-Day Test for Homogeneity [3]	0.2681	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	3 (33.3)
No	8 (80.0)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.25, 15.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.36, 7.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.33	
95% CI of the absolute risk difference	(-52.87, 26.20)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.5770	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: <20%

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=9)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	1 (11.1)
No	9 (90.0)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse odds ratio	(0.06, 21.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	
95% CI of the inverse risk ratio	(0.08, 15.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.11	
95% CI of the absolute risk difference	(-28.81, 26.59)	
p-value	0.9372	
p-value of Breslow-Day Test for Homogeneity [3]	0.4807	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (50.0)	2 (22.2)
No	5 (50.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	
95% CI of the inverse odds ratio	(0.04, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.11, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	27.78	
95% CI of the absolute risk difference	(-13.43, 68.99)	
p-value	0.2101	
p-value of Breslow-Day Test for Homogeneity [3]	0.6320	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (14.3)	2 (20.0)
No	6 (85.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.11, 20.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse risk ratio	(0.16, 12.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.71	
95% CI of the absolute risk difference	(-41.58, 30.16)	
p-value	0.7610	
p-value of Breslow-Day Test for Homogeneity [3]	0.7743	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (28.6)	6 (60.0)
No	5 (71.4)	4 (40.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	
95% CI of the inverse odds ratio	(0.47, 29.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	
95% CI of the inverse risk ratio	(0.59, 7.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.43	
95% CI of the absolute risk difference	(-76.62, 13.76)	
p-value	0.2014	
p-value of Breslow-Day Test for Homogeneity [3]	0.0841	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	3 (30.0)
No	5 (71.4)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	
95% CI of the inverse odds ratio	(0.13, 8.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	
95% CI of the inverse risk ratio	(0.23, 4.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.43	
95% CI of the absolute risk difference	(-45.32, 42.47)	
p-value	0.9493	
p-value of Breslow-Day Test for Homogeneity [3]	0.9671	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (28.6)	4 (40.0)
No	5 (71.4)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.21, 13.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse risk ratio	(0.35, 5.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	
95% CI of the absolute risk difference	(-56.62, 33.76)	
p-value	0.6275	
p-value of Breslow-Day Test for Homogeneity [3]	0.8155	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	2 (20.0)
No	4 (57.1)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.04, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	
95% CI of the inverse risk ratio	(0.10, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.86	
95% CI of the absolute risk difference	(-21.40, 67.11)	
p-value	0.3087	
p-value of Breslow-Day Test for Homogeneity [3]	0.8674	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	3 (30.0)
No	3 (42.9)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	
95% CI of the inverse odds ratio	(0.04, 2.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	
95% CI of the inverse risk ratio	(0.17, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	27.14	
95% CI of the absolute risk difference	(-19.23, 73.52)	
p-value	0.2631	
p-value of Breslow-Day Test for Homogeneity [3]	0.8433	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	3 (30.0)
No	4 (57.1)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	
95% CI of the inverse odds ratio	(0.08, 4.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.20, 2.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.86	
95% CI of the absolute risk difference	(-33.52, 59.23)	
p-value	0.5851	
p-value of Breslow-Day Test for Homogeneity [3]	0.3142	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (71.4)	4 (40.0)
No	2 (28.6)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.03, 2.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.23, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.43	
95% CI of the absolute risk difference	(-13.76, 76.62)	
p-value	0.2014	
p-value of Breslow-Day Test for Homogeneity [3]	0.3413	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	6 (60.0)
No	5 (71.4)	4 (40.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	
95% CI of the inverse odds ratio	(0.47, 29.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	
95% CI of the inverse risk ratio	(0.59, 7.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.43	
95% CI of the absolute risk difference	(-76.62, 13.76)	
p-value	0.2014	
p-value of Breslow-Day Test for Homogeneity [3]	0.4387	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	7 (70.0)
No	3 (42.9)	3 (30.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	
95% CI of the inverse odds ratio	(0.23, 13.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	
95% CI of the inverse risk ratio	(0.57, 2.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.86	
95% CI of the absolute risk difference	(-59.23, 33.52)	
p-value	0.5851	
p-value of Breslow-Day Test for Homogeneity [3]	0.3684	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (14.3)	1 (10.0)
No	6 (85.7)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.03, 12.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.05, 9.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.29	
95% CI of the absolute risk difference	(-27.62, 36.19)	
p-value	0.7872	
p-value of Breslow-Day Test for Homogeneity [3]	0.7741	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	2 (20.0)
No	4 (57.1)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.04, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	
95% CI of the inverse risk ratio	(0.10, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.86	
95% CI of the absolute risk difference	(-21.40, 67.11)	
p-value	0.3087	
p-value of Breslow-Day Test for Homogeneity [3]	0.1269	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	1 (10.0)
No	5 (71.4)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse odds ratio	(0.02, 3.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	
95% CI of the inverse risk ratio	(0.04, 3.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	18.57	
95% CI of the absolute risk difference	(-19.71, 56.86)	
p-value	0.3229	
p-value of Breslow-Day Test for Homogeneity [3]	0.4144	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (28.6)	3 (30.0)
No	5 (71.4)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	
95% CI of the inverse odds ratio	(0.13, 8.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	
95% CI of the inverse risk ratio	(0.23, 4.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.43	
95% CI of the absolute risk difference	(-45.32, 42.47)	
p-value	0.9493	
p-value of Breslow-Day Test for Homogeneity [3]	0.6802	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	2 (20.0)
No	4 (57.1)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.04, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	
95% CI of the inverse risk ratio	(0.10, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.86	
95% CI of the absolute risk difference	(-21.40, 67.11)	
p-value	0.3087	
p-value of Breslow-Day Test for Homogeneity [3]	0.0283	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	5 (50.0)
No	3 (42.9)	5 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.11, 5.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	
95% CI of the inverse risk ratio	(0.36, 2.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	
95% CI of the absolute risk difference	(-40.86, 55.15)	
p-value	0.7715	
p-value of Breslow-Day Test for Homogeneity [3]	0.0976	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (14.3)	2 (20.0)
No	6 (85.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.11, 20.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse risk ratio	(0.16, 12.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.71	
95% CI of the absolute risk difference	(-41.58, 30.16)	
p-value	0.7610	
p-value of Breslow-Day Test for Homogeneity [3]	0.2681	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	4 (40.0)
No	4 (57.1)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse odds ratio	(0.13, 6.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	
95% CI of the inverse risk ratio	(0.30, 2.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.86	
95% CI of the absolute risk difference	(-44.74, 50.46)	
p-value	0.9062	
p-value of Breslow-Day Test for Homogeneity [3]	0.5770	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.5
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline MRI-PDFF
(Label Population based on Modified Intent-to-Treat Population)

Baseline MRI-PDFF: >=20%

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=10)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	1 (10.0)
No	5 (71.4)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse odds ratio	(0.02, 3.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	
95% CI of the inverse risk ratio	(0.04, 3.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	18.57	
95% CI of the absolute risk difference	(-19.71, 56.86)	
p-value	0.3229	
p-value of Breslow-Day Test for Homogeneity [3]	0.4807	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	3 (30.0)
No	4 (57.1)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	
95% CI of the inverse odds ratio	(0.08, 4.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.20, 2.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.86	
95% CI of the absolute risk difference	(-33.52, 59.23)	
p-value	0.5851	
p-value of Breslow-Day Test for Homogeneity [3]	0.6320	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NASH = Non-alcoholic steatohepatitis; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	4 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	
95% CI of the inverse odds ratio	(0.08, 76.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	
95% CI of the inverse risk ratio	(0.11, 42.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	
95% CI of the absolute risk difference	(-51.62, 28.76)	
p-value	0.6005	
p-value of Breslow-Day Test for Homogeneity [3]	0.5115	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (50.0)	2 (33.3)
No	2 (50.0)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.04, 6.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.15, 2.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-45.17, 78.50)	
p-value	0.5982	
p-value of Breslow-Day Test for Homogeneity [3]	0.5131	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	4 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	
95% CI of the inverse odds ratio	(0.08, 76.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	
95% CI of the inverse risk ratio	(0.11, 42.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	
95% CI of the absolute risk difference	(-51.62, 28.76)	
p-value	0.6005	
p-value of Breslow-Day Test for Homogeneity [3]	0.4114	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (25.0)	1 (16.7)
No	3 (75.0)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.03, 13.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.06, 7.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-43.53, 60.20)	
p-value	0.7469	
p-value of Breslow-Day Test for Homogeneity [3]	0.5176	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (75.0)	0
No	1 (25.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.03	
95% CI of the inverse odds ratio	(0.00, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	
95% CI of the inverse risk ratio	(0.01, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	62.86	
95% CI of the absolute risk difference	(18.39, 100.00)	
p-value	0.0228	
p-value of Breslow-Day Test for Homogeneity [3]	0.0297	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (75.0)	0
No	1 (25.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.03	
95% CI of the inverse odds ratio	(0.00, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	
95% CI of the inverse risk ratio	(0.01, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	62.86	
95% CI of the absolute risk difference	(18.39, 100.00)	
p-value	0.0228	
p-value of Breslow-Day Test for Homogeneity [3]	0.0280	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (50.0)	0
No	2 (50.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.00, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.86	
95% CI of the absolute risk difference	(-4.94, 90.66)	
p-value	0.0910	
p-value of Breslow-Day Test for Homogeneity [3]	0.0966	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (50.0)	0
No	2 (50.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.00, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.86	
95% CI of the absolute risk difference	(-4.94, 90.66)	
p-value	0.0910	
p-value of Breslow-Day Test for Homogeneity [3]	0.0585	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (33.3)
No	4 (100)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	
95% CI of the inverse odds ratio	(0.18, 136.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.57	
95% CI of the inverse risk ratio	(0.21, 59.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.71	
95% CI of the absolute risk difference	(-69.89, 18.46)	
p-value	0.3105	
p-value of Breslow-Day Test for Homogeneity [3]	0.3538	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (75.0)	2 (33.3)
No	1 (25.0)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	
95% CI of the inverse odds ratio	(0.01, 2.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.13, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	41.67	
95% CI of the absolute risk difference	(-15.11, 98.44)	
p-value	0.1967	
p-value of Breslow-Day Test for Homogeneity [3]	0.1306	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	4 (100)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	2 (33.3)
No	4 (100)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	
95% CI of the inverse odds ratio	(0.18, 136.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.57	
95% CI of the inverse risk ratio	(0.21, 59.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.71	
95% CI of the absolute risk difference	(-69.89, 18.46)	
p-value	0.3105	
p-value of Breslow-Day Test for Homogeneity [3]	0.1769	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	4 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	
95% CI of the inverse odds ratio	(0.08, 76.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	
95% CI of the inverse risk ratio	(0.11, 42.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	
95% CI of the absolute risk difference	(-51.62, 28.76)	
p-value	0.6005	
p-value of Breslow-Day Test for Homogeneity [3]	0.2500	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	2 (33.3)
No	4 (100)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	
95% CI of the inverse odds ratio	(0.18, 136.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.57	
95% CI of the inverse risk ratio	(0.21, 59.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.71	
95% CI of the absolute risk difference	(-69.89, 18.46)	
p-value	0.3105	
p-value of Breslow-Day Test for Homogeneity [3]	0.2340	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	4 (100)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (25.0)	4 (66.7)
No	3 (75.0)	2 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.00	
95% CI of the inverse odds ratio	(0.35, 101.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse risk ratio	(0.45, 15.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-41.67	
95% CI of the absolute risk difference	(-98.44, 15.11)	
p-value	0.1967	
p-value of Breslow-Day Test for Homogeneity [3]	0.4753	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	4 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	
95% CI of the inverse odds ratio	(0.08, 76.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	
95% CI of the inverse risk ratio	(0.11, 42.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	
95% CI of the absolute risk difference	(-51.62, 28.76)	
p-value	0.6005	
p-value of Breslow-Day Test for Homogeneity [3]	0.6442	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	2 (33.3)
No	4 (100)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	
95% CI of the inverse odds ratio	(0.18, 136.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.57	
95% CI of the inverse risk ratio	(0.21, 59.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.71	
95% CI of the absolute risk difference	(-69.89, 18.46)	
p-value	0.3105	
p-value of Breslow-Day Test for Homogeneity [3]	0.2310	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: <5

Parameter Response Statistic/Category	MGL-3196 (N=4)	Placebo (N=6)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	4 (100)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (50.0)	0
No	2 (50.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.00, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.86	
95% CI of the absolute risk difference	(-4.94, 90.66)	
p-value	0.0910	
p-value of Breslow-Day Test for Homogeneity [3]	0.1222	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (15.4)	3 (23.1)
No	11 (84.6)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	
95% CI of the inverse odds ratio	(0.23, 11.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.30, 7.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.69	
95% CI of the absolute risk difference	(-37.85, 22.46)	
p-value	0.6188	
p-value of Breslow-Day Test for Homogeneity [3]	0.5115	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (46.2)	7 (53.8)
No	7 (53.8)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	
95% CI of the inverse odds ratio	(0.29, 6.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.54, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.69	
95% CI of the absolute risk difference	(-46.02, 30.63)	
p-value	0.6949	
p-value of Breslow-Day Test for Homogeneity [3]	0.5131	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (30.8)	4 (30.8)
No	9 (69.2)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.19, 5.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.32, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-35.48, 35.48)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4114	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	7 (53.8)
No	8 (61.5)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	
95% CI of the inverse odds ratio	(0.39, 8.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse risk ratio	(0.60, 3.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-53.25, 22.48)	
p-value	0.4314	
p-value of Breslow-Day Test for Homogeneity [3]	0.5176	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (30.8)	4 (30.8)
No	9 (69.2)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.19, 5.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.32, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-35.48, 35.48)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0297	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	5 (38.5)
No	8 (61.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.21, 4.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.38, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-37.40, 37.40)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0280	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (23.1)	3 (23.1)
No	10 (76.9)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.16, 6.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.25, 4.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-32.39, 32.39)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0966	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	6 (46.2)
No	8 (61.5)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	
95% CI of the inverse odds ratio	(0.29, 6.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse risk ratio	(0.49, 2.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.69	
95% CI of the absolute risk difference	(-45.56, 30.17)	
p-value	0.6914	
p-value of Breslow-Day Test for Homogeneity [3]	0.0585	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (30.8)	6 (46.2)
No	9 (69.2)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.93	
95% CI of the inverse odds ratio	(0.39, 9.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.55, 4.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-52.31, 21.55)	
p-value	0.4201	
p-value of Breslow-Day Test for Homogeneity [3]	0.3538	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (46.2)	8 (61.5)
No	7 (53.8)	5 (38.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	
95% CI of the inverse odds ratio	(0.39, 8.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.64, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-53.25, 22.48)	
p-value	0.4314	
p-value of Breslow-Day Test for Homogeneity [3]	0.1306	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (23.1)	3 (23.1)
No	10 (76.9)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.16, 6.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.25, 4.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-32.39, 32.39)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	4 (30.8)
No	8 (61.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	
95% CI of the inverse odds ratio	(0.14, 3.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse risk ratio	(0.28, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.69	
95% CI of the absolute risk difference	(-28.76, 44.15)	
p-value	0.6802	
p-value of Breslow-Day Test for Homogeneity [3]	0.1769	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (30.8)	2 (15.4)
No	9 (69.2)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	
95% CI of the inverse odds ratio	(0.06, 2.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.11, 2.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.38	
95% CI of the absolute risk difference	(-16.46, 47.23)	
p-value	0.3519	
p-value of Breslow-Day Test for Homogeneity [3]	0.2500	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (30.8)	4 (30.8)
No	9 (69.2)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.19, 5.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.32, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-35.48, 35.48)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.2340	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (23.1)	5 (38.5)
No	10 (76.9)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	
95% CI of the inverse odds ratio	(0.38, 11.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.50, 5.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-50.37, 19.60)	
p-value	0.3954	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	7 (53.8)
No	8 (61.5)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	
95% CI of the inverse odds ratio	(0.39, 8.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	
95% CI of the inverse risk ratio	(0.60, 3.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-53.25, 22.48)	
p-value	0.4314	
p-value of Breslow-Day Test for Homogeneity [3]	0.4753	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (7.7)	3 (23.1)
No	12 (92.3)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.60	
95% CI of the inverse odds ratio	(0.32, 40.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse risk ratio	(0.36, 25.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.38	
95% CI of the absolute risk difference	(-42.48, 11.71)	
p-value	0.2770	
p-value of Breslow-Day Test for Homogeneity [3]	0.6442	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (38.5)	5 (38.5)
No	8 (61.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.21, 4.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.38, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-37.40, 37.40)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.2310	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.6
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Stage of NASH
(Label Population based on Modified Intent-to-Treat Population)

Stage of NASH: >=5

Parameter Response Statistic/Category	MGL-3196 (N=13)	Placebo (N=13)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (23.1)	2 (15.4)
No	10 (76.9)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	
95% CI of the inverse odds ratio	(0.08, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.13, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.69	
95% CI of the absolute risk difference	(-22.46, 37.85)	
p-value	0.6188	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (46.2)	5 (38.5)
No	7 (53.8)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse odds ratio	(0.15, 3.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse risk ratio	(0.34, 2.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.69	
95% CI of the absolute risk difference	(-30.17, 45.56)	
p-value	0.6914	
p-value of Breslow-Day Test for Homogeneity [3]	0.1222	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (9.1)	2 (28.6)
No	10 (90.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.29, 55.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.14	
95% CI of the inverse risk ratio	(0.35, 28.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.48	
95% CI of the absolute risk difference	(-57.01, 18.05)	
p-value	0.2796	
p-value of Breslow-Day Test for Homogeneity [3]	0.4593	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (45.5)	5 (71.4)
No	6 (54.5)	2 (28.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.40, 22.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	
95% CI of the inverse risk ratio	(0.71, 3.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.97	
95% CI of the absolute risk difference	(-70.54, 18.59)	
p-value	0.2796	
p-value of Breslow-Day Test for Homogeneity [3]	0.2119	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (18.2)	3 (42.9)
No	9 (81.8)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.38	
95% CI of the inverse odds ratio	(0.40, 28.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.36	
95% CI of the inverse risk ratio	(0.52, 10.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-24.68	
95% CI of the absolute risk difference	(-67.84, 18.49)	
p-value	0.2545	
p-value of Breslow-Day Test for Homogeneity [3]	0.1720	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (36.4)	5 (71.4)
No	7 (63.6)	2 (28.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.38	
95% CI of the inverse odds ratio	(0.56, 33.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	
95% CI of the inverse risk ratio	(0.79, 4.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-35.06	
95% CI of the absolute risk difference	(-78.97, 8.84)	
p-value	0.1469	
p-value of Breslow-Day Test for Homogeneity [3]	0.2064	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (36.4)	2 (28.6)
No	7 (63.6)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse odds ratio	(0.09, 5.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	
95% CI of the inverse risk ratio	(0.19, 3.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.79	
95% CI of the absolute risk difference	(-36.12, 51.70)	
p-value	0.7324	
p-value of Breslow-Day Test for Homogeneity [3]	0.4115	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (36.4)	3 (42.9)
No	7 (63.6)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	
95% CI of the inverse odds ratio	(0.19, 9.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	
95% CI of the inverse risk ratio	(0.37, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.49	
95% CI of the absolute risk difference	(-52.88, 39.90)	
p-value	0.7829	
p-value of Breslow-Day Test for Homogeneity [3]	0.0842	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (27.3)	0
No	8 (72.7)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.16	
95% CI of the inverse odds ratio	(0.01, 3.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.01, 3.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.92	
95% CI of the absolute risk difference	(-7.79, 53.62)	
p-value	0.2094	
p-value of Breslow-Day Test for Homogeneity [3]	0.2560	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (45.5)	1 (14.3)
No	6 (54.5)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.31	
95% CI of the inverse risk ratio	(0.05, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.17	
95% CI of the absolute risk difference	(-8.05, 70.38)	
p-value	0.1715	
p-value of Breslow-Day Test for Homogeneity [3]	0.2154	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (9.1)	2 (28.6)
No	10 (90.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.29, 55.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.14	
95% CI of the inverse risk ratio	(0.35, 28.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.48	
95% CI of the absolute risk difference	(-57.01, 18.05)	
p-value	0.2796	
p-value of Breslow-Day Test for Homogeneity [3]	0.4012	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (36.4)	3 (42.9)
No	7 (63.6)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	
95% CI of the inverse odds ratio	(0.19, 9.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	
95% CI of the inverse risk ratio	(0.37, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.49	
95% CI of the absolute risk difference	(-52.88, 39.90)	
p-value	0.7829	
p-value of Breslow-Day Test for Homogeneity [3]	0.3231	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (9.1)	2 (28.6)
No	10 (90.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.29, 55.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.14	
95% CI of the inverse risk ratio	(0.35, 28.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.48	
95% CI of the absolute risk difference	(-57.01, 18.05)	
p-value	0.2796	
p-value of Breslow-Day Test for Homogeneity [3]	0.0869	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (18.2)	4 (57.1)
No	9 (81.8)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.00	
95% CI of the inverse odds ratio	(0.70, 51.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.14	
95% CI of the inverse risk ratio	(0.77, 12.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-38.96	
95% CI of the absolute risk difference	(-82.13, 4.21)	
p-value	0.0874	
p-value of Breslow-Day Test for Homogeneity [3]	0.0237	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (18.2)	1 (14.3)
No	9 (81.8)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.05, 10.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	
95% CI of the inverse risk ratio	(0.09, 7.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.90	
95% CI of the absolute risk difference	(-30.62, 38.41)	
p-value	0.8288	
p-value of Breslow-Day Test for Homogeneity [3]	0.7214	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (18.2)	2 (28.6)
No	9 (81.8)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.19, 16.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	
95% CI of the inverse risk ratio	(0.28, 8.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.39	
95% CI of the absolute risk difference	(-50.88, 30.10)	
p-value	0.6052	
p-value of Breslow-Day Test for Homogeneity [3]	0.7060	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (18.2)	2 (28.6)
No	9 (81.8)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.19, 16.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	
95% CI of the inverse risk ratio	(0.28, 8.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.39	
95% CI of the absolute risk difference	(-50.88, 30.10)	
p-value	0.6052	
p-value of Breslow-Day Test for Homogeneity [3]	0.9643	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (27.3)	5 (71.4)
No	8 (72.7)	2 (28.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.67	
95% CI of the inverse odds ratio	(0.81, 54.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.62	
95% CI of the inverse risk ratio	(0.90, 7.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-44.16	
95% CI of the absolute risk difference	(-86.73, -1.58)	
p-value	0.0661	
p-value of Breslow-Day Test for Homogeneity [3]	0.1914	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (14.3)
No	11 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.31	
95% CI of the inverse odds ratio	(0.19, 150.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	
95% CI of the inverse risk ratio	(0.21, 97.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.58	
95% CI of the absolute risk difference	(-43.90, 14.73)	
p-value	0.2869	
p-value of Breslow-Day Test for Homogeneity [3]	0.3714	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (18.2)	1 (14.3)
No	9 (81.8)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.05, 10.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	
95% CI of the inverse risk ratio	(0.09, 7.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.90	
95% CI of the absolute risk difference	(-30.62, 38.41)	
p-value	0.8288	
p-value of Breslow-Day Test for Homogeneity [3]	0.8629	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: Yes

Parameter Response Statistic/Category	MGL-3196 (N=11)	Placebo (N=7)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (18.2)	1 (14.3)
No	9 (81.8)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.05, 10.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	
95% CI of the inverse risk ratio	(0.09, 7.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.90	
95% CI of the absolute risk difference	(-30.62, 38.41)	
p-value	0.8288	
p-value of Breslow-Day Test for Homogeneity [3]	0.8034	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (45.5)	3 (42.9)
No	6 (54.5)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse odds ratio	(0.13, 6.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	
95% CI of the inverse risk ratio	(0.32, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.60	
95% CI of the absolute risk difference	(-44.41, 49.61)	
p-value	0.9139	
p-value of Breslow-Day Test for Homogeneity [3]	0.3081	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (16.7)	2 (16.7)
No	5 (83.3)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.07, 13.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.11, 8.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-36.52, 36.52)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4593	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (50.0)	4 (33.3)
No	3 (50.0)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.07, 3.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.22, 2.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-31.42, 64.75)	
p-value	0.4941	
p-value of Breslow-Day Test for Homogeneity [3]	0.2119	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (33.3)	2 (16.7)
No	4 (66.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.04, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.09, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-26.55, 59.88)	
p-value	0.4227	
p-value of Breslow-Day Test for Homogeneity [3]	0.1720	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (33.3)	3 (25.0)
No	4 (66.7)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.08, 5.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.17, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-36.64, 53.31)	
p-value	0.7098	
p-value of Breslow-Day Test for Homogeneity [3]	0.2064	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (50.0)	2 (16.7)
No	3 (50.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.07, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	
95% CI of the absolute risk difference	(-11.89, 78.56)	
p-value	0.1366	
p-value of Breslow-Day Test for Homogeneity [3]	0.4115	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (66.7)	2 (16.7)
No	2 (33.3)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	
95% CI of the inverse odds ratio	(0.01, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	
95% CI of the inverse risk ratio	(0.06, 1.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	50.00	
95% CI of the absolute risk difference	(6.79, 93.21)	
p-value	0.0339	
p-value of Breslow-Day Test for Homogeneity [3]	0.0842	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (33.3)	3 (25.0)
No	4 (66.7)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.08, 5.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.17, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-36.64, 53.31)	
p-value	0.7098	
p-value of Breslow-Day Test for Homogeneity [3]	0.2560	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (33.3)	5 (41.7)
No	4 (66.7)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	
95% CI of the inverse odds ratio	(0.18, 11.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse risk ratio	(0.34, 4.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-55.25, 38.58)	
p-value	0.7324	
p-value of Breslow-Day Test for Homogeneity [3]	0.2154	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (50.0)	6 (50.0)
No	3 (50.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.14, 7.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.38, 2.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-49.00, 49.00)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4012	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (83.3)	7 (58.3)
No	1 (16.7)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse odds ratio	(0.02, 3.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.39, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.00	
95% CI of the absolute risk difference	(-15.83, 65.83)	
p-value	0.2888	
p-value of Breslow-Day Test for Homogeneity [3]	0.3231	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (33.3)	1 (8.3)
No	4 (66.7)	11 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	
95% CI of the inverse odds ratio	(0.01, 2.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	
95% CI of the inverse risk ratio	(0.03, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.00	
95% CI of the absolute risk difference	(-15.83, 65.83)	
p-value	0.1797	
p-value of Breslow-Day Test for Homogeneity [3]	0.0869	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (50.0)	2 (16.7)
No	3 (50.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.07, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	
95% CI of the absolute risk difference	(-11.89, 78.56)	
p-value	0.1366	
p-value of Breslow-Day Test for Homogeneity [3]	0.0237	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (33.3)	2 (16.7)
No	4 (66.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	
95% CI of the inverse odds ratio	(0.04, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.09, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-26.55, 59.88)	
p-value	0.4227	
p-value of Breslow-Day Test for Homogeneity [3]	0.7214	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (33.3)	4 (33.3)
No	4 (66.7)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.13, 8.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.25, 4.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-46.20, 46.20)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.7060	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (16.7)	3 (25.0)
No	5 (83.3)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.13, 20.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.20, 11.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-46.93, 30.26)	
p-value	0.6885	
p-value of Breslow-Day Test for Homogeneity [3]	0.9643	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (50.0)	6 (50.0)
No	3 (50.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.14, 7.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.38, 2.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-49.00, 49.00)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.1914	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (16.7)	3 (25.0)
No	5 (83.3)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.13, 20.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.20, 11.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-46.93, 30.26)	
p-value	0.6885	
p-value of Breslow-Day Test for Homogeneity [3]	0.3714	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (50.0)	6 (50.0)
No	3 (50.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.14, 7.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.38, 2.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-49.00, 49.00)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8629	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.7
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Type 2 Diabetes
(Label Population based on Modified Intent-to-Treat Population)

Type 2 Diabetes: No

Parameter Response Statistic/Category	MGL-3196 (N=6)	Placebo (N=12)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (16.7)	1 (8.3)
No	5 (83.3)	11 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse odds ratio	(0.02, 8.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.04, 6.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-25.34, 42.00)	
p-value	0.5959	
p-value of Breslow-Day Test for Homogeneity [3]	0.8034	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (50.0)	2 (16.7)
No	3 (50.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.02, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.07, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	
95% CI of the absolute risk difference	(-11.89, 78.56)	
p-value	0.1366	
p-value of Breslow-Day Test for Homogeneity [3]	0.3081	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; ALT = Alanine aminotransferase; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (8.3)	4 (28.6)
No	11 (91.7)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.40	
95% CI of the inverse odds ratio	(0.42, 46.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.43	
95% CI of the inverse risk ratio	(0.44, 26.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.24	
95% CI of the absolute risk difference	(-48.60, 8.13)	
p-value	0.1918	
p-value of Breslow-Day Test for Homogeneity [3]	0.1153	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	9 (64.3)
No	7 (58.3)	5 (35.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.52	
95% CI of the inverse odds ratio	(0.52, 12.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	
95% CI of the inverse risk ratio	(0.71, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.62	
95% CI of the absolute risk difference	(-60.14, 14.90)	
p-value	0.2488	
p-value of Breslow-Day Test for Homogeneity [3]	0.0178	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	5 (35.7)
No	9 (75.0)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.30, 9.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	
95% CI of the inverse risk ratio	(0.43, 4.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	
95% CI of the absolute risk difference	(-45.79, 24.36)	
p-value	0.5551	
p-value of Breslow-Day Test for Homogeneity [3]	0.2301	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (33.3)	8 (57.1)
No	8 (66.7)	6 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.54, 13.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	
95% CI of the inverse risk ratio	(0.68, 4.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.81	
95% CI of the absolute risk difference	(-61.00, 13.38)	
p-value	0.2247	
p-value of Breslow-Day Test for Homogeneity [3]	0.0495	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (33.3)	4 (28.6)
No	8 (66.7)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.15, 4.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.27, 2.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	
95% CI of the absolute risk difference	(-30.89, 40.42)	
p-value	0.7931	
p-value of Breslow-Day Test for Homogeneity [3]	0.0909	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	5 (35.7)
No	7 (58.3)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	
95% CI of the inverse odds ratio	(0.16, 3.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.32, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.95	
95% CI of the absolute risk difference	(-31.57, 43.48)	
p-value	0.7558	
p-value of Breslow-Day Test for Homogeneity [3]	0.0908	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (33.3)	3 (21.4)
No	8 (66.7)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	
95% CI of the inverse odds ratio	(0.09, 3.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	
95% CI of the inverse risk ratio	(0.18, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	
95% CI of the absolute risk difference	(-22.35, 46.16)	
p-value	0.4951	
p-value of Breslow-Day Test for Homogeneity [3]	0.4443	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (50.0)	6 (42.9)
No	6 (50.0)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.16, 3.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.37, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	
95% CI of the absolute risk difference	(-31.23, 45.51)	
p-value	0.7157	
p-value of Breslow-Day Test for Homogeneity [3]	0.3775	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	7 (50.0)
No	9 (75.0)	7 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.56, 16.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse risk ratio	(0.66, 6.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-25.00	
95% CI of the absolute risk difference	(-60.86, 10.86)	
p-value	0.1915	
p-value of Breslow-Day Test for Homogeneity [3]	0.5359	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (50.0)	9 (64.3)
No	6 (50.0)	5 (35.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.37, 8.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.65, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.29	
95% CI of the absolute risk difference	(-52.10, 23.53)	
p-value	0.4623	
p-value of Breslow-Day Test for Homogeneity [3]	0.1376	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (16.7)	3 (21.4)
No	10 (83.3)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	
95% CI of the inverse odds ratio	(0.19, 9.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.26, 6.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	
95% CI of the absolute risk difference	(-34.87, 25.35)	
p-value	0.7587	
p-value of Breslow-Day Test for Homogeneity [3]	0.2775	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (33.3)	6 (42.9)
No	8 (66.7)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.30, 7.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.47, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-46.72, 27.67)	
p-value	0.6188	
p-value of Breslow-Day Test for Homogeneity [3]	0.2449	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	3 (21.4)
No	9 (75.0)	11 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	
95% CI of the inverse odds ratio	(0.13, 5.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.21, 3.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	
95% CI of the absolute risk difference	(-29.02, 36.16)	
p-value	0.8294	
p-value of Breslow-Day Test for Homogeneity [3]	0.3678	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (25.0)	6 (42.9)
No	9 (75.0)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse odds ratio	(0.42, 12.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	
95% CI of the inverse risk ratio	(0.54, 5.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-17.86	
95% CI of the absolute risk difference	(-53.53, 17.81)	
p-value	0.3400	
p-value of Breslow-Day Test for Homogeneity [3]	0.1781	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (25.0)	5 (35.7)
No	9 (75.0)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.30, 9.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	
95% CI of the inverse risk ratio	(0.43, 4.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	
95% CI of the absolute risk difference	(-45.79, 24.36)	
p-value	0.5551	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (41.7)	9 (64.3)
No	7 (58.3)	5 (35.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.52	
95% CI of the inverse odds ratio	(0.52, 12.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	
95% CI of the inverse risk ratio	(0.71, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.62	
95% CI of the absolute risk difference	(-60.14, 14.90)	
p-value	0.2488	
p-value of Breslow-Day Test for Homogeneity [3]	0.9727	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (8.3)	4 (28.6)
No	11 (91.7)	10 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.40	
95% CI of the inverse odds ratio	(0.42, 46.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.43	
95% CI of the inverse risk ratio	(0.44, 26.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.24	
95% CI of the absolute risk difference	(-48.60, 8.13)	
p-value	0.1918	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (33.3)	6 (42.9)
No	8 (66.7)	8 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.30, 7.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.47, 3.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-46.72, 27.67)	
p-value	0.6188	
p-value of Breslow-Day Test for Homogeneity [3]	0.8194	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=12)	Placebo (N=14)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (16.7)	2 (14.3)
No	10 (83.3)	12 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse odds ratio	(0.10, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.14, 5.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	
95% CI of the absolute risk difference	(-25.56, 30.32)	
p-value	0.8668	
p-value of Breslow-Day Test for Homogeneity [3]	0.3732	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (50.0)	5 (35.7)
No	6 (50.0)	9 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse odds ratio	(0.12, 2.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	
95% CI of the inverse risk ratio	(0.29, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	
95% CI of the absolute risk difference	(-23.53, 52.10)	
p-value	0.4623	
p-value of Breslow-Day Test for Homogeneity [3]	0.2466	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.1153	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	0
No	2 (40.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.06	
95% CI of the inverse odds ratio	(0.00, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	50.00	
95% CI of the absolute risk difference	(4.78, 95.22)	
p-value	0.0662	
p-value of Breslow-Day Test for Homogeneity [3]	0.0178	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.2301	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (40.0)	0
No	3 (60.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	
95% CI of the inverse odds ratio	(0.00, 3.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse risk ratio	(0.01, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	
95% CI of the absolute risk difference	(-11.89, 78.56)	
p-value	0.1824	
p-value of Breslow-Day Test for Homogeneity [3]	0.0495	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (60.0)	0
No	2 (40.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.06	
95% CI of the inverse odds ratio	(0.00, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	50.00	
95% CI of the absolute risk difference	(4.78, 95.22)	
p-value	0.0662	
p-value of Breslow-Day Test for Homogeneity [3]	0.0909	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	0
No	2 (40.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.06	
95% CI of the inverse odds ratio	(0.00, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse risk ratio	(0.01, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	50.00	
95% CI of the absolute risk difference	(4.78, 95.22)	
p-value	0.0662	
p-value of Breslow-Day Test for Homogeneity [3]	0.0908	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.4443	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.3775	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	1 (20.0)
No	4 (80.0)	4 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.05, 22.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.08, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-49.58, 49.58)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.5359	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (60.0)	1 (20.0)
No	2 (40.0)	4 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	
95% CI of the inverse odds ratio	(0.01, 2.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.05, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.00	
95% CI of the absolute risk difference	(-15.44, 95.44)	
p-value	0.1967	
p-value of Breslow-Day Test for Homogeneity [3]	0.1376	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.2775	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.2449	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.3678	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.1781	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	5 (100)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	2 (40.0)
No	4 (80.0)	3 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.16, 45.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse risk ratio	(0.26, 15.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.00	
95% CI of the absolute risk difference	(-75.44, 35.44)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.9727	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	5 (100)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (20.0)	1 (20.0)
No	4 (80.0)	4 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.05, 22.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.08, 11.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-49.58, 49.58)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8194	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.8
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline ALT by Gender

(Label Population based on Modified Intent-to-Treat Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

Parameter Response Statistic/Category	MGL-3196 (N=5)	Placebo (N=5)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (20.0)	0
No	4 (80.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	
95% CI of the inverse odds ratio	(0.01, 8.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.02, 6.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-24.44, 57.77)	
p-value	0.4386	
p-value of Breslow-Day Test for Homogeneity [3]	0.3732	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (40.0)	0
No	3 (60.0)	5 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	
95% CI of the inverse odds ratio	(0.00, 3.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse risk ratio	(0.01, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	
95% CI of the absolute risk difference	(-11.89, 78.56)	
p-value	0.1824	
p-value of Breslow-Day Test for Homogeneity [3]	0.2466	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; LDL = low density lipoprotein; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	2 (28.6)
No	5 (71.4)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.10, 10.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.19, 5.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-47.33, 47.33)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.2466	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (85.7)	3 (42.9)
No	1 (14.3)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	
95% CI of the inverse odds ratio	(0.01, 1.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.20, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	42.86	
95% CI of the absolute risk difference	(-2.04, 87.76)	
p-value	0.0943	
p-value of Breslow-Day Test for Homogeneity [3]	0.0266	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	1 (14.3)
No	4 (57.1)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse odds ratio	(0.02, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.04, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-16.33, 73.47)	
p-value	0.2367	
p-value of Breslow-Day Test for Homogeneity [3]	0.0800	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	2 (28.6)
No	3 (42.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.03, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.13, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-21.07, 78.21)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.0770	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (57.1)	2 (28.6)
No	3 (42.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.03, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.13, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-21.07, 78.21)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.7735	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	2 (28.6)
No	3 (42.9)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.03, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.13, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-21.07, 78.21)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.7270	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	1 (14.3)
No	4 (57.1)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse odds ratio	(0.02, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.04, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-16.33, 73.47)	
p-value	0.2367	
p-value of Breslow-Day Test for Homogeneity [3]	0.4534	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (57.1)	3 (42.9)
No	3 (42.9)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse odds ratio	(0.07, 4.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse risk ratio	(0.26, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	
95% CI of the absolute risk difference	(-37.56, 66.13)	
p-value	0.5930	
p-value of Breslow-Day Test for Homogeneity [3]	0.8225	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	3 (42.9)
No	4 (57.1)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.12, 8.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.30, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-51.84, 51.84)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.2415	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (71.4)	3 (42.9)
No	2 (28.6)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.03, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.23, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-21.07, 78.21)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.1681	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	1 (14.3)
No	5 (71.4)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.03, 6.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.06, 4.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	
95% CI of the absolute risk difference	(-28.05, 56.62)	
p-value	0.5148	
p-value of Breslow-Day Test for Homogeneity [3]	0.4332	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	3 (42.9)
No	4 (57.1)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.12, 8.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.30, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-51.84, 51.84)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8474	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (42.9)	1 (14.3)
No	4 (57.1)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse odds ratio	(0.02, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse risk ratio	(0.04, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-16.33, 73.47)	
p-value	0.2367	
p-value of Breslow-Day Test for Homogeneity [3]	0.2489	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	3 (42.9)
No	4 (57.1)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.12, 8.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.30, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-51.84, 51.84)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.5022	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (14.3)	1 (14.3)
No	6 (85.7)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.05, 19.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.08, 13.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-36.66, 36.66)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.7029	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	4 (57.1)
No	4 (57.1)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse odds ratio	(0.21, 14.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.46, 3.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.29	
95% CI of the absolute risk difference	(-66.13, 37.56)	
p-value	0.5930	
p-value of Breslow-Day Test for Homogeneity [3]	0.6656	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (14.3)
No	7 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.46	
95% CI of the inverse odds ratio	(0.12, 100.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse risk ratio	(0.14, 63.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-44.33, 19.33)	
p-value	0.4497	
p-value of Breslow-Day Test for Homogeneity [3]	0.5553	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (42.9)	2 (28.6)
No	4 (57.1)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	
95% CI of the inverse odds ratio	(0.06, 4.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.16, 2.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	
95% CI of the absolute risk difference	(-35.35, 63.92)	
p-value	0.5770	
p-value of Breslow-Day Test for Homogeneity [3]	0.2582	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: <100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=7)	Placebo (N=7)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (28.6)	1 (14.3)
No	5 (71.4)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.03, 6.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse risk ratio	(0.06, 4.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.29	
95% CI of the absolute risk difference	(-28.05, 56.62)	
p-value	0.5148	
p-value of Breslow-Day Test for Homogeneity [3]	0.7371	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (71.4)	3 (42.9)
No	2 (28.6)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.03, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.23, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	28.57	
95% CI of the absolute risk difference	(-21.07, 78.21)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.7735	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (16.7)
No	10 (100)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	
95% CI of the inverse odds ratio	(0.21, 117.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.23	
95% CI of the inverse risk ratio	(0.23, 79.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.69	
95% CI of the absolute risk difference	(-39.39, 10.02)	
p-value	0.2784	
p-value of Breslow-Day Test for Homogeneity [3]	0.2466	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	6 (50.0)
No	8 (80.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.59, 27.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.64, 9.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.00	
95% CI of the absolute risk difference	(-67.62, 7.62)	
p-value	0.1453	
p-value of Breslow-Day Test for Homogeneity [3]	0.0266	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	4 (33.3)
No	9 (90.0)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	
95% CI of the inverse odds ratio	(0.41, 49.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	
95% CI of the inverse risk ratio	(0.44, 25.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.33	
95% CI of the absolute risk difference	(-55.85, 9.18)	
p-value	0.1935	
p-value of Breslow-Day Test for Homogeneity [3]	0.0800	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	6 (50.0)
No	8 (80.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse odds ratio	(0.59, 27.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.64, 9.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-30.00	
95% CI of the absolute risk difference	(-67.62, 7.62)	
p-value	0.1453	
p-value of Breslow-Day Test for Homogeneity [3]	0.0770	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (30.0)	2 (16.7)
No	7 (70.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	
95% CI of the inverse odds ratio	(0.06, 3.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.11, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-22.04, 48.71)	
p-value	0.4574	
p-value of Breslow-Day Test for Homogeneity [3]	0.7735	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (40.0)	3 (25.0)
No	6 (60.0)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.08, 3.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse risk ratio	(0.18, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.00	
95% CI of the absolute risk difference	(-24.02, 54.02)	
p-value	0.4520	
p-value of Breslow-Day Test for Homogeneity [3]	0.7270	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	2 (16.7)
No	8 (80.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.09, 7.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse risk ratio	(0.14, 4.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.33	
95% CI of the absolute risk difference	(-29.21, 35.88)	
p-value	0.8400	
p-value of Breslow-Day Test for Homogeneity [3]	0.4534	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (30.0)	3 (25.0)
No	7 (70.0)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	
95% CI of the inverse odds ratio	(0.12, 5.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse risk ratio	(0.21, 3.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	
95% CI of the absolute risk difference	(-32.51, 42.51)	
p-value	0.7932	
p-value of Breslow-Day Test for Homogeneity [3]	0.8225	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	5 (41.7)
No	9 (90.0)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.43	
95% CI of the inverse odds ratio	(0.60, 68.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.17	
95% CI of the inverse risk ratio	(0.58, 30.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.67	
95% CI of the absolute risk difference	(-65.19, 1.86)	
p-value	0.0968	
p-value of Breslow-Day Test for Homogeneity [3]	0.2415	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (40.0)	7 (58.3)
No	6 (60.0)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	
95% CI of the inverse odds ratio	(0.38, 11.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	
95% CI of the inverse risk ratio	(0.59, 3.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.33	
95% CI of the absolute risk difference	(-59.56, 22.90)	
p-value	0.3918	
p-value of Breslow-Day Test for Homogeneity [3]	0.1681	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	2 (16.7)
No	9 (90.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.14, 23.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.18, 15.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.67	
95% CI of the absolute risk difference	(-34.78, 21.45)	
p-value	0.6500	
p-value of Breslow-Day Test for Homogeneity [3]	0.4332	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	3 (25.0)
No	8 (80.0)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse odds ratio	(0.18, 10.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse risk ratio	(0.26, 6.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.00	
95% CI of the absolute risk difference	(-39.85, 29.85)	
p-value	0.7805	
p-value of Breslow-Day Test for Homogeneity [3]	0.8474	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	2 (16.7)
No	9 (90.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse odds ratio	(0.14, 23.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.18, 15.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.67	
95% CI of the absolute risk difference	(-34.78, 21.45)	
p-value	0.6500	
p-value of Breslow-Day Test for Homogeneity [3]	0.2489	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (10.0)	3 (25.0)
No	9 (90.0)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.26, 34.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.31, 20.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.00	
95% CI of the absolute risk difference	(-45.76, 15.76)	
p-value	0.3637	
p-value of Breslow-Day Test for Homogeneity [3]	0.5022	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (20.0)	4 (33.3)
No	8 (80.0)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.28, 14.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse risk ratio	(0.38, 7.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.33	
95% CI of the absolute risk difference	(-49.75, 23.08)	
p-value	0.4844	
p-value of Breslow-Day Test for Homogeneity [3]	0.7029	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (30.0)	7 (58.3)
No	7 (70.0)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	
95% CI of the inverse odds ratio	(0.55, 19.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.94	
95% CI of the inverse risk ratio	(0.67, 5.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-28.33	
95% CI of the absolute risk difference	(-68.14, 11.48)	
p-value	0.1839	
p-value of Breslow-Day Test for Homogeneity [3]	0.6656	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	3 (25.0)
No	9 (90.0)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.26, 34.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.31, 20.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.00	
95% CI of the absolute risk difference	(-45.76, 15.76)	
p-value	0.3637	
p-value of Breslow-Day Test for Homogeneity [3]	0.5553	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (20.0)	5 (41.7)
No	8 (80.0)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	
95% CI of the inverse odds ratio	(0.42, 19.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	
95% CI of the inverse risk ratio	(0.51, 8.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.67	
95% CI of the absolute risk difference	(-58.99, 15.65)	
p-value	0.2773	
p-value of Breslow-Day Test for Homogeneity [3]	0.2582	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.9
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by LDL at Baseline
(Label Population based on Modified Intent-to-Treat Population)

LDL at Baseline: ≥ 100 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=10)	Placebo (N=12)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (10.0)	1 (8.3)
No	9 (90.0)	11 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	
95% CI of the inverse odds ratio	(0.04, 15.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse risk ratio	(0.06, 11.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.67	
95% CI of the absolute risk difference	(-22.63, 25.96)	
p-value	0.8923	
p-value of Breslow-Day Test for Homogeneity [3]	0.7371	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (30.0)	2 (16.7)
No	7 (70.0)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	
95% CI of the inverse odds ratio	(0.06, 3.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.11, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-22.04, 48.71)	
p-value	0.4574	
p-value of Breslow-Day Test for Homogeneity [3]	0.7735	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	3 (23.1)
No	7 (77.8)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	
95% CI of the inverse odds ratio	(0.14, 8.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse risk ratio	(0.22, 5.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	
95% CI of the absolute risk difference	(-36.38, 34.67)	
p-value	0.9625	
p-value of Breslow-Day Test for Homogeneity [3]	0.2952	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	5 (38.5)
No	4 (44.4)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.09, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	
95% CI of the inverse risk ratio	(0.28, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.09	
95% CI of the absolute risk difference	(-24.78, 58.97)	
p-value	0.4285	
p-value of Breslow-Day Test for Homogeneity [3]	0.1809	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	3 (23.1)
No	7 (77.8)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	
95% CI of the inverse odds ratio	(0.14, 8.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse risk ratio	(0.22, 5.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	
95% CI of the absolute risk difference	(-36.38, 34.67)	
p-value	0.9625	
p-value of Breslow-Day Test for Homogeneity [3]	0.8212	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	4 (30.8)
No	7 (77.8)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	
95% CI of the inverse odds ratio	(0.22, 11.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	
95% CI of the inverse risk ratio	(0.32, 6.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.55	
95% CI of the absolute risk difference	(-45.52, 28.43)	
p-value	0.6581	
p-value of Breslow-Day Test for Homogeneity [3]	0.8670	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (55.6)	4 (30.8)
No	4 (44.4)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	
95% CI of the inverse odds ratio	(0.06, 2.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	
95% CI of the inverse risk ratio	(0.20, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	24.79	
95% CI of the absolute risk difference	(-16.24, 65.82)	
p-value	0.2450	
p-value of Breslow-Day Test for Homogeneity [3]	0.4239	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	4 (30.8)
No	4 (44.4)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	
95% CI of the inverse odds ratio	(0.06, 2.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	
95% CI of the inverse risk ratio	(0.20, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	24.79	
95% CI of the absolute risk difference	(-16.24, 65.82)	
p-value	0.2450	
p-value of Breslow-Day Test for Homogeneity [3]	0.9677	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (55.6)	2 (15.4)
No	4 (44.4)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	
95% CI of the inverse odds ratio	(0.02, 1.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	
95% CI of the inverse risk ratio	(0.07, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	40.17	
95% CI of the absolute risk difference	(2.24, 78.10)	
p-value	0.0467	
p-value of Breslow-Day Test for Homogeneity [3]	0.0357	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (66.7)	3 (23.1)
No	3 (33.3)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	
95% CI of the inverse odds ratio	(0.02, 1.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	
95% CI of the inverse risk ratio	(0.12, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	43.59	
95% CI of the absolute risk difference	(5.21, 81.97)	
p-value	0.0409	
p-value of Breslow-Day Test for Homogeneity [3]	0.0131	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: <=150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	5 (38.5)
No	6 (66.7)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.21, 7.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	
95% CI of the inverse risk ratio	(0.36, 3.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.13	
95% CI of the absolute risk difference	(-45.72, 35.47)	
p-value	0.8058	
p-value of Breslow-Day Test for Homogeneity [3]	0.2803	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	7 (53.8)
No	4 (44.4)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	
95% CI of the inverse odds ratio	(0.17, 5.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	
95% CI of the inverse risk ratio	(0.45, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.71	
95% CI of the absolute risk difference	(-40.58, 44.00)	
p-value	0.9369	
p-value of Breslow-Day Test for Homogeneity [3]	0.9604	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	2 (15.4)
No	8 (88.9)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	
95% CI of the inverse odds ratio	(0.11, 18.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	
95% CI of the inverse risk ratio	(0.15, 13.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.27	
95% CI of the absolute risk difference	(-32.67, 24.12)	
p-value	0.7740	
p-value of Breslow-Day Test for Homogeneity [3]	0.6383	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	5 (38.5)
No	7 (77.8)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	
95% CI of the inverse odds ratio	(0.32, 15.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	
95% CI of the inverse risk ratio	(0.43, 7.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.24	
95% CI of the absolute risk difference	(-54.15, 21.67)	
p-value	0.4214	
p-value of Breslow-Day Test for Homogeneity [3]	0.2429	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (15.4)
No	7 (77.8)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	
95% CI of the inverse odds ratio	(0.07, 5.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	
95% CI of the inverse risk ratio	(0.12, 4.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.84	
95% CI of the absolute risk difference	(-26.66, 40.34)	
p-value	0.6827	
p-value of Breslow-Day Test for Homogeneity [3]	0.9733	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	4 (30.8)
No	7 (77.8)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	
95% CI of the inverse odds ratio	(0.22, 11.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	
95% CI of the inverse risk ratio	(0.32, 6.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.55	
95% CI of the absolute risk difference	(-45.52, 28.43)	
p-value	0.6581	
p-value of Breslow-Day Test for Homogeneity [3]	0.9813	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	3 (23.1)
No	7 (77.8)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	
95% CI of the inverse odds ratio	(0.14, 8.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	
95% CI of the inverse risk ratio	(0.22, 5.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	
95% CI of the absolute risk difference	(-36.38, 34.67)	
p-value	0.9625	
p-value of Breslow-Day Test for Homogeneity [3]	0.4807	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	8 (61.5)
No	6 (66.7)	5 (38.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.20	
95% CI of the inverse odds ratio	(0.54, 18.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	
95% CI of the inverse risk ratio	(0.67, 5.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-28.21	
95% CI of the absolute risk difference	(-68.80, 12.39)	
p-value	0.1933	
p-value of Breslow-Day Test for Homogeneity [3]	0.6462	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (15.4)
No	9 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.13	
95% CI of the inverse odds ratio	(0.18, 96.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.57	
95% CI of the inverse risk ratio	(0.19, 66.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.86	
95% CI of the absolute risk difference	(-37.04, 11.33)	
p-value	0.3478	
p-value of Breslow-Day Test for Homogeneity [3]	0.5034	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	5 (38.5)
No	7 (77.8)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	
95% CI of the inverse odds ratio	(0.32, 15.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	
95% CI of the inverse risk ratio	(0.43, 7.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.24	
95% CI of the absolute risk difference	(-54.15, 21.67)	
p-value	0.4214	
p-value of Breslow-Day Test for Homogeneity [3]	0.5185	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: ≤150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=13)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	1 (7.7)
No	6 (66.7)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	
95% CI of the inverse odds ratio	(0.01, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	
95% CI of the inverse risk ratio	(0.03, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.64	
95% CI of the absolute risk difference	(-8.39, 59.68)	
p-value	0.1252	
p-value of Breslow-Day Test for Homogeneity [3]	0.0618	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (66.7)	3 (23.1)
No	3 (33.3)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	
95% CI of the inverse odds ratio	(0.02, 1.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	
95% CI of the inverse risk ratio	(0.12, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	43.59	
95% CI of the absolute risk difference	(5.21, 81.97)	
p-value	0.0409	
p-value of Breslow-Day Test for Homogeneity [3]	0.1241	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	8 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	
95% CI of the inverse odds ratio	(0.16, 135.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	
95% CI of the inverse risk ratio	(0.18, 80.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	
95% CI of the absolute risk difference	(-49.75, 18.01)	
p-value	0.3409	
p-value of Breslow-Day Test for Homogeneity [3]	0.2952	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	4 (66.7)
No	5 (62.5)	2 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	
95% CI of the inverse odds ratio	(0.36, 30.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.62, 5.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.17	
95% CI of the absolute risk difference	(-79.65, 21.31)	
p-value	0.2801	
p-value of Breslow-Day Test for Homogeneity [3]	0.1809	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	2 (33.3)
No	6 (75.0)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.15, 15.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.26, 6.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-56.53, 39.87)	
p-value	0.7327	
p-value of Breslow-Day Test for Homogeneity [3]	0.8212	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	4 (66.7)
No	4 (50.0)	2 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.22, 17.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.55, 3.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.67	
95% CI of the absolute risk difference	(-67.88, 34.55)	
p-value	0.5329	
p-value of Breslow-Day Test for Homogeneity [3]	0.8670	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	0
No	6 (75.0)	6 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	
95% CI of the inverse odds ratio	(0.01, 5.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.26	
95% CI of the inverse risk ratio	(0.01, 4.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.63	
95% CI of the absolute risk difference	(-14.30, 55.57)	
p-value	0.2942	
p-value of Breslow-Day Test for Homogeneity [3]	0.4239	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	1 (16.7)
No	5 (62.5)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.03, 4.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.06, 3.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.83	
95% CI of the absolute risk difference	(-24.05, 65.72)	
p-value	0.3932	
p-value of Breslow-Day Test for Homogeneity [3]	0.9677	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	8 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	
95% CI of the inverse odds ratio	(0.16, 135.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	
95% CI of the inverse risk ratio	(0.18, 80.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	
95% CI of the absolute risk difference	(-49.75, 18.01)	
p-value	0.3409	
p-value of Breslow-Day Test for Homogeneity [3]	0.0357	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (12.5)	3 (50.0)
No	7 (87.5)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.00	
95% CI of the inverse odds ratio	(0.50, 97.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse risk ratio	(0.54, 29.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-37.50	
95% CI of the absolute risk difference	(-83.61, 8.61)	
p-value	0.1243	
p-value of Breslow-Day Test for Homogeneity [3]	0.0131	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (50.0)
No	7 (87.5)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.00	
95% CI of the inverse odds ratio	(0.50, 97.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.00	
95% CI of the inverse risk ratio	(0.54, 29.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-37.50	
95% CI of the absolute risk difference	(-83.61, 8.61)	
p-value	0.1243	
p-value of Breslow-Day Test for Homogeneity [3]	0.2803	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	3 (50.0)
No	4 (50.0)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.12, 8.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.35, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-52.93, 52.93)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.9604	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	1 (16.7)
No	6 (75.0)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.04, 8.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.08, 5.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-33.97, 50.64)	
p-value	0.7069	
p-value of Breslow-Day Test for Homogeneity [3]	0.6383	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	1 (16.7)
No	5 (62.5)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.03, 4.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.06, 3.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.83	
95% CI of the absolute risk difference	(-24.05, 65.72)	
p-value	0.3932	
p-value of Breslow-Day Test for Homogeneity [3]	0.2429	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	1 (16.7)
No	6 (75.0)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.04, 8.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.08, 5.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-33.97, 50.64)	
p-value	0.7069	
p-value of Breslow-Day Test for Homogeneity [3]	0.9733	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	2 (33.3)
No	6 (75.0)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.15, 15.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.26, 6.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-56.53, 39.87)	
p-value	0.7327	
p-value of Breslow-Day Test for Homogeneity [3]	0.9813	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	2 (33.3)
No	7 (87.5)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse odds ratio	(0.24, 51.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse risk ratio	(0.31, 23.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	
95% CI of the absolute risk difference	(-64.97, 23.30)	
p-value	0.3472	
p-value of Breslow-Day Test for Homogeneity [3]	0.4807	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	3 (50.0)
No	5 (62.5)	3 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	
95% CI of the inverse odds ratio	(0.19, 14.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.40, 4.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.50	
95% CI of the absolute risk difference	(-64.71, 39.71)	
p-value	0.6400	
p-value of Breslow-Day Test for Homogeneity [3]	0.6462	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	2 (33.3)
No	7 (87.5)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse odds ratio	(0.24, 51.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse risk ratio	(0.31, 23.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	
95% CI of the absolute risk difference	(-64.97, 23.30)	
p-value	0.3472	
p-value of Breslow-Day Test for Homogeneity [3]	0.5034	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	2 (33.3)
No	5 (62.5)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse odds ratio	(0.09, 7.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse risk ratio	(0.21, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	
95% CI of the absolute risk difference	(-46.31, 54.65)	
p-value	0.8721	
p-value of Breslow-Day Test for Homogeneity [3]	0.5185	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.10
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Triglycerides at Baseline
(Label Population based on Modified Intent-to-Treat Population)

Triglycerides at Baseline: >150 mg/dL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=6)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (16.7)
No	8 (100)	5 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	
95% CI of the inverse odds ratio	(0.16, 135.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.86	
95% CI of the inverse risk ratio	(0.18, 80.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.87	
95% CI of the absolute risk difference	(-49.75, 18.01)	
p-value	0.3409	
p-value of Breslow-Day Test for Homogeneity [3]	0.0618	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	2 (33.3)
No	6 (75.0)	4 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.15, 15.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse risk ratio	(0.26, 6.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	
95% CI of the absolute risk difference	(-56.53, 39.87)	
p-value	0.7327	
p-value of Breslow-Day Test for Homogeneity [3]	0.1241	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; TIMP = Tissue Inhibitor of Metalloproteinases; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (28.6)
No	3 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	
95% CI of the inverse odds ratio	(0.12, 87.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.15, 40.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	
95% CI of the absolute risk difference	(-64.38, 26.88)	
p-value	0.4795	
p-value of Breslow-Day Test for Homogeneity [3]	0.3739	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	3 (42.9)
No	2 (66.7)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.09, 25.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.21, 7.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-74.25, 55.20)	
p-value	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.8049	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (33.3)	2 (28.6)
No	2 (66.7)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.04, 14.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.12, 6.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	
95% CI of the absolute risk difference	(-58.21, 67.73)	
p-value	0.8803	
p-value of Breslow-Day Test for Homogeneity [3]	0.8086	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	3 (42.9)
No	2 (66.7)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.09, 25.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.21, 7.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-74.25, 55.20)	
p-value	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.9257	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (66.7)	1 (14.3)
No	1 (33.3)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.00, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.03, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	52.38	
95% CI of the absolute risk difference	(-6.93, 100.00)	
p-value	0.0976	
p-value of Breslow-Day Test for Homogeneity [3]	0.2744	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (66.7)	1 (14.3)
No	1 (33.3)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.08	
95% CI of the inverse odds ratio	(0.00, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	
95% CI of the inverse risk ratio	(0.03, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	52.38	
95% CI of the absolute risk difference	(-6.93, 100.00)	
p-value	0.0976	
p-value of Breslow-Day Test for Homogeneity [3]	0.2414	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	3 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	1 (14.3)
No	3 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	
95% CI of the inverse odds ratio	(0.05, 51.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.08, 29.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	
95% CI of the absolute risk difference	(-48.46, 35.96)	
p-value	0.7842	
p-value of Breslow-Day Test for Homogeneity [3]	0.4367	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	3 (42.9)
No	3 (100)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	
95% CI of the inverse odds ratio	(0.21, 144.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse risk ratio	(0.23, 52.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	
95% CI of the absolute risk difference	(-78.50, 16.00)	
p-value	0.2790	
p-value of Breslow-Day Test for Homogeneity [3]	0.3149	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	0	3 (42.9)
No	3 (100)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	
95% CI of the inverse odds ratio	(0.21, 144.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse risk ratio	(0.23, 52.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-31.25	
95% CI of the absolute risk difference	(-78.50, 16.00)	
p-value	0.2790	
p-value of Breslow-Day Test for Homogeneity [3]	0.1702	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (33.3)	1 (14.3)
No	2 (66.7)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.01, 8.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	
95% CI of the inverse risk ratio	(0.04, 4.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.05	
95% CI of the absolute risk difference	(-40.26, 78.36)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.5083	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	4 (57.1)
No	2 (66.7)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.16, 45.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	
95% CI of the inverse risk ratio	(0.31, 9.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.81	
95% CI of the absolute risk difference	(-88.54, 40.92)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.3288	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (33.3)	2 (28.6)
No	2 (66.7)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.04, 14.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse risk ratio	(0.12, 6.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	
95% CI of the absolute risk difference	(-58.21, 67.73)	
p-value	0.8803	
p-value of Breslow-Day Test for Homogeneity [3]	0.6478	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	3 (42.9)
No	2 (66.7)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.09, 25.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.21, 7.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-74.25, 55.20)	
p-value	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.9051	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (14.3)
No	3 (100)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	
95% CI of the inverse odds ratio	(0.05, 51.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse risk ratio	(0.08, 29.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.25	
95% CI of the absolute risk difference	(-48.46, 35.96)	
p-value	0.7842	
p-value of Breslow-Day Test for Homogeneity [3]	0.6094	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	4 (57.1)
No	2 (66.7)	3 (42.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.16, 45.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	
95% CI of the inverse risk ratio	(0.31, 9.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-23.81	
95% CI of the absolute risk difference	(-88.54, 40.92)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.9727	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (28.6)
No	3 (100)	5 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	
95% CI of the inverse odds ratio	(0.12, 87.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	
95% CI of the inverse risk ratio	(0.15, 40.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.75	
95% CI of the absolute risk difference	(-64.38, 26.88)	
p-value	0.4795	
p-value of Breslow-Day Test for Homogeneity [3]	0.5184	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	3 (42.9)
No	2 (66.7)	4 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	
95% CI of the inverse odds ratio	(0.09, 25.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse risk ratio	(0.21, 7.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-74.25, 55.20)	
p-value	0.7782	
p-value of Breslow-Day Test for Homogeneity [3]	0.9133	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: <229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=3)	Placebo (N=7)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	0
No	3 (100)	7 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse odds ratio	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	
95% CI of the inverse risk ratio	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	
95% CI of the absolute risk difference	NE	
p-value	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (33.3)	1 (14.3)
No	2 (66.7)	6 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.01, 8.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	
95% CI of the inverse risk ratio	(0.04, 4.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.05	
95% CI of the absolute risk difference	(-40.26, 78.36)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.8237	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (14.3)	2 (16.7)
No	12 (85.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.14, 10.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.19, 7.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	
95% CI of the absolute risk difference	(-30.32, 25.56)	
p-value	0.8668	
p-value of Breslow-Day Test for Homogeneity [3]	0.3739	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	7 (50.0)	6 (50.0)
No	7 (50.0)	6 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse odds ratio	(0.21, 4.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	
95% CI of the inverse risk ratio	(0.46, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	
95% CI of the absolute risk difference	(-38.55, 38.55)	
p-value	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8049	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (21.4)	3 (25.0)
No	11 (78.6)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	
95% CI of the inverse odds ratio	(0.20, 7.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.29, 4.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.57	
95% CI of the absolute risk difference	(-36.16, 29.02)	
p-value	0.8294	
p-value of Breslow-Day Test for Homogeneity [3]	0.8086	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (35.7)	5 (41.7)
No	9 (64.3)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	
95% CI of the inverse odds ratio	(0.26, 6.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.44, 3.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.95	
95% CI of the absolute risk difference	(-43.48, 31.57)	
p-value	0.7558	
p-value of Breslow-Day Test for Homogeneity [3]	0.9257	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (35.7)	3 (25.0)
No	9 (64.3)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.11, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.21, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.71	
95% CI of the absolute risk difference	(-24.36, 45.79)	
p-value	0.5551	
p-value of Breslow-Day Test for Homogeneity [3]	0.2744	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (42.9)	4 (33.3)
No	8 (57.1)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.13, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	
95% CI of the inverse risk ratio	(0.29, 2.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.52	
95% CI of the absolute risk difference	(-27.67, 46.72)	
p-value	0.6188	
p-value of Breslow-Day Test for Homogeneity [3]	0.2414	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (35.7)	3 (25.0)
No	9 (64.3)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse odds ratio	(0.11, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	
95% CI of the inverse risk ratio	(0.21, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.71	
95% CI of the absolute risk difference	(-24.36, 45.79)	
p-value	0.5551	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	7 (50.0)	5 (41.7)
No	7 (50.0)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	
95% CI of the inverse odds ratio	(0.15, 3.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse risk ratio	(0.36, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.33	
95% CI of the absolute risk difference	(-29.93, 46.60)	
p-value	0.6709	
p-value of Breslow-Day Test for Homogeneity [3]	0.4367	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (28.6)	5 (41.7)
No	10 (71.4)	7 (58.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	
95% CI of the inverse odds ratio	(0.35, 9.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	
95% CI of the inverse risk ratio	(0.50, 4.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.10	
95% CI of the absolute risk difference	(-49.67, 23.48)	
p-value	0.4841	
p-value of Breslow-Day Test for Homogeneity [3]	0.3149	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	9 (64.3)	7 (58.3)
No	5 (35.7)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	
95% CI of the inverse odds ratio	(0.16, 3.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	
95% CI of the inverse risk ratio	(0.49, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.95	
95% CI of the absolute risk difference	(-31.57, 43.48)	
p-value	0.7558	
p-value of Breslow-Day Test for Homogeneity [3]	0.1702	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (14.3)	2 (16.7)
No	12 (85.7)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.14, 10.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.19, 7.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	
95% CI of the absolute risk difference	(-30.32, 25.56)	
p-value	0.8668	
p-value of Breslow-Day Test for Homogeneity [3]	0.5083	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (28.6)	2 (16.7)
No	10 (71.4)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.07, 3.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	
95% CI of the inverse risk ratio	(0.13, 2.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.90	
95% CI of the absolute risk difference	(-19.79, 43.60)	
p-value	0.4726	
p-value of Breslow-Day Test for Homogeneity [3]	0.3288	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (21.4)	1 (8.3)
No	11 (78.6)	11 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.03, 3.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	
95% CI of the inverse risk ratio	(0.05, 3.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.10	
95% CI of the absolute risk difference	(-13.49, 39.68)	
p-value	0.3562	
p-value of Breslow-Day Test for Homogeneity [3]	0.6478	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (21.4)	3 (25.0)
No	11 (78.6)	9 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	
95% CI of the inverse odds ratio	(0.20, 7.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.29, 4.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.57	
95% CI of the absolute risk difference	(-36.16, 29.02)	
p-value	0.8294	
p-value of Breslow-Day Test for Homogeneity [3]	0.9051	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (21.4)	4 (33.3)
No	11 (78.6)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.83	
95% CI of the inverse odds ratio	(0.32, 10.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	
95% CI of the inverse risk ratio	(0.43, 5.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	
95% CI of the absolute risk difference	(-46.16, 22.35)	
p-value	0.4951	
p-value of Breslow-Day Test for Homogeneity [3]	0.6094	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (35.7)	7 (58.3)
No	9 (64.3)	5 (41.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.52	
95% CI of the inverse odds ratio	(0.52, 12.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	
95% CI of the inverse risk ratio	(0.70, 3.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.62	
95% CI of the absolute risk difference	(-60.14, 14.90)	
p-value	0.2488	
p-value of Breslow-Day Test for Homogeneity [3]	0.9727	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (7.1)	2 (16.7)
No	13 (92.9)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	
95% CI of the inverse odds ratio	(0.21, 32.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	
95% CI of the inverse risk ratio	(0.24, 22.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	
95% CI of the absolute risk difference	(-34.56, 15.51)	
p-value	0.4486	
p-value of Breslow-Day Test for Homogeneity [3]	0.5184	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (28.6)	4 (33.3)
No	10 (71.4)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.24, 6.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse risk ratio	(0.37, 3.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	
95% CI of the absolute risk difference	(-40.42, 30.89)	
p-value	0.7931	
p-value of Breslow-Day Test for Homogeneity [3]	0.9133	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.11
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline TIMP
(Label Population based on Modified Intent-to-Treat Population)

Baseline TIMP: >=229 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=14)	Placebo (N=12)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (21.4)	2 (16.7)
No	11 (78.6)	10 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse odds ratio	(0.10, 5.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	
95% CI of the inverse risk ratio	(0.15, 3.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	
95% CI of the absolute risk difference	(-25.35, 34.87)	
p-value	0.7587	
p-value of Breslow-Day Test for Homogeneity [3]	NE	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	7 (50.0)	4 (33.3)
No	7 (50.0)	8 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.10, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse risk ratio	(0.26, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	
95% CI of the absolute risk difference	(-20.71, 54.05)	
p-value	0.3912	
p-value of Breslow-Day Test for Homogeneity [3]	0.8237	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; HA = Hyaluronic Acid; NE = Not Estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	3 (33.3)
No	8 (100)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.15	
95% CI of the inverse odds ratio	(0.40, 210.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.30	
95% CI of the inverse risk ratio	(0.37, 106.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.44	
95% CI of the absolute risk difference	(-62.58, 3.69)	
p-value	0.1160	
p-value of Breslow-Day Test for Homogeneity [3]	0.0618	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	4 (44.4)
No	5 (62.5)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse odds ratio	(0.19, 9.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	
95% CI of the inverse risk ratio	(0.37, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.94	
95% CI of the absolute risk difference	(-53.63, 39.74)	
p-value	0.7715	
p-value of Breslow-Day Test for Homogeneity [3]	0.7058	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (33.3)
No	7 (87.5)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse odds ratio	(0.28, 43.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse risk ratio	(0.34, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	
95% CI of the absolute risk difference	(-59.22, 17.56)	
p-value	0.3121	
p-value of Breslow-Day Test for Homogeneity [3]	0.2321	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	4 (44.4)
No	6 (75.0)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	
95% CI of the inverse odds ratio	(0.30, 19.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.44, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	
95% CI of the absolute risk difference	(-63.65, 24.76)	
p-value	0.4024	
p-value of Breslow-Day Test for Homogeneity [3]	0.4508	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (50.0)	2 (22.2)
No	4 (50.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	
95% CI of the inverse odds ratio	(0.04, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.11, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	27.78	
95% CI of the absolute risk difference	(-16.25, 71.80)	
p-value	0.2316	
p-value of Breslow-Day Test for Homogeneity [3]	0.7098	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	2 (22.2)
No	4 (50.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	
95% CI of the inverse odds ratio	(0.04, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	
95% CI of the inverse risk ratio	(0.11, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	27.78	
95% CI of the absolute risk difference	(-16.25, 71.80)	
p-value	0.2316	
p-value of Breslow-Day Test for Homogeneity [3]	0.6617	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	2 (22.2)
No	6 (75.0)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse odds ratio	(0.09, 8.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse risk ratio	(0.16, 4.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.78	
95% CI of the absolute risk difference	(-37.70, 43.25)	
p-value	0.8928	
p-value of Breslow-Day Test for Homogeneity [3]	0.4245	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	3 (33.3)
No	5 (62.5)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse odds ratio	(0.11, 6.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse risk ratio	(0.25, 3.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.17	
95% CI of the absolute risk difference	(-41.37, 49.71)	
p-value	0.8576	
p-value of Breslow-Day Test for Homogeneity [3]	0.7521	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	5 (55.6)
No	8 (100)	4 (44.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	20.78	
95% CI of the inverse odds ratio	(0.92, 466.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.90	
95% CI of the inverse risk ratio	(0.63, 155.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-49.44	
95% CI of the absolute risk difference	(-83.72, -15.17)	
p-value	0.0206	
p-value of Breslow-Day Test for Homogeneity [3]	0.0168	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	6 (66.7)
No	5 (62.5)	3 (33.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	
95% CI of the inverse odds ratio	(0.45, 24.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.65, 4.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.17	
95% CI of the absolute risk difference	(-74.71, 16.37)	
p-value	0.2291	
p-value of Breslow-Day Test for Homogeneity [3]	0.0944	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	2 (22.2)
No	7 (87.5)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.15, 27.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.20, 16.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.72	
95% CI of the absolute risk difference	(-45.26, 25.82)	
p-value	0.5997	
p-value of Breslow-Day Test for Homogeneity [3]	0.3761	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	4 (44.4)
No	6 (75.0)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	
95% CI of the inverse odds ratio	(0.30, 19.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.44, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	
95% CI of the absolute risk difference	(-63.65, 24.76)	
p-value	0.4024	
p-value of Breslow-Day Test for Homogeneity [3]	0.2901	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	1 (11.1)
No	7 (87.5)	8 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	
95% CI of the inverse odds ratio	(0.05, 16.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	
95% CI of the inverse risk ratio	(0.07, 12.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.39	
95% CI of the absolute risk difference	(-29.38, 32.16)	
p-value	0.9293	
p-value of Breslow-Day Test for Homogeneity [3]	0.7606	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (12.5)	2 (22.2)
No	7 (87.5)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.15, 27.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.20, 16.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.72	
95% CI of the absolute risk difference	(-45.26, 25.82)	
p-value	0.5997	
p-value of Breslow-Day Test for Homogeneity [3]	0.8049	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (33.3)
No	7 (87.5)	6 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse odds ratio	(0.28, 43.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse risk ratio	(0.34, 20.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.83	
95% CI of the absolute risk difference	(-59.22, 17.56)	
p-value	0.3121	
p-value of Breslow-Day Test for Homogeneity [3]	0.4110	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	5 (55.6)
No	5 (62.5)	4 (44.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	
95% CI of the inverse odds ratio	(0.30, 14.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	
95% CI of the inverse risk ratio	(0.51, 4.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-18.06	
95% CI of the absolute risk difference	(-64.74, 28.63)	
p-value	0.4566	
p-value of Breslow-Day Test for Homogeneity [3]	0.7913	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (22.2)
No	8 (100)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.67	
95% CI of the inverse odds ratio	(0.23, 137.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.50	
95% CI of the inverse risk ratio	(0.25, 81.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	
95% CI of the absolute risk difference	(-50.17, 11.28)	
p-value	0.2458	
p-value of Breslow-Day Test for Homogeneity [3]	0.3538	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (25.0)	4 (44.4)
No	6 (75.0)	5 (55.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	
95% CI of the inverse odds ratio	(0.30, 19.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.44, 7.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-19.44	
95% CI of the absolute risk difference	(-63.65, 24.76)	
p-value	0.4024	
p-value of Breslow-Day Test for Homogeneity [3]	0.4749	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: <50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=9)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	2 (22.2)
No	7 (87.5)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.15, 27.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.78	
95% CI of the inverse risk ratio	(0.20, 16.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.72	
95% CI of the absolute risk difference	(-45.26, 25.82)	
p-value	0.5997	
p-value of Breslow-Day Test for Homogeneity [3]	0.1174	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	2 (22.2)
No	5 (62.5)	7 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	
95% CI of the inverse odds ratio	(0.06, 3.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	
95% CI of the inverse risk ratio	(0.13, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.28	
95% CI of the absolute risk difference	(-27.89, 58.44)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.8207	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	1 (10.0)
No	7 (77.8)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	
95% CI of the inverse odds ratio	(0.03, 5.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse risk ratio	(0.05, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.22	
95% CI of the absolute risk difference	(-20.69, 45.14)	
p-value	0.4657	
p-value of Breslow-Day Test for Homogeneity [3]	0.0618	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	5 (50.0)
No	4 (44.4)	5 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.13, 4.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.38, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-39.32, 50.44)	
p-value	0.8087	
p-value of Breslow-Day Test for Homogeneity [3]	0.7058	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	2 (20.0)
No	6 (66.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.06, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.13, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-26.20, 52.87)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.2321	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (40.0)
No	5 (55.6)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse odds ratio	(0.13, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.31, 2.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.44	
95% CI of the absolute risk difference	(-40.01, 48.89)	
p-value	0.8447	
p-value of Breslow-Day Test for Homogeneity [3]	0.4508	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	2 (20.0)
No	6 (66.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.06, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.13, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-26.20, 52.87)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.7098	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	3 (30.0)
No	5 (55.6)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	
95% CI of the inverse odds ratio	(0.08, 3.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	
95% CI of the inverse risk ratio	(0.20, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.44	
95% CI of the absolute risk difference	(-28.69, 57.58)	
p-value	0.5146	
p-value of Breslow-Day Test for Homogeneity [3]	0.6617	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	1 (10.0)
No	6 (66.7)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse odds ratio	(0.02, 2.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse risk ratio	(0.04, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.33	
95% CI of the absolute risk difference	(-12.64, 59.31)	
p-value	0.2129	
p-value of Breslow-Day Test for Homogeneity [3]	0.4245	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	3 (30.0)
No	5 (55.6)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	
95% CI of the inverse odds ratio	(0.08, 3.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	
95% CI of the inverse risk ratio	(0.20, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.44	
95% CI of the absolute risk difference	(-28.69, 57.58)	
p-value	0.5146	
p-value of Breslow-Day Test for Homogeneity [3]	0.7521	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	4 (44.4)	3 (30.0)
No	5 (55.6)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	
95% CI of the inverse odds ratio	(0.08, 3.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	
95% CI of the inverse risk ratio	(0.20, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.44	
95% CI of the absolute risk difference	(-28.69, 57.58)	
p-value	0.5146	
p-value of Breslow-Day Test for Homogeneity [3]	0.0168	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (66.7)	4 (40.0)
No	3 (33.3)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	
95% CI of the inverse odds ratio	(0.05, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.25, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.67	
95% CI of the absolute risk difference	(-16.58, 69.92)	
p-value	0.2451	
p-value of Breslow-Day Test for Homogeneity [3]	0.0944	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	1 (10.0)
No	7 (77.8)	9 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	
95% CI of the inverse odds ratio	(0.03, 5.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	
95% CI of the inverse risk ratio	(0.05, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.22	
95% CI of the absolute risk difference	(-20.69, 45.14)	
p-value	0.4657	
p-value of Breslow-Day Test for Homogeneity [3]	0.3761	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	2 (20.0)
No	6 (66.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.06, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.13, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-26.20, 52.87)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.2901	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (33.3)	2 (20.0)
No	6 (66.7)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.06, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	
95% CI of the inverse risk ratio	(0.13, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	
95% CI of the absolute risk difference	(-26.20, 52.87)	
p-value	0.5099	
p-value of Breslow-Day Test for Homogeneity [3]	0.7606	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	4 (40.0)
No	6 (66.7)	6 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	
95% CI of the inverse odds ratio	(0.20, 8.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse risk ratio	(0.36, 3.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.67	
95% CI of the absolute risk difference	(-49.92, 36.58)	
p-value	0.7636	
p-value of Breslow-Day Test for Homogeneity [3]	0.8049	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (20.0)
No	7 (77.8)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	
95% CI of the inverse odds ratio	(0.10, 7.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.16, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.22	
95% CI of the absolute risk difference	(-34.55, 39.00)	
p-value	0.9056	
p-value of Breslow-Day Test for Homogeneity [3]	0.4110	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	6 (60.0)
No	6 (66.7)	4 (40.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	
95% CI of the inverse odds ratio	(0.46, 19.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse risk ratio	(0.63, 5.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-26.67	
95% CI of the absolute risk difference	(-69.92, 16.58)	
p-value	0.2451	
p-value of Breslow-Day Test for Homogeneity [3]	0.7913	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	2 (20.0)
No	8 (88.9)	8 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	
95% CI of the inverse odds ratio	(0.15, 26.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	
95% CI of the inverse risk ratio	(0.19, 16.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.89	
95% CI of the absolute risk difference	(-41.08, 23.30)	
p-value	0.5957	
p-value of Breslow-Day Test for Homogeneity [3]	0.3538	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (33.3)	3 (30.0)
No	6 (66.7)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	
95% CI of the inverse odds ratio	(0.12, 5.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.24, 3.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.33	
95% CI of the absolute risk difference	(-38.56, 45.23)	
p-value	0.8760	
p-value of Breslow-Day Test for Homogeneity [3]	0.4749	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.12
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline HA
(Label Population based on Modified Intent-to-Treat Population)

Baseline HA: >=50 ug/L

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=10)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	0
No	7 (77.8)	10 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	
95% CI of the inverse odds ratio	(0.01, 3.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	
95% CI of the inverse risk ratio	(0.01, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	20.45	
95% CI of the absolute risk difference	(-9.07, 49.98)	
p-value	0.1810	
p-value of Breslow-Day Test for Homogeneity [3]	0.1174	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	3 (30.0)
No	4 (44.4)	7 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.34	
95% CI of the inverse odds ratio	(0.05, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	
95% CI of the inverse risk ratio	(0.18, 1.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.56	
95% CI of the absolute risk difference	(-17.58, 68.69)	
p-value	0.2599	
p-value of Breslow-Day Test for Homogeneity [3]	0.8207	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QoL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Abbreviations: HR-QoL SF-36 = health-related quality of life short form 36; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; PRO-C3 = N-terminal type III collagen pro-peptide; NE = Not Estimable.

[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of $\geq$ MCID from baseline.

[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from Chi-square test. For this unadjusted analysis, only Baseline and Week 36 data will be considered. Patients with no Week 36 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the stratification factor.

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (27.3)
No	7 (87.5)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.63	
95% CI of the inverse odds ratio	(0.22, 31.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	
95% CI of the inverse risk ratio	(0.27, 17.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.77	
95% CI of the absolute risk difference	(-49.67, 20.13)	
p-value	0.4355	
p-value of Breslow-Day Test for Homogeneity [3]	0.6705	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	5 (45.5)
No	4 (50.0)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	
95% CI of the inverse odds ratio	(0.13, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	
95% CI of the inverse risk ratio	(0.35, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.55	
95% CI of the absolute risk difference	(-40.91, 50.00)	
p-value	0.8447	
p-value of Breslow-Day Test for Homogeneity [3]	0.7634	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	3 (27.3)
No	5 (62.5)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.09, 4.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse risk ratio	(0.20, 2.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.23	
95% CI of the absolute risk difference	(-32.41, 52.87)	
p-value	0.6358	
p-value of Breslow-Day Test for Homogeneity [3]	0.3776	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	4 (36.4)
No	4 (50.0)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	
95% CI of the inverse odds ratio	(0.09, 3.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse risk ratio	(0.26, 2.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.64	
95% CI of the absolute risk difference	(-31.18, 58.45)	
p-value	0.5522	
p-value of Breslow-Day Test for Homogeneity [3]	0.1991	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	5 (62.5)	2 (18.2)
No	3 (37.5)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	
95% CI of the inverse odds ratio	(0.02, 1.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	
95% CI of the inverse risk ratio	(0.07, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	44.32	
95% CI of the absolute risk difference	(3.76, 84.88)	
p-value	0.0480	
p-value of Breslow-Day Test for Homogeneity [3]	0.1577	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	6 (75.0)	2 (18.2)
No	2 (25.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.07	
95% CI of the inverse odds ratio	(0.01, 0.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	
95% CI of the inverse risk ratio	(0.07, 0.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	56.82	
95% CI of the absolute risk difference	(19.14, 94.50)	
p-value	0.0133	
p-value of Breslow-Day Test for Homogeneity [3]	0.0268	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	2 (18.2)
No	5 (62.5)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	
95% CI of the inverse odds ratio	(0.05, 3.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	
95% CI of the inverse risk ratio	(0.10, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.32	
95% CI of the absolute risk difference	(-21.24, 59.88)	
p-value	0.3451	
p-value of Breslow-Day Test for Homogeneity [3]	0.8607	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	4 (36.4)
No	5 (62.5)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	
95% CI of the inverse odds ratio	(0.14, 6.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	
95% CI of the inverse risk ratio	(0.30, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.14	
95% CI of the absolute risk difference	(-42.84, 45.11)	
p-value	0.9596	
p-value of Breslow-Day Test for Homogeneity [3]	0.5620	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	6 (54.5)
No	6 (75.0)	5 (45.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.60	
95% CI of the inverse odds ratio	(0.49, 26.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	
95% CI of the inverse risk ratio	(0.59, 8.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.55	
95% CI of the absolute risk difference	(-71.57, 12.48)	
p-value	0.1978	
p-value of Breslow-Day Test for Homogeneity [3]	0.4589	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	6 (54.5)
No	4 (50.0)	5 (45.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.19, 7.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	
95% CI of the inverse risk ratio	(0.45, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.55	
95% CI of the absolute risk difference	(-50.00, 40.91)	
p-value	0.8447	
p-value of Breslow-Day Test for Homogeneity [3]	0.7634	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	2 (18.2)
No	6 (75.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	
95% CI of the inverse odds ratio	(0.07, 6.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse risk ratio	(0.13, 4.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.82	
95% CI of the absolute risk difference	(-30.86, 44.50)	
p-value	0.7189	
p-value of Breslow-Day Test for Homogeneity [3]	0.7742	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	5 (45.5)
No	5 (62.5)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	
95% CI of the inverse odds ratio	(0.22, 8.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	
95% CI of the inverse risk ratio	(0.40, 3.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.95	
95% CI of the absolute risk difference	(-52.58, 36.67)	
p-value	0.7288	
p-value of Breslow-Day Test for Homogeneity [3]	0.5298	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	2 (18.2)
No	5 (62.5)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	
95% CI of the inverse odds ratio	(0.05, 3.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	
95% CI of the inverse risk ratio	(0.10, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.32	
95% CI of the absolute risk difference	(-21.24, 59.88)	
p-value	0.3451	
p-value of Breslow-Day Test for Homogeneity [3]	0.5372	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	4 (36.4)
No	5 (62.5)	7 (63.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	
95% CI of the inverse odds ratio	(0.14, 6.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	
95% CI of the inverse risk ratio	(0.30, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.14	
95% CI of the absolute risk difference	(-42.84, 45.11)	
p-value	0.9596	
p-value of Breslow-Day Test for Homogeneity [3]	0.5291	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	3 (37.5)	3 (27.3)
No	5 (62.5)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	
95% CI of the inverse odds ratio	(0.09, 4.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	
95% CI of the inverse risk ratio	(0.20, 2.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.23	
95% CI of the absolute risk difference	(-32.41, 52.87)	
p-value	0.6358	
p-value of Breslow-Day Test for Homogeneity [3]	0.1091	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	6 (54.5)
No	4 (50.0)	5 (45.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	
95% CI of the inverse odds ratio	(0.19, 7.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	
95% CI of the inverse risk ratio	(0.45, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.55	
95% CI of the absolute risk difference	(-50.00, 40.91)	
p-value	0.8447	
p-value of Breslow-Day Test for Homogeneity [3]	0.2650	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (12.5)	3 (27.3)
No	7 (87.5)	8 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.63	
95% CI of the inverse odds ratio	(0.22, 31.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	
95% CI of the inverse risk ratio	(0.27, 17.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.77	
95% CI of the absolute risk difference	(-49.67, 20.13)	
p-value	0.4355	
p-value of Breslow-Day Test for Homogeneity [3]	0.5156	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	3 (37.5)	5 (45.5)
No	5 (62.5)	6 (54.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	
95% CI of the inverse odds ratio	(0.22, 8.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	
95% CI of the inverse risk ratio	(0.40, 3.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.95	
95% CI of the absolute risk difference	(-52.58, 36.67)	
p-value	0.7288	
p-value of Breslow-Day Test for Homogeneity [3]	0.9066	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: <17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=8)	Placebo (N=11)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (25.0)	1 (9.1)
No	6 (75.0)	10 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	
95% CI of the inverse odds ratio	(0.02, 4.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	
95% CI of the inverse risk ratio	(0.04, 3.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.91	
95% CI of the absolute risk difference	(-18.57, 50.39)	
p-value	0.3478	
p-value of Breslow-Day Test for Homogeneity [3]	0.4998	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (50.0)	2 (18.2)
No	4 (50.0)	9 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	
95% CI of the inverse odds ratio	(0.03, 1.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	
95% CI of the inverse risk ratio	(0.09, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	31.82	
95% CI of the absolute risk difference	(-9.65, 73.29)	
p-value	0.1407	
p-value of Breslow-Day Test for Homogeneity [3]	0.3983	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 12 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Physical Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	1 (12.5)
No	8 (88.9)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.06, 21.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.08, 15.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	
95% CI of the absolute risk difference	(-32.16, 29.38)	
p-value	0.9293	
p-value of Breslow-Day Test for Homogeneity [3]	0.6705	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	4 (50.0)
No	5 (55.6)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	
95% CI of the inverse odds ratio	(0.19, 8.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.41, 3.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	
95% CI of the absolute risk difference	(-53.04, 41.92)	
p-value	0.8188	
p-value of Breslow-Day Test for Homogeneity [3]	0.7634	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 13 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Role Physical		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	2 (25.0)
No	8 (88.9)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.19, 36.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse risk ratio	(0.25, 20.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	
95% CI of the absolute risk difference	(-50.25, 22.47)	
p-value	0.4534	
p-value of Breslow-Day Test for Homogeneity [3]	0.3776	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	4 (50.0)
No	7 (77.8)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	
95% CI of the inverse odds ratio	(0.43, 28.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse risk ratio	(0.55, 9.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-27.78	
95% CI of the absolute risk difference	(-71.80, 16.25)	
p-value	0.2316	
p-value of Breslow-Day Test for Homogeneity [3]	0.1991	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 14 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Bodily Pain		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (25.0)
No	7 (77.8)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse odds ratio	(0.12, 10.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.20, 6.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	
95% CI of the absolute risk difference	(-43.25, 37.70)	
p-value	0.8928	
p-value of Breslow-Day Test for Homogeneity [3]	0.1577	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	3 (37.5)
No	7 (77.8)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	
95% CI of the inverse odds ratio	(0.25, 17.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.69	
95% CI of the inverse risk ratio	(0.37, 7.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.28	
95% CI of the absolute risk difference	(-58.44, 27.89)	
p-value	0.4902	
p-value of Breslow-Day Test for Homogeneity [3]	0.0268	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 15 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
General Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	1 (12.5)
No	7 (77.8)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.04, 6.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.06, 5.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.72	
95% CI of the absolute risk difference	(-25.82, 45.26)	
p-value	0.5997	
p-value of Breslow-Day Test for Homogeneity [3]	0.8607	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	2 (25.0)
No	5 (55.6)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	
95% CI of the inverse odds ratio	(0.05, 3.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.14, 2.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.44	
95% CI of the absolute risk difference	(-24.76, 63.65)	
p-value	0.4024	
p-value of Breslow-Day Test for Homogeneity [3]	0.5620	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 16 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Vitality		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	2 (22.2)	2 (25.0)
No	7 (77.8)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse odds ratio	(0.12, 10.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.20, 6.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	
95% CI of the absolute risk difference	(-43.25, 37.70)	
p-value	0.8928	
p-value of Breslow-Day Test for Homogeneity [3]	0.4589	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	5 (55.6)	4 (50.0)
No	4 (44.4)	4 (50.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	
95% CI of the inverse odds ratio	(0.12, 5.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	
95% CI of the inverse risk ratio	(0.36, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.56	
95% CI of the absolute risk difference	(-41.92, 53.04)	
p-value	0.8188	
p-value of Breslow-Day Test for Homogeneity [3]	0.7634	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 17 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Social Functioning		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	1 (12.5)
No	8 (88.9)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.06, 21.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.08, 15.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	
95% CI of the absolute risk difference	(-32.16, 29.38)	
p-value	0.9293	
p-value of Breslow-Day Test for Homogeneity [3]	0.7742	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	1 (12.5)
No	7 (77.8)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	
95% CI of the inverse odds ratio	(0.04, 6.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	
95% CI of the inverse risk ratio	(0.06, 5.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.72	
95% CI of the absolute risk difference	(-25.82, 45.26)	
p-value	0.5997	
p-value of Breslow-Day Test for Homogeneity [3]	0.5298	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 18 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Role Emotional		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	1 (12.5)
No	8 (88.9)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.06, 21.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.08, 15.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	
95% CI of the absolute risk difference	(-32.16, 29.38)	
p-value	0.9293	
p-value of Breslow-Day Test for Homogeneity [3]	0.5372	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	1 (11.1)	2 (25.0)
No	8 (88.9)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	
95% CI of the inverse odds ratio	(0.19, 36.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.25	
95% CI of the inverse risk ratio	(0.25, 20.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.89	
95% CI of the absolute risk difference	(-50.25, 22.47)	
p-value	0.4534	
p-value of Breslow-Day Test for Homogeneity [3]	0.5291	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 19 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Mental Health		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	2 (25.0)
No	9 (100)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.31	
95% CI of the inverse odds ratio	(0.30, 178.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.56	
95% CI of the inverse risk ratio	(0.31, 100.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-22.78	
95% CI of the absolute risk difference	(-55.01, 9.45)	
p-value	0.1740	
p-value of Breslow-Day Test for Homogeneity [3]	0.1091	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	5 (62.5)
No	7 (77.8)	3 (37.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.83	
95% CI of the inverse odds ratio	(0.70, 48.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.81	
95% CI of the inverse risk ratio	(0.74, 10.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-40.28	
95% CI of the absolute risk difference	(-83.44, 2.89)	
p-value	0.0921	
p-value of Breslow-Day Test for Homogeneity [3]	0.2650	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 20 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Mental Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	0	1 (12.5)
No	9 (100)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.80	
95% CI of the inverse odds ratio	(0.13, 107.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	
95% CI of the inverse risk ratio	(0.15, 71.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.67	
95% CI of the absolute risk difference	(-39.51, 16.18)	
p-value	0.4080	
p-value of Breslow-Day Test for Homogeneity [3]	0.5156	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	2 (22.2)	2 (25.0)
No	7 (77.8)	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	
95% CI of the inverse odds ratio	(0.12, 10.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.20, 6.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	
95% CI of the absolute risk difference	(-43.25, 37.70)	
p-value	0.8928	
p-value of Breslow-Day Test for Homogeneity [3]	0.9066	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 21 of 21
Data Cut-off Date: 15MAY2018

AMNOG Table PRO5.13
Summary of Response in HR-QOL SF-36 at Week 36 by Domain/Component
by Baseline PRO-C3
(Label Population based on Modified Intent-to-Treat Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

Parameter Response Statistic/Category	MGL-3196 (N=9)	Placebo (N=8)
Physical Component Score		
Minimal Clinically Important Difference of 15% [1], n (%)		
Yes	1 (11.1)	1 (12.5)
No	8 (88.9)	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	
95% CI of the inverse odds ratio	(0.06, 21.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	
95% CI of the inverse risk ratio	(0.08, 15.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	
95% CI of the absolute risk difference	(-32.16, 29.38)	
p-value	0.9293	
p-value of Breslow-Day Test for Homogeneity [3]	0.4998	
Minimal Clinically Important Difference of 5% [1], n (%)		
Yes	4 (44.4)	3 (37.5)
No	5 (55.6)	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	
95% CI of the inverse odds ratio	(0.11, 5.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	
95% CI of the inverse risk ratio	(0.27, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.94	
95% CI of the absolute risk difference	(-39.74, 53.63)	
p-value	0.7715	
p-value of Breslow-Day Test for Homogeneity [3]	0.3983	

Program: t-pro05-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Events n:			
Total TEAEs	15	29	44
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	1	4	5
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	3 (50.0)	8 (66.7)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.07, 3.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.31, 1.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.67		
95% CI of the absolute risk difference	(-64.75, 31.42)		
p-value	0.4941		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (50.0)	8 (66.7)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.07, 3.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.31, 1.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.67		
95% CI of the absolute risk difference	(-64.75, 31.42)		
p-value	0.4941		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	1 (16.7)	3 (25.0)	4 (22.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		
95% CI of the odds ratio	(0.05, 7.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the risk ratio	(0.09, 5.13)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.33		
95% CI of the absolute risk difference	(-46.93, 30.26)		
p-value	0.6885		
p-value of Breslow-Day Test for Homogeneity [2]	0.1500		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (33.3)	3 (25.0)	5 (27.8)
Moderate	1 (16.7)	5 (41.7)	6 (33.3)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	1 (16.7)	1 (8.3)	2 (11.1)
Moderate	0	2 (16.7)	2 (11.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Events n:			
Total TEAEs	63	22	85
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	15	1	16
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	10 (83.3)	7 (87.5)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.05, 9.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.66, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17		
95% CI of the absolute risk difference	(-35.31, 26.98)		
p-value	0.7982		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any Serious TEAE	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Severe TEAEs	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (83.3)	7 (87.5)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.05, 9.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.66, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17		
95% CI of the absolute risk difference	(-35.31, 26.98)		
p-value	0.7982		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	6 (50.0)	1 (12.5)	7 (35.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.00		
95% CI of the odds ratio	(0.65, 75.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00		
95% CI of the risk ratio	(0.59, 27.25)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	37.50		
95% CI of the absolute risk difference	(1.09, 73.91)		
p-value	0.0850		
p-value of Breslow-Day Test for Homogeneity [2]	0.1500		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.2
Treatment-Emergent Adverse Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (50.0)	3 (37.5)	9 (45.0)
Moderate	4 (33.3)	3 (37.5)	7 (35.0)
Severe	0	1 (12.5)	1 (5.0)
Maximum Severity of Treatment-related TEAEs			
Mild	6 (50.0)	0	6 (30.0)
Moderate	0	1 (12.5)	1 (5.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Events n:			
Total TEAEs	39	23	62
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	7	1	8
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	8 (80.0)	8 (66.7)	16 (72.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.28, 14.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20		
95% CI of the risk ratio	(0.72, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.33		
95% CI of the absolute risk difference	(-23.08, 49.75)		
p-value	0.4844		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any Serious TEAE	0	1 (8.3)	1 (4.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 9.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 8.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.99		
95% CI of the absolute risk difference	(-28.28, 14.29)		
p-value	0.5368		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Severe TEAEs	0	1 (8.3)	1 (4.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 9.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 8.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.99		
95% CI of the absolute risk difference	(-28.28, 14.29)		
p-value	0.5368		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	8 (66.7)	16 (72.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.28, 14.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20		
95% CI of the risk ratio	(0.72, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.33		
95% CI of the absolute risk difference	(-23.08, 49.75)		
p-value	0.4844		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	1 (8.3)	5 (22.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.33		
95% CI of the odds ratio	(0.66, 81.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.80		
95% CI of the risk ratio	(0.63, 36.34)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	31.67		
95% CI of the absolute risk difference	(-2.49, 65.82)		
p-value	0.0776		
p-value of Breslow-Day Test for Homogeneity [2]	0.2044		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (50.0)	4 (33.3)	9 (40.9)
Moderate	3 (30.0)	3 (25.0)	6 (27.3)
Severe	0	1 (8.3)	1 (4.5)
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	0	4 (18.2)
Moderate	0	1 (8.3)	1 (4.5)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Events n:			
Total TEAEs	39	28	67
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	9	4	13
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	5 (62.5)	7 (87.5)	12 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the odds ratio	(0.02, 3.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the risk ratio	(0.39, 1.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-65.63, 15.63)		
p-value	0.2482		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	7 (87.5)	12 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the odds ratio	(0.02, 3.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the risk ratio	(0.39, 1.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-65.63, 15.63)		
p-value	0.2482		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any TEAEs leading to Study Discontinuation	0	1 (12.5)	1 (6.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 8.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the risk ratio	(0.02, 7.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.11		
95% CI of the absolute risk difference	(-39.69, 17.47)		
p-value	0.4533		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	3 (37.5)	6 (37.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.13, 7.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.28, 3.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-47.44, 47.44)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.2044		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.3
Treatment-Emergent Adverse Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (37.5)	2 (25.0)	5 (31.3)
Moderate	2 (25.0)	5 (62.5)	7 (43.8)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	1 (12.5)	4 (25.0)
Moderate	0	2 (25.0)	2 (12.5)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Events n:			
Total TEAEs	38	27	65
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	6	2	8
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (62.5)	9 (69.2)	14 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		
95% CI of the odds ratio	(0.12, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		
95% CI of the risk ratio	(0.47, 1.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.73		
95% CI of the absolute risk difference	(-48.62, 35.16)		
p-value	0.7507		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Severe TEAEs	0	1 (7.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49		
95% CI of the odds ratio	(0.02, 13.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52		
95% CI of the risk ratio	(0.02, 11.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.16		
95% CI of the absolute risk difference	(-27.21, 16.90)		
p-value	0.6683		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	9 (69.2)	14 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		
95% CI of the odds ratio	(0.12, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		
95% CI of the risk ratio	(0.47, 1.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.73		
95% CI of the absolute risk difference	(-48.62, 35.16)		
p-value	0.7507		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	1 (7.7)	4 (19.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.20		
95% CI of the odds ratio	(0.60, 87.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.88		
95% CI of the risk ratio	(0.61, 39.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	29.81		
95% CI of the absolute risk difference	(-6.73, 66.35)		
p-value	0.0912		
p-value of Breslow-Day Test for Homogeneity [2]	0.1848		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (50.0)	4 (30.8)	8 (38.1)
Moderate	1 (12.5)	4 (30.8)	5 (23.8)
Severe	0	1 (7.7)	1 (4.8)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	0	3 (14.3)
Moderate	0	1 (7.7)	1 (4.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Events n:			
Total TEAEs	40	24	64
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	10	3	13
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (80.0)	6 (85.7)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the odds ratio	(0.05, 9.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.61, 1.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.71		
95% CI of the absolute risk difference	(-41.58, 30.16)		
p-value	0.7610		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any Serious TEAE	0	1 (14.3)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		
95% CI of the odds ratio	(0.01, 5.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the risk ratio	(0.01, 5.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.20		
95% CI of the absolute risk difference	(-43.92, 15.51)		
p-value	0.3192		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	6 (85.7)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the odds ratio	(0.05, 9.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.61, 1.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.71		
95% CI of the absolute risk difference	(-41.58, 30.16)		
p-value	0.7610		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any TEAEs leading to Study Discontinuation	0	1 (14.3)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		
95% CI of the odds ratio	(0.01, 5.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the risk ratio	(0.01, 5.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.20		
95% CI of the absolute risk difference	(-43.92, 15.51)		
p-value	0.3192		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	3 (42.9)	7 (41.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the odds ratio	(0.13, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.30, 2.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86		
95% CI of the absolute risk difference	(-50.46, 44.74)		
p-value	0.9062		
p-value of Breslow-Day Test for Homogeneity [2]	0.1848		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.4
Treatment-Emergent Adverse Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (40.0)	2 (28.6)	6 (35.3)
Moderate	4 (40.0)	4 (57.1)	8 (47.1)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	1 (14.3)	5 (29.4)
Moderate	0	2 (28.6)	2 (11.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Events n:			
Total TEAEs	45	20	65
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	11	3	14
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (72.7)	8 (88.9)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.03, 3.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.53, 1.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.16		
95% CI of the absolute risk difference	(-49.54, 17.22)		
p-value	0.3687		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any Serious TEAE	0	1 (11.1)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		
95% CI of the odds ratio	(0.01, 6.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		
95% CI of the risk ratio	(0.01, 6.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83		
95% CI of the absolute risk difference	(-35.69, 14.02)		
p-value	0.3788		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (72.7)	8 (88.9)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.03, 3.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.53, 1.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.16		
95% CI of the absolute risk difference	(-49.54, 17.22)		
p-value	0.3687		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (36.4)	2 (22.2)	6 (30.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.27, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64		
95% CI of the risk ratio	(0.38, 6.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.14		
95% CI of the absolute risk difference	(-25.18, 53.46)		
p-value	0.4924		
p-value of Breslow-Day Test for Homogeneity [2]	0.7257		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (45.5)	5 (55.6)	10 (50.0)
Moderate	3 (27.3)	3 (33.3)	6 (30.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (36.4)	0	4 (20.0)
Moderate	0	2 (22.2)	2 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Events n:			
Total TEAEs	33	31	64
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	5	2	7
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (71.4)	7 (63.6)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12		
95% CI of the risk ratio	(0.59, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.79		
95% CI of the absolute risk difference	(-36.12, 51.70)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Severe TEAEs	0	1 (9.1)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		
95% CI of the odds ratio	(0.02, 13.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the risk ratio	(0.02, 10.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25		
95% CI of the absolute risk difference	(-31.38, 18.88)		
p-value	0.6481		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (71.4)	7 (63.6)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12		
95% CI of the risk ratio	(0.59, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.79		
95% CI of the absolute risk difference	(-36.12, 51.70)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (9.1)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		
95% CI of the odds ratio	(0.02, 13.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the risk ratio	(0.02, 10.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25		
95% CI of the absolute risk difference	(-31.38, 18.88)		
p-value	0.6481		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (42.9)	2 (18.2)	5 (27.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38		
95% CI of the odds ratio	(0.40, 28.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.36		
95% CI of the risk ratio	(0.52, 10.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.68		
95% CI of the absolute risk difference	(-18.49, 67.84)		
p-value	0.2545		
p-value of Breslow-Day Test for Homogeneity [2]	0.7257		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.5
Treatment-Emergent Adverse Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (42.9)	1 (9.1)	4 (22.2)
Moderate	2 (28.6)	5 (45.5)	7 (38.9)
Severe	0	1 (9.1)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (42.9)	1 (9.1)	4 (22.2)
Moderate	0	1 (9.1)	1 (5.6)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Events n:			
Total TEAEs	6	13	19
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	2	2
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	1 (20.0)	4 (66.7)	5 (45.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13		
95% CI of the odds ratio	(0.01, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.05, 1.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-46.67		
95% CI of the absolute risk difference	(-98.16, 4.83)		
p-value	0.1217		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Severe TEAEs	0	1 (16.7)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 10.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 7.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.10		
95% CI of the absolute risk difference	(-50.69, 24.50)		
p-value	0.5142		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	1 (20.0)	4 (66.7)	5 (45.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13		
95% CI of the odds ratio	(0.01, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.05, 1.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-46.67		
95% CI of the absolute risk difference	(-98.16, 4.83)		
p-value	0.1217		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	0	1 (16.7)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 10.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 7.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.10		
95% CI of the absolute risk difference	(-50.69, 24.50)		
p-value	0.5142		
p-value of Breslow-Day Test for Homogeneity [2]	0.1140		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	1 (20.0)	1 (16.7)	2 (18.2)
Moderate	0	2 (33.3)	2 (18.2)
Severe	0	1 (16.7)	1 (9.1)
Maximum Severity of Treatment-related TEAEs			
Mild	0	0	0
Moderate	0	1 (16.7)	1 (9.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Events n:			
Total TEAEs	72	38	110
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	16	3	19
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	12 (92.3)	11 (78.6)	23 (85.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.27		
95% CI of the odds ratio	(0.29, 36.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		
95% CI of the risk ratio	(0.86, 1.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.74		
95% CI of the absolute risk difference	(-12.18, 39.66)		
p-value	0.3154		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any Serious TEAE	0	1 (7.1)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 8.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the risk ratio	(0.02, 8.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.43		
95% CI of the absolute risk difference	(-24.46, 11.60)		
p-value	0.4948		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	12 (92.3)	11 (78.6)	23 (85.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.27		
95% CI of the odds ratio	(0.29, 36.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		
95% CI of the risk ratio	(0.86, 1.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.74		
95% CI of the absolute risk difference	(-12.18, 39.66)		
p-value	0.3154		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any TEAEs leading to Study Discontinuation	0	1 (7.1)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 8.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the risk ratio	(0.02, 8.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.43		
95% CI of the absolute risk difference	(-24.46, 11.60)		
p-value	0.4948		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	7 (53.8)	3 (21.4)	10 (37.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.28		
95% CI of the odds ratio	(0.80, 22.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.51		
95% CI of the risk ratio	(0.82, 7.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	32.42		
95% CI of the absolute risk difference	(-2.17, 67.01)		
p-value	0.0814		
p-value of Breslow-Day Test for Homogeneity [2]	0.1140		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.6
Treatment-Emergent Adverse Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	7 (53.8)	5 (35.7)	12 (44.4)
Moderate	5 (38.5)	6 (42.9)	11 (40.7)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	7 (53.8)	1 (7.1)	8 (29.6)
Moderate	0	2 (14.3)	2 (7.4)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Events n:			
Total TEAEs	57	19	76
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	11	1	12
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	9 (75.0)	8 (100)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.54, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-49.50, -0.50)		
p-value	0.1250		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	9 (75.0)	8 (100)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.54, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-49.50, -0.50)		
p-value	0.1250		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (33.3)	1 (12.5)	5 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.50		
95% CI of the odds ratio	(0.31, 39.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.67		
95% CI of the risk ratio	(0.36, 19.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.83		
95% CI of the absolute risk difference	(-14.33, 56.00)		
p-value	0.2918		
p-value of Breslow-Day Test for Homogeneity [2]	0.9240		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (41.7)	4 (50.0)	9 (45.0)
Moderate	4 (33.3)	4 (50.0)	8 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (33.3)	0	4 (20.0)
Moderate	0	1 (12.5)	1 (5.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Events n:			
Total TEAEs	21	32	53
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	5	4	9
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	4 (66.7)	7 (58.3)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		
95% CI of the risk ratio	(0.54, 2.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33		
95% CI of the absolute risk difference	(-38.58, 55.25)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any Serious TEAE	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Severe TEAEs	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	4 (66.7)	7 (58.3)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		
95% CI of the risk ratio	(0.54, 2.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33		
95% CI of the absolute risk difference	(-38.58, 55.25)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (50.0)	3 (25.0)	6 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.38, 23.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the risk ratio	(0.56, 7.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-21.91, 71.91)		
p-value	0.2888		
p-value of Breslow-Day Test for Homogeneity [2]	0.9240		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.7
Treatment-Emergent Adverse Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (50.0)	2 (16.7)	5 (27.8)
Moderate	1 (16.7)	4 (33.3)	5 (27.8)
Severe	0	1 (8.3)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (50.0)	1 (8.3)	4 (22.2)
Moderate	0	2 (16.7)	2 (11.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as ""Severe"".
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Events n:			
Total TEAEs	65	36	101
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	15	3	18
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	10 (76.9)	12 (80.0)	22 (78.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		
95% CI of the odds ratio	(0.14, 5.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		
95% CI of the risk ratio	(0.65, 1.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.08		
95% CI of the absolute risk difference	(-33.64, 27.49)		
p-value	0.8431		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any Serious TEAE	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Severe TEAEs	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (76.9)	12 (80.0)	22 (78.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		
95% CI of the odds ratio	(0.14, 5.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		
95% CI of the risk ratio	(0.65, 1.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.08		
95% CI of the absolute risk difference	(-33.64, 27.49)		
p-value	0.8431		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any TEAEs leading to Study Discontinuation	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	6 (46.2)	3 (20.0)	9 (32.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.43		
95% CI of the odds ratio	(0.65, 18.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.31		
95% CI of the risk ratio	(0.72, 7.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	26.15		
95% CI of the absolute risk difference	(-7.67, 59.98)		
p-value	0.1394		
p-value of Breslow-Day Test for Homogeneity [2]	0.4858		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (46.2)	6 (40.0)	12 (42.9)
Moderate	4 (30.8)	5 (33.3)	9 (32.1)
Severe	0	1 (6.7)	1 (3.6)
Maximum Severity of Treatment-related TEAEs			
Mild	6 (46.2)	1 (6.7)	7 (25.0)
Moderate	0	2 (13.3)	2 (7.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Events n:			
Total TEAEs	13	15	28
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	1	2	3
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	3 (60.0)	3 (60.0)	6 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.08, 12.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.36, 2.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-60.73, 60.73)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (60.0)	3 (60.0)	6 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.08, 12.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.36, 2.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-60.73, 60.73)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	1 (20.0)	1 (20.0)	2 (20.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.05, 22.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.08, 11.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-49.58, 49.58)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.4858		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.8
Treatment-Emergent Adverse Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (40.0)	0	2 (20.0)
Moderate	1 (20.0)	3 (60.0)	4 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	1 (20.0)	0	1 (10.0)
Moderate	0	1 (20.0)	1 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; LDL = low density lipoprotein.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Events n:			
Total TEAEs	30	6	36
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	4	0	4
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	5 (62.5)	4 (57.1)	9 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the odds ratio	(0.16, 9.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		
95% CI of the risk ratio	(0.47, 2.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.36		
95% CI of the absolute risk difference	(-44.34, 55.05)		
p-value	0.8327		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	4 (57.1)	9 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the odds ratio	(0.16, 9.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		
95% CI of the risk ratio	(0.47, 2.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.36		
95% CI of the absolute risk difference	(-44.34, 55.05)		
p-value	0.8327		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	0	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.77		
95% CI of the odds ratio	(0.23, 143.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.44		
95% CI of the risk ratio	(0.25, 79.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	21.53		
95% CI of the absolute risk difference	(-12.20, 55.26)		
p-value	0.2452		
p-value of Breslow-Day Test for Homogeneity [2]	0.3494		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (25.0)	3 (42.9)	5 (33.3)
Moderate	3 (37.5)	1 (14.3)	4 (26.7)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	0	2 (13.3)
Moderate	0	0	0
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Events n:			
Total TEAEs	48	45	93
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	12	5	17
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	8 (80.0)	11 (84.6)	19 (82.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73		
95% CI of the odds ratio	(0.08, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.64, 1.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.62		
95% CI of the absolute risk difference	(-36.23, 27.00)		
p-value	0.7722		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any Serious TEAE	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Severe TEAEs	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	11 (84.6)	19 (82.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73		
95% CI of the odds ratio	(0.08, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.64, 1.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.62		
95% CI of the absolute risk difference	(-36.23, 27.00)		
p-value	0.7722		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any TEAEs leading to Study Discontinuation	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (50.0)	4 (30.8)	9 (39.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25		
95% CI of the odds ratio	(0.41, 12.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.63		
95% CI of the risk ratio	(0.58, 4.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	19.23		
95% CI of the absolute risk difference	(-20.64, 59.10)		
p-value	0.3489		
p-value of Breslow-Day Test for Homogeneity [2]	0.3494		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.9
Treatment-Emergent Adverse Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (60.0)	3 (23.1)	9 (39.1)
Moderate	2 (20.0)	7 (53.8)	9 (39.1)
Severe	0	1 (7.7)	1 (4.3)
Maximum Severity of Treatment-related TEAEs			
Mild	5 (50.0)	1 (7.7)	6 (26.1)
Moderate	0	3 (23.1)	3 (13.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Events n:			
Total TEAEs	42	44	86
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	7	4	11
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	7 (70.0)	12 (85.7)	19 (79.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the odds ratio	(0.05, 2.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.52, 1.29)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.71		
95% CI of the absolute risk difference	(-49.52, 18.09)		
p-value	0.3500		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any Serious TEAE	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Severe TEAEs	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	7 (70.0)	12 (85.7)	19 (79.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the odds ratio	(0.05, 2.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.52, 1.29)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.71		
95% CI of the absolute risk difference	(-49.52, 18.09)		
p-value	0.3500		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any TEAEs leading to Study Discontinuation	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	3 (21.4)	7 (29.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.44		
95% CI of the odds ratio	(0.41, 14.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		
95% CI of the risk ratio	(0.53, 6.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.57		
95% CI of the absolute risk difference	(-18.63, 55.77)		
p-value	0.3237		
p-value of Breslow-Day Test for Homogeneity [2]	0.8983		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: <=150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (40.0)	5 (35.7)	9 (37.5)
Moderate	3 (30.0)	6 (42.9)	9 (37.5)
Severe	0	1 (7.1)	1 (4.2)
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	1 (7.1)	5 (20.8)
Moderate	0	2 (14.3)	2 (8.3)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Events n:			
Total TEAEs	36	7	43
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	9	1	10
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	6 (75.0)	3 (50.0)	9 (64.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.31, 28.84)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the risk ratio	(0.61, 3.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-25.01, 75.01)		
p-value	0.3340		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	6 (75.0)	3 (50.0)	9 (64.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.31, 28.84)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the risk ratio	(0.61, 3.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-25.01, 75.01)		
p-value	0.3340		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	1 (16.7)	4 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.23, 39.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25		
95% CI of the risk ratio	(0.30, 16.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.83		
95% CI of the absolute risk difference	(-24.05, 65.72)		
p-value	0.3932		
p-value of Breslow-Day Test for Homogeneity [2]	0.8983		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.10
Treatment-Emergent Adverse Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (50.0)	1 (16.7)	5 (35.7)
Moderate	2 (25.0)	2 (33.3)	4 (28.6)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	0	3 (21.4)
Moderate	0	1 (16.7)	1 (7.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Events n:			
Total TEAEs	10	20	30
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	2	2
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	3 (75.0)	6 (85.7)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.02, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88		
95% CI of the risk ratio	(0.46, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71		
95% CI of the absolute risk difference	(-60.44, 39.01)		
p-value	0.6576		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Severe TEAEs	0	1 (14.3)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		
95% CI of the odds ratio	(0.02, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		
95% CI of the risk ratio	(0.03, 10.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.75		
95% CI of the absolute risk difference	(-46.47, 28.97)		
p-value	0.6705		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (75.0)	6 (85.7)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.02, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88		
95% CI of the risk ratio	(0.46, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71		
95% CI of the absolute risk difference	(-60.44, 39.01)		
p-value	0.6576		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	0	1 (14.3)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		
95% CI of the odds ratio	(0.02, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		
95% CI of the risk ratio	(0.03, 10.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.75		
95% CI of the absolute risk difference	(-46.47, 28.97)		
p-value	0.6705		
p-value of Breslow-Day Test for Homogeneity [2]	0.2152		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (50.0)	3 (42.9)	5 (45.5)
Moderate	1 (25.0)	2 (28.6)	3 (27.3)
Severe	0	1 (14.3)	1 (9.1)
Maximum Severity of Treatment-related TEAEs			
Mild	0	0	0
Moderate	0	1 (14.3)	1 (9.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: ≥ 229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Events n:			
Total TEAEs	68	31	99
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	16	3	19
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	10 (71.4)	9 (69.2)	19 (70.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11		
95% CI of the odds ratio	(0.21, 5.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03		
95% CI of the risk ratio	(0.63, 1.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.20		
95% CI of the absolute risk difference	(-32.29, 36.69)		
p-value	0.9006		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any Serious TEAE	0	1 (7.7)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 7.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31		
95% CI of the risk ratio	(0.01, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.38		
95% CI of the absolute risk difference	(-25.96, 11.19)		
p-value	0.4331		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (71.4)	9 (69.2)	19 (70.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11		
95% CI of the odds ratio	(0.21, 5.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03		
95% CI of the risk ratio	(0.63, 1.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.20		
95% CI of the absolute risk difference	(-32.29, 36.69)		
p-value	0.9006		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any TEAEs leading to Study Discontinuation	0	1 (7.7)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 7.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31		
95% CI of the risk ratio	(0.01, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.38		
95% CI of the absolute risk difference	(-25.96, 11.19)		
p-value	0.4331		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	7 (50.0)	3 (23.1)	10 (37.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.33		
95% CI of the odds ratio	(0.63, 17.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17		
95% CI of the risk ratio	(0.71, 6.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	26.92		
95% CI of the absolute risk difference	(-7.87, 61.72)		
p-value	0.1478		
p-value of Breslow-Day Test for Homogeneity [2]	0.2152		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.11
Treatment-Emergent Adverse Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (42.9)	3 (23.1)	9 (33.3)
Moderate	4 (28.6)	6 (46.2)	10 (37.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	7 (50.0)	1 (7.7)	8 (29.6)
Moderate	0	2 (15.4)	2 (7.4)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; HA = Hyaluronic Acid.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Events n:			
Total TEAEs	23	28	51
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	4	3	7
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (62.5)	7 (70.0)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.10, 5.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.46, 1.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.50		
95% CI of the absolute risk difference	(-51.46, 36.46)		
p-value	0.7373		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Severe TEAEs	0	1 (10.0)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 10.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the risk ratio	(0.02, 8.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.08		
95% CI of the absolute risk difference	(-33.28, 17.12)		
p-value	0.5490		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	7 (70.0)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.10, 5.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.46, 1.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.50		
95% CI of the absolute risk difference	(-51.46, 36.46)		
p-value	0.7373		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (10.0)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 10.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the risk ratio	(0.02, 8.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.08		
95% CI of the absolute risk difference	(-33.28, 17.12)		
p-value	0.5490		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	2 (20.0)	4 (22.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33		
95% CI of the odds ratio	(0.14, 12.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the risk ratio	(0.22, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.00		
95% CI of the absolute risk difference	(-33.92, 43.92)		
p-value	0.7998		
p-value of Breslow-Day Test for Homogeneity [2]	0.4678		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (37.5)	3 (30.0)	6 (33.3)
Moderate	2 (25.0)	3 (30.0)	5 (27.8)
Severe	0	1 (10.0)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	1 (10.0)	3 (16.7)
Moderate	0	1 (10.0)	1 (5.6)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Events n:			
Total TEAEs	55	23	78
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	12	2	14
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (80.0)	8 (80.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.11, 8.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.65, 1.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-35.06, 35.06)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any Serious TEAE	0	1 (10.0)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the odds ratio	(0.01, 8.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the risk ratio	(0.02, 7.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.09		
95% CI of the absolute risk difference	(-32.81, 14.63)		
p-value	0.4583		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	8 (80.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.11, 8.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.65, 1.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-35.06, 35.06)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (50.0)	2 (20.0)	7 (35.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00		
95% CI of the odds ratio	(0.55, 29.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50		
95% CI of the risk ratio	(0.63, 10.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.00		
95% CI of the absolute risk difference	(-9.69, 69.69)		
p-value	0.1596		
p-value of Breslow-Day Test for Homogeneity [2]	0.4678		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.12
Treatment-Emergent Adverse Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (50.0)	3 (30.0)	8 (40.0)
Moderate	3 (30.0)	5 (50.0)	8 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	5 (50.0)	0	5 (25.0)
Moderate	0	2 (20.0)	2 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as "Severe".

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Events n:			
Total TEAEs	27	23	50
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	3	3	6
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	6 (75.0)	7 (63.6)	13 (68.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71		
95% CI of the odds ratio	(0.23, 12.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18		
95% CI of the risk ratio	(0.65, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.36		
95% CI of the absolute risk difference	(-29.97, 52.70)		
p-value	0.5988		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Severe TEAEs	0	1 (9.1)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the odds ratio	(0.01, 11.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		
95% CI of the risk ratio	(0.02, 9.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.94		
95% CI of the absolute risk difference	(-30.90, 17.02)		
p-value	0.5916		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	6 (75.0)	7 (63.6)	13 (68.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71		
95% CI of the odds ratio	(0.23, 12.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18		
95% CI of the risk ratio	(0.65, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.36		
95% CI of the absolute risk difference	(-29.97, 52.70)		
p-value	0.5988		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	2 (18.2)	4 (21.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the odds ratio	(0.16, 13.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.38		
95% CI of the risk ratio	(0.24, 7.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.82		
95% CI of the absolute risk difference	(-30.86, 44.50)		
p-value	0.7189		
p-value of Breslow-Day Test for Homogeneity [2]	0.5522		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (62.5)	4 (36.4)	9 (47.4)
Moderate	1 (12.5)	2 (18.2)	3 (15.8)
Severe	0	1 (9.1)	1 (5.3)
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	1 (9.1)	3 (15.8)
Moderate	0	1 (9.1)	1 (5.3)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Events n:			
Total TEAEs	51	25	76
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	13	2	15
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	7 (77.8)	7 (87.5)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.04, 6.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.57, 1.38)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.72		
95% CI of the absolute risk difference	(-45.26, 25.82)		
p-value	0.5997		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any Serious TEAE	0	1 (12.5)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26		
95% CI of the odds ratio	(0.01, 7.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.01, 6.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.67		
95% CI of the absolute risk difference	(-39.51, 16.18)		
p-value	0.4080		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	7 (77.8)	7 (87.5)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.04, 6.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.57, 1.38)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.72		
95% CI of the absolute risk difference	(-45.26, 25.82)		
p-value	0.5997		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (55.6)	2 (25.0)	7 (41.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.75		
95% CI of the odds ratio	(0.47, 29.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.22		
95% CI of the risk ratio	(0.58, 8.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.56		
95% CI of the absolute risk difference	(-13.65, 74.76)		
p-value	0.2014		
p-value of Breslow-Day Test for Homogeneity [2]	0.5522		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S1.13
Treatment-Emergent Adverse Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (33.3)	2 (25.0)	5 (29.4)
Moderate	4 (44.4)	5 (62.5)	9 (52.9)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	5 (55.6)	0	5 (29.4)
Moderate	0	2 (25.0)	2 (11.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.2

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.2
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Male

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	2 (33.3)	2	1 (8.3)	1	3 (16.7)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.50					
95% CI of the odds ratio	(0.38, 78.57)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00					
95% CI of the risk ratio	(0.45, 35.79)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00					
95% CI of the absolute risk difference	(-15.83, 65.83)					
p-value	0.1797					
p-value of Breslow-Day Test for Homogeneity [2]	0.2307					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.2
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Female

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	7 (58.3)	11	0	0	7 (35.0)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	23.18					
95% CI of the odds ratio	(1.09, 492.95)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	10.38					
95% CI of the risk ratio	(0.67, 159.81)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	52.14					
95% CI of the absolute risk difference	(21.39, 82.88)					
p-value	0.0124					
p-value of Breslow-Day Test for Homogeneity [2]	0.2307					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.3
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)
Ethnicity: Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=12)		Overall (N=22)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.3
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)
Ethnicity: Not Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=8)		Overall (N=16)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.4
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)
Fibrosis Stage at Baseline: 2

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=13)		Overall (N=21)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.4
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=7)		Overall (N=17)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.5
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)
Baseline MRI-PDFF: <20%

System Organ Class Preferred Term	MGL-3196 (N=11)		Placebo (N=9)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.5
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)
Baseline MRI-PDFF: >=20%

System Organ Class Preferred Term	MGL-3196 (N=7)		Placebo (N=11)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.6

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.6
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)
Stage of NASH: <5

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=6)		Overall (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	1 (20.0)	1	0	0	1 (9.1)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.33					
95% CI of the odds ratio	(0.14, 132.32)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.50					
95% CI of the risk ratio	(0.17, 70.94)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.86					
95% CI of the absolute risk difference	(-21.70, 57.41)					
p-value	0.3737					
p-value of Breslow-Day Test for Homogeneity [2]	0.7834					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.6
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=14)		Overall (N=27)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	8 (61.5)	12	1 (7.1)	1	9 (33.3)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	20.80					
95% CI of the odds ratio	(2.04, 211.79)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	8.62					
95% CI of the risk ratio	(1.24, 59.77)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	54.40					
95% CI of the absolute risk difference	(24.71, 84.08)					
p-value	0.0027					
p-value of Breslow-Day Test for Homogeneity [2]	0.7834					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.7
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)
Type 2 Diabetes: Yes

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.7
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.8

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event; ALT = Alanine aminotransferase.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.8
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=15)		Overall (N=28)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	7 (53.8)	11	1 (6.7)	1	8 (28.6)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	16.33					
95% CI of the odds ratio	(1.63, 163.44)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	8.08					
95% CI of the risk ratio	(1.14, 57.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	47.18					
95% CI of the absolute risk difference	(17.28, 77.07)					
p-value	0.0059					
p-value of Breslow-Day Test for Homogeneity [2]	0.6520					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.8
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=5)		Overall (N=10)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	2 (40.0)	2	0	0	2 (20.0)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.86					
95% CI of the odds ratio	(0.28, 217.11)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.00					
95% CI of the risk ratio	(0.30, 83.69)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	33.33					
95% CI of the absolute risk difference	(-11.89, 78.56)					
p-value	0.1824					
p-value of Breslow-Day Test for Homogeneity [2]	0.6520					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.9
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)
LDL at Baseline: <100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=7)		Overall (N=15)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.9
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)
LDL at Baseline: >=100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=13)		Overall (N=23)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.10

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.10

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: <=150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=14)		Overall (N=24)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	5 (50.0)	9	1 (7.1)	1	6 (25.0)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	13.00					
95% CI of the odds ratio	(1.20, 140.73)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.00					
95% CI of the risk ratio	(0.96, 51.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	42.86					
95% CI of the absolute risk difference	(9.06, 76.66)					
p-value	0.0168					
p-value of Breslow-Day Test for Homogeneity [2]	0.5049					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.10

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=6)		Overall (N=14)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	4 (50.0)	4	0	0	4 (28.6)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	13.00					
95% CI of the odds ratio	(0.55, 306.21)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.00					
95% CI of the risk ratio	(0.45, 109.47)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	42.86					
95% CI of the absolute risk difference	(5.03, 80.69)					
p-value	0.0665					
p-value of Breslow-Day Test for Homogeneity [2]	0.5049					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.11

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.11

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=4)		Placebo (N=7)		Overall (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	2 (50.0)	2	0	0	2 (18.2)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	15.00					
95% CI of the odds ratio	(0.52, 430.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	8.00					
95% CI of the risk ratio	(0.48, 134.66)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	43.75					
95% CI of the absolute risk difference	(-3.18, 90.68)					
p-value	0.0685					
p-value of Breslow-Day Test for Homogeneity [2]	0.4871					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.11
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)
Baseline TIMP: >=229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=14)		Placebo (N=13)		Overall (N=27)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	7 (50.0)	11	1 (7.7)	1	8 (29.6)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	12.00					
95% CI of the odds ratio	(1.21, 118.89)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.50					
95% CI of the risk ratio	(0.92, 45.90)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	42.31					
95% CI of the absolute risk difference	(12.38, 72.24)					
p-value	0.0161					
p-value of Breslow-Day Test for Homogeneity [2]	0.4871					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.12

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Abbreviation: TEAE = Treatment-emergent adverse event; HA = Hyaluronic Acid.

Note: Adverse events are coded using MedDRA version 19.1.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s02-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.12

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=10)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	3 (37.5)	3	1 (10.0)	1	4 (22.2)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.40					
95% CI of the odds ratio	(0.44, 66.67)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.75					
95% CI of the risk ratio	(0.48, 29.52)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	27.50					
95% CI of the absolute risk difference	(-10.86, 65.86)					
p-value	0.1632					
p-value of Breslow-Day Test for Homogeneity [2]	0.1963					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 3
Data Cut-off Date: 15MAY2018

AMNOG Table S2.12

Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=10)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders						
Diarrhoea	6 (60.0)	10	0	0	6 (30.0)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	30.33					
95% CI of the odds ratio	(1.39, 660.76)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	13.00					
95% CI of the risk ratio	(0.83, 203.83)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	54.55					
95% CI of the absolute risk difference	(22.99, 86.10)					
p-value	0.0060					
p-value of Breslow-Day Test for Homogeneity [2]	0.1963					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.13
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)
Baseline PRO-C3: <17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=11)		Overall (N=19)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S2.13
Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)
Baseline PRO-C3: >=17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=9)		Placebo (N=8)		Overall (N=17)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.2
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Male

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.2
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Female

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.3
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=12)		Overall (N=22)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.3
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=8)		Overall (N=16)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.4
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=13)		Overall (N=21)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.4
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=7)		Overall (N=17)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.5
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)
Baseline MRI-PDFF: <20%

System Organ Class Preferred Term	MGL-3196 (N=11)		Placebo (N=9)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.5
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)
Baseline MRI-PDFF: >=20%

System Organ Class Preferred Term	MGL-3196 (N=7)		Placebo (N=11)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.6
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=6)		Overall (N=11)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.6
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=14)		Overall (N=27)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.7
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.7
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.8
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=15)		Overall (N=28)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.8
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=5)		Overall (N=10)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.9
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=7)		Overall (N=15)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.9
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)
LDL at Baseline: >=100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=13)		Overall (N=23)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.10
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)
Triglycerides at Baseline: <=150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=14)		Overall (N=24)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.10
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)
Triglycerides at Baseline: >150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=6)		Overall (N=14)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.11
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=4)		Placebo (N=7)		Overall (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.11
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)
Baseline TIMP: >=229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=14)		Placebo (N=13)		Overall (N=27)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.12
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=10)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.12
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=10)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.13
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=11)		Overall (N=19)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S3.13
Severe Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)
Baseline PRO-C3: >=17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=9)		Placebo (N=8)		Overall (N=17)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the severity is missing for an AE, the event is assumed to be severe.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.2
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Male

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.2
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Female

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.3
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=12)		Overall (N=22)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.3
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=8)		Overall (N=16)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.4
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=13)		Overall (N=21)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.4
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=7)		Overall (N=17)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.5
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

System Organ Class Preferred Term	MGL-3196 (N=11)		Placebo (N=9)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.5
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

System Organ Class Preferred Term	MGL-3196 (N=7)		Placebo (N=11)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.6
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=6)		Overall (N=11)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.6
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=14)		Overall (N=27)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.7
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.7
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.8
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=15)		Overall (N=28)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.8
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline ALT by Gender
(Label Population based on Safety Population)
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=5)		Overall (N=10)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.9
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=7)		Overall (N=15)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.9
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)
LDL at Baseline: >=100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=13)		Overall (N=23)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.10
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)
Triglycerides at Baseline: <=150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=14)		Overall (N=24)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.10
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)
Triglycerides at Baseline: >150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=6)		Overall (N=14)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.11
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=4)		Placebo (N=7)		Overall (N=11)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.11
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=14)		Placebo (N=13)		Overall (N=27)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.12
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=10)		Overall (N=18)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.12
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=10)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.13
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=11)		Overall (N=19)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S4.13
Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)
Baseline PRO-C3: >=17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=9)		Placebo (N=8)		Overall (N=17)	
	Patients	Events	Patients	Events	Patients	Events
	n (%)	n	n (%)	n	n (%)	n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A SE-TEAE is defined as any serious AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald’s asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.
Program: t-s02-subgroup.sas

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.2
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Male

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.2
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Gender
(Label Population based on Safety Population)

Gender: Female

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.3
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=12)		Overall (N=22)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.3
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=8)		Overall (N=16)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.4
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=13)		Overall (N=21)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.4
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=7)		Overall (N=17)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.5
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

System Organ Class Preferred Term	MGL-3196 (N=11)		Placebo (N=9)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.5
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

System Organ Class Preferred Term	MGL-3196 (N=7)		Placebo (N=11)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.6
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=6)		Overall (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.6
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=14)		Overall (N=27)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; NASH = Non-alcoholic steatohepatitis.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.7
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

System Organ Class Preferred Term	MGL-3196 (N=12)		Placebo (N=8)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.7
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

System Organ Class Preferred Term	MGL-3196 (N=6)		Placebo (N=12)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.8						
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term						
by Baseline ALT by Gender						
(Label Population based on Safety Population)						
Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L						
System Organ Class Preferred Term	MGL-3196 (N=13)		Placebo (N=15)		Overall (N=28)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.8						
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term						
by Baseline ALT by Gender						
(Label Population based on Safety Population)						
Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L						
System Organ Class Preferred Term	MGL-3196 (N=5)		Placebo (N=5)		Overall (N=10)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; ALT = Alanine aminotransferase.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.9
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=7)		Overall (N=15)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.9
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: >=100 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=13)		Overall (N=23)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; LDL = low density lipoprotein.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.10
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: <=150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=14)		Overall (N=24)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.10
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=6)		Overall (N=14)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.11
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=4)		Placebo (N=7)		Overall (N=11)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.11
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

System Organ Class Preferred Term	MGL-3196 (N=14)		Placebo (N=13)		Overall (N=27)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.12
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=10)		Overall (N=18)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.12
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

System Organ Class Preferred Term	MGL-3196 (N=10)		Placebo (N=10)		Overall (N=20)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; HA = Hyaluronic Acid.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.13
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=8)		Placebo (N=11)		Overall (N=19)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 2
Data Cut-off Date: 15MAY2018

AMNOG Table S6.13
Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation - by System Organ Class and Preferred Term
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: >=17.5 ng/mL

System Organ Class Preferred Term	MGL-3196 (N=9)		Placebo (N=8)		Overall (N=17)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

No subjects met the criteria for this table.

Abbreviation: TEAE = Treatment-emergent adverse event; PRO-C3 = N-terminal type III collagen pro-peptide.
Note: Adverse events are coded using MedDRA version 19.1.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug. Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the Label Population.
Program: t-s06-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.2

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary

by Gender

(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Events n:			
Total TEAEs	15	29	44
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	1	4	5
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	3 (50.0)	8 (66.7)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.07, 3.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.31, 1.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.67		
95% CI of the absolute risk difference	(-64.75, 31.42)		
p-value	0.4941		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (50.0)	8 (66.7)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.07, 3.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.31, 1.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.67		
95% CI of the absolute risk difference	(-64.75, 31.42)		
p-value	0.4941		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	1 (16.7)	3 (25.0)	4 (22.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		
95% CI of the odds ratio	(0.05, 7.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the risk ratio	(0.09, 5.13)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.33		
95% CI of the absolute risk difference	(-46.93, 30.26)		
p-value	0.6885		
p-value of Breslow-Day Test for Homogeneity [2]	0.1500		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Male

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (33.3)	3 (25.0)	5 (27.8)
Moderate	1 (16.7)	5 (41.7)	6 (33.3)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	1 (16.7)	1 (8.3)	2 (11.1)
Moderate	0	2 (16.7)	2 (11.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Events n:			
Total TEAEs	63	22	85
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	15	1	16
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	10 (83.3)	7 (87.5)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.05, 9.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.66, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17		
95% CI of the absolute risk difference	(-35.31, 26.98)		
p-value	0.7982		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any Serious TEAE	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Severe TEAEs	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (83.3)	7 (87.5)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.05, 9.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.66, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.17		
95% CI of the absolute risk difference	(-35.31, 26.98)		
p-value	0.7982		
p-value of Breslow-Day Test for Homogeneity [2]	0.8305		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	6 (50.0)	1 (12.5)	7 (35.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.00		
95% CI of the odds ratio	(0.65, 75.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00		
95% CI of the risk ratio	(0.59, 27.25)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	37.50		
95% CI of the absolute risk difference	(1.09, 73.91)		
p-value	0.0850		
p-value of Breslow-Day Test for Homogeneity [2]	0.1500		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.2
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Gender
(Label Population based on Safety Population)

Gender: Female

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (50.0)	3 (37.5)	9 (45.0)
Moderate	4 (33.3)	3 (37.5)	7 (35.0)
Severe	0	1 (12.5)	1 (5.0)
Maximum Severity of Treatment-related TEAEs			
Mild	6 (50.0)	0	6 (30.0)
Moderate	0	1 (12.5)	1 (5.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.3

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary

by Ethnicity

(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Events n:			
Total TEAEs	39	23	62
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	7	1	8
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	8 (80.0)	8 (66.7)	16 (72.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.28, 14.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20		
95% CI of the risk ratio	(0.72, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.33		
95% CI of the absolute risk difference	(-23.08, 49.75)		
p-value	0.4844		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any Serious TEAE	0	1 (8.3)	1 (4.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 9.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 8.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.99		
95% CI of the absolute risk difference	(-28.28, 14.29)		
p-value	0.5368		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Severe TEAEs	0	1 (8.3)	1 (4.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 9.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 8.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.99		
95% CI of the absolute risk difference	(-28.28, 14.29)		
p-value	0.5368		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	8 (66.7)	16 (72.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.28, 14.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20		
95% CI of the risk ratio	(0.72, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.33		
95% CI of the absolute risk difference	(-23.08, 49.75)		
p-value	0.4844		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	1 (8.3)	5 (22.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.33		
95% CI of the odds ratio	(0.66, 81.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.80		
95% CI of the risk ratio	(0.63, 36.34)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	31.67		
95% CI of the absolute risk difference	(-2.49, 65.82)		
p-value	0.0776		
p-value of Breslow-Day Test for Homogeneity [2]	0.2044		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Hispanic or Latino

	MGL-3196 (N=10)	Placebo (N=12)	Overall (N=22)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (50.0)	4 (33.3)	9 (40.9)
Moderate	3 (30.0)	3 (25.0)	6 (27.3)
Severe	0	1 (8.3)	1 (4.5)
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	0	4 (18.2)
Moderate	0	1 (8.3)	1 (4.5)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Events n:			
Total TEAEs	39	28	67
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	9	4	13
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	5 (62.5)	7 (87.5)	12 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the odds ratio	(0.02, 3.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the risk ratio	(0.39, 1.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-65.63, 15.63)		
p-value	0.2482		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	7 (87.5)	12 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the odds ratio	(0.02, 3.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the risk ratio	(0.39, 1.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-65.63, 15.63)		
p-value	0.2482		
p-value of Breslow-Day Test for Homogeneity [2]	0.1819		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any TEAEs leading to Study Discontinuation	0	1 (12.5)	1 (6.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 8.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the risk ratio	(0.02, 7.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.11		
95% CI of the absolute risk difference	(-39.69, 17.47)		
p-value	0.4533		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	3 (37.5)	6 (37.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.13, 7.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.28, 3.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-47.44, 47.44)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.2044		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.3
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Ethnicity
(Label Population based on Safety Population)

Ethnicity: Not Hispanic or Latino

	MGL-3196 (N=8)	Placebo (N=8)	Overall (N=16)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (37.5)	2 (25.0)	5 (31.3)
Moderate	2 (25.0)	5 (62.5)	7 (43.8)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	1 (12.5)	4 (25.0)
Moderate	0	2 (25.0)	2 (12.5)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.4

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Events n:			
Total TEAEs	38	27	65
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	6	2	8
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (62.5)	9 (69.2)	14 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		
95% CI of the odds ratio	(0.12, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		
95% CI of the risk ratio	(0.47, 1.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.73		
95% CI of the absolute risk difference	(-48.62, 35.16)		
p-value	0.7507		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Severe TEAEs	0	1 (7.7)	1 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49		
95% CI of the odds ratio	(0.02, 13.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52		
95% CI of the risk ratio	(0.02, 11.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.16		
95% CI of the absolute risk difference	(-27.21, 16.90)		
p-value	0.6683		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	9 (69.2)	14 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		
95% CI of the odds ratio	(0.12, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		
95% CI of the risk ratio	(0.47, 1.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.73		
95% CI of the absolute risk difference	(-48.62, 35.16)		
p-value	0.7507		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	1 (7.7)	4 (19.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.20		
95% CI of the odds ratio	(0.60, 87.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.88		
95% CI of the risk ratio	(0.61, 39.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	29.81		
95% CI of the absolute risk difference	(-6.73, 66.35)		
p-value	0.0912		
p-value of Breslow-Day Test for Homogeneity [2]	0.1848		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 2

	MGL-3196 (N=8)	Placebo (N=13)	Overall (N=21)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (50.0)	4 (30.8)	8 (38.1)
Moderate	1 (12.5)	4 (30.8)	5 (23.8)
Severe	0	1 (7.7)	1 (4.8)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	0	3 (14.3)
Moderate	0	1 (7.7)	1 (4.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Events n:			
Total TEAEs	40	24	64
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	10	3	13
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (80.0)	6 (85.7)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the odds ratio	(0.05, 9.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.61, 1.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.71		
95% CI of the absolute risk difference	(-41.58, 30.16)		
p-value	0.7610		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any Serious TEAE	0	1 (14.3)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		
95% CI of the odds ratio	(0.01, 5.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the risk ratio	(0.01, 5.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.20		
95% CI of the absolute risk difference	(-43.92, 15.51)		
p-value	0.3192		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	6 (85.7)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67		
95% CI of the odds ratio	(0.05, 9.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.61, 1.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.71		
95% CI of the absolute risk difference	(-41.58, 30.16)		
p-value	0.7610		
p-value of Breslow-Day Test for Homogeneity [2]	0.9487		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any TEAEs leading to Study Discontinuation	0	1 (14.3)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		
95% CI of the odds ratio	(0.01, 5.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		
95% CI of the risk ratio	(0.01, 5.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.20		
95% CI of the absolute risk difference	(-43.92, 15.51)		
p-value	0.3192		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	3 (42.9)	7 (41.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the odds ratio	(0.13, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93		
95% CI of the risk ratio	(0.30, 2.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86		
95% CI of the absolute risk difference	(-50.46, 44.74)		
p-value	0.9062		
p-value of Breslow-Day Test for Homogeneity [2]	0.1848		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.4

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population based on Safety Population)

Fibrosis Stage at Baseline: 3

	MGL-3196 (N=10)	Placebo (N=7)	Overall (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (40.0)	2 (28.6)	6 (35.3)
Moderate	4 (40.0)	4 (57.1)	8 (47.1)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	1 (14.3)	5 (29.4)
Moderate	0	2 (28.6)	2 (11.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; MRI-PDFF = Proton density fat fraction magnetic resonance imaging.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Events n:			
Total TEAEs	45	20	65
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	11	3	14
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (72.7)	8 (88.9)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.03, 3.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.53, 1.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.16		
95% CI of the absolute risk difference	(-49.54, 17.22)		
p-value	0.3687		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any Serious TEAE	0	1 (11.1)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		
95% CI of the odds ratio	(0.01, 6.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		
95% CI of the risk ratio	(0.01, 6.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.83		
95% CI of the absolute risk difference	(-35.69, 14.02)		
p-value	0.3788		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (72.7)	8 (88.9)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.03, 3.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.53, 1.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-16.16		
95% CI of the absolute risk difference	(-49.54, 17.22)		
p-value	0.3687		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (36.4)	2 (22.2)	6 (30.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the odds ratio	(0.27, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64		
95% CI of the risk ratio	(0.38, 6.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.14		
95% CI of the absolute risk difference	(-25.18, 53.46)		
p-value	0.4924		
p-value of Breslow-Day Test for Homogeneity [2]	0.7257		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: <20%

	MGL-3196 (N=11)	Placebo (N=9)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (45.5)	5 (55.6)	10 (50.0)
Moderate	3 (27.3)	3 (33.3)	6 (30.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (36.4)	0	4 (20.0)
Moderate	0	2 (22.2)	2 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Events n:			
Total TEAEs	33	31	64
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	5	2	7
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (71.4)	7 (63.6)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12		
95% CI of the risk ratio	(0.59, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.79		
95% CI of the absolute risk difference	(-36.12, 51.70)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Severe TEAEs	0	1 (9.1)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		
95% CI of the odds ratio	(0.02, 13.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the risk ratio	(0.02, 10.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25		
95% CI of the absolute risk difference	(-31.38, 18.88)		
p-value	0.6481		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (71.4)	7 (63.6)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12		
95% CI of the risk ratio	(0.59, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.79		
95% CI of the absolute risk difference	(-36.12, 51.70)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.3674		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (9.1)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		
95% CI of the odds ratio	(0.02, 13.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the risk ratio	(0.02, 10.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.25		
95% CI of the absolute risk difference	(-31.38, 18.88)		
p-value	0.6481		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (42.9)	2 (18.2)	5 (27.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38		
95% CI of the odds ratio	(0.40, 28.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.36		
95% CI of the risk ratio	(0.52, 10.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.68		
95% CI of the absolute risk difference	(-18.49, 67.84)		
p-value	0.2545		
p-value of Breslow-Day Test for Homogeneity [2]	0.7257		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.5
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline MRI-PDFF
(Label Population based on Safety Population)

Baseline MRI-PDFF: >=20%

	MGL-3196 (N=7)	Placebo (N=11)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (42.9)	1 (9.1)	4 (22.2)
Moderate	2 (28.6)	5 (45.5)	7 (38.9)
Severe	0	1 (9.1)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (42.9)	1 (9.1)	4 (22.2)
Moderate	0	1 (9.1)	1 (5.6)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; NASH = Non-alcoholic steatohepatitis.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Events n:			
Total TEAEs	6	13	19
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	2	2
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	1 (20.0)	4 (66.7)	5 (45.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13		
95% CI of the odds ratio	(0.01, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.05, 1.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-46.67		
95% CI of the absolute risk difference	(-98.16, 4.83)		
p-value	0.1217		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Severe TEAEs	0	1 (16.7)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 10.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 7.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.10		
95% CI of the absolute risk difference	(-50.69, 24.50)		
p-value	0.5142		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	1 (20.0)	4 (66.7)	5 (45.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13		
95% CI of the odds ratio	(0.01, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.05, 1.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-46.67		
95% CI of the absolute risk difference	(-98.16, 4.83)		
p-value	0.1217		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	0	1 (16.7)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 10.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the risk ratio	(0.02, 7.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.10		
95% CI of the absolute risk difference	(-50.69, 24.50)		
p-value	0.5142		
p-value of Breslow-Day Test for Homogeneity [2]	0.1140		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: <5

	MGL-3196 (N=5)	Placebo (N=6)	Overall (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	1 (20.0)	1 (16.7)	2 (18.2)
Moderate	0	2 (33.3)	2 (18.2)
Severe	0	1 (16.7)	1 (9.1)
Maximum Severity of Treatment-related TEAEs			
Mild	0	0	0
Moderate	0	1 (16.7)	1 (9.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Events n:			
Total TEAEs	72	38	110
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	16	3	19
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	12 (92.3)	11 (78.6)	23 (85.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.27		
95% CI of the odds ratio	(0.29, 36.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		
95% CI of the risk ratio	(0.86, 1.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.74		
95% CI of the absolute risk difference	(-12.18, 39.66)		
p-value	0.3154		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any Serious TEAE	0	1 (7.1)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 8.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the risk ratio	(0.02, 8.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.43		
95% CI of the absolute risk difference	(-24.46, 11.60)		
p-value	0.4948		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	12 (92.3)	11 (78.6)	23 (85.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.27		
95% CI of the odds ratio	(0.29, 36.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		
95% CI of the risk ratio	(0.86, 1.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.74		
95% CI of the absolute risk difference	(-12.18, 39.66)		
p-value	0.3154		
p-value of Breslow-Day Test for Homogeneity [2]	0.0678		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any TEAEs leading to Study Discontinuation	0	1 (7.1)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the odds ratio	(0.01, 8.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the risk ratio	(0.02, 8.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.43		
95% CI of the absolute risk difference	(-24.46, 11.60)		
p-value	0.4948		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	7 (53.8)	3 (21.4)	10 (37.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.28		
95% CI of the odds ratio	(0.80, 22.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.51		
95% CI of the risk ratio	(0.82, 7.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	32.42		
95% CI of the absolute risk difference	(-2.17, 67.01)		
p-value	0.0814		
p-value of Breslow-Day Test for Homogeneity [2]	0.1140		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.6
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Stage of NASH
(Label Population based on Safety Population)

Stage of NASH: >=5

	MGL-3196 (N=13)	Placebo (N=14)	Overall (N=27)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	7 (53.8)	5 (35.7)	12 (44.4)
Moderate	5 (38.5)	6 (42.9)	11 (40.7)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	7 (53.8)	1 (7.1)	8 (29.6)
Moderate	0	2 (14.3)	2 (7.4)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Events n:			
Total TEAEs	57	19	76
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	11	1	12
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	9 (75.0)	8 (100)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.54, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-49.50, -0.50)		
p-value	0.1250		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	9 (75.0)	8 (100)	17 (85.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		
95% CI of the risk ratio	(0.54, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-25.00		
95% CI of the absolute risk difference	(-49.50, -0.50)		
p-value	0.1250		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	1 (12.5)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		
95% CI of the odds ratio	(0.01, 5.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		
95% CI of the risk ratio	(0.01, 5.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.82		
95% CI of the absolute risk difference	(-39.32, 13.68)		
p-value	0.3037		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (33.3)	1 (12.5)	5 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.50		
95% CI of the odds ratio	(0.31, 39.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.67		
95% CI of the risk ratio	(0.36, 19.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.83		
95% CI of the absolute risk difference	(-14.33, 56.00)		
p-value	0.2918		
p-value of Breslow-Day Test for Homogeneity [2]	0.9240		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: Yes

	MGL-3196 (N=12)	Placebo (N=8)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (41.7)	4 (50.0)	9 (45.0)
Moderate	4 (33.3)	4 (50.0)	8 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	4 (33.3)	0	4 (20.0)
Moderate	0	1 (12.5)	1 (5.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Events n:			
Total TEAEs	21	32	53
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	5	4	9
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	4 (66.7)	7 (58.3)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		
95% CI of the risk ratio	(0.54, 2.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33		
95% CI of the absolute risk difference	(-38.58, 55.25)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any Serious TEAE	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Severe TEAEs	0	1 (8.3)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		
95% CI of the odds ratio	(0.02, 16.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		
95% CI of the risk ratio	(0.03, 13.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.40		
95% CI of the absolute risk difference	(-30.19, 21.40)		
p-value	0.7546		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	4 (66.7)	7 (58.3)	11 (61.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		
95% CI of the odds ratio	(0.18, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		
95% CI of the risk ratio	(0.54, 2.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33		
95% CI of the absolute risk difference	(-38.58, 55.25)		
p-value	0.7324		
p-value of Breslow-Day Test for Homogeneity [2]	0.1364		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (50.0)	3 (25.0)	6 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.38, 23.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		
95% CI of the risk ratio	(0.56, 7.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-21.91, 71.91)		
p-value	0.2888		
p-value of Breslow-Day Test for Homogeneity [2]	0.9240		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.7
Treatment-Emergent Adverse Events- Excluding Disease Related Events - Overall Summary
by Type 2 Diabetes
(Label Population based on Safety Population)

Type 2 Diabetes: No

	MGL-3196 (N=6)	Placebo (N=12)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (50.0)	2 (16.7)	5 (27.8)
Moderate	1 (16.7)	4 (33.3)	5 (27.8)
Severe	0	1 (8.3)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	3 (50.0)	1 (8.3)	4 (22.2)
Moderate	0	2 (16.7)	2 (11.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; ALT = Alanine aminotransferase.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Events n:			
Total TEAEs	65	36	101
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	15	3	18
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	10 (76.9)	12 (80.0)	22 (78.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		
95% CI of the odds ratio	(0.14, 5.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		
95% CI of the risk ratio	(0.65, 1.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.08		
95% CI of the absolute risk difference	(-33.64, 27.49)		
p-value	0.8431		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any Serious TEAE	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Severe TEAEs	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (76.9)	12 (80.0)	22 (78.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		
95% CI of the odds ratio	(0.14, 5.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		
95% CI of the risk ratio	(0.65, 1.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.08		
95% CI of the absolute risk difference	(-33.64, 27.49)		
p-value	0.8431		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any TEAEs leading to Study Discontinuation	0	1 (6.7)	1 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		
95% CI of the odds ratio	(0.01, 9.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		
95% CI of the risk ratio	(0.02, 8.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80		
95% CI of the absolute risk difference	(-23.08, 11.47)		
p-value	0.5249		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	6 (46.2)	3 (20.0)	9 (32.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.43		
95% CI of the odds ratio	(0.65, 18.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.31		
95% CI of the risk ratio	(0.72, 7.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	26.15		
95% CI of the absolute risk difference	(-7.67, 59.98)		
p-value	0.1394		
p-value of Breslow-Day Test for Homogeneity [2]	0.4858		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT >=30 U/L and males with baseline ALT >=45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT ≥ 30 U/L and males with baseline ALT ≥ 45 U/L

	MGL-3196 (N=13)	Placebo (N=15)	Overall (N=28)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (46.2)	6 (40.0)	12 (42.9)
Moderate	4 (30.8)	5 (33.3)	9 (32.1)
Severe	0	1 (6.7)	1 (3.6)
Maximum Severity of Treatment-related TEAEs			
Mild	6 (46.2)	1 (6.7)	7 (25.0)
Moderate	0	2 (13.3)	2 (7.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Events n:			
Total TEAEs	13	15	28
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	1	2	3
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	3 (60.0)	3 (60.0)	6 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.08, 12.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.36, 2.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-60.73, 60.73)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (60.0)	3 (60.0)	6 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.08, 12.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.36, 2.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-60.73, 60.73)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.9085		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	1 (20.0)	1 (20.0)	2 (20.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.05, 22.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.08, 11.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-49.58, 49.58)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.4858		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.8

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline ALT by Gender

(Label Population based on Safety Population)

Baseline ALT by Gender: Females with baseline ALT <30 U/L and males with baseline ALT <45 U/L

	MGL-3196 (N=5)	Placebo (N=5)	Overall (N=10)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (40.0)	0	2 (20.0)
Moderate	1 (20.0)	3 (60.0)	4 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	1 (20.0)	0	1 (10.0)
Moderate	0	1 (20.0)	1 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; LDL = low density lipoprotein.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the Label Population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Events n:			
Total TEAEs	30	6	36
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	4	0	4
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	5 (62.5)	4 (57.1)	9 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the odds ratio	(0.16, 9.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		
95% CI of the risk ratio	(0.47, 2.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.36		
95% CI of the absolute risk difference	(-44.34, 55.05)		
p-value	0.8327		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	4 (57.1)	9 (60.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the odds ratio	(0.16, 9.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		
95% CI of the risk ratio	(0.47, 2.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.36		
95% CI of the absolute risk difference	(-44.34, 55.05)		
p-value	0.8327		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	0	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.77		
95% CI of the odds ratio	(0.23, 143.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.44		
95% CI of the risk ratio	(0.25, 79.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	21.53		
95% CI of the absolute risk difference	(-12.20, 55.26)		
p-value	0.2452		
p-value of Breslow-Day Test for Homogeneity [2]	0.3494		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: <100 mg/dL

	MGL-3196 (N=8)	Placebo (N=7)	Overall (N=15)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (25.0)	3 (42.9)	5 (33.3)
Moderate	3 (37.5)	1 (14.3)	4 (26.7)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	0	2 (13.3)
Moderate	0	0	0
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Events n:			
Total TEAEs	48	45	93
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	12	5	17
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	8 (80.0)	11 (84.6)	19 (82.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73		
95% CI of the odds ratio	(0.08, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.64, 1.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.62		
95% CI of the absolute risk difference	(-36.23, 27.00)		
p-value	0.7722		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any Serious TEAE	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Severe TEAEs	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	11 (84.6)	19 (82.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73		
95% CI of the odds ratio	(0.08, 6.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		
95% CI of the risk ratio	(0.64, 1.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.62		
95% CI of the absolute risk difference	(-36.23, 27.00)		
p-value	0.7722		
p-value of Breslow-Day Test for Homogeneity [2]	0.7225		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any TEAEs leading to Study Discontinuation	0	1 (7.7)	1 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		
95% CI of the odds ratio	(0.01, 10.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		
95% CI of the risk ratio	(0.02, 9.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.17		
95% CI of the absolute risk difference	(-26.52, 14.18)		
p-value	0.5725		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (50.0)	4 (30.8)	9 (39.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25		
95% CI of the odds ratio	(0.41, 12.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.63		
95% CI of the risk ratio	(0.58, 4.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	19.23		
95% CI of the absolute risk difference	(-20.64, 59.10)		
p-value	0.3489		
p-value of Breslow-Day Test for Homogeneity [2]	0.3494		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.9
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by LDL at Baseline
(Label Population based on Safety Population)

LDL at Baseline: ≥ 100 mg/dL

	MGL-3196 (N=10)	Placebo (N=13)	Overall (N=23)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (60.0)	3 (23.1)	9 (39.1)
Moderate	2 (20.0)	7 (53.8)	9 (39.1)
Severe	0	1 (7.7)	1 (4.3)
Maximum Severity of Treatment-related TEAEs			
Mild	5 (50.0)	1 (7.7)	6 (26.1)
Moderate	0	3 (23.1)	3 (13.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.10

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Events n:			
Total TEAEs	42	44	86
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	7	4	11
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	7 (70.0)	12 (85.7)	19 (79.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the odds ratio	(0.05, 2.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.52, 1.29)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.71		
95% CI of the absolute risk difference	(-49.52, 18.09)		
p-value	0.3500		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any Serious TEAE	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Severe TEAEs	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	7 (70.0)	12 (85.7)	19 (79.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		
95% CI of the odds ratio	(0.05, 2.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		
95% CI of the risk ratio	(0.52, 1.29)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.71		
95% CI of the absolute risk difference	(-49.52, 18.09)		
p-value	0.3500		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: ≤150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any TEAEs leading to Study Discontinuation	0	1 (7.1)	1 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		
95% CI of the odds ratio	(0.02, 11.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		
95% CI of the risk ratio	(0.02, 10.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.45		
95% CI of the absolute risk difference	(-25.00, 14.09)		
p-value	0.6061		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	4 (40.0)	3 (21.4)	7 (29.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.44		
95% CI of the odds ratio	(0.41, 14.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		
95% CI of the risk ratio	(0.53, 6.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.57		
95% CI of the absolute risk difference	(-18.63, 55.77)		
p-value	0.3237		
p-value of Breslow-Day Test for Homogeneity [2]	0.8983		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: <=150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: <=150 mg/dL

	MGL-3196 (N=10)	Placebo (N=14)	Overall (N=24)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (40.0)	5 (35.7)	9 (37.5)
Moderate	3 (30.0)	6 (42.9)	9 (37.5)
Severe	0	1 (7.1)	1 (4.2)
Maximum Severity of Treatment-related TEAEs			
Mild	4 (40.0)	1 (7.1)	5 (20.8)
Moderate	0	2 (14.3)	2 (8.3)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Events n:			
Total TEAEs	36	7	43
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	9	1	10
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	6 (75.0)	3 (50.0)	9 (64.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.31, 28.84)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the risk ratio	(0.61, 3.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-25.01, 75.01)		
p-value	0.3340		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	6 (75.0)	3 (50.0)	9 (64.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.31, 28.84)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the risk ratio	(0.61, 3.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.00		
95% CI of the absolute risk difference	(-25.01, 75.01)		
p-value	0.3340		
p-value of Breslow-Day Test for Homogeneity [2]	0.1793		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	3 (37.5)	1 (16.7)	4 (28.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.00		
95% CI of the odds ratio	(0.23, 39.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25		
95% CI of the risk ratio	(0.30, 16.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	20.83		
95% CI of the absolute risk difference	(-24.05, 65.72)		
p-value	0.3932		
p-value of Breslow-Day Test for Homogeneity [2]	0.8983		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.10
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Triglycerides at Baseline
(Label Population based on Safety Population)

Triglycerides at Baseline: >150 mg/dL

	MGL-3196 (N=8)	Placebo (N=6)	Overall (N=14)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	4 (50.0)	1 (16.7)	5 (35.7)
Moderate	2 (25.0)	2 (33.3)	4 (28.6)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	3 (37.5)	0	3 (21.4)
Moderate	0	1 (16.7)	1 (7.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.11

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary

by Baseline TIMP

(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; TIMP = Tissue Inhibitor of Metalloproteinases.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Events n:			
Total TEAEs	10	20	30
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	0	2	2
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	3 (75.0)	6 (85.7)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.02, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88		
95% CI of the risk ratio	(0.46, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71		
95% CI of the absolute risk difference	(-60.44, 39.01)		
p-value	0.6576		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Severe TEAEs	0	1 (14.3)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		
95% CI of the odds ratio	(0.02, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		
95% CI of the risk ratio	(0.03, 10.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.75		
95% CI of the absolute risk difference	(-46.47, 28.97)		
p-value	0.6705		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	3 (75.0)	6 (85.7)	9 (81.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.02, 11.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88		
95% CI of the risk ratio	(0.46, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.71		
95% CI of the absolute risk difference	(-60.44, 39.01)		
p-value	0.6576		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	0	1 (14.3)	1 (9.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		
95% CI of the odds ratio	(0.02, 14.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		
95% CI of the risk ratio	(0.03, 10.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.75		
95% CI of the absolute risk difference	(-46.47, 28.97)		
p-value	0.6705		
p-value of Breslow-Day Test for Homogeneity [2]	0.2152		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: <229 ug/L

	MGL-3196 (N=4)	Placebo (N=7)	Overall (N=11)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	2 (50.0)	3 (42.9)	5 (45.5)
Moderate	1 (25.0)	2 (28.6)	3 (27.3)
Severe	0	1 (14.3)	1 (9.1)
Maximum Severity of Treatment-related TEAEs			
Mild	0	0	0
Moderate	0	1 (14.3)	1 (9.1)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Events n:			
Total TEAEs	68	31	99
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	16	3	19
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	10 (71.4)	9 (69.2)	19 (70.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11		
95% CI of the odds ratio	(0.21, 5.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03		
95% CI of the risk ratio	(0.63, 1.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.20		
95% CI of the absolute risk difference	(-32.29, 36.69)		
p-value	0.9006		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any Serious TEAE	0	1 (7.7)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 7.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31		
95% CI of the risk ratio	(0.01, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.38		
95% CI of the absolute risk difference	(-25.96, 11.19)		
p-value	0.4331		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	10 (71.4)	9 (69.2)	19 (70.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11		
95% CI of the odds ratio	(0.21, 5.80)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03		
95% CI of the risk ratio	(0.63, 1.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.20		
95% CI of the absolute risk difference	(-32.29, 36.69)		
p-value	0.9006		
p-value of Breslow-Day Test for Homogeneity [2]	0.6536		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any TEAEs leading to Study Discontinuation	0	1 (7.7)	1 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		
95% CI of the odds ratio	(0.01, 7.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31		
95% CI of the risk ratio	(0.01, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.38		
95% CI of the absolute risk difference	(-25.96, 11.19)		
p-value	0.4331		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	7 (50.0)	3 (23.1)	10 (37.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.33		
95% CI of the odds ratio	(0.63, 17.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17		
95% CI of the risk ratio	(0.71, 6.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	26.92		
95% CI of the absolute risk difference	(-7.87, 61.72)		
p-value	0.1478		
p-value of Breslow-Day Test for Homogeneity [2]	0.2152		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.11
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline TIMP
(Label Population based on Safety Population)

Baseline TIMP: >=229 ug/L

	MGL-3196 (N=14)	Placebo (N=13)	Overall (N=27)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	6 (42.9)	3 (23.1)	9 (33.3)
Moderate	4 (28.6)	6 (46.2)	10 (37.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	7 (50.0)	1 (7.7)	8 (29.6)
Moderate	0	2 (15.4)	2 (7.4)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11

Data Cut-off Date: 15MAY2018

AMNOG Table S7.12

Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary

by Baseline HA

(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; HA = Hyaluronic Acid.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Events n:			
Total TEAEs	23	28	51
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	4	3	7
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	5 (62.5)	7 (70.0)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.10, 5.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.46, 1.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.50		
95% CI of the absolute risk difference	(-51.46, 36.46)		
p-value	0.7373		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Severe TEAEs	0	1 (10.0)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 10.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the risk ratio	(0.02, 8.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.08		
95% CI of the absolute risk difference	(-33.28, 17.12)		
p-value	0.5490		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	5 (62.5)	7 (70.0)	12 (66.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		
95% CI of the odds ratio	(0.10, 5.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.46, 1.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.50		
95% CI of the absolute risk difference	(-51.46, 36.46)		
p-value	0.7373		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any TEAEs leading to Study Discontinuation	0	1 (10.0)	1 (5.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		
95% CI of the odds ratio	(0.01, 10.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the risk ratio	(0.02, 8.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.08		
95% CI of the absolute risk difference	(-33.28, 17.12)		
p-value	0.5490		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	2 (20.0)	4 (22.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33		
95% CI of the odds ratio	(0.14, 12.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		
95% CI of the risk ratio	(0.22, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.00		
95% CI of the absolute risk difference	(-33.92, 43.92)		
p-value	0.7998		
p-value of Breslow-Day Test for Homogeneity [2]	0.4678		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: <50 ug/L

	MGL-3196 (N=8)	Placebo (N=10)	Overall (N=18)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (37.5)	3 (30.0)	6 (33.3)
Moderate	2 (25.0)	3 (30.0)	5 (27.8)
Severe	0	1 (10.0)	1 (5.6)
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	1 (10.0)	3 (16.7)
Moderate	0	1 (10.0)	1 (5.6)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Events n:			
Total TEAEs	55	23	78
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	12	2	14
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	8 (80.0)	8 (80.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.11, 8.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.65, 1.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-35.06, 35.06)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any Serious TEAE	0	1 (10.0)	1 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the odds ratio	(0.01, 8.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		
95% CI of the risk ratio	(0.02, 7.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.09		
95% CI of the absolute risk difference	(-32.81, 14.63)		
p-value	0.4583		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	8 (80.0)	8 (80.0)	16 (80.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the odds ratio	(0.11, 8.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		
95% CI of the risk ratio	(0.65, 1.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		
95% CI of the absolute risk difference	(-35.06, 35.06)		
p-value	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.8228		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (50.0)	2 (20.0)	7 (35.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00		
95% CI of the odds ratio	(0.55, 29.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50		
95% CI of the risk ratio	(0.63, 10.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.00		
95% CI of the absolute risk difference	(-9.69, 69.69)		
p-value	0.1596		
p-value of Breslow-Day Test for Homogeneity [2]	0.4678		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.12
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline HA
(Label Population based on Safety Population)

Baseline HA: >=50 ug/L

	MGL-3196 (N=10)	Placebo (N=10)	Overall (N=20)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (50.0)	3 (30.0)	8 (40.0)
Moderate	3 (30.0)	5 (50.0)	8 (40.0)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	5 (50.0)	0	5 (25.0)
Moderate	0	2 (20.0)	2 (10.0)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 1 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; NE = Not estimable; PRO-C3 = N-terminal type III collagen pro-peptide.

Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.

Note: A TEAE is defined as any AE that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post dosing period. AE worsening applies to severity, or relationship to study drug.

Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Severe'.

Note: If the relationship is missing for an AE, the event is assumed to be related.

Note: Percentages are based on the number of patients in the Label Population.

[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the stratification factor.

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 2 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Events n:			
Total TEAEs	27	23	50
Total Serious TEAEs	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	3	3	6
Total Severe TEAEs	0	1	1
Patients n (%):			
Any TEAE	6 (75.0)	7 (63.6)	13 (68.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71		
95% CI of the odds ratio	(0.23, 12.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18		
95% CI of the risk ratio	(0.65, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.36		
95% CI of the absolute risk difference	(-29.97, 52.70)		
p-value	0.5988		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 3 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Severe TEAEs	0	1 (9.1)	1 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		
95% CI of the odds ratio	(0.01, 11.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		
95% CI of the risk ratio	(0.02, 9.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.94		
95% CI of the absolute risk difference	(-30.90, 17.02)		
p-value	0.5916		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	6 (75.0)	7 (63.6)	13 (68.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71		
95% CI of the odds ratio	(0.23, 12.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18		
95% CI of the risk ratio	(0.65, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.36		
95% CI of the absolute risk difference	(-29.97, 52.70)		
p-value	0.5988		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 4 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	2 (25.0)	2 (18.2)	4 (21.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		
95% CI of the odds ratio	(0.16, 13.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.38		
95% CI of the risk ratio	(0.24, 7.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.82		
95% CI of the absolute risk difference	(-30.86, 44.50)		
p-value	0.7189		
p-value of Breslow-Day Test for Homogeneity [2]	0.5522		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 5 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 6 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: <17.5 ng/mL

	MGL-3196 (N=8)	Placebo (N=11)	Overall (N=19)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	5 (62.5)	4 (36.4)	9 (47.4)
Moderate	1 (12.5)	2 (18.2)	3 (15.8)
Severe	0	1 (9.1)	1 (5.3)
Maximum Severity of Treatment-related TEAEs			
Mild	2 (25.0)	1 (9.1)	3 (15.8)
Moderate	0	1 (9.1)	1 (5.3)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 7 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Events n:			
Total TEAEs	51	25	76
Total Serious TEAEs	0	1	1
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0
Total TEAEs Related to Study Drug	13	2	15
Total Severe TEAEs	0	0	0
Patients n (%):			
Any TEAE	7 (77.8)	7 (87.5)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.04, 6.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.57, 1.38)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.72		
95% CI of the absolute risk difference	(-45.26, 25.82)		
p-value	0.5997		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any Serious TEAE	0	1 (12.5)	1 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26		
95% CI of the odds ratio	(0.01, 7.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		
95% CI of the risk ratio	(0.01, 6.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.67		
95% CI of the absolute risk difference	(-39.51, 16.18)		
p-value	0.4080		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 8 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Mild or Moderate TEAEs	7 (77.8)	7 (87.5)	14 (82.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		
95% CI of the odds ratio	(0.04, 6.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89		
95% CI of the risk ratio	(0.57, 1.38)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.72		
95% CI of the absolute risk difference	(-45.26, 25.82)		
p-value	0.5997		
p-value of Breslow-Day Test for Homogeneity [2]	0.4605		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 9 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAE	5 (55.6)	2 (25.0)	7 (41.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.75		
95% CI of the odds ratio	(0.47, 29.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.22		
95% CI of the risk ratio	(0.58, 8.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.56		
95% CI of the absolute risk difference	(-13.65, 74.76)		
p-value	0.2014		
p-value of Breslow-Day Test for Homogeneity [2]	0.5522		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 10 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Treatment-related Serious TEAE	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Severe TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-05

Page 11 of 11
Data Cut-off Date: 15MAY2018

AMNOG Table S7.13
Treatment-Emergent Adverse Events - Excluding Disease Related Events - Overall Summary
by Baseline PRO-C3
(Label Population based on Safety Population)

Baseline PRO-C3: ≥ 17.5 ng/mL

	MGL-3196 (N=9)	Placebo (N=8)	Overall (N=17)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Any Treatment-related Fatal TEAEs	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the odds ratio	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		
95% CI of the risk ratio	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		
95% CI of the absolute risk difference	NE		
p-value	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE		
Maximum Severity of TEAEs			
Mild	3 (33.3)	2 (25.0)	5 (29.4)
Moderate	4 (44.4)	5 (62.5)	9 (52.9)
Severe	0	0	0
Maximum Severity of Treatment-related TEAEs			
Mild	5 (55.6)	0	5 (29.4)
Moderate	0	2 (25.0)	2 (11.8)
Severe	0	0	0

Program: t-s01-subgroup.sas

Date of creation: 29AUG2025